{"PMC7458526": [["In the past 5 years, the need to increase the diversity of the cardiovascular workforce has become a prominent focus of the American College of Cardiology (ACC), along with several cardiovascular subspecialty societies.", [["cardiovascular", "ANATOMY", 63, 77], ["cardiovascular", "ANATOMY", 181, 195], ["cardiovascular", "ANATOMICAL_SYSTEM", 63, 77], ["prominent", "OBSERVATION_MODIFIER", 101, 110]]], ["In doing so, the ACC seeks to \u201charness the power of the diversity of its members to advance patient care, spur innovation, and improve health equity among individual patients and populations\u201d (1).", [["patient", "ORGANISM", 92, 99], ["patients", "ORGANISM", 166, 174], ["patient", "SPECIES", 92, 99], ["patients", "SPECIES", 166, 174], ["spur innovation", "TREATMENT", 106, 121]]], ["In 2016, just 12.8% of adult cardiology fellows met the Association of American Medical Colleges definition of under-represented minorities (URMs) (2), and representation in subspecialty fellowships was even worse: 9.2% of interventional, 10.3% of electrophysiology, and 15.7% of advanced heart failure transplant cardiology fellows.", [["heart", "ANATOMY", 289, 294], ["heart failure", "DISEASE", 289, 302], ["heart", "ORGAN", 289, 294], ["interventional", "TREATMENT", 223, 237], ["electrophysiology", "TEST", 248, 265], ["advanced heart failure", "PROBLEM", 280, 302], ["heart", "ANATOMY", 289, 294], ["failure", "OBSERVATION", 295, 302]]], ["The outlook for attracting more women into cardiology is also grim.", [["women", "ORGANISM", 32, 37], ["women", "SPECIES", 32, 37]]], ["Although the proportion of fellows who were women doubled from 10.1% in 1991 to 21.3% in 2016, even the more recent \u201cimproved\u201d number is lower than that for every other subspecialty in medicine back in 1991 except gastrointestinal and pulmonary/critical care (4).", [["gastrointestinal", "ANATOMY", 214, 230], ["pulmonary", "ANATOMY", 235, 244], ["women", "ORGANISM", 44, 49], ["gastrointestinal", "ORGAN", 214, 230], ["pulmonary", "ORGAN", 235, 244], ["women", "SPECIES", 44, 49], ["pulmonary", "ANATOMY", 235, 244]]], ["The urgency to address diversity in cardiology is further heightened by the current dual crises of coronavirus disease-2019 and police brutality, which demonstrate in stark terms the glaring health disparities and structural racism endemic in the United States.", [["coronavirus disease", "DISEASE", 99, 118], ["coronavirus", "ORGANISM", 99, 110], ["coronavirus disease", "PROBLEM", 99, 118], ["urgency", "OBSERVATION", 4, 11], ["coronavirus disease", "OBSERVATION", 99, 118], ["racism", "OBSERVATION_MODIFIER", 225, 231]]], ["Clearly, increasing female and URM trainees in cardiology is a critical part of the solution.", [["increasing", "OBSERVATION_MODIFIER", 9, 19], ["female", "OBSERVATION", 20, 26]]]], "73da2e0b941b861db4a65191605a10422fc5b3a6": [["IntroductionCoronaviruses are single-positive-strand RNA viruses with a genome size of approximately 30 kbp, belonging to the family Coronaviridae, subfamily Coronavirinae.", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 12, 25], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 133, 146], ["Coronaviruses", "PROTEIN", 12, 25], ["strand RNA viruses", "PROBLEM", 46, 64], ["strand RNA viruses", "OBSERVATION", 46, 64], ["size", "OBSERVATION_MODIFIER", 79, 83]]], ["The subfamily Coronavirinae has been further classified into four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus [6] .", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 14, 27], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 74, 90], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 92, 107], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 109, 125], ["Alphacoronavirus", "PROBLEM", 74, 90], ["Betacoronavirus", "TREATMENT", 92, 107], ["Gammacoronavirus", "TREATMENT", 109, 125], ["Deltacoronavirus", "TREATMENT", 131, 147]]], ["In cats, feline coronavirus (FCoV) of the genus Alphacoronavirus has been identified.IntroductionThe FCoV virion is mainly composed of nucleocapsid (N), envelope (E), membrane (M), and peplomer spike (S) proteins [6] .", [["membrane", "ANATOMY", 167, 175], ["feline coronavirus", "DISEASE", 9, 27], ["cats", "ORGANISM", 3, 7], ["feline coronavirus", "ORGANISM", 9, 27], ["FCoV", "CANCER", 29, 33], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 48, 64], ["FCoV", "GENE_OR_GENE_PRODUCT", 101, 105], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 135, 151], ["membrane", "CELLULAR_COMPONENT", 167, 175], ["FCoV virion", "PROTEIN", 101, 112], ["nucleocapsid (N), envelope (E), membrane (M)", "PROTEIN", 135, 179], ["peplomer spike (S) proteins", "PROTEIN", 185, 212], ["cats", "SPECIES", 3, 7], ["feline coronavirus", "SPECIES", 9, 27], ["feline coronavirus", "SPECIES", 9, 27], ["FCoV", "SPECIES", 29, 33], ["feline coronavirus", "PROBLEM", 9, 27], ["the genus Alphacoronavirus", "PROBLEM", 38, 64], ["The FCoV virion", "TREATMENT", 97, 112], ["feline coronavirus", "OBSERVATION", 9, 27], ["genus Alphacoronavirus", "OBSERVATION", 42, 64], ["FCoV virion", "OBSERVATION", 101, 112]]], ["There are two genotypes/serotypes of FCoV: FCoV has been classified into types I and II based on the amino acid sequence of its S protein [10, 19] .", [["FCoV", "CHEMICAL", 37, 41], ["FCoV", "CHEMICAL", 43, 47], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 101, 111], ["FCoV", "GENE_OR_GENE_PRODUCT", 37, 41], ["FCoV", "GENE_OR_GENE_PRODUCT", 43, 47], ["amino acid", "AMINO_ACID", 101, 111], ["FCoV", "PROTEIN", 43, 47], ["amino acid sequence", "PROTEIN", 101, 120], ["S protein", "PROTEIN", 128, 137], ["FCoV", "SPECIES", 37, 41], ["FCoV", "PROBLEM", 43, 47], ["the amino acid sequence", "TEST", 97, 120]]], ["Type II FCoV was previously suggested to be produced by recombination between type I FCoV and type II canine coronavirus (CCoV) [7, 31] .", [["Type II FCoV", "GENE_OR_GENE_PRODUCT", 0, 12], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 78, 89], ["type II canine coronavirus", "ORGANISM", 94, 120], ["Type II FCoV", "PROTEIN", 0, 12], ["canine coronavirus", "SPECIES", 102, 120], ["type I FCoV", "SPECIES", 78, 89], ["type II canine coronavirus", "SPECIES", 94, 120], ["CCoV", "SPECIES", 122, 126], ["Type II FCoV", "PROBLEM", 0, 12], ["type I FCoV", "PROBLEM", 78, 89], ["type II canine coronavirus", "PROBLEM", 94, 120], ["FCoV", "OBSERVATION", 8, 12]]], ["Separate from these genotypes/serotypes, FCoV has been classified into two biotypes: weakly pathogenic feline enteric coronavirus (FECV; low-virulent FCoV) and strongly pathogenic feline infectious peritonitis virus (FIPV; virulent FCoV) [20] .", [["FCoV", "CHEMICAL", 41, 45], ["feline enteric coronavirus", "DISEASE", 103, 129], ["feline infectious peritonitis", "DISEASE", 180, 209], ["FCoV", "GENE_OR_GENE_PRODUCT", 41, 45], ["feline enteric coronavirus", "ORGANISM", 103, 129], ["FCoV", "ORGANISM", 150, 154], ["feline infectious peritonitis virus", "ORGANISM", 180, 215], ["FCoV", "PROTEIN", 41, 45], ["feline enteric coronavirus", "SPECIES", 103, 129], ["feline infectious peritonitis virus", "SPECIES", 180, 215], ["FCoV", "SPECIES", 41, 45], ["feline enteric coronavirus", "SPECIES", 103, 129], ["FECV", "SPECIES", 131, 135], ["FCoV", "SPECIES", 150, 154], ["feline infectious peritonitis virus", "SPECIES", 180, 215], ["FIPV", "SPECIES", 217, 221], ["these genotypes/serotypes", "PROBLEM", 14, 39], ["FCoV", "PROBLEM", 41, 45], ["weakly pathogenic feline enteric coronavirus", "PROBLEM", 85, 129], ["FECV", "TEST", 131, 135], ["low-virulent FCoV", "PROBLEM", 137, 154], ["strongly pathogenic feline infectious peritonitis virus", "PROBLEM", 160, 215], ["enteric coronavirus", "ANATOMY", 110, 129], ["virulent FCoV", "OBSERVATION_MODIFIER", 141, 154], ["pathogenic feline", "OBSERVATION_MODIFIER", 169, 186], ["infectious", "OBSERVATION_MODIFIER", 187, 197], ["peritonitis", "OBSERVATION", 198, 209]]], ["The etiology of the pathogenesis of FECV/FIPV has not yet been elucidated in detail.", [["FECV", "GENE_OR_GENE_PRODUCT", 36, 40], ["FIPV", "GENE_OR_GENE_PRODUCT", 41, 45], ["the pathogenesis of FECV/FIPV", "PROBLEM", 16, 45]]], ["Two theories currently exist: an ''internal mutation theory'' and a ''circulating virulent/ avirulent theory'' [1, 3, 21] .", [["an ''internal mutation theory''", "PROBLEM", 30, 61]]], ["FIPV causes a fatal disease called FIP in wild and domestic cats [20] .", [["FIPV", "CHEMICAL", 0, 4], ["FIP", "DISEASE", 35, 38], ["cats", "SPECIES", 60, 64], ["FIPV", "SPECIES", 0, 4], ["a fatal disease", "PROBLEM", 12, 27], ["FIP", "PROBLEM", 35, 38], ["fatal disease", "OBSERVATION", 14, 27]]], ["Although antiviral agents and vaccines against FIPV infection have been investigated, no method has yet been established for practical use.IntroductionSince type I FCoV infection is dominant in the field [9, 16, 18, 26] , antiviral agents and vaccines need to be developed against type I FCoV infection.", [["FIPV infection", "DISEASE", 47, 61], ["infection", "DISEASE", 169, 178], ["type I FCoV infection", "DISEASE", 281, 302], ["FIPV", "SIMPLE_CHEMICAL", 47, 51], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 157, 168], ["type I FCoV", "ORGANISM", 281, 292], ["FIPV", "SPECIES", 47, 51], ["type I FCoV", "SPECIES", 281, 292], ["antiviral agents", "TREATMENT", 9, 25], ["vaccines", "TREATMENT", 30, 38], ["FIPV infection", "PROBLEM", 47, 61], ["type I FCoV infection", "PROBLEM", 157, 178], ["antiviral agents", "TREATMENT", 222, 238], ["vaccines", "TREATMENT", 243, 251], ["type I FCoV infection", "PROBLEM", 281, 302], ["FCoV", "OBSERVATION_MODIFIER", 164, 168], ["infection", "OBSERVATION", 169, 178], ["dominant", "OBSERVATION_MODIFIER", 182, 190], ["FCoV", "OBSERVATION_MODIFIER", 288, 292], ["infection", "OBSERVATION", 293, 302]]], ["However, type II FCoV is mainly used in studies on FIP because the propagation of type I FCoV in feline cell lines and monocytes/macrophages is weaker than that of type II FCoV.", [["cell lines", "ANATOMY", 104, 114], ["monocytes", "ANATOMY", 119, 128], ["macrophages", "ANATOMY", 129, 140], ["FIP", "DISEASE", 51, 54], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 9, 21], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 82, 93], ["feline cell lines", "CELL", 97, 114], ["monocytes", "CELL", 119, 128], ["macrophages", "CELL", 129, 140], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 164, 176], ["type II FCoV", "PROTEIN", 9, 21], ["type I FCoV", "PROTEIN", 82, 93], ["feline cell lines", "CELL_LINE", 97, 114], ["monocytes", "CELL_TYPE", 119, 128], ["macrophages", "CELL_TYPE", 129, 140], ["type II FCoV", "PROTEIN", 164, 176], ["feline", "SPECIES", 97, 103], ["type II FCoV", "PROBLEM", 9, 21], ["FIP", "TREATMENT", 51, 54], ["type I FCoV", "PROBLEM", 82, 93], ["monocytes/macrophages", "TEST", 119, 140], ["type II", "OBSERVATION_MODIFIER", 9, 16], ["FCoV", "OBSERVATION", 17, 21], ["feline cell lines", "OBSERVATION", 97, 114], ["monocytes", "ANATOMY", 119, 128], ["macrophages", "OBSERVATION", 129, 140]]], ["Although recombinant type I FCoV has recently been prepared by reverse genetics [30] , studies on type I FCoV have not progressed.", [["recombinant type I FCoV", "GENE_OR_GENE_PRODUCT", 9, 32], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 98, 109], ["recombinant type I FCoV", "PROTEIN", 9, 32], ["type I FCoV", "PROTEIN", 98, 109], ["recombinant type I FCoV", "PROBLEM", 9, 32]]], ["Differences have been identified in the following events between types I and II FCoV: replicative ability in cell lines and monocytes/macrophages [29] , the amino acid sequence and immunogenicity of the S protein [10, 19] , and the virus receptor used to enter cells & Tsutomu Hohdatsu hohdatsu@vmas.kitasato-u.ac.jp [4, 8] .", [["cell lines", "ANATOMY", 109, 119], ["monocytes", "ANATOMY", 124, 133], ["macrophages", "ANATOMY", 134, 145], ["cells", "ANATOMY", 261, 266], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "CHEMICAL", 157, 167], ["cell lines", "CELL", 109, 119], ["monocytes", "CELL", 124, 133], ["macrophages", "CELL", 134, 145], ["amino acid", "AMINO_ACID", 157, 167], ["cells", "CELL", 261, 266], ["cell lines", "CELL_LINE", 109, 119], ["monocytes", "CELL_TYPE", 124, 133], ["macrophages", "CELL_TYPE", 134, 145], ["amino acid sequence", "PROTEIN", 157, 176], ["S protein", "PROTEIN", 203, 212], ["virus receptor", "PROTEIN", 232, 246], ["monocytes/macrophages", "TEST", 124, 145], ["the amino acid sequence", "TEST", 153, 176], ["the S protein", "TEST", 199, 212], ["the virus receptor", "TREATMENT", 228, 246], ["cell lines", "OBSERVATION", 109, 119]]], ["However, differences in other events remain unclear, and the virus receptor for type I FCoV has not yet been identified.IntroductionCholesterol is an essential component in animal cells [12] .", [["cells", "ANATOMY", 180, 185], ["Cholesterol", "CHEMICAL", 132, 143], ["Cholesterol", "CHEMICAL", 132, 143], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 80, 91], ["Cholesterol", "SIMPLE_CHEMICAL", 132, 143], ["cells", "CELL", 180, 185], ["virus receptor", "PROTEIN", 61, 75], ["type I FCoV", "PROTEIN", 80, 91], ["animal cells", "CELL_TYPE", 173, 185], ["the virus receptor", "TREATMENT", 57, 75], ["type I FCoV", "PROBLEM", 80, 91], ["essential", "OBSERVATION_MODIFIER", 150, 159], ["component", "OBSERVATION_MODIFIER", 160, 169], ["animal cells", "OBSERVATION", 173, 185]]], ["It has been shown to play a role in viral infection of cells.", [["cells", "ANATOMY", 55, 60], ["infection", "DISEASE", 42, 51], ["cells", "CELL", 55, 60], ["viral infection of cells", "PROBLEM", 36, 60], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infection", "OBSERVATION", 42, 51]]], ["For example, host cell cholesterol levels have been shown to influence the replication of human hepatitis C virus (HCV), human immunodeficiency virus, and dengue virus [14, 17, 36] , but not that of vesicular stomatitis virus (VSV) [13, 22] .", [["cell", "ANATOMY", 18, 22], ["cholesterol", "CHEMICAL", 23, 34], ["human hepatitis C", "DISEASE", 90, 107], ["human immunodeficiency virus", "DISEASE", 121, 149], ["dengue", "DISEASE", 155, 161], ["vesicular stomatitis", "DISEASE", 199, 219], ["cholesterol", "CHEMICAL", 23, 34], ["host cell", "CELL", 13, 22], ["human", "ORGANISM", 90, 95], ["hepatitis C virus", "ORGANISM", 96, 113], ["HCV", "ORGANISM", 115, 118], ["human immunodeficiency virus", "ORGANISM", 121, 149], ["dengue virus", "ORGANISM", 155, 167], ["vesicular stomatitis virus", "ORGANISM", 199, 225], ["VSV", "ORGANISM", 227, 230], ["human", "SPECIES", 90, 95], ["hepatitis C virus", "SPECIES", 96, 113], ["human", "SPECIES", 121, 126], ["immunodeficiency virus", "SPECIES", 127, 149], ["dengue virus", "SPECIES", 155, 167], ["vesicular stomatitis virus", "SPECIES", 199, 225], ["human hepatitis C virus", "SPECIES", 90, 113], ["HCV", "SPECIES", 115, 118], ["human immunodeficiency virus", "SPECIES", 121, 149], ["dengue virus", "SPECIES", 155, 167], ["vesicular stomatitis virus", "SPECIES", 199, 225], ["VSV", "SPECIES", 227, 230], ["host cell cholesterol levels", "TEST", 13, 41], ["human hepatitis C virus (HCV)", "PROBLEM", 90, 119], ["human immunodeficiency virus", "PROBLEM", 121, 149], ["dengue virus", "PROBLEM", 155, 167], ["vesicular stomatitis virus", "PROBLEM", 199, 225], ["host cell cholesterol", "OBSERVATION", 13, 34], ["vesicular stomatitis", "ANATOMY", 199, 219]]], ["Furthermore, cholesterol contained in the envelope of influenza virus has been shown to affect infection of cells [27] .", [["cells", "ANATOMY", 108, 113], ["cholesterol", "CHEMICAL", 13, 24], ["influenza virus", "DISEASE", 54, 69], ["infection", "DISEASE", 95, 104], ["cholesterol", "CHEMICAL", 13, 24], ["cholesterol", "SIMPLE_CHEMICAL", 13, 24], ["influenza virus", "ORGANISM", 54, 69], ["cells", "CELL", 108, 113], ["influenza virus", "SPECIES", 54, 69], ["influenza virus", "SPECIES", 54, 69], ["cholesterol", "TEST", 13, 24], ["influenza virus", "PROBLEM", 54, 69], ["infection of cells", "PROBLEM", 95, 113], ["influenza virus", "OBSERVATION", 54, 69]]], ["Cholesterol contained in host cells was previously reported to be involved in host cell infection by mouse hepatitis virus (MHV) and severe acute respiratory syndrome coronavirus (SARS-CoV) [5, 33] , which, like FCoV both belong to the family Coronaviridae.", [["cells", "ANATOMY", 30, 35], ["cell", "ANATOMY", 83, 87], ["Cholesterol", "CHEMICAL", 0, 11], ["infection", "DISEASE", 88, 97], ["mouse hepatitis virus (MHV)", "DISEASE", 101, 128], ["acute respiratory syndrome coronavirus", "DISEASE", 140, 178], ["SARS", "DISEASE", 180, 184], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["host cells", "CELL", 25, 35], ["host cell", "CELL", 78, 87], ["mouse hepatitis virus (MHV)", "ORGANISM", 101, 128], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 133, 178], ["SARS-CoV", "ORGANISM", 180, 188], ["FCoV", "GENE_OR_GENE_PRODUCT", 212, 216], ["host cells", "CELL_TYPE", 25, 35], ["mouse", "SPECIES", 101, 106], ["hepatitis virus", "SPECIES", 107, 122], ["mouse hepatitis virus", "SPECIES", 101, 122], ["MHV", "SPECIES", 124, 127], ["severe acute respiratory syndrome coronavirus", "SPECIES", 133, 178], ["SARS-CoV", "SPECIES", 180, 188], ["Cholesterol contained in host cells", "PROBLEM", 0, 35], ["host cell infection", "PROBLEM", 78, 97], ["mouse hepatitis virus", "PROBLEM", 101, 122], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 133, 178], ["host cells", "OBSERVATION", 25, 35], ["host cell infection", "OBSERVATION", 78, 97], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["respiratory syndrome coronavirus", "OBSERVATION", 146, 178]]], ["Transmissible gastroenteritis virus (TGEV) and type II CCoV infections involve cellular and viral cholesterol [23, 25] .", [["cellular", "ANATOMY", 79, 87], ["Transmissible gastroenteritis", "DISEASE", 0, 29], ["infections", "DISEASE", 60, 70], ["cholesterol", "CHEMICAL", 98, 109], ["cholesterol", "CHEMICAL", 98, 109], ["Transmissible gastroenteritis virus", "ORGANISM", 0, 35], ["TGEV", "ORGANISM", 37, 41], ["type II CCoV", "ORGANISM", 47, 59], ["cellular", "CELL", 79, 87], ["cholesterol", "SIMPLE_CHEMICAL", 98, 109], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["TGEV", "SPECIES", 37, 41], ["type II CCoV", "SPECIES", 47, 59], ["Transmissible gastroenteritis virus (TGEV", "PROBLEM", 0, 41], ["type II CCoV infections", "PROBLEM", 47, 70], ["viral cholesterol", "TEST", 92, 109], ["gastroenteritis", "OBSERVATION", 14, 29], ["infections", "OBSERVATION", 60, 70], ["viral cholesterol", "OBSERVATION", 92, 109]]], ["The S protein of type II FCoV is homologous to those of TGEV and type II CCoV, and the infection of cells by type II FCoV was previously shown to be only slightly influenced by cholesterol [35] .", [["cells", "ANATOMY", 100, 105], ["infection", "DISEASE", 87, 96], ["cholesterol", "CHEMICAL", 177, 188], ["cholesterol", "CHEMICAL", 177, 188], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 17, 29], ["TGEV", "ORGANISM", 56, 60], ["type II CCoV", "GENE_OR_GENE_PRODUCT", 65, 77], ["cells", "CELL", 100, 105], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 109, 121], ["cholesterol", "SIMPLE_CHEMICAL", 177, 188], ["S protein", "PROTEIN", 4, 13], ["type II FCoV", "PROTEIN", 17, 29], ["type II FCoV", "PROTEIN", 109, 121], ["TGEV", "SPECIES", 56, 60], ["The S protein", "TEST", 0, 13], ["type II FCoV", "PROBLEM", 17, 29], ["TGEV", "PROBLEM", 56, 60], ["type II CCoV", "PROBLEM", 65, 77], ["the infection of cells", "PROBLEM", 83, 105], ["type II FCoV", "PROBLEM", 109, 121], ["cholesterol", "TEST", 177, 188], ["type II", "OBSERVATION_MODIFIER", 17, 24], ["FCoV", "OBSERVATION", 25, 29], ["infection", "OBSERVATION", 87, 96]]], ["On the other hand, the relationship between type I FCoV and cholesterol remains to be investigated.IntroductionIn the present study, we determined whether cellular and viral cholesterol levels influenced the infectivity of FCoV types I and II in cell culture.Cell cultures and virusesFelis catus whole fetus (fcwf)-4 cells (kindly supplied by Dr. M. C. Horzinek of State University of Utrecht) were grown in Eagle's minimum essential medium containing 50 % L-15 medium, 5 % fetal calf serum (FCS), and 100 U of penicillin and 100 lg of streptomycin per ml.", [["cellular", "ANATOMY", 155, 163], ["cell culture", "ANATOMY", 246, 258], ["Cell cultures", "ANATOMY", 259, 272], ["fetus", "ANATOMY", 302, 307], ["fcwf)-4 cells", "ANATOMY", 309, 322], ["fetal calf serum", "ANATOMY", 474, 490], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 174, 185], ["penicillin", "CHEMICAL", 511, 521], ["streptomycin", "CHEMICAL", 536, 548], ["cholesterol", "CHEMICAL", 60, 71], ["cholesterol", "CHEMICAL", 174, 185], ["penicillin", "CHEMICAL", 511, 521], ["streptomycin", "CHEMICAL", 536, 548], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 44, 55], ["cholesterol", "SIMPLE_CHEMICAL", 60, 71], ["cellular", "CELL", 155, 163], ["cholesterol", "SIMPLE_CHEMICAL", 174, 185], ["FCoV types I", "GENE_OR_GENE_PRODUCT", 223, 235], ["cell culture", "CELL", 246, 258], ["Cell cultures", "CELL", 259, 272], ["Felis catus", "ORGANISM", 284, 295], ["fetus", "ORGANISM", 302, 307], ["fcwf)-4 cells", "CELL", 309, 322], ["fetal calf", "ORGANISM_SUBSTANCE", 474, 484], ["serum", "ORGANISM_SUBSTANCE", 485, 490], ["FCS", "ORGANISM_SUBSTANCE", 492, 495], ["penicillin", "SIMPLE_CHEMICAL", 511, 521], ["streptomycin", "SIMPLE_CHEMICAL", 536, 548], ["type I FCoV", "PROTEIN", 44, 55], ["Felis catus", "SPECIES", 284, 295], ["calf", "SPECIES", 480, 484], ["Felis catus", "SPECIES", 284, 295], ["the present study", "TEST", 114, 131], ["cellular and viral cholesterol levels", "TEST", 155, 192], ["II in cell culture", "TEST", 240, 258], ["Cell cultures", "TEST", 259, 272], ["viruses", "PROBLEM", 277, 284], ["fetal calf serum", "TEST", 474, 490], ["FCS", "TEST", 492, 495], ["penicillin", "TREATMENT", 511, 521], ["streptomycin", "TREATMENT", 536, 548], ["fetal calf", "ANATOMY", 474, 484]]], ["The type I FCoV KU-2 strain (FCoV-I KU-2) was isolated in our laboratory, and the type I FCoV Black strain (FCoV-I Black) and the type I FCoV UCD-1 strain (FCoV-I UCD-1) were kindly supplied by Dr. J. K. Yamamoto of the University of Florida.", [["FCoV-I KU-2", "CELL", 29, 40], ["FCoV-I", "ORGANISM", 108, 114], ["FCoV-I UCD-1", "CELL", 156, 168], ["type I FCoV Black strain (FCoV-I Black)", "SPECIES", 82, 121], ["type I FCoV UCD-1", "SPECIES", 130, 147], ["FCoV-I UCD-1", "SPECIES", 156, 168], ["The type I FCoV KU", "TEST", 0, 18], ["FCoV", "TEST", 29, 33], ["the type I FCoV Black strain", "PROBLEM", 78, 106], ["the type I FCoV UCD", "PROBLEM", 126, 145], ["FCoV", "TEST", 156, 160], ["FCoV KU", "OBSERVATION", 11, 18], ["FCoV UCD", "OBSERVATION", 137, 145]]], ["The type II FCoV 79-1146 strain (FCoV-II 79-1146) was kindly provided by Dr. M. C.Cell cultures and virusesHorzinek.", [["Cell cultures", "ANATOMY", 82, 95], ["type II FCoV 79-1146", "CHEMICAL", 4, 24], ["FCoV-II 79-1146", "CHEMICAL", 33, 48], ["Horzinek", "CHEMICAL", 107, 115], ["FCoV-II 79-1146", "CELL", 33, 48], ["Cell cultures", "CELL", 82, 95], ["The type II FCoV", "TEST", 0, 16], ["FCoV", "TEST", 33, 37], ["Cell cultures", "TEST", 82, 95], ["viruses", "PROBLEM", 100, 107], ["Horzinek", "TREATMENT", 107, 115]]], ["VSV (New Jersey strain) was obtained from the Laboratory of Veterinary Microbiology at Kitasato University.", [["VSV", "ORGANISM", 0, 3], ["VSV", "SPECIES", 0, 3]]], ["These viruses were grown in fcwf-4 cells at 37\u00b0C.CompoundsMethyl-b-cyclodextrin (MbCD) and water-soluble cholesterol were obtained from Sigma Aldrich (USA).", [["fcwf-4 cells", "ANATOMY", 28, 40], ["CompoundsMethyl-b-cyclodextrin", "CHEMICAL", 49, 79], ["MbCD", "CHEMICAL", 81, 85], ["cholesterol", "CHEMICAL", 105, 116], ["CompoundsMethyl-b-cyclodextrin", "CHEMICAL", 49, 79], ["MbCD", "CHEMICAL", 81, 85], ["cholesterol", "CHEMICAL", 105, 116], ["fcwf-4 cells", "CELL", 28, 40], ["CompoundsMethyl-b-cyclodextrin", "SIMPLE_CHEMICAL", 49, 79], ["MbCD", "SIMPLE_CHEMICAL", 81, 85], ["water-soluble", "SIMPLE_CHEMICAL", 91, 104], ["cholesterol", "SIMPLE_CHEMICAL", 105, 116], ["Sigma", "ORGANISM", 136, 141], ["Aldrich (USA", "ORGANISM", 142, 154], ["fcwf-4 cells", "CELL_LINE", 28, 40], ["These viruses", "PROBLEM", 0, 13], ["CompoundsMethyl-b-cyclodextrin (MbCD)", "TREATMENT", 49, 86], ["water-soluble cholesterol", "TREATMENT", 91, 116], ["viruses", "OBSERVATION", 6, 13], ["grown", "OBSERVATION_MODIFIER", 19, 24]]], ["These compounds were diluted to the desired concentrations in maintenance medium.Detection of cellular cholesterolThe cellular cholesterol content of fcwf-4 cells was evaluated using a Cholesterol Cell-Based Detection Assay Kit (Cayman Chemical, USA) according to the manufacturer's instructions.", [["cellular", "ANATOMY", 94, 102], ["cellular", "ANATOMY", 118, 126], ["fcwf-4 cells", "ANATOMY", 150, 162], ["Cell", "ANATOMY", 197, 201], ["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "CHEMICAL", 127, 138], ["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "CHEMICAL", 127, 138], ["Cholesterol", "CHEMICAL", 185, 196], ["cellular", "CELL", 94, 102], ["cellular", "CELL", 118, 126], ["cholesterol", "SIMPLE_CHEMICAL", 127, 138], ["fcwf-4 cells", "CELL", 150, 162], ["fcwf-4 cells", "CELL_LINE", 150, 162], ["cellular cholesterol", "TEST", 94, 114], ["The cellular cholesterol content", "TEST", 114, 146], ["a Cholesterol Cell", "TEST", 183, 201], ["cellular cholesterol", "OBSERVATION", 94, 114], ["cellular", "OBSERVATION", 118, 126], ["cholesterol content", "OBSERVATION", 127, 146]]], ["Briefly, fcwf-4 cells were grown on an 8-well Lab-Tek Chamber Slide (Thermo Fisher Scientific, USA).", [["fcwf-4 cells", "ANATOMY", 9, 21], ["fcwf-4 cells", "CELL", 9, 21], ["fcwf-4 cells", "CELL_LINE", 9, 21]]], ["Confluent fcwf-4 cell monolayers were cultured in medium containing 16 mM MbCD at 37\u00b0C for 30 min.", [["fcwf-4 cell monolayers", "ANATOMY", 10, 32], ["MbCD", "CHEMICAL", 74, 78], ["MbCD", "CHEMICAL", 74, 78], ["fcwf-4 cell monolayers", "CELL", 10, 32], ["MbCD", "SIMPLE_CHEMICAL", 74, 78], ["fcwf-4 cell monolayers", "CELL_LINE", 10, 32], ["Confluent fcwf-4 cell monolayers", "PROBLEM", 0, 32], ["4 cell monolayers", "OBSERVATION", 15, 32]]], ["After washing with PBS, cells were cultured in medium containing 0.5 mg of water-soluble cholesterol per ml at 37\u00b0C for 30 min.", [["cells", "ANATOMY", 24, 29], ["cholesterol", "CHEMICAL", 89, 100], ["cholesterol", "CHEMICAL", 89, 100], ["cells", "CELL", 24, 29], ["cholesterol", "SIMPLE_CHEMICAL", 89, 100], ["PBS", "TREATMENT", 19, 22], ["cells", "TREATMENT", 24, 29], ["water-soluble cholesterol", "TREATMENT", 75, 100]]], ["After fixing and staining, filipin-III-binding cells were analyzed using a Leica FW4000 fluorescence microscope (Germany).Cytotoxic effects of compoundsCell viability was measured using a WST-8 assay, as described previously [28] .", [["cells", "ANATOMY", 47, 52], ["Cell", "ANATOMY", 152, 156], ["filipin-III", "CHEMICAL", 27, 38], ["filipin-III", "SIMPLE_CHEMICAL", 27, 38], ["cells", "CELL", 47, 52], ["Cell", "CELL", 152, 156], ["filipin-III-binding cells", "CELL_LINE", 27, 52], ["staining", "TEST", 17, 25], ["filipin-III-binding cells", "TREATMENT", 27, 52], ["Cytotoxic effects of compounds", "PROBLEM", 122, 152], ["Cell viability", "TEST", 152, 166], ["a WST", "TEST", 186, 191], ["compounds", "OBSERVATION", 143, 152], ["viability", "OBSERVATION_MODIFIER", 157, 166]]], ["Briefly, fcwf-4 cells were seeded in 96-well plates.", [["fcwf-4 cells", "ANATOMY", 9, 21], ["fcwf-4 cells", "CELL", 9, 21], ["fcwf-4 cells", "CELL_LINE", 9, 21], ["fcwf-4 cells", "TREATMENT", 9, 21]]], ["MbCD or water-soluble cholesterol was added in triplicate to the wells.", [["MbCD", "CHEMICAL", 0, 4], ["cholesterol", "CHEMICAL", 22, 33], ["cholesterol", "CHEMICAL", 22, 33], ["MbCD", "SIMPLE_CHEMICAL", 0, 4], ["water-soluble", "SIMPLE_CHEMICAL", 8, 21], ["cholesterol", "SIMPLE_CHEMICAL", 22, 33], ["water-soluble cholesterol", "TREATMENT", 8, 33]]], ["After 48 hours, the culture supernatants were removed, WST-8 solution (WST-8 Cell Proliferation Assay Kit; Kishida Chemical Co., Ltd., Japan) was added, and the cells were returned to the incubator for 1 hour.", [["supernatants", "ANATOMY", 28, 40], ["Cell", "ANATOMY", 77, 81], ["cells", "ANATOMY", 161, 166], ["WST-8", "CHEMICAL", 55, 60], ["WST-8 Cell", "CELL", 71, 81], ["cells", "CELL", 161, 166], ["the culture supernatants", "TEST", 16, 40], ["WST", "TEST", 55, 58], ["WST", "TEST", 71, 74], ["Assay", "TEST", 96, 101], ["Kit", "TEST", 102, 105]]], ["The absorbance of formazan produced was measured at 450 nm using a 96-well spectrophotometric plate reader as described by the manufacturer.", [["formazan", "CHEMICAL", 18, 26], ["formazan", "CHEMICAL", 18, 26], ["formazan", "SIMPLE_CHEMICAL", 18, 26], ["a 96-well spectrophotometric plate", "TREATMENT", 65, 99], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["Cytotoxicity was calculated using the following formula: Cytotoxicity (%) = [(OD of untreated cells -compound-treated cells)/ (OD of compound-untreated cells)] 9 100.Effects of cellular cholesterol depletion on FCoV infection in fcwf-4 cellsThe method for the depletion of cholesterol from cells was modified from that described by Ren et al. [25] .", [["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 118, 123], ["cells", "ANATOMY", 152, 157], ["cellular", "ANATOMY", 177, 185], ["fcwf-4 cells", "ANATOMY", 229, 241], ["cells", "ANATOMY", 290, 295], ["cholesterol", "CHEMICAL", 186, 197], ["infection", "DISEASE", 216, 225], ["cholesterol", "CHEMICAL", 273, 284], ["cholesterol", "CHEMICAL", 186, 197], ["cholesterol", "CHEMICAL", 273, 284], ["cells", "CELL", 94, 99], ["cells", "CELL", 118, 123], ["cells", "CELL", 152, 157], ["cellular", "CELL", 177, 185], ["cholesterol", "SIMPLE_CHEMICAL", 186, 197], ["FCoV", "SIMPLE_CHEMICAL", 211, 215], ["fcwf-4 cells", "CELL", 229, 241], ["cholesterol", "SIMPLE_CHEMICAL", 273, 284], ["cells", "CELL", 290, 295], ["fcwf-4 cells", "CELL_LINE", 229, 241], ["Cytotoxicity", "TEST", 0, 12], ["Cytotoxicity", "TEST", 57, 69], ["untreated cells", "PROBLEM", 84, 99], ["compound-treated cells", "PROBLEM", 101, 123], ["compound-untreated cells", "PROBLEM", 133, 157], ["cellular cholesterol depletion", "PROBLEM", 177, 207], ["FCoV infection in fcwf", "PROBLEM", 211, 233], ["The method", "TREATMENT", 241, 251], ["the depletion of cholesterol from cells", "TREATMENT", 256, 295], ["cellular cholesterol depletion", "OBSERVATION", 177, 207], ["FCoV", "OBSERVATION_MODIFIER", 211, 215], ["infection", "OBSERVATION", 216, 225], ["4 cells", "OBSERVATION_MODIFIER", 234, 241]]], ["Briefly, confluent fcwf-4 cell monolayers were cultured in medium containing MbCD ranging from 0 to 16 mM in 24-well multi-plates at 37\u00b0C for 30 min.", [["fcwf-4 cell monolayers", "ANATOMY", 19, 41], ["fcwf-4 cell monolayers", "CELL", 19, 41], ["MbCD", "SIMPLE_CHEMICAL", 77, 81], ["confluent fcwf-4 cell monolayers", "CELL_LINE", 9, 41], ["confluent fcwf-4 cell monolayers", "PROBLEM", 9, 41], ["confluent", "OBSERVATION_MODIFIER", 9, 18], ["4 cell", "OBSERVATION_MODIFIER", 24, 30], ["monolayers", "OBSERVATION_MODIFIER", 31, 41]]], ["After washing with phosphate-buffered saline (PBS), the virus (multiplicity of infection [MOI], 0.01) was adsorbed into the cells at 37\u00b0C for 1 hour.", [["cells", "ANATOMY", 124, 129], ["phosphate", "CHEMICAL", 19, 28], ["infection", "DISEASE", 79, 88], ["phosphate", "CHEMICAL", 19, 28], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 19, 44], ["cells", "CELL", 124, 129], ["phosphate-buffered saline (PBS", "TREATMENT", 19, 49], ["the virus", "PROBLEM", 52, 61], ["infection", "PROBLEM", 79, 88], ["infection", "OBSERVATION", 79, 88]]], ["After washing, cells were cultured in maintenance medium with 1.5 % carboxymethyl cellulose (CMC-MEM).", [["cells", "ANATOMY", 15, 20], ["carboxymethyl cellulose", "CHEMICAL", 68, 91], ["CMC-MEM", "CHEMICAL", 93, 100], ["carboxymethyl", "CHEMICAL", 68, 81], ["cells", "CELL", 15, 20], ["carboxymethyl cellulose", "SIMPLE_CHEMICAL", 68, 91], ["cells", "TREATMENT", 15, 20], ["1.5 % carboxymethyl cellulose", "TREATMENT", 62, 91]]], ["Cell monolayers were incubated at 37\u00b0C for 48 hours, fixed, and stained with 1 % crystal violet solution containing 10 % buffered formalin, and the plaques were then counted.", [["Cell monolayers", "ANATOMY", 0, 15], ["plaques", "ANATOMY", 148, 155], ["formalin", "CHEMICAL", 130, 138], ["Cell monolayers", "CELL", 0, 15], ["formalin", "SIMPLE_CHEMICAL", 130, 138], ["plaques", "MULTI-TISSUE_STRUCTURE", 148, 155], ["Cell monolayers", "TEST", 0, 15], ["1 % crystal violet solution", "TREATMENT", 77, 104], ["the plaques", "PROBLEM", 144, 155], ["plaques", "OBSERVATION", 148, 155]]], ["The percentage of plaque decrease or increase was determined using the following formula: Percentage of the plaque number (%) = [(plaque number of compound-treated cells)/ (plaque number of untreated cells)] 9 100.Effects of cellular cholesterol replenishment on FCoV infection in fcwf-4 cellsThe method of replenishment of cholesterol-depleted cells was modified from that described by Ren et al. [25] .", [["plaque", "ANATOMY", 18, 24], ["plaque", "ANATOMY", 108, 114], ["plaque", "ANATOMY", 130, 136], ["cells", "ANATOMY", 164, 169], ["plaque", "ANATOMY", 173, 179], ["cells", "ANATOMY", 200, 205], ["cellular", "ANATOMY", 225, 233], ["fcwf-4 cells", "ANATOMY", 281, 293], ["cells", "ANATOMY", 345, 350], ["cholesterol", "CHEMICAL", 234, 245], ["infection", "DISEASE", 268, 277], ["cholesterol", "CHEMICAL", 324, 335], ["cholesterol", "CHEMICAL", 234, 245], ["cholesterol", "CHEMICAL", 324, 335], ["plaque", "PATHOLOGICAL_FORMATION", 18, 24], ["cells", "CELL", 164, 169], ["cells", "CELL", 200, 205], ["cellular", "CELL", 225, 233], ["cholesterol", "SIMPLE_CHEMICAL", 234, 245], ["FCoV", "SIMPLE_CHEMICAL", 263, 267], ["fcwf-4 cells", "CELL", 281, 293], ["cholesterol", "SIMPLE_CHEMICAL", 324, 335], ["cells", "CELL", 345, 350], ["fcwf-4 cells", "CELL_LINE", 281, 293], ["cholesterol-depleted cells", "CELL_TYPE", 324, 350], ["plaque", "PROBLEM", 18, 24], ["Percentage", "TEST", 90, 100], ["the plaque number", "TEST", 104, 121], ["compound-treated cells", "PROBLEM", 147, 169], ["cellular cholesterol replenishment", "PROBLEM", 225, 259], ["FCoV infection", "PROBLEM", 263, 277], ["replenishment of cholesterol-depleted cells", "TREATMENT", 307, 350], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["plaque", "OBSERVATION", 18, 24], ["decrease", "OBSERVATION_MODIFIER", 25, 33], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["plaque", "OBSERVATION", 108, 114], ["cellular cholesterol", "OBSERVATION", 225, 245], ["replenishment", "OBSERVATION_MODIFIER", 246, 259], ["FCoV infection", "OBSERVATION", 263, 277]]], ["Briefly, confluent fcwf-4 cell monolayers were cultured in medium containing 16 mM MbCD in 24-well multi-plates at 37\u00b0C for 30 min.", [["fcwf-4 cell monolayers", "ANATOMY", 19, 41], ["MbCD", "CHEMICAL", 83, 87], ["MbCD", "CHEMICAL", 83, 87], ["fcwf-4 cell monolayers", "CELL", 19, 41], ["MbCD", "SIMPLE_CHEMICAL", 83, 87], ["confluent fcwf-4 cell monolayers", "CELL_LINE", 9, 41], ["confluent fcwf-4 cell monolayers", "PROBLEM", 9, 41], ["mM MbCD", "TEST", 80, 87], ["confluent", "OBSERVATION_MODIFIER", 9, 18], ["4 cell", "OBSERVATION_MODIFIER", 24, 30], ["monolayers", "OBSERVATION_MODIFIER", 31, 41]]], ["After washing with PBS, cells were cultured in medium containing water-soluble cholesterol ranging from 0 to 2.5 mg/ml at 37\u00b0C for 30 min.", [["cells", "ANATOMY", 24, 29], ["cholesterol", "CHEMICAL", 79, 90], ["cholesterol", "CHEMICAL", 79, 90], ["cells", "CELL", 24, 29], ["cholesterol", "SIMPLE_CHEMICAL", 79, 90], ["PBS", "TREATMENT", 19, 22], ["cells", "TREATMENT", 24, 29], ["water-soluble cholesterol", "TREATMENT", 65, 90]]], ["Cells were washed and the virus (MOI, 0.01) was adsorbed onto the cells at 37\u00b0C for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 66, 71], ["Cells", "CELL", 0, 5], ["cells", "CELL", 66, 71], ["Cells", "TEST", 0, 5], ["the virus (MOI", "TREATMENT", 22, 36]]], ["After washing, cells were cultured in CMC-MEM or medium without carboxymethyl cellulose (MEM).", [["cells", "ANATOMY", 15, 20], ["CMC-MEM", "CHEMICAL", 38, 45], ["carboxymethyl cellulose", "CHEMICAL", 64, 87], ["MEM", "CHEMICAL", 89, 92], ["carboxymethyl", "CHEMICAL", 64, 77], ["cells", "CELL", 15, 20], ["carboxymethyl cellulose", "SIMPLE_CHEMICAL", 64, 87], ["cells", "TEST", 15, 20], ["carboxymethyl cellulose", "TREATMENT", 64, 87]]], ["In the case of cultured in CMC-MEM, the cell monolayers were incubated at 37\u00b0C for 48 hours, fixed, and stained with 1 % crystal violet solution containing 10 % buffered formalin, and the resulting plaques were then counted.", [["cell monolayers", "ANATOMY", 40, 55], ["plaques", "ANATOMY", 198, 205], ["formalin", "CHEMICAL", 170, 178], ["CMC-MEM", "CELL", 27, 34], ["cell monolayers", "CELL", 40, 55], ["formalin", "SIMPLE_CHEMICAL", 170, 178], ["plaques", "PATHOLOGICAL_FORMATION", 198, 205], ["the cell monolayers", "TEST", 36, 55], ["1 % crystal violet solution", "TREATMENT", 117, 144], ["the resulting plaques", "PROBLEM", 184, 205], ["plaques", "OBSERVATION", 198, 205]]], ["The percentage of plaques (%) was determined by the method described above.", [["plaques", "ANATOMY", 18, 25], ["plaques", "PATHOLOGICAL_FORMATION", 18, 25], ["plaques", "PROBLEM", 18, 25], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["plaques", "OBSERVATION", 18, 25]]], ["When MEM was used, the culture supernatants were collected 48 hours postinfection, and virus titers were determined by the TCID 50 assay.Effects of cellular cholesterol replenishment on FCoV infection in fcwf-4 cellsImmunofluorescence assay fcwf-4 cells were grown on an 8-well Lab-Tek chamber slide (Thermo Fisher Scientific, USA).", [["supernatants", "ANATOMY", 31, 43], ["cellular", "ANATOMY", 148, 156], ["fcwf-4 cells", "ANATOMY", 204, 216], ["fcwf-4 cells", "ANATOMY", 241, 253], ["MEM", "CHEMICAL", 5, 8], ["cholesterol", "CHEMICAL", 157, 168], ["infection", "DISEASE", 191, 200], ["cholesterol", "CHEMICAL", 157, 168], ["cellular", "CELL", 148, 156], ["cholesterol", "SIMPLE_CHEMICAL", 157, 168], ["FCoV", "SIMPLE_CHEMICAL", 186, 190], ["fcwf-4 cells", "CELL", 204, 216], ["fcwf-4 cells", "CELL", 241, 253], ["fcwf-4 cells", "CELL_LINE", 204, 216], ["fcwf-4 cells", "CELL_LINE", 241, 253], ["the culture supernatants", "TEST", 19, 43], ["virus titers", "TEST", 87, 99], ["cellular cholesterol replenishment", "TEST", 148, 182], ["FCoV infection", "PROBLEM", 186, 200], ["fcwf", "TEST", 204, 208], ["Immunofluorescence assay fcwf", "TEST", 216, 245], ["cellular cholesterol", "OBSERVATION", 148, 168], ["FCoV infection", "OBSERVATION", 186, 200]]], ["Confluent fcwf-4 cell monolayers were cultured in medium containing 16 mM of MbCD at 37\u00b0C for 30 min.", [["fcwf-4 cell monolayers", "ANATOMY", 10, 32], ["MbCD", "CHEMICAL", 77, 81], ["fcwf-4 cell monolayers", "CELL", 10, 32], ["MbCD", "SIMPLE_CHEMICAL", 77, 81], ["fcwf-4 cell monolayers", "CELL_LINE", 10, 32], ["Confluent fcwf-4 cell monolayers", "PROBLEM", 0, 32], ["4 cell monolayers", "OBSERVATION", 15, 32]]], ["After washing with PBS, cells were cultured in medium containing 0.5 mg of water-soluble cholesterol per ml at 37\u00b0C for 30 min.", [["cells", "ANATOMY", 24, 29], ["cholesterol", "CHEMICAL", 89, 100], ["cholesterol", "CHEMICAL", 89, 100], ["cells", "CELL", 24, 29], ["cholesterol", "SIMPLE_CHEMICAL", 89, 100], ["PBS", "TREATMENT", 19, 22], ["cells", "TREATMENT", 24, 29], ["water-soluble cholesterol", "TREATMENT", 75, 100]]], ["Cells were washed, and the virus (MOI, 0.01) was adsorbed into the cells at 37\u00b0C for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 67, 72], ["Cells", "CELL", 0, 5], ["cells", "CELL", 67, 72], ["Cells", "TEST", 0, 5], ["the virus (MOI", "TREATMENT", 23, 37]]], ["After washing, cells were cultured in MEM.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["cells", "PROBLEM", 15, 20]]], ["The cell monolayers were incubated at 37\u00b0C. After 12 hours, N protein levels were determined by an immunofluorescence assay (IFA) as described previously [11] .Effects on infectivity of depletion and replenishment of cholesterol from the virusThe method for depletion and replenishment of cholesterol from the virus was modified from that described by Pratelli and Colao [23] .", [["cell monolayers", "ANATOMY", 4, 19], ["cholesterol", "CHEMICAL", 217, 228], ["cholesterol", "CHEMICAL", 289, 300], ["cholesterol", "CHEMICAL", 217, 228], ["cholesterol", "CHEMICAL", 289, 300], ["cell monolayers", "CELL", 4, 19], ["cholesterol", "SIMPLE_CHEMICAL", 217, 228], ["cholesterol", "SIMPLE_CHEMICAL", 289, 300], ["The cell monolayers", "TEST", 0, 19], ["N protein levels", "TEST", 60, 76], ["an immunofluorescence assay", "TEST", 96, 123], ["infectivity of depletion", "PROBLEM", 171, 195], ["replenishment of cholesterol", "TREATMENT", 200, 228], ["the virus", "PROBLEM", 234, 243], ["depletion", "PROBLEM", 258, 267], ["replenishment of cholesterol", "TREATMENT", 272, 300], ["the virus", "PROBLEM", 306, 315], ["cell monolayers", "OBSERVATION", 4, 19], ["depletion", "OBSERVATION", 186, 195]]], ["Briefly, the virus (MOI, 0.1) was incubated with medium containing 16 mM MbCD at 37\u00b0C for 1 hour.", [["MbCD", "CHEMICAL", 73, 77], ["MbCD", "CHEMICAL", 73, 77], ["MbCD", "SIMPLE_CHEMICAL", 73, 77]]], ["In order to specifically determine whether cholesterol depletion by MbCD affected the number of plaques caused by FCoV, MbCD-treated FCoV was adsorbed onto the cells at 37\u00b0C for 1 hour.", [["plaques", "ANATOMY", 96, 103], ["cells", "ANATOMY", 160, 165], ["cholesterol", "CHEMICAL", 43, 54], ["MbCD", "CHEMICAL", 68, 72], ["plaques", "DISEASE", 96, 103], ["FCoV", "CHEMICAL", 114, 118], ["MbCD", "CHEMICAL", 120, 124], ["FCoV", "CHEMICAL", 133, 137], ["cholesterol", "CHEMICAL", 43, 54], ["MbCD", "CHEMICAL", 68, 72], ["MbCD", "CHEMICAL", 120, 124], ["cholesterol", "SIMPLE_CHEMICAL", 43, 54], ["MbCD", "SIMPLE_CHEMICAL", 68, 72], ["plaques", "PATHOLOGICAL_FORMATION", 96, 103], ["FCoV", "SIMPLE_CHEMICAL", 114, 118], ["MbCD", "SIMPLE_CHEMICAL", 120, 124], ["FCoV", "SIMPLE_CHEMICAL", 133, 137], ["cells", "CELL", 160, 165], ["MbCD", "PROTEIN", 120, 124], ["FCoV", "SPECIES", 114, 118], ["cholesterol depletion", "PROBLEM", 43, 64], ["MbCD", "PROBLEM", 68, 72], ["plaques", "PROBLEM", 96, 103], ["FCoV", "PROBLEM", 114, 118], ["MbCD", "PROBLEM", 120, 124], ["FCoV", "PROBLEM", 133, 137], ["cholesterol depletion", "OBSERVATION", 43, 64], ["plaques", "OBSERVATION", 96, 103], ["FCoV", "OBSERVATION", 114, 118]]], ["MbCD-treated viral suspensions were diluted 1:9 in medium before infection to avoid the carry-over effects of MbCD on fcwf-4 cells.", [["fcwf-4 cells", "ANATOMY", 118, 130], ["MbCD", "CHEMICAL", 0, 4], ["infection", "DISEASE", 65, 74], ["MbCD", "CHEMICAL", 110, 114], ["MbCD", "SIMPLE_CHEMICAL", 0, 4], ["MbCD", "SIMPLE_CHEMICAL", 110, 114], ["fcwf-4 cells", "CELL", 118, 130], ["fcwf-4 cells", "CELL_LINE", 118, 130], ["MbCD", "PROBLEM", 0, 4], ["viral suspensions", "TREATMENT", 13, 30], ["infection", "PROBLEM", 65, 74], ["MbCD", "PROBLEM", 110, 114]]], ["After washing, cells were cultured in CMC-MEM or MEM.", [["cells", "ANATOMY", 15, 20], ["MEM", "CHEMICAL", 49, 52], ["cells", "CELL", 15, 20]]], ["In order to analyze infection efficiency after viral cholesterol replenishment, the virus (MOI, 0.1) was incubated with medium containing 16 mM MbCD at 37\u00b0C for 30 min.", [["infection", "DISEASE", 20, 29], ["cholesterol", "CHEMICAL", 53, 64], ["MbCD", "CHEMICAL", 144, 148], ["cholesterol", "CHEMICAL", 53, 64], ["MbCD", "CHEMICAL", 144, 148], ["cholesterol", "SIMPLE_CHEMICAL", 53, 64], ["MbCD", "SIMPLE_CHEMICAL", 144, 148], ["infection efficiency", "PROBLEM", 20, 40], ["viral cholesterol replenishment", "TREATMENT", 47, 78], ["the virus (MOI", "TREATMENT", 80, 94]]], ["MbCD-treated viral suspensions were then incubated with medium containing water-soluble cholesterol ranging from 0 to 2.5 mg/ml at 37\u00b0C for 1 hour.", [["MbCD", "CHEMICAL", 0, 4], ["cholesterol", "CHEMICAL", 88, 99], ["cholesterol", "CHEMICAL", 88, 99], ["MbCD", "SIMPLE_CHEMICAL", 0, 4], ["cholesterol", "SIMPLE_CHEMICAL", 88, 99], ["MbCD", "PROBLEM", 0, 4], ["viral suspensions", "TREATMENT", 13, 30], ["medium containing water-soluble cholesterol", "TREATMENT", 56, 99]]], ["Cholesterol-and MbCD-treated FCoV were adsorbed onto cells at 37\u00b0C for 1 hour in order to specifically determine whether cholesterol replenishment affected the number of plaques caused by FCoV.", [["FCoV", "ANATOMY", 29, 33], ["cells", "ANATOMY", 53, 58], ["plaques", "ANATOMY", 170, 177], ["Cholesterol", "CHEMICAL", 0, 11], ["MbCD", "CHEMICAL", 16, 20], ["cholesterol", "CHEMICAL", 121, 132], ["plaques", "DISEASE", 170, 177], ["FCoV", "CHEMICAL", 188, 192], ["Cholesterol", "CHEMICAL", 0, 11], ["MbCD", "CHEMICAL", 16, 20], ["cholesterol", "CHEMICAL", 121, 132], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["MbCD", "SIMPLE_CHEMICAL", 16, 20], ["FCoV", "SIMPLE_CHEMICAL", 29, 33], ["cells", "CELL", 53, 58], ["cholesterol", "SIMPLE_CHEMICAL", 121, 132], ["plaques", "PATHOLOGICAL_FORMATION", 170, 177], ["FCoV", "PROTEIN", 188, 192], ["Cholesterol", "TEST", 0, 11], ["MbCD", "PROBLEM", 16, 20], ["FCoV", "PROBLEM", 29, 33], ["cholesterol replenishment", "PROBLEM", 121, 146], ["plaques", "PROBLEM", 170, 177], ["plaques", "OBSERVATION", 170, 177], ["FCoV", "OBSERVATION", 188, 192]]], ["In an attempt to avoid the carry-over effects of cholesterol and MbCD on fcwf-4 cells, cholesterol-and MbCD-treated viral suspensions were diluted 1:9 in medium before infection.", [["fcwf-4 cells", "ANATOMY", 73, 85], ["cholesterol", "CHEMICAL", 49, 60], ["MbCD", "CHEMICAL", 65, 69], ["cholesterol", "CHEMICAL", 87, 98], ["MbCD", "CHEMICAL", 103, 107], ["infection", "DISEASE", 168, 177], ["cholesterol", "CHEMICAL", 49, 60], ["MbCD", "CHEMICAL", 65, 69], ["cholesterol", "CHEMICAL", 87, 98], ["MbCD", "CHEMICAL", 103, 107], ["cholesterol", "SIMPLE_CHEMICAL", 49, 60], ["MbCD", "SIMPLE_CHEMICAL", 65, 69], ["fcwf-4 cells", "CELL", 73, 85], ["cholesterol", "SIMPLE_CHEMICAL", 87, 98], ["MbCD", "SIMPLE_CHEMICAL", 103, 107], ["fcwf-4 cells", "CELL_LINE", 73, 85], ["cholesterol", "TEST", 49, 60], ["MbCD", "PROBLEM", 65, 69], ["fcwf", "TEST", 73, 77], ["cholesterol", "TEST", 87, 98], ["MbCD", "TREATMENT", 103, 107], ["viral suspensions", "TREATMENT", 116, 133], ["infection", "PROBLEM", 168, 177], ["infection", "OBSERVATION", 168, 177]]], ["Cells were washed, and the virus was adsorbed onto the cells at 37\u00b0C for 1 hour.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 55, 60], ["Cells", "CELL", 0, 5], ["cells", "CELL", 55, 60], ["Cells", "TEST", 0, 5], ["the virus", "PROBLEM", 23, 32]]], ["After washing, cells were cultured in CMC-MEM at 37\u00b0C for 48 hours.", [["cells", "ANATOMY", 15, 20], ["CMC", "CHEMICAL", 38, 41], ["cells", "CELL", 15, 20], ["cells", "TREATMENT", 15, 20]]], ["The cells were fixed and stained with 1 % crystal violet solution containing 10 % buffered formalin, and the resulting plaques were counted.", [["cells", "ANATOMY", 4, 9], ["plaques", "ANATOMY", 119, 126], ["formalin", "CHEMICAL", 91, 99], ["cells", "CELL", 4, 9], ["formalin", "SIMPLE_CHEMICAL", 91, 99], ["plaques", "PATHOLOGICAL_FORMATION", 119, 126], ["1 % crystal violet solution", "TREATMENT", 38, 65], ["10 % buffered formalin", "TREATMENT", 77, 99], ["the resulting plaques", "PROBLEM", 105, 126], ["plaques", "OBSERVATION", 119, 126]]], ["The number of plaques, expressed as a percentage of the control, was measured by the method described above.Statistical analysisData from only two groups were analyzed by Student's ttest (Welch's t-test or Bartlett's test), and multiple groups were analyzed by one-way ANOVA followed by Tukey's test.The cytotoxic effects of MbCD and exogenous cholesterolThe cytotoxic effects of MbCD and exogenous cholesterol in fcwf-4 cells are shown in Tables 1 and 2.", [["plaques", "ANATOMY", 14, 21], ["fcwf-4 cells", "ANATOMY", 414, 426], ["plaques", "DISEASE", 14, 21], ["MbCD", "CHEMICAL", 325, 329], ["cholesterol", "CHEMICAL", 344, 355], ["MbCD", "CHEMICAL", 380, 384], ["cholesterol", "CHEMICAL", 399, 410], ["MbCD", "CHEMICAL", 325, 329], ["cholesterol", "CHEMICAL", 344, 355], ["MbCD", "CHEMICAL", 380, 384], ["cholesterol", "CHEMICAL", 399, 410], ["plaques", "PATHOLOGICAL_FORMATION", 14, 21], ["MbCD", "SIMPLE_CHEMICAL", 325, 329], ["cholesterol", "SIMPLE_CHEMICAL", 344, 355], ["MbCD", "SIMPLE_CHEMICAL", 380, 384], ["cholesterol", "SIMPLE_CHEMICAL", 399, 410], ["fcwf-4 cells", "CELL", 414, 426], ["fcwf-4 cells", "CELL_LINE", 414, 426], ["plaques", "PROBLEM", 14, 21], ["Statistical analysisData", "TEST", 108, 132], ["Student's ttest", "TEST", 171, 186], ["Welch's t-test", "TEST", 188, 202], ["Bartlett's test", "TEST", 206, 221], ["Tukey's test", "TEST", 287, 299], ["MbCD", "PROBLEM", 325, 329], ["exogenous cholesterol", "TEST", 334, 355], ["MbCD", "PROBLEM", 380, 384], ["exogenous cholesterol in fcwf", "TEST", 389, 418], ["number", "OBSERVATION_MODIFIER", 4, 10], ["plaques", "OBSERVATION", 14, 21], ["cytotoxic effects", "OBSERVATION", 304, 321], ["exogenous cholesterol", "OBSERVATION", 334, 355], ["cytotoxic effects", "OBSERVATION", 359, 376], ["exogenous cholesterol", "OBSERVATION", 389, 410]]], ["Exogenous cholesterol slightly exhibited cytotoxicity at 5 mg/ml.Effects of MbCD and exogenous cholesterol on cellular membranesWe investigated changes in the cellular cholesterol content of fcwf-4 cells treated with MbCD and water-soluble cholesterol (exogenous cholesterol) using filipin III as a fluorescent stain for cholesterol.", [["cellular membranes", "ANATOMY", 110, 128], ["cellular", "ANATOMY", 159, 167], ["fcwf-4 cells", "ANATOMY", 191, 203], ["cholesterol", "CHEMICAL", 10, 21], ["MbCD", "CHEMICAL", 76, 80], ["cholesterol", "CHEMICAL", 95, 106], ["cholesterol", "CHEMICAL", 168, 179], ["MbCD", "CHEMICAL", 217, 221], ["cholesterol", "CHEMICAL", 240, 251], ["cholesterol", "CHEMICAL", 263, 274], ["filipin III", "CHEMICAL", 282, 293], ["cholesterol", "CHEMICAL", 321, 332], ["cholesterol", "CHEMICAL", 10, 21], ["MbCD", "CHEMICAL", 76, 80], ["cholesterol", "CHEMICAL", 95, 106], ["cholesterol", "CHEMICAL", 168, 179], ["MbCD", "CHEMICAL", 217, 221], ["cholesterol", "CHEMICAL", 240, 251], ["cholesterol", "CHEMICAL", 263, 274], ["filipin III", "CHEMICAL", 282, 293], ["cholesterol", "CHEMICAL", 321, 332], ["cholesterol", "SIMPLE_CHEMICAL", 10, 21], ["MbCD", "SIMPLE_CHEMICAL", 76, 80], ["cholesterol", "SIMPLE_CHEMICAL", 95, 106], ["cellular membranes", "CELLULAR_COMPONENT", 110, 128], ["cellular", "CELL", 159, 167], ["cholesterol", "SIMPLE_CHEMICAL", 168, 179], ["fcwf-4 cells", "CELL", 191, 203], ["MbCD", "SIMPLE_CHEMICAL", 217, 221], ["cholesterol", "SIMPLE_CHEMICAL", 240, 251], ["cholesterol", "SIMPLE_CHEMICAL", 263, 274], ["filipin", "SIMPLE_CHEMICAL", 282, 289], ["cholesterol", "SIMPLE_CHEMICAL", 321, 332], ["fcwf-4 cells", "CELL_LINE", 191, 203], ["filipin III", "PROTEIN", 282, 293], ["Exogenous cholesterol slightly exhibited cytotoxicity", "PROBLEM", 0, 53], ["MbCD", "PROBLEM", 76, 80], ["exogenous cholesterol on cellular membranes", "PROBLEM", 85, 128], ["MbCD", "TREATMENT", 217, 221], ["water-soluble cholesterol (exogenous cholesterol", "TREATMENT", 226, 274], ["filipin III", "TREATMENT", 282, 293], ["a fluorescent stain", "TEST", 297, 316], ["cholesterol", "TEST", 321, 332], ["cholesterol", "OBSERVATION_MODIFIER", 10, 21], ["slightly exhibited", "OBSERVATION_MODIFIER", 22, 40], ["cytotoxicity", "OBSERVATION", 41, 53], ["exogenous cholesterol", "OBSERVATION", 85, 106], ["cellular membranes", "OBSERVATION", 110, 128], ["cellular cholesterol content", "OBSERVATION", 159, 187]]], ["Cellular cholesterol levels specifically decreased in fcwf-4 cells treated with 16 mM MbCD ( Fig. 1A and B) and slightly decreased in cells treated with 4 mM MbCD (data not shown).", [["Cellular", "ANATOMY", 0, 8], ["fcwf-4 cells", "ANATOMY", 54, 66], ["cells", "ANATOMY", 134, 139], ["cholesterol", "CHEMICAL", 9, 20], ["cholesterol", "CHEMICAL", 9, 20], ["MbCD", "CHEMICAL", 86, 90], ["MbCD", "CHEMICAL", 158, 162], ["Cellular", "CELL", 0, 8], ["cholesterol", "SIMPLE_CHEMICAL", 9, 20], ["fcwf-4 cells", "CELL", 54, 66], ["MbCD", "SIMPLE_CHEMICAL", 86, 90], ["B", "GENE_OR_GENE_PRODUCT", 105, 106], ["cells", "CELL", 134, 139], ["MbCD", "SIMPLE_CHEMICAL", 158, 162], ["fcwf-4 cells", "CELL_LINE", 54, 66], ["Cellular cholesterol levels", "TEST", 0, 27], ["16 mM MbCD ( Fig", "TREATMENT", 80, 96], ["slightly decreased in cells", "PROBLEM", 112, 139], ["4 mM MbCD", "TREATMENT", 153, 162], ["cholesterol", "OBSERVATION", 9, 20], ["decreased", "OBSERVATION_MODIFIER", 41, 50], ["slightly", "OBSERVATION_MODIFIER", 112, 120], ["decreased", "OBSERVATION_MODIFIER", 121, 130]]], ["The cellular cholesterol level in fcwf-4 cells treated with 16 mM MbCD followed by the addition of 0.5 mg/ml of exogenous cholesterol returned to a level similar to that in untreated-fcwf-4 cells (Fig.1A and C) .Efficiency of depletion and replenishment of cellular cholesterol on FCoVIn order to confirm the effects of the cellular depletion of cholesterol on FCoV infection, fcwf-4 cells were pretreated with MbCD ranging from 0 mM to 16 mM, followed by virus inoculation.", [["cellular", "ANATOMY", 4, 12], ["fcwf-4 cells", "ANATOMY", 34, 46], ["fcwf-4 cells", "ANATOMY", 183, 195], ["cellular", "ANATOMY", 257, 265], ["cellular", "ANATOMY", 324, 332], ["fcwf-4 cells", "ANATOMY", 377, 389], ["cholesterol", "CHEMICAL", 13, 24], ["MbCD", "CHEMICAL", 66, 70], ["cholesterol", "CHEMICAL", 122, 133], ["cholesterol", "CHEMICAL", 266, 277], ["cholesterol", "CHEMICAL", 346, 357], ["infection", "DISEASE", 366, 375], ["MbCD", "CHEMICAL", 411, 415], ["cholesterol", "CHEMICAL", 13, 24], ["MbCD", "CHEMICAL", 66, 70], ["cholesterol", "CHEMICAL", 122, 133], ["cholesterol", "CHEMICAL", 266, 277], ["cholesterol", "CHEMICAL", 346, 357], ["MbCD", "CHEMICAL", 411, 415], ["cellular", "CELL", 4, 12], ["cholesterol", "SIMPLE_CHEMICAL", 13, 24], ["fcwf-4 cells", "CELL", 34, 46], ["cholesterol", "SIMPLE_CHEMICAL", 122, 133], ["fcwf-4 cells", "CELL", 183, 195], ["C", "CELL", 208, 209], ["cellular", "CELL", 257, 265], ["cholesterol", "SIMPLE_CHEMICAL", 266, 277], ["cellular", "CELL", 324, 332], ["cholesterol", "SIMPLE_CHEMICAL", 346, 357], ["FCoV", "SIMPLE_CHEMICAL", 361, 365], ["fcwf-4 cells", "CELL", 377, 389], ["MbCD", "SIMPLE_CHEMICAL", 411, 415], ["fcwf-4 cells", "CELL_LINE", 34, 46], ["untreated-fcwf-4 cells", "CELL_LINE", 173, 195], ["fcwf-4 cells", "CELL_LINE", 377, 389], ["The cellular cholesterol level", "TEST", 0, 30], ["fcwf", "TEST", 34, 38], ["16 mM MbCD", "TREATMENT", 60, 70], ["exogenous cholesterol", "TEST", 112, 133], ["Fig", "TEST", 197, 200], ["depletion", "PROBLEM", 226, 235], ["cellular cholesterol", "TREATMENT", 257, 277], ["FCoVIn order", "TREATMENT", 281, 293], ["the cellular depletion of cholesterol", "PROBLEM", 320, 357], ["FCoV infection", "PROBLEM", 361, 375], ["MbCD", "TREATMENT", 411, 415], ["virus inoculation", "PROBLEM", 456, 473], ["cellular cholesterol", "OBSERVATION", 4, 24], ["depletion", "OBSERVATION", 226, 235], ["cellular cholesterol", "OBSERVATION", 257, 277], ["cellular depletion", "OBSERVATION", 324, 342], ["cholesterol", "OBSERVATION_MODIFIER", 346, 357], ["FCoV infection", "OBSERVATION", 361, 375]]], ["The number of plaques caused by FCoV-I KU-2 was reduced by MbCD treatment in a dose-dependent manner (Fig. 2) .", [["plaques", "ANATOMY", 14, 21], ["plaques", "DISEASE", 14, 21], ["MbCD", "CHEMICAL", 59, 63], ["MbCD", "CHEMICAL", 59, 63], ["plaques", "PATHOLOGICAL_FORMATION", 14, 21], ["FCoV-I KU-2", "GENE_OR_GENE_PRODUCT", 32, 43], ["MbCD", "SIMPLE_CHEMICAL", 59, 63], ["plaques", "PROBLEM", 14, 21], ["FCoV", "TEST", 32, 36], ["MbCD treatment", "TREATMENT", 59, 73], ["plaques", "OBSERVATION", 14, 21], ["FCoV", "OBSERVATION", 32, 36]]], ["The number of plaques caused by FCoV-II 79-1146 was reduced in cells treated with 16 mM MbCD but did not show a significant difference between treatment and control (0 mM MbCD).", [["plaques", "ANATOMY", 14, 21], ["cells", "ANATOMY", 63, 68], ["plaques", "DISEASE", 14, 21], ["FCoV-II 79-1146", "CHEMICAL", 32, 47], ["MbCD", "CHEMICAL", 88, 92], ["MbCD", "CHEMICAL", 171, 175], ["plaques", "PATHOLOGICAL_FORMATION", 14, 21], ["cells", "CELL", 63, 68], ["MbCD", "SIMPLE_CHEMICAL", 88, 92], ["plaques", "PROBLEM", 14, 21], ["FCoV", "TEST", 32, 36], ["16 mM MbCD", "TREATMENT", 82, 92], ["treatment and control (0 mM MbCD)", "TREATMENT", 143, 176], ["plaques", "OBSERVATION", 14, 21], ["FCoV", "OBSERVATION", 32, 36], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["difference", "OBSERVATION", 124, 134]]], ["In contrast, the number of plaques caused by VSV was not affected by pretreatment with MbCD.", [["plaques", "ANATOMY", 27, 34], ["plaques", "DISEASE", 27, 34], ["MbCD", "CHEMICAL", 87, 91], ["MbCD", "CHEMICAL", 87, 91], ["plaques", "PATHOLOGICAL_FORMATION", 27, 34], ["VSV", "ORGANISM", 45, 48], ["MbCD", "SIMPLE_CHEMICAL", 87, 91], ["VSV", "SPECIES", 45, 48], ["plaques", "PROBLEM", 27, 34], ["VSV", "PROBLEM", 45, 48], ["MbCD", "PROBLEM", 87, 91], ["plaques", "OBSERVATION", 27, 34], ["VSV", "OBSERVATION", 45, 48]]], ["Cholesterol-depleted fcwf-4 cells were replenished by addition of exogenous cholesterol before virus inoculation in order to determine whether cellular cholesterol is important for FCoV-I infection.", [["fcwf-4 cells", "ANATOMY", 21, 33], ["cellular", "ANATOMY", 143, 151], ["Cholesterol", "CHEMICAL", 0, 11], ["cholesterol", "CHEMICAL", 76, 87], ["cholesterol", "CHEMICAL", 152, 163], ["infection", "DISEASE", 188, 197], ["Cholesterol", "CHEMICAL", 0, 11], ["cholesterol", "CHEMICAL", 76, 87], ["cholesterol", "CHEMICAL", 152, 163], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["fcwf-4 cells", "CELL", 21, 33], ["cholesterol", "SIMPLE_CHEMICAL", 76, 87], ["cellular", "CELL", 143, 151], ["cholesterol", "SIMPLE_CHEMICAL", 152, 163], ["FCoV-I", "GENE_OR_GENE_PRODUCT", 181, 187], ["fcwf-4 cells", "CELL_LINE", 21, 33], ["FCoV-I", "SPECIES", 181, 187], ["Cholesterol", "TEST", 0, 11], ["depleted fcwf", "PROBLEM", 12, 25], ["exogenous cholesterol", "TREATMENT", 66, 87], ["virus inoculation", "TREATMENT", 95, 112], ["cellular cholesterol", "TEST", 143, 163], ["FCoV", "PROBLEM", 181, 185], ["I infection", "PROBLEM", 186, 197], ["depleted", "OBSERVATION", 12, 20], ["infection", "OBSERVATION", 188, 197]]], ["The number of plaques caused by FCoV-I KU-2 was increased by treatment with exogenous cholesterol in a dose-dependent manner (Fig. 3) .", [["plaques", "ANATOMY", 14, 21], ["plaques", "DISEASE", 14, 21], ["cholesterol", "CHEMICAL", 86, 97], ["cholesterol", "CHEMICAL", 86, 97], ["FCoV-I KU-2", "GENE_OR_GENE_PRODUCT", 32, 43], ["cholesterol", "SIMPLE_CHEMICAL", 86, 97], ["plaques", "PROBLEM", 14, 21], ["FCoV", "TEST", 32, 36], ["exogenous cholesterol", "TREATMENT", 76, 97], ["number", "OBSERVATION_MODIFIER", 4, 10], ["plaques", "OBSERVATION", 14, 21], ["FCoV", "OBSERVATION", 32, 36]]], ["In contrast, the number of plaques caused by FCoV-II 79-1146 increased slightly, but VSV was not affected by replenishment with exogenous cholesterol.Efficiency of depletion and replenishment of cellular cholesterol on FCoVThe influence of cellular cholesterol on the replication of other type I FCoVs was investigated.", [["plaques", "ANATOMY", 27, 34], ["cellular", "ANATOMY", 195, 203], ["cellular", "ANATOMY", 240, 248], ["plaques", "DISEASE", 27, 34], ["FCoV-II 79-1146", "CHEMICAL", 45, 60], ["cholesterol", "CHEMICAL", 138, 149], ["cholesterol", "CHEMICAL", 204, 215], ["cholesterol", "CHEMICAL", 249, 260], ["cholesterol", "CHEMICAL", 138, 149], ["cholesterol", "CHEMICAL", 204, 215], ["cholesterol", "CHEMICAL", 249, 260], ["plaques", "PATHOLOGICAL_FORMATION", 27, 34], ["FCoV-II 79-1146", "GENE_OR_GENE_PRODUCT", 45, 60], ["VSV", "ORGANISM", 85, 88], ["cholesterol", "SIMPLE_CHEMICAL", 138, 149], ["cellular", "CELL", 195, 203], ["cholesterol", "SIMPLE_CHEMICAL", 204, 215], ["cellular", "CELL", 240, 248], ["cholesterol", "SIMPLE_CHEMICAL", 249, 260], ["type I FCoVs", "GENE_OR_GENE_PRODUCT", 289, 301], ["type I FCoVs", "PROTEIN", 289, 301], ["VSV", "SPECIES", 85, 88], ["plaques", "PROBLEM", 27, 34], ["FCoV", "TEST", 45, 49], ["VSV", "TEST", 85, 88], ["Efficiency of depletion", "PROBLEM", 150, 173], ["replenishment of cellular cholesterol", "TREATMENT", 178, 215], ["cellular cholesterol", "TREATMENT", 240, 260], ["other type I FCoVs", "TREATMENT", 283, 301], ["plaques", "OBSERVATION", 27, 34], ["FCoV", "OBSERVATION", 45, 49], ["increased", "OBSERVATION_MODIFIER", 61, 70], ["slightly", "OBSERVATION_MODIFIER", 71, 79], ["exogenous cholesterol", "OBSERVATION", 128, 149], ["depletion", "OBSERVATION", 164, 173], ["cellular cholesterol", "OBSERVATION", 195, 215], ["cellular cholesterol", "OBSERVATION", 240, 260]]], ["The number of plaques caused by FCoV-I KU-2, FCoV-I Black, and FCoV-I UCD-1 was reduced by treatment with 16 mM MbCD (Fig. 4A) .", [["plaques", "ANATOMY", 14, 21], ["plaques", "DISEASE", 14, 21], ["MbCD", "CHEMICAL", 112, 116], ["plaques", "PATHOLOGICAL_FORMATION", 14, 21], ["KU-2", "GENE_OR_GENE_PRODUCT", 39, 43], ["FCoV-I UCD-1", "GENE_OR_GENE_PRODUCT", 63, 75], ["FCoV", "PROTEIN", 45, 49], ["FCoV", "PROTEIN", 63, 67], ["I UCD", "PROTEIN", 68, 73], ["plaques", "PROBLEM", 14, 21], ["FCoV", "TEST", 32, 36], ["FCoV", "TEST", 45, 49], ["FCoV", "TEST", 63, 67], ["16 mM MbCD", "TREATMENT", 106, 116], ["plaques", "OBSERVATION", 14, 21], ["FCoV", "OBSERVATION", 32, 36]]], ["However, exogenous cholesterol restored the number of plaques caused by these viruses in a dose-dependent manner.", [["plaques", "ANATOMY", 54, 61], ["cholesterol", "CHEMICAL", 19, 30], ["plaques", "DISEASE", 54, 61], ["cholesterol", "CHEMICAL", 19, 30], ["cholesterol", "SIMPLE_CHEMICAL", 19, 30], ["plaques", "PATHOLOGICAL_FORMATION", 54, 61], ["plaques", "PROBLEM", 54, 61], ["exogenous cholesterol", "OBSERVATION", 9, 30], ["number", "OBSERVATION_MODIFIER", 44, 50], ["plaques", "OBSERVATION", 54, 61], ["viruses", "OBSERVATION", 78, 85]]], ["When 0.5 mg of exogenous cholesterol per ml was added, the number of plaques caused by FCoV-I Black and FCoV-I UCD-1 was significantly higher than without treatment with MbCD and exogenous cholesterol.", [["plaques", "ANATOMY", 69, 76], ["cholesterol", "CHEMICAL", 25, 36], ["plaques", "DISEASE", 69, 76], ["MbCD", "CHEMICAL", 170, 174], ["cholesterol", "CHEMICAL", 189, 200], ["cholesterol", "CHEMICAL", 25, 36], ["MbCD", "CHEMICAL", 170, 174], ["cholesterol", "CHEMICAL", 189, 200], ["cholesterol", "SIMPLE_CHEMICAL", 25, 36], ["plaques", "PATHOLOGICAL_FORMATION", 69, 76], ["FCoV-I UCD-1", "GENE_OR_GENE_PRODUCT", 104, 116], ["MbCD", "SIMPLE_CHEMICAL", 170, 174], ["cholesterol", "SIMPLE_CHEMICAL", 189, 200], ["exogenous cholesterol per ml", "TREATMENT", 15, 43], ["plaques", "PROBLEM", 69, 76], ["FCoV-I UCD", "TEST", 104, 114], ["treatment", "TREATMENT", 155, 164], ["MbCD", "TREATMENT", 170, 174], ["plaques", "OBSERVATION", 69, 76], ["FCoV", "OBSERVATION", 87, 91], ["exogenous cholesterol", "OBSERVATION", 179, 200]]], ["In contrast, cellular cholesterol Cell viability (%) 98.7 \u00b1 1.6 1) 100.7 \u00b1 3.0 1) 97.7 \u00b1 1.8 1) 98.6 \u00b1 2.1 1) 98.4 \u00b1 3.3 1) 96.3 \u00b1 2.6 1) 1) Cell viability (% mean \u00b1 SE); n = 3 Cell viability (%) 99.1 \u00b1 1.9 1) 98.5 \u00b1 1.8 1) 98.9 \u00b1 1.7 1) 96.9 \u00b1 2.3 1) 91.9 \u00b1 2.5 1) 80.2 \u00b1 7.3 1) 1) Cell viability (% mean \u00b1 SE); n = 3 Fig. 6A) .", [["cellular", "ANATOMY", 13, 21], ["Cell", "ANATOMY", 34, 38], ["Cell", "ANATOMY", 141, 145], ["Cell", "ANATOMY", 177, 181], ["Cell", "ANATOMY", 283, 287], ["cholesterol", "CHEMICAL", 22, 33], ["cholesterol", "CHEMICAL", 22, 33], ["cellular", "CELL", 13, 21], ["Cell", "CELL", 34, 38], ["Cell", "CELL", 141, 145], ["Cell", "CELL", 177, 181], ["Cell", "CELL", 283, 287], ["cellular cholesterol Cell viability", "TEST", 13, 48], ["\u00b1", "TEST", 73, 74], ["\u00b1", "TEST", 87, 88], ["\u00b1", "TEST", 101, 102], ["\u00b1", "TEST", 115, 116], ["\u00b1", "TEST", 129, 130], ["Cell viability", "TEST", 141, 155], ["mean", "TEST", 159, 163], ["SE", "TEST", 166, 168], ["n", "TEST", 171, 172], ["Cell viability", "TEST", 177, 191], ["\u00b1", "TEST", 201, 202], ["\u00b1", "TEST", 215, 216], ["\u00b1", "TEST", 229, 230], ["\u00b1", "TEST", 243, 244], ["\u00b1", "TEST", 257, 258], ["\u00b1", "TEST", 271, 272], ["Cell viability", "TEST", 283, 297], ["mean", "TEST", 301, 305], ["SE", "TEST", 308, 310], ["cholesterol Cell viability", "OBSERVATION", 22, 48]]], ["However, addition of 2.5 mg of exogenous cholesterol per ml did not increase the number of plaques caused by type-I FCoV.", [["plaques", "ANATOMY", 91, 98], ["cholesterol", "CHEMICAL", 41, 52], ["plaques", "DISEASE", 91, 98], ["cholesterol", "CHEMICAL", 41, 52], ["cholesterol", "SIMPLE_CHEMICAL", 41, 52], ["plaques", "PATHOLOGICAL_FORMATION", 91, 98], ["type-I FCoV", "GENE_OR_GENE_PRODUCT", 109, 120], ["type-I FCoV", "SPECIES", 109, 120], ["exogenous cholesterol", "TREATMENT", 31, 52], ["plaques", "PROBLEM", 91, 98], ["plaques", "OBSERVATION", 91, 98]]], ["Virus titers in culture supernatants showed similar changes; however, no significant differences were noted (Fig. 6B) .Efficiency of depletion and replenishment of cholesterol in virionsIn order to confirm the effects of cholesterol depletion on the envelope of FCoV, the virus was treated with 16 mM MbCD prior to inoculation.", [["supernatants", "ANATOMY", 24, 36], ["cholesterol", "CHEMICAL", 164, 175], ["cholesterol", "CHEMICAL", 221, 232], ["MbCD", "CHEMICAL", 301, 305], ["cholesterol", "CHEMICAL", 164, 175], ["cholesterol", "CHEMICAL", 221, 232], ["MbCD", "CHEMICAL", 301, 305], ["Virus", "ORGANISM", 0, 5], ["cholesterol", "SIMPLE_CHEMICAL", 164, 175], ["cholesterol", "SIMPLE_CHEMICAL", 221, 232], ["FCoV", "GENE_OR_GENE_PRODUCT", 262, 266], ["MbCD", "SIMPLE_CHEMICAL", 301, 305], ["FCoV", "PROTEIN", 262, 266], ["Virus titers", "TEST", 0, 12], ["culture supernatants", "TEST", 16, 36], ["significant differences", "PROBLEM", 73, 96], ["depletion", "PROBLEM", 133, 142], ["replenishment of cholesterol in virions", "TREATMENT", 147, 186], ["cholesterol depletion", "PROBLEM", 221, 242], ["the envelope of FCoV", "TREATMENT", 246, 266], ["the virus", "PROBLEM", 268, 277], ["16 mM MbCD", "TREATMENT", 295, 305], ["inoculation", "TREATMENT", 315, 326], ["no", "UNCERTAINTY", 70, 72], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["depletion", "OBSERVATION", 133, 142], ["cholesterol depletion", "OBSERVATION", 221, 242]]], ["Treatment with MbCD reduced the number of plaques caused by FCoV-I KU-2 (Fig. 7) , and exogenous cholesterol restored the number of plaques caused by FCoV-I KU-2 in a dose-dependent manner; however, no significant differences were noted (Fig. 7) .", [["plaques", "ANATOMY", 42, 49], ["plaques", "ANATOMY", 132, 139], ["MbCD", "CHEMICAL", 15, 19], ["plaques", "DISEASE", 42, 49], ["cholesterol", "CHEMICAL", 97, 108], ["plaques", "DISEASE", 132, 139], ["MbCD", "CHEMICAL", 15, 19], ["cholesterol", "CHEMICAL", 97, 108], ["MbCD", "SIMPLE_CHEMICAL", 15, 19], ["plaques", "PATHOLOGICAL_FORMATION", 42, 49], ["KU-2", "GENE_OR_GENE_PRODUCT", 67, 71], ["cholesterol", "SIMPLE_CHEMICAL", 97, 108], ["plaques", "PATHOLOGICAL_FORMATION", 132, 139], ["KU-2", "GENE_OR_GENE_PRODUCT", 157, 161], ["Treatment", "TREATMENT", 0, 9], ["MbCD", "TREATMENT", 15, 19], ["plaques", "PROBLEM", 42, 49], ["FCoV", "TEST", 60, 64], ["plaques", "PROBLEM", 132, 139], ["FCoV", "TEST", 150, 154], ["significant differences", "PROBLEM", 202, 225], ["plaques", "OBSERVATION", 42, 49], ["plaques", "OBSERVATION", 132, 139]]], ["In contrast to FCoV-I KU-2, viral cholesterol depletion and replenishment did not affect the number of plaques caused by FCoV-II 79-1146.DiscussionBetween 70 and 98 % of FCoV-infected cats in the field have been reported to be infected with type I FCoV [9, 16, 18, 26] .", [["plaques", "ANATOMY", 103, 110], ["cholesterol", "CHEMICAL", 34, 45], ["plaques", "DISEASE", 103, 110], ["FCoV-II 79-1146", "CHEMICAL", 121, 136], ["FCoV", "CHEMICAL", 170, 174], ["cholesterol", "CHEMICAL", 34, 45], ["FCoV-II 79-1146", "CHEMICAL", 121, 136], ["KU-2", "GENE_OR_GENE_PRODUCT", 22, 26], ["viral", "ORGANISM", 28, 33], ["cholesterol", "SIMPLE_CHEMICAL", 34, 45], ["plaques", "PATHOLOGICAL_FORMATION", 103, 110], ["FCoV", "GENE_OR_GENE_PRODUCT", 170, 174], ["cats", "ORGANISM", 184, 188], ["cats", "SPECIES", 184, 188], ["type I FCoV", "SPECIES", 241, 252], ["FCoV", "TEST", 15, 19], ["viral cholesterol depletion", "PROBLEM", 28, 55], ["plaques", "PROBLEM", 103, 110], ["FCoV", "TEST", 170, 174], ["cholesterol depletion", "OBSERVATION", 34, 55], ["plaques", "OBSERVATION", 103, 110], ["infected", "OBSERVATION", 227, 235]]], ["This finding demonstrates that type I FCoV needs to be examined in more detail in studies on the prevention and treatment of feline FCoV infection.", [["FCoV infection", "DISEASE", 132, 146], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 31, 42], ["feline", "ORGANISM", 125, 131], ["FCoV", "CANCER", 132, 136], ["type I FCoV", "PROTEIN", 31, 42], ["feline", "SPECIES", 125, 131], ["FCoV", "SPECIES", 132, 136], ["type I FCoV", "PROBLEM", 31, 42], ["the prevention", "TREATMENT", 93, 107], ["treatment", "TREATMENT", 112, 121], ["feline FCoV infection", "PROBLEM", 125, 146], ["feline FCoV infection", "OBSERVATION", 125, 146]]], ["However, no study using type I FCoV has been conducted to date because the propagation of type I FCoV in feline cell lines is low.", [["cell lines", "ANATOMY", 112, 122], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 24, 35], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 90, 101], ["feline", "ORGANISM", 105, 111], ["cell lines", "CELL", 112, 122], ["type I FCoV", "PROTEIN", 24, 35], ["type I FCoV", "PROTEIN", 90, 101], ["feline cell lines", "CELL_LINE", 105, 122], ["feline", "SPECIES", 105, 111], ["study", "TEST", 12, 17], ["type I FCoV", "PROBLEM", 24, 35], ["type I FCoV in feline cell lines", "TREATMENT", 90, 122], ["FCoV", "OBSERVATION", 97, 101], ["feline cell lines", "OBSERVATION", 105, 122], ["low", "OBSERVATION_MODIFIER", 126, 129]]], ["Type II FCoV uses feline aminopeptidase N (fAPN) as a receptor [8, 34] , and infection of cells with this virus has been studied in detail.", [["cells", "ANATOMY", 90, 95], ["infection", "DISEASE", 77, 86], ["Type II FCoV", "GENE_OR_GENE_PRODUCT", 0, 12], ["feline aminopeptidase N", "GENE_OR_GENE_PRODUCT", 18, 41], ["fAPN", "GENE_OR_GENE_PRODUCT", 43, 47], ["cells", "CELL", 90, 95], ["Type II FCoV", "PROTEIN", 0, 12], ["feline aminopeptidase N", "PROTEIN", 18, 41], ["fAPN", "PROTEIN", 43, 47], ["Type II FCoV", "PROBLEM", 0, 12], ["feline aminopeptidase N (fAPN)", "TREATMENT", 18, 48], ["infection of cells", "PROBLEM", 77, 95], ["this virus", "PROBLEM", 101, 111], ["FCoV", "OBSERVATION", 8, 12], ["infection", "OBSERVATION", 77, 86]]], ["In contrast, the virus receptor for type I FCoV has not been identified, and the mechanism underlying cell infection has not yet been elucidated.", [["cell", "ANATOMY", 102, 106], ["infection", "DISEASE", 107, 116], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 36, 47], ["cell", "CELL", 102, 106], ["virus receptor", "PROTEIN", 17, 31], ["type I FCoV", "PROTEIN", 36, 47], ["type I FCoV", "SPECIES", 36, 47], ["the virus receptor", "TREATMENT", 13, 31], ["type I FCoV", "PROBLEM", 36, 47], ["the mechanism underlying cell infection", "PROBLEM", 77, 116], ["FCoV", "OBSERVATION", 43, 47], ["cell infection", "OBSERVATION", 102, 116]]], ["Therefore, a basic analysis of type I FCoV is needed for the development of effective antiviral drugs against type I FCoV, which is prevalent in the field.", [["type I FCoV", "DISEASE", 110, 121], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 31, 42], ["type I FCoV", "PROTEIN", 31, 42], ["type I FCoV", "SPECIES", 110, 121], ["a basic analysis", "TEST", 11, 27], ["type I FCoV", "PROBLEM", 31, 42], ["effective antiviral drugs", "TREATMENT", 76, 101], ["type I FCoV", "PROBLEM", 110, 121]]], ["In the present study, we discovered that the dependence of the infection on cholesterol differs between types I and II FCoV.", [["infection", "DISEASE", 63, 72], ["cholesterol", "CHEMICAL", 76, 87], ["cholesterol", "CHEMICAL", 76, 87], ["cholesterol", "SIMPLE_CHEMICAL", 76, 87], ["the present study", "TEST", 3, 20], ["the infection", "PROBLEM", 59, 72], ["dependence", "OBSERVATION_MODIFIER", 45, 55], ["infection", "OBSERVATION", 63, 72], ["FCoV", "OBSERVATION", 119, 123]]], ["We recently reported that the rate of inhibition of viral replication by a viroporin inhibitor differed between types I and II FCoV [28] .", [["viroporin", "GENE_OR_GENE_PRODUCT", 75, 84], ["viral replication", "TREATMENT", 52, 69], ["a viroporin inhibitor", "TREATMENT", 73, 94], ["viral replication", "OBSERVATION", 52, 69]]], ["Based on these findings, it is desirable to use type I FCoV, in addition to type II FCoV, for the development of effective antiviral drugs.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 48, 59], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 76, 88], ["type I FCoV", "PROTEIN", 48, 59], ["type I FCoV", "PROBLEM", 48, 59], ["type II FCoV", "PROBLEM", 76, 88], ["effective antiviral drugs", "TREATMENT", 113, 138], ["effective", "OBSERVATION_MODIFIER", 113, 122], ["antiviral drugs", "OBSERVATION", 123, 138]]], ["We depleted cellular cholesterol in fcwf-4 cells using MbCD.", [["cellular", "ANATOMY", 12, 20], ["fcwf-4 cells", "ANATOMY", 36, 48], ["cholesterol", "CHEMICAL", 21, 32], ["cholesterol", "CHEMICAL", 21, 32], ["cellular", "CELL", 12, 20], ["cholesterol", "SIMPLE_CHEMICAL", 21, 32], ["fcwf-4 cells", "CELL", 36, 48], ["MbCD", "CELL", 55, 59], ["fcwf-4 cells", "CELL_LINE", 36, 48], ["cellular cholesterol", "TEST", 12, 32], ["MbCD", "TREATMENT", 55, 59], ["cellular cholesterol", "OBSERVATION", 12, 32]]], ["Cell membrane cholesterol is extracted by binding to the hydrophobic cores of MbCD [15] .", [["Cell membrane", "ANATOMY", 0, 13], ["cholesterol", "CHEMICAL", 14, 25], ["cholesterol", "CHEMICAL", 14, 25], ["Cell membrane", "CELLULAR_COMPONENT", 0, 13], ["cholesterol", "SIMPLE_CHEMICAL", 14, 25], ["Cell membrane cholesterol", "TEST", 0, 25], ["membrane cholesterol", "OBSERVATION", 5, 25]]], ["Nystatin is frequently used, as well as MbCD, to analyze cholesteroldependent viral cell infection; however, it sequesters, rather than removes cell membrane cholesterol [32] .", [["cell", "ANATOMY", 84, 88], ["cell membrane", "ANATOMY", 144, 157], ["Nystatin", "CHEMICAL", 0, 8], ["viral cell infection", "DISEASE", 78, 98], ["cholesterol", "CHEMICAL", 158, 169], ["Nystatin", "CHEMICAL", 0, 8], ["cholesterol", "CHEMICAL", 158, 169], ["Nystatin", "SIMPLE_CHEMICAL", 0, 8], ["MbCD", "SIMPLE_CHEMICAL", 40, 44], ["cell", "CELL", 84, 88], ["cell membrane", "CELLULAR_COMPONENT", 144, 157], ["Nystatin", "TREATMENT", 0, 8], ["MbCD", "TREATMENT", 40, 44], ["cholesteroldependent viral cell infection", "PROBLEM", 57, 98], ["cell membrane cholesterol", "TEST", 144, 169], ["viral cell infection", "OBSERVATION", 78, 98]]], ["Moreover, strong cytotoxicity was noted in fcwf-4 cells treated with nystatin in a preliminary experiment.", [["fcwf-4 cells", "ANATOMY", 43, 55], ["nystatin", "CHEMICAL", 69, 77], ["nystatin", "CHEMICAL", 69, 77], ["fcwf-4 cells", "CELL", 43, 55], ["nystatin", "SIMPLE_CHEMICAL", 69, 77], ["fcwf-4 cells", "CELL_LINE", 43, 55], ["strong cytotoxicity", "PROBLEM", 10, 29], ["nystatin", "TREATMENT", 69, 77], ["strong", "OBSERVATION_MODIFIER", 10, 16], ["cytotoxicity", "OBSERVATION", 17, 29]]], ["Therefore, we selected MbCD.DiscussionThe involvement of cholesterol in the entry of an enveloped virus has been reported previously [24] .", [["cholesterol", "CHEMICAL", 57, 68], ["cholesterol", "CHEMICAL", 57, 68], ["MbCD", "CANCER", 23, 27], ["cholesterol", "SIMPLE_CHEMICAL", 57, 68], ["an enveloped virus", "PROBLEM", 85, 103], ["virus", "OBSERVATION", 98, 103]]], ["Based on the type of cholesterol dependence they display, viruses can be divided into four groups: i) envelope cholesterol (e.g., influenza virus) [27] , ii) cell membrane cholesterol (e.g., Ebola virus) [2] , iii) both envelope and cell membrane cholesterol (e.g., human immunodeficiency virus) [36] , and iv) no cholesterol involvement in cell infection (e.g., VSV) [13, 22] .", [["cell membrane", "ANATOMY", 158, 171], ["cell membrane", "ANATOMY", 233, 246], ["cell", "ANATOMY", 341, 345], ["cholesterol", "CHEMICAL", 21, 32], ["cholesterol", "CHEMICAL", 111, 122], ["cholesterol", "CHEMICAL", 172, 183], ["cholesterol", "CHEMICAL", 247, 258], ["human immunodeficiency virus", "DISEASE", 266, 294], ["cholesterol", "CHEMICAL", 314, 325], ["infection", "DISEASE", 346, 355], ["cholesterol", "CHEMICAL", 21, 32], ["cholesterol", "CHEMICAL", 111, 122], ["cholesterol", "CHEMICAL", 172, 183], ["cholesterol", "CHEMICAL", 247, 258], ["cholesterol", "CHEMICAL", 314, 325], ["cholesterol", "SIMPLE_CHEMICAL", 21, 32], ["cholesterol", "SIMPLE_CHEMICAL", 111, 122], ["influenza virus", "ORGANISM", 130, 145], ["cell membrane", "CELLULAR_COMPONENT", 158, 171], ["cholesterol", "SIMPLE_CHEMICAL", 172, 183], ["Ebola virus", "ORGANISM", 191, 202], ["cell membrane", "CELLULAR_COMPONENT", 233, 246], ["cholesterol", "SIMPLE_CHEMICAL", 247, 258], ["human immunodeficiency virus", "ORGANISM", 266, 294], ["cholesterol", "SIMPLE_CHEMICAL", 314, 325], ["cell", "CELL", 341, 345], ["VSV", "ORGANISM", 363, 366], ["influenza virus", "SPECIES", 130, 145], ["Ebola virus", "SPECIES", 191, 202], ["human", "SPECIES", 266, 271], ["immunodeficiency virus", "SPECIES", 272, 294], ["Ebola virus", "SPECIES", 191, 202], ["human immunodeficiency virus", "SPECIES", 266, 294], ["VSV", "SPECIES", 363, 366], ["cholesterol dependence", "PROBLEM", 21, 43], ["viruses", "PROBLEM", 58, 65], ["envelope cholesterol", "TEST", 102, 122], ["influenza virus)", "PROBLEM", 130, 146], ["cell membrane cholesterol", "TEST", 158, 183], ["Ebola virus)", "PROBLEM", 191, 203], ["cell membrane cholesterol", "TEST", 233, 258], ["human immunodeficiency virus", "PROBLEM", 266, 294], ["cholesterol involvement in cell infection", "PROBLEM", 314, 355], ["cell infection", "OBSERVATION", 341, 355]]], ["The coronaviruses MHV and SARS-CoV of the genus Betacoronavirus belong to the second group [5, 33] , while TGEV and type II canine coronavirus (CCoV) of the genus Alphacoronavirus belong to the third group [23, 25] .", [["canine coronavirus", "DISEASE", 124, 142], ["coronaviruses MHV", "ORGANISM", 4, 21], ["SARS-CoV", "ORGANISM", 26, 34], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 48, 63], ["TGEV", "ORGANISM", 107, 111], ["type II canine coronavirus", "ORGANISM", 116, 142], ["CCoV", "CANCER", 144, 148], ["coronaviruses", "SPECIES", 4, 17], ["SARS-CoV", "SPECIES", 26, 34], ["TGEV", "SPECIES", 107, 111], ["canine coronavirus", "SPECIES", 124, 142], ["MHV", "SPECIES", 18, 21], ["SARS-CoV", "SPECIES", 26, 34], ["TGEV", "SPECIES", 107, 111], ["type II canine coronavirus", "SPECIES", 116, 142], ["CCoV", "SPECIES", 144, 148], ["The coronaviruses MHV", "PROBLEM", 0, 21], ["SARS", "TEST", 26, 30], ["TGEV", "PROBLEM", 107, 111], ["type II canine coronavirus", "PROBLEM", 116, 142], ["coronaviruses MHV", "OBSERVATION", 4, 21], ["genus Betacoronavirus", "OBSERVATION", 42, 63], ["genus Alphacoronavirus", "ANATOMY", 157, 179]]], ["Based on our results, type I FCoV belongs to the second or third group, and type II FCoV belongs to the second or fourth group, suggesting that the cholesterol dependence of infection differs between FCoV types I and II.DiscussionMbCD slightly inhibited type II FCoV replication.", [["cholesterol", "CHEMICAL", 148, 159], ["infection", "DISEASE", 174, 183], ["cholesterol", "CHEMICAL", 148, 159], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 22, 33], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 76, 88], ["cholesterol", "SIMPLE_CHEMICAL", 148, 159], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 254, 266], ["type I FCoV", "PROTEIN", 22, 33], ["type II FCoV", "PROTEIN", 76, 88], ["type I FCoV", "PROBLEM", 22, 33], ["type II FCoV", "PROBLEM", 76, 88], ["the cholesterol dependence of infection", "PROBLEM", 144, 183], ["slightly inhibited type II FCoV replication", "PROBLEM", 235, 278], ["FCoV", "OBSERVATION", 84, 88], ["cholesterol dependence", "OBSERVATION", 148, 170], ["infection", "OBSERVATION", 174, 183], ["FCoV replication", "OBSERVATION", 262, 278]]], ["A previous report showed that cholesterol had a slight effect on infection by FCoV-II 79-1146.", [["cholesterol", "CHEMICAL", 30, 41], ["infection", "DISEASE", 65, 74], ["FCoV-II 79-1146", "CHEMICAL", 78, 93], ["cholesterol", "CHEMICAL", 30, 41], ["cholesterol", "SIMPLE_CHEMICAL", 30, 41], ["cholesterol", "TEST", 30, 41], ["a slight effect on infection", "PROBLEM", 46, 74], ["slight", "OBSERVATION_MODIFIER", 48, 54], ["effect", "OBSERVATION_MODIFIER", 55, 61], ["infection", "OBSERVATION", 65, 74]]], ["It has been suggested that type II FCoV does not require much cholesterol for infection.DiscussionThe virus receptor for type II FCoV is fAPN [8, 34] , whereas that for type I FCoV has not yet been identified.", [["cholesterol", "CHEMICAL", 62, 73], ["infection", "DISEASE", 78, 87], ["cholesterol", "CHEMICAL", 62, 73], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 27, 39], ["cholesterol", "SIMPLE_CHEMICAL", 62, 73], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 121, 133], ["fAPN", "GENE_OR_GENE_PRODUCT", 137, 141], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 169, 180], ["type II FCoV", "PROTEIN", 121, 133], ["type I FCoV", "PROTEIN", 169, 180], ["type II FCoV", "PROBLEM", 27, 39], ["infection", "PROBLEM", 78, 87], ["The virus receptor", "TREATMENT", 98, 116], ["type II FCoV", "PROBLEM", 121, 133], ["type I FCoV", "PROBLEM", 169, 180], ["infection", "OBSERVATION", 78, 87]]], ["Tekes et al. [29] suggested that fAPN functions as a virus receptor for type I FCoV, although it is very inefficient.", [["fAPN", "GENE_OR_GENE_PRODUCT", 33, 37], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 72, 83], ["fAPN", "PROTEIN", 33, 37], ["type I FCoV", "PROTEIN", 72, 83], ["type I FCoV", "SPECIES", 72, 83], ["fAPN functions", "PROBLEM", 33, 47], ["a virus receptor", "TREATMENT", 51, 67], ["type I FCoV", "PROBLEM", 72, 83]]], ["Based on this hypothesis, type I FCoV might enter cells using fAPN and a cofactor (coreceptor).", [["cells", "ANATOMY", 50, 55], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 26, 37], ["cells", "CELL", 50, 55], ["fAPN", "GENE_OR_GENE_PRODUCT", 62, 66], ["type I FCoV", "PROTEIN", 26, 37], ["fAPN", "PROTEIN", 62, 66], ["cofactor", "PROTEIN", 73, 81], ["coreceptor", "PROTEIN", 83, 93], ["this hypothesis", "PROBLEM", 9, 24], ["type I FCoV", "PROBLEM", 26, 37], ["fAPN", "TREATMENT", 62, 66], ["a cofactor (coreceptor)", "TREATMENT", 71, 94]]], ["MHV fuses with the cell membrane, utilizing cholesterol after binding to carcinoembryonic antigen-related cell adhesion molecule (CEACAM), and enters cells using cholesterol in the absence of CEACAM [33] .", [["cell membrane", "ANATOMY", 19, 32], ["cells", "ANATOMY", 150, 155], ["cholesterol", "CHEMICAL", 44, 55], ["cholesterol", "CHEMICAL", 162, 173], ["cholesterol", "CHEMICAL", 44, 55], ["cholesterol", "CHEMICAL", 162, 173], ["MHV", "ORGANISM", 0, 3], ["cell membrane", "CELLULAR_COMPONENT", 19, 32], ["cholesterol", "SIMPLE_CHEMICAL", 44, 55], ["carcinoembryonic antigen-related cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 73, 128], ["CEACAM", "GENE_OR_GENE_PRODUCT", 130, 136], ["cells", "CELL", 150, 155], ["cholesterol", "SIMPLE_CHEMICAL", 162, 173], ["carcinoembryonic antigen-related cell adhesion molecule", "PROTEIN", 73, 128], ["CEACAM", "PROTEIN", 130, 136], ["MHV", "SPECIES", 0, 3], ["the cell membrane", "TREATMENT", 15, 32], ["carcinoembryonic antigen", "TEST", 73, 97], ["cell adhesion molecule", "PROBLEM", 106, 128], ["cholesterol", "TEST", 162, 173], ["cell membrane", "OBSERVATION", 19, 32], ["cell adhesion molecule", "OBSERVATION", 106, 128]]], ["Cholesterol may also function as an essential cofactor in type I FCoV infection.", [["Cholesterol", "CHEMICAL", 0, 11], ["infection", "DISEASE", 70, 79], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 58, 69], ["type I FCoV", "SPECIES", 58, 69], ["Cholesterol", "TEST", 0, 11], ["type I FCoV infection", "PROBLEM", 58, 79], ["essential", "OBSERVATION_MODIFIER", 36, 45], ["cofactor", "OBSERVATION", 46, 54], ["type I", "OBSERVATION_MODIFIER", 58, 64], ["FCoV", "OBSERVATION_MODIFIER", 65, 69], ["infection", "OBSERVATION", 70, 79]]], ["Furthermore, the envelope cholesterol of type I FCoV has been suggested to be involved in infection, as shown in Figure 7 .", [["cholesterol", "CHEMICAL", 26, 37], ["FCoV", "CHEMICAL", 48, 52], ["infection", "DISEASE", 90, 99], ["cholesterol", "CHEMICAL", 26, 37], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 41, 52], ["type I FCoV", "PROTEIN", 41, 52], ["type I FCoV", "SPECIES", 41, 52], ["type I FCoV", "PROBLEM", 41, 52], ["infection", "PROBLEM", 90, 99], ["infection", "OBSERVATION", 90, 99]]], ["Further investigations are needed in order to determine whether the envelope cholesterol of type I FCoV plays an important role in cell infection.DiscussionAlthough it currently remains unclear whether the results of the present study provide direct evidence regarding the cell entry mechanism of field strains of type I FCoV, they may be useful for determining the mechanism responsible.", [["cell", "ANATOMY", 131, 135], ["cell", "ANATOMY", 273, 277], ["cholesterol", "CHEMICAL", 77, 88], ["infection", "DISEASE", 136, 145], ["cholesterol", "CHEMICAL", 77, 88], ["cholesterol", "SIMPLE_CHEMICAL", 77, 88], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 92, 103], ["cell", "CELL", 131, 135], ["cell", "CELL", 273, 277], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 314, 325], ["type I FCoV", "PROTEIN", 92, 103], ["type I FCoV", "SPECIES", 314, 325], ["Further investigations", "TEST", 0, 22], ["type I FCoV", "PROBLEM", 92, 103], ["cell infection", "PROBLEM", 131, 145], ["the present study", "TEST", 217, 234], ["type I FCoV", "PROBLEM", 314, 325], ["cell infection", "OBSERVATION", 131, 145]]], ["Previous studies on the FCoV replication mechanism were mainly performed using type II FCoV.", [["FCoV", "GENE_OR_GENE_PRODUCT", 24, 28], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 79, 91], ["type II FCoV", "PROTEIN", 79, 91], ["Previous studies", "TEST", 0, 16], ["the FCoV replication mechanism", "TEST", 20, 50]]], ["Therefore, our study may be more useful than previous studies using type II FCoV for elucidating the cell entry mechanism of field strains of type I FCoV.DiscussionIn this study, the dependence of the infection on cholesterol markedly differed between types I and II FCoV.", [["cell", "ANATOMY", 101, 105], ["infection", "DISEASE", 201, 210], ["cholesterol", "CHEMICAL", 214, 225], ["cholesterol", "CHEMICAL", 214, 225], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 68, 80], ["cell", "CELL", 101, 105], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 142, 153], ["cholesterol", "SIMPLE_CHEMICAL", 214, 225], ["type II FCoV", "PROTEIN", 68, 80], ["type I FCoV", "SPECIES", 142, 153], ["our study", "TEST", 11, 20], ["previous studies", "TEST", 45, 61], ["type II FCoV", "TREATMENT", 68, 80], ["this study", "TEST", 167, 177], ["the infection", "PROBLEM", 197, 210], ["infection", "OBSERVATION", 201, 210]]], ["Since type I FCoV is dominant in the field, studies using type I FCoV are desirable.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 6, 17], ["type I FCoV", "GENE_OR_GENE_PRODUCT", 58, 69], ["type I FCoV", "PROTEIN", 6, 17], ["type I FCoV", "PROTEIN", 58, 69], ["type I FCoV", "PROBLEM", 58, 69], ["FCoV", "OBSERVATION", 13, 17], ["dominant", "OBSERVATION_MODIFIER", 21, 29]]], ["Our results may be useful for obtaining a deeper understanding of type I FCoV.", [["type I FCoV", "GENE_OR_GENE_PRODUCT", 66, 77], ["type I FCoV", "PROTEIN", 66, 77]]]], "PMC7283670": [["INTRODUCTIONCoVs were recognized as \u201cnovel respiratory tract viruses\u201d over half a century ago.", [["respiratory tract viruses", "DISEASE", 43, 68], ["INTRODUCTIONCoVs", "TREATMENT", 0, 16], ["novel respiratory tract viruses", "PROBLEM", 37, 68], ["respiratory tract", "ANATOMY", 43, 60]]], ["The title was conferred in 1962, following the examination of samples collected from individuals who had manifested symptoms of respiratory tract infection (Hamre & Procknow, 1966).", [["samples", "ANATOMY", 62, 69], ["respiratory tract", "ANATOMY", 128, 145], ["respiratory tract infection", "DISEASE", 128, 155], ["tract", "ORGANISM_SUBDIVISION", 140, 145], ["the examination", "TEST", 43, 58], ["samples", "TEST", 62, 69], ["symptoms", "PROBLEM", 116, 124], ["respiratory tract infection", "PROBLEM", 128, 155], ["respiratory tract", "ANATOMY", 128, 145], ["infection", "OBSERVATION", 146, 155]]], ["Initially, CoVs were not considered as highly pathogenic for humans.", [["CoVs", "GENE_OR_GENE_PRODUCT", 11, 15], ["humans", "ORGANISM", 61, 67], ["CoVs", "PROTEIN", 11, 15], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67], ["CoVs", "PROBLEM", 11, 15], ["pathogenic", "OBSERVATION", 46, 56]]], ["That was until 2002, however, that CoVs emerged in the form of Severe Acute Respiratory Syndrome (SARS) in the Guangdong state of China (Sahin et al., 2020).", [["Acute Respiratory Syndrome", "DISEASE", 70, 96], ["SARS", "DISEASE", 98, 102], ["Severe Acute Respiratory Syndrome", "PROBLEM", 63, 96], ["SARS", "PROBLEM", 98, 102], ["Severe", "OBSERVATION_MODIFIER", 63, 69], ["Acute", "OBSERVATION_MODIFIER", 70, 75], ["Respiratory Syndrome", "OBSERVATION", 76, 96]]], ["Almost a decade later, another highly pathogenic CoV appeared in the Middle East countries, which similarly led to severe respiratory symptoms of acute onset.", [["respiratory", "ANATOMY", 122, 133], ["CoV", "ORGANISM", 49, 52], ["another highly pathogenic CoV", "PROBLEM", 23, 52], ["severe respiratory symptoms", "PROBLEM", 115, 142], ["acute onset", "PROBLEM", 146, 157], ["pathogenic CoV", "OBSERVATION", 38, 52], ["Middle", "ANATOMY_MODIFIER", 69, 75], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["respiratory symptoms", "OBSERVATION", 122, 142], ["acute", "OBSERVATION_MODIFIER", 146, 151]]], ["The then\u2010novel species was named Middle East Respiratory Syndrome Coronavirus (MERS\u2010CoV; Zaki, Van Boheemen, Bestebroer, Osterhaus, & Fouchier, 2012).INTRODUCTIONIn December 2019, a cluster of insidious Coronavirus infections was reported in the Huanan Seafood Market, located in Wuhan State of Hubei Province in China.", [["Coronavirus infections", "DISEASE", 203, 225], ["Middle East Respiratory Syndrome Coronavirus (MERS\u2010CoV", "SPECIES", 33, 87], ["The then\u2010novel species", "TEST", 0, 22], ["Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 33, 77], ["insidious Coronavirus infections", "PROBLEM", 193, 225], ["Middle", "OBSERVATION_MODIFIER", 33, 39], ["Respiratory Syndrome", "OBSERVATION", 45, 65], ["insidious", "OBSERVATION_MODIFIER", 193, 202], ["Coronavirus infections", "OBSERVATION", 203, 225]]], ["It was then that a pneumonia epidemic of unknown cause became the focus of global attention (Sahin et al., 2020).", [["pneumonia", "DISEASE", 19, 28], ["a pneumonia epidemic", "PROBLEM", 17, 37], ["pneumonia", "OBSERVATION", 19, 28]]], ["Chinese authorities announced on January 7, 2020 that a new type of CoV (novel CoV, nCoV) was isolated (Imperial College London, 2020; World Health Organization, 2020).", [["CoV", "ORGANISM", 68, 71], ["CoV", "ORGANISM", 79, 82], ["nCoV", "GENE_OR_GENE_PRODUCT", 84, 88]]], ["On December 12, 2019, a pneumonia case of unknown origin was reported in Wuhan, China.", [["pneumonia", "DISEASE", 24, 33], ["a pneumonia case", "PROBLEM", 22, 38], ["pneumonia", "OBSERVATION", 24, 33]]], ["Initial laboratory tests ruled out Influenza and infection with recognized CoVs.", [["Influenza", "DISEASE", 35, 44], ["infection", "DISEASE", 49, 58], ["CoVs", "PATHOLOGICAL_FORMATION", 75, 79], ["Initial laboratory tests", "TEST", 0, 24], ["Influenza", "PROBLEM", 35, 44], ["infection", "PROBLEM", 49, 58], ["Influenza", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 49, 58]]], ["Following the incident, 27 new cases of pneumonia of viral origin were officially reported on December 31, 2019.", [["pneumonia", "DISEASE", 40, 49], ["pneumonia of viral origin", "PROBLEM", 40, 65], ["pneumonia", "OBSERVATION", 40, 49], ["viral origin", "OBSERVATION", 53, 65]]], ["A week later on January 7, 2020, the Chinese authorities announced that a new species of CoV was isolated in the country (Zumla, Hui, Azhar, Memish, & Maeurer, 2020).INTRODUCTIONGiven the whereabouts of the first case ever reported, the infection was speculated to have been contracted from a zoonotic agent.", [["infection", "DISEASE", 237, 246], ["CoV", "ORGANISM", 89, 92], ["a new species of CoV", "PROBLEM", 72, 92], ["the infection", "PROBLEM", 233, 246], ["a zoonotic agent", "TREATMENT", 291, 307], ["infection", "OBSERVATION", 237, 246]]], ["Etiologic investigations on patients who had been hospitalized with a similar medical history supported the likelihood of a viral infection transmitted from animals to humans (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). nCoV was duly reported to have been originated from wild bats.", [["viral infection", "DISEASE", 124, 139], ["nCoV", "CHEMICAL", 253, 257], ["patients", "ORGANISM", 28, 36], ["humans", "ORGANISM", 168, 174], ["nCoV", "GENE_OR_GENE_PRODUCT", 253, 257], ["nCoV", "PROTEIN", 253, 257], ["patients", "SPECIES", 28, 36], ["humans", "SPECIES", 168, 174], ["humans", "SPECIES", 168, 174], ["nCoV", "SPECIES", 253, 257], ["a viral infection", "PROBLEM", 122, 139], ["viral", "OBSERVATION_MODIFIER", 124, 129], ["infection", "OBSERVATION", 130, 139], ["wild bats", "OBSERVATION", 305, 314]]], ["Falling in the category of group 2 \u03b2\u2010CoVs, the novel Coronavirus only shares a 70% similarity in genetic sequence with its predecessor, SARS\u2010CoV, which also belongs to the exact same family (Gralinski & Menachery, 2020).INTRODUCTIONThe tantalizing surge in the number of cases infected with SARS\u2010CoV\u20102 in China, despite the closure of markets and evacuation of the vicinity, fulfilled the burden of proof that the virus can also be transmitted from human to human.", [["SARS", "DISEASE", 291, 295], ["CoV\u20102", "CHEMICAL", 296, 301], ["Coronavirus", "CANCER", 53, 64], ["SARS\u2010CoV", "ORGANISM", 136, 144], ["human", "ORGANISM", 449, 454], ["human", "ORGANISM", 458, 463], ["human", "SPECIES", 449, 454], ["human", "SPECIES", 458, 463], ["SARS\u2010CoV", "SPECIES", 136, 144], ["human", "SPECIES", 449, 454], ["human", "SPECIES", 458, 463], ["the novel Coronavirus", "PROBLEM", 43, 64], ["SARS", "PROBLEM", 291, 295], ["the closure of markets", "TREATMENT", 320, 342], ["evacuation", "TREATMENT", 347, 357], ["the virus", "PROBLEM", 410, 419], ["infected", "OBSERVATION", 277, 285], ["closure", "OBSERVATION", 324, 331], ["virus", "OBSERVATION", 414, 419]]], ["Soon thereafter, peculiar cases of acute respiratory syndrome started appearing in other Asian countries, ultimately spreading to North America and Europe.", [["respiratory", "ANATOMY", 41, 52], ["acute respiratory syndrome", "DISEASE", 35, 61], ["acute respiratory syndrome", "PROBLEM", 35, 61], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome", "OBSERVATION", 41, 61]]], ["Following an emergent briefing on January 30, 2020, The World Health Organization (WHO) declared the outbreak of COVID\u201019 as a Public Health Emergency of International Concern (Organization, 2020).INTRODUCTIONThe epidemic began to emerge with the advent of the Chinese New Year, a traditionally important festival that is heavily celebrated across the country.", [["COVID", "DISEASE", 113, 118]]], ["The coincidence paved the way for SARS\u2010CoV\u20102 to turn into an unprecedented massive Coronavirus outbreak, which required extensive measurements to be contained.", [["SARS", "DISEASE", 34, 38], ["SARS\u2010CoV\u20102", "TREATMENT", 34, 44], ["an unprecedented massive Coronavirus outbreak", "PROBLEM", 58, 103], ["massive", "OBSERVATION_MODIFIER", 75, 82], ["Coronavirus", "OBSERVATION", 83, 94]]], ["With a population of 10 million, Wuhan City also served as an important pathway for millions of people traveling in celebration of the Spring Festival.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102]]], ["Accordingly, the number of cases to be diagnosed with COVID\u201019 showed an overwhelming increase between January 10\u201322, 2020 (Chen, Zhang et al., 2020).INTRODUCTIONDespite the arbitrary speculations, not only did the recent outbreak of COVID\u201019 egress the country of origin, it also proceeded to become a global concern in the form of a pandemic (Yang et al., 2020).", [["COVID", "DISEASE", 54, 59], ["COVID", "DISEASE", 234, 239], ["overwhelming", "OBSERVATION_MODIFIER", 73, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["global", "OBSERVATION", 303, 309]]], ["COVID\u201019 is an acute self\u2010resolving respiratory disease in most of the cases, however, it can also be fatal in some cases.", [["respiratory", "ANATOMY", 36, 47], ["respiratory disease", "DISEASE", 36, 55], ["an acute self\u2010resolving respiratory disease", "PROBLEM", 12, 55], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["self\u2010resolving", "OBSERVATION_MODIFIER", 21, 35], ["respiratory disease", "OBSERVATION", 36, 55]]], ["The disease was initially reported to have a mortality rate of 2%.", [["The disease", "PROBLEM", 0, 11], ["a mortality rate", "TEST", 43, 59], ["disease", "OBSERVATION", 4, 11]]], ["If severe, COVID\u201019 might result in death as a result of the preceding extensive alveolar damage, and failure of the lungs (Xu et al., 2020).", [["alveolar", "ANATOMY", 81, 89], ["lungs", "ANATOMY", 117, 122], ["death", "DISEASE", 36, 41], ["alveolar damage", "DISEASE", 81, 96], ["alveolar", "TISSUE", 81, 89], ["lungs", "ORGAN", 117, 122], ["death", "PROBLEM", 36, 41], ["the preceding extensive alveolar damage", "PROBLEM", 57, 96], ["failure of the lungs", "PROBLEM", 102, 122], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["extensive", "OBSERVATION_MODIFIER", 71, 80], ["alveolar", "ANATOMY_MODIFIER", 81, 89], ["damage", "OBSERVATION", 90, 96], ["failure", "OBSERVATION", 102, 109], ["lungs", "ANATOMY", 117, 122]]], ["As of February 15, 2020, a total of 66,580 cases had been confirmed, with over 1,524 deaths.", [["deaths", "DISEASE", 85, 91]]], ["However, there have no specific reports on pathology, as performing an autopsy or biopsy was not possible in most of the cases (Chan et al., 2020; Huang et al., 2020).", [["an autopsy", "TEST", 68, 78], ["biopsy", "TEST", 82, 88]]], ["Represents the WHO situation reports on March 24, 2020 (www.WHO.int).INTRODUCTIONA total of 8,096 SARS cases and 774 deaths across 29 countries were reported for an overall case\u2010fatality rate (CFR) of 9.6%.", [["SARS", "DISEASE", 98, 102], ["deaths", "DISEASE", 117, 123], ["an overall case\u2010fatality rate", "TEST", 162, 191], ["CFR", "TEST", 193, 196]]], ["MERS is still not contained and is thus far responsible for 2,494 confirmed cases and 858 deaths across 27 countries for a CFR of 34.4%.", [["deaths", "DISEASE", 90, 96], ["a CFR", "TEST", 121, 126]]], ["Despite the much higher CFR of 9.6% and 34.4% for SARS and MERS, the novel Coronavirus epidemic has led to a larger death toll.", [["SARS", "DISEASE", 50, 54], ["MERS", "DISEASE", 59, 63], ["death", "DISEASE", 116, 121], ["the much higher CFR", "TEST", 8, 27], ["SARS", "PROBLEM", 50, 54], ["MERS", "PROBLEM", 59, 63], ["the novel Coronavirus epidemic", "PROBLEM", 65, 95], ["larger", "OBSERVATION_MODIFIER", 109, 115]]], ["The Chinese government had reported 72,528 confirmed cases, with 1,870 deaths, as of February 18, 2020.", [["deaths", "DISEASE", 71, 77]]], ["These statistics yield a crude CFR of 2.6%.", [["a crude CFR", "TEST", 23, 34]]], ["However, one should not haste to generalize this number, as most possibly the total number of patients with COVID\u201019 is much higher.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["COVID\u2010", "TREATMENT", 108, 114]]], ["That is, because the cases are not readily identifiable, as many asymptomatic patients are missed during the process (Wu et al., 2020; Yan et al., 2020).", [["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["not readily identifiable", "UNCERTAINTY", 31, 55]]], ["Despite the higher transmissibility than SARS and MERS, COVID\u201019 is still a relatively unknown disease and requires further investigations to be fully understood (Yan et al., 2020).Respiratory system ::: PATHOGENESISSARS\u2010CoV\u20102 tends to infect the respiratory tract, thus, pneumonia is a primary clinical finding in patients with COVID\u201019 (Huang et al., 2020; Li, Guan, et al., 2020; Zhu et al., 2020).", [["respiratory tract", "ANATOMY", 247, 264], ["SARS", "DISEASE", 41, 45], ["pneumonia", "DISEASE", 272, 281], ["respiratory tract", "ORGANISM_SUBDIVISION", 247, 264], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["SARS", "PROBLEM", 41, 45], ["further investigations", "TEST", 116, 138], ["the respiratory tract", "PROBLEM", 243, 264], ["pneumonia", "PROBLEM", 272, 281], ["disease", "OBSERVATION", 95, 102], ["respiratory tract", "ANATOMY", 247, 264], ["pneumonia", "OBSERVATION", 272, 281]]], ["However, pneumonia is only a component of the SARS that might develop in some cases.", [["pneumonia", "DISEASE", 9, 18], ["SARS", "DISEASE", 46, 50], ["pneumonia", "PROBLEM", 9, 18], ["the SARS", "PROBLEM", 42, 50], ["pneumonia", "OBSERVATION", 9, 18], ["SARS", "OBSERVATION", 46, 50]]], ["The resulting SARS may then be aggravated and lead to serious conditions that are extremely difficult to control, for example, septic shock, metabolic acidosis, and coagulation dysfunction (Kofi Ayittey, Dzuvor, Kormla Ayittey, Bennita Chiwero, & Habib, 2020).Respiratory system ::: PATHOGENESISInvestigation on the radiological findings of COVID\u201019\u2010associated pneumonia have yielded little, if any, information that are mostly unspecific.", [["SARS", "DISEASE", 14, 18], ["septic shock", "DISEASE", 127, 139], ["metabolic acidosis", "DISEASE", 141, 159], ["coagulation dysfunction", "DISEASE", 165, 188], ["pneumonia", "DISEASE", 361, 370], ["The resulting SARS", "PROBLEM", 0, 18], ["serious conditions", "PROBLEM", 54, 72], ["septic shock", "PROBLEM", 127, 139], ["metabolic acidosis", "PROBLEM", 141, 159], ["coagulation dysfunction", "PROBLEM", 165, 188], ["Dzuvor", "TREATMENT", 204, 210], ["COVID\u201019\u2010associated pneumonia", "PROBLEM", 341, 370], ["septic shock", "OBSERVATION", 127, 139], ["metabolic acidosis", "OBSERVATION", 141, 159], ["coagulation dysfunction", "OBSERVATION", 165, 188], ["pneumonia", "OBSERVATION", 361, 370], ["little", "OBSERVATION_MODIFIER", 384, 390], ["mostly", "OBSERVATION_MODIFIER", 421, 427], ["unspecific", "OBSERVATION", 428, 438]]], ["Progressive lung lesions are usually detected in patients with COVID\u201019, about 1 week after the onset of signs and symptoms (Ooi et al., 2004).", [["lung lesions", "ANATOMY", 12, 24], ["lung lesions", "DISEASE", 12, 24], ["lung lesions", "CANCER", 12, 24], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Progressive lung lesions", "PROBLEM", 0, 24], ["signs and symptoms", "PROBLEM", 105, 123], ["lung", "ANATOMY", 12, 16], ["lesions", "OBSERVATION", 17, 24]]], ["The lesions then become aggravated during the 2nd week, and lead to formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week.", [["lesions", "ANATOMY", 4, 11], ["reticular opacities", "ANATOMY", 91, 110], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["irregular reticular opacities", "PROBLEM", 81, 110], ["ground glass opacities", "PROBLEM", 122, 144], ["CT", "TEST", 178, 180], ["lesions", "OBSERVATION", 4, 11], ["aggravated", "OBSERVATION", 24, 34], ["irregular", "OBSERVATION_MODIFIER", 81, 90], ["reticular", "OBSERVATION_MODIFIER", 91, 100], ["opacities", "OBSERVATION", 101, 110], ["mixed", "OBSERVATION_MODIFIER", 111, 116], ["ground glass opacities", "OBSERVATION", 122, 144]]], ["In a recent cohort study, 85.7% (54/63) of subjects with COVID\u201019\u2010associated pneumonia showed disease progression, defined by an increased extent of GGO, on early follow\u2010up CT (Pan et al., 2020).", [["COVID", "DISEASE", 57, 62], ["pneumonia", "DISEASE", 77, 86], ["GGO", "DISEASE", 149, 152], ["a recent cohort study", "TEST", 3, 24], ["COVID\u2010", "TEST", 57, 63], ["pneumonia", "PROBLEM", 77, 86], ["disease progression", "PROBLEM", 94, 113], ["an increased extent of GGO", "PROBLEM", 126, 152], ["early follow\u2010up CT", "TEST", 157, 175], ["pneumonia", "OBSERVATION", 77, 86], ["disease", "OBSERVATION", 94, 101], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["extent", "OBSERVATION_MODIFIER", 139, 145], ["GGO", "OBSERVATION", 149, 152]]], ["Pulmonary fibrous cords was reported in one particular patient that displayed signs of improvement, as the inflammatory secretions had been absorbed (Pan & Guan, 2020).", [["Pulmonary fibrous cords", "ANATOMY", 0, 23], ["Pulmonary fibrous cords", "TISSUE", 0, 23], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["Pulmonary fibrous cords", "PROBLEM", 0, 23], ["the inflammatory secretions", "PROBLEM", 103, 130], ["fibrous cords", "OBSERVATION", 10, 23], ["improvement", "OBSERVATION_MODIFIER", 87, 98], ["inflammatory", "OBSERVATION_MODIFIER", 107, 119]]], ["Long\u2010term complications of COVID\u201019 in patients with severe pneumonia might include an array of fibrotic changes often observed in the late stages of lung injury, for example, reticulation, interlobular septal thickening, and traction bronchiectasis (Kim, 2020).Immune system ::: PATHOGENESISThere have been several reports that indicated meager Cytolethal Distending Toxin\u2010induced lymphocytes, with a density as low as 200 cells/mm3 in three patients with SARS\u2010CoV infection (Chu et al., 2014; Zhou et al., 2014).", [["lung", "ANATOMY", 150, 154], ["interlobular septal", "ANATOMY", 190, 209], ["lymphocytes", "ANATOMY", 382, 393], ["cells", "ANATOMY", 424, 429], ["COVID", "DISEASE", 27, 32], ["pneumonia", "DISEASE", 60, 69], ["lung injury", "DISEASE", 150, 161], ["interlobular septal thickening", "DISEASE", 190, 220], ["bronchiectasis", "DISEASE", 235, 249], ["SARS", "DISEASE", 457, 461], ["CoV infection", "DISEASE", 462, 475], ["patients", "ORGANISM", 39, 47], ["lung", "ORGAN", 150, 154], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 190, 209], ["Cytolethal Distending Toxin\u2010induced lymphocytes", "CELL", 346, 393], ["patients", "ORGANISM", 443, 451], ["CoV", "ORGANISM", 462, 465], ["Cytolethal Distending Toxin\u2010induced lymphocytes", "CELL_LINE", 346, 393], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 443, 451], ["COVID\u2010", "TREATMENT", 27, 33], ["severe pneumonia", "PROBLEM", 53, 69], ["fibrotic changes", "PROBLEM", 96, 112], ["lung injury", "PROBLEM", 150, 161], ["reticulation", "PROBLEM", 176, 188], ["interlobular septal thickening", "PROBLEM", 190, 220], ["traction bronchiectasis", "PROBLEM", 226, 249], ["meager Cytolethal Distending Toxin\u2010induced lymphocytes", "PROBLEM", 339, 393], ["a density", "PROBLEM", 400, 409], ["SARS", "PROBLEM", 457, 461], ["CoV infection", "PROBLEM", 462, 475], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["pneumonia", "OBSERVATION", 60, 69], ["array", "OBSERVATION_MODIFIER", 87, 92], ["fibrotic", "OBSERVATION", 96, 104], ["late stages", "OBSERVATION_MODIFIER", 135, 146], ["lung", "ANATOMY", 150, 154], ["injury", "OBSERVATION", 155, 161], ["reticulation", "OBSERVATION_MODIFIER", 176, 188], ["interlobular", "ANATOMY_MODIFIER", 190, 202], ["septal", "ANATOMY_MODIFIER", 203, 209], ["thickening", "OBSERVATION", 210, 220], ["traction", "OBSERVATION_MODIFIER", 226, 234], ["bronchiectasis", "OBSERVATION", 235, 249], ["Distending", "OBSERVATION_MODIFIER", 357, 367], ["Toxin\u2010induced lymphocytes", "OBSERVATION", 368, 393], ["density", "OBSERVATION", 402, 409], ["infection", "OBSERVATION", 466, 475]]], ["As in the case of SARS\u2010CoV\u20102, it has been suspected that infection with this type of CoV might lead to inflammatory cytokine storm (Chen, Liu, et al., 2020; Zumla et al., 2020); a life\u2010threatening condition characterized by elevated levels of interleukin 6 (IL\u20106) in plasma.", [["plasma", "ANATOMY", 267, 273], ["SARS", "DISEASE", 18, 22], ["infection", "DISEASE", 57, 66], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 23, 28], ["CoV", "ORGANISM", 85, 88], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 243, 256], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 258, 262], ["plasma", "ORGANISM_SUBSTANCE", 267, 273], ["inflammatory cytokine", "PROTEIN", 103, 124], ["interleukin 6", "PROTEIN", 243, 256], ["IL\u20106", "PROTEIN", 258, 262], ["SARS", "PROBLEM", 18, 22], ["infection", "PROBLEM", 57, 66], ["CoV", "PROBLEM", 85, 88], ["inflammatory cytokine storm", "PROBLEM", 103, 130], ["a life\u2010threatening condition", "PROBLEM", 178, 206], ["elevated levels of interleukin", "PROBLEM", 224, 254], ["infection", "OBSERVATION", 57, 66], ["inflammatory", "OBSERVATION_MODIFIER", 103, 115]]], ["A number of investigations recently conducted on COVID\u201019 have reported that IL\u20106 levels was actually higher in the patients with severe disease (Cai, 2020; Chen, Liu, et al., 2020; Xiang et al., 2020).", [["IL\u20106", "GENE_OR_GENE_PRODUCT", 77, 81], ["patients", "ORGANISM", 116, 124], ["IL\u20106", "PROTEIN", 77, 81], ["patients", "SPECIES", 116, 124], ["IL\u20106 levels", "TEST", 77, 88], ["severe disease", "PROBLEM", 130, 144], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["disease", "OBSERVATION", 137, 144]]], ["This could highlight the importance of IL\u20106 as a biomarker for evaluation of disease severity (Chen, Zhao, et al., 2020).Liver damage ::: PATHOGENESISImpaired liver function tests have been reported for a number of patients with SARS\u2010CoV\u20102 infection, suggesting hepatic damage as an extrapulmonary complication of COVID\u201019 in almost one half of the patients (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020).", [["Liver", "ANATOMY", 121, 126], ["liver", "ANATOMY", 159, 164], ["hepatic", "ANATOMY", 262, 269], ["Liver damage", "DISEASE", 121, 133], ["SARS", "DISEASE", 229, 233], ["infection", "DISEASE", 240, 249], ["hepatic damage", "DISEASE", 262, 276], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 39, 43], ["Liver", "ORGAN", 121, 126], ["liver", "ORGAN", 159, 164], ["patients", "ORGANISM", 215, 223], ["hepatic", "ORGAN", 262, 269], ["patients", "ORGANISM", 349, 357], ["IL\u20106", "PROTEIN", 39, 43], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 349, 357], ["a biomarker", "TEST", 47, 58], ["evaluation", "TEST", 63, 73], ["disease severity", "PROBLEM", 77, 93], ["Liver damage", "PROBLEM", 121, 133], ["PATHOGENESISImpaired liver function tests", "TEST", 138, 179], ["SARS", "PROBLEM", 229, 233], ["CoV\u20102 infection", "PROBLEM", 234, 249], ["hepatic damage", "PROBLEM", 262, 276], ["an extrapulmonary complication", "PROBLEM", 280, 310], ["COVID\u2010", "TREATMENT", 314, 320], ["damage", "OBSERVATION", 127, 133], ["liver", "ANATOMY", 159, 164], ["infection", "OBSERVATION", 240, 249], ["suggesting", "UNCERTAINTY", 251, 261], ["hepatic", "ANATOMY", 262, 269], ["damage", "OBSERVATION", 270, 276], ["extrapulmonary", "ANATOMY", 283, 297], ["complication", "OBSERVATION", 298, 310]]], ["A recent study has concluded that liver function abnormality might stem from infection of bile duct cells with SARS\u2010CoV\u20102.", [["liver", "ANATOMY", 34, 39], ["bile duct cells", "ANATOMY", 90, 105], ["liver function abnormality", "DISEASE", 34, 60], ["infection of bile duct", "DISEASE", 77, 99], ["SARS", "DISEASE", 111, 115], ["liver", "ORGAN", 34, 39], ["bile duct cells", "CELL", 90, 105], ["bile duct cells", "CELL_TYPE", 90, 105], ["A recent study", "TEST", 0, 14], ["liver function abnormality", "PROBLEM", 34, 60], ["infection of bile duct cells", "PROBLEM", 77, 105], ["SARS", "PROBLEM", 111, 115], ["liver", "ANATOMY", 34, 39], ["infection", "OBSERVATION", 77, 86], ["bile duct", "ANATOMY", 90, 99]]], ["Nonetheless, the alkaline phosphatase value, which is an index of bile duct damage, were not specific in patients with COVID\u201019 (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020).", [["bile duct", "ANATOMY", 66, 75], ["bile duct damage", "DISEASE", 66, 82], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 17, 37], ["bile duct", "MULTI-TISSUE_STRUCTURE", 66, 75], ["patients", "ORGANISM", 105, 113], ["alkaline phosphatase", "PROTEIN", 17, 37], ["patients", "SPECIES", 105, 113], ["the alkaline phosphatase value", "TEST", 13, 43], ["bile duct damage", "PROBLEM", 66, 82], ["bile duct", "ANATOMY", 66, 75]]], ["Investigation of liver biopsy specimens was accompanied by new pathological findings.", [["liver biopsy specimens", "ANATOMY", 17, 39], ["liver biopsy specimens", "CANCER", 17, 39], ["Investigation of liver biopsy specimens", "TEST", 0, 39], ["new pathological findings", "PROBLEM", 59, 84], ["liver", "ANATOMY", 17, 22], ["biopsy", "OBSERVATION", 23, 29], ["new", "OBSERVATION_MODIFIER", 59, 62], ["pathological", "OBSERVATION", 63, 75]]], ["Scientists have reported moderate microvascular steatosis, and mild lobular and portal activity in these patients, that suggests liver damage may have arisen from either SARS\u2010CoV\u20102 infection or drug\u2010induced liver (Xu et al., 2020).Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes ::: PATHOGENESISAn essential player in maintenance of electrolyte balance and blood pressure, ACE2 is regarded by many as the principal counter\u2010regulatory arm in the axis of renin\u2013angiotensin\u2010aldosterone system (RAAS; Santos, Ferreira, & Sim\u00f5es e Silva, 2008).", [["microvascular", "ANATOMY", 34, 47], ["lobular", "ANATOMY", 68, 75], ["portal", "ANATOMY", 80, 86], ["liver", "ANATOMY", 129, 134], ["liver", "ANATOMY", 207, 212], ["Myocardial", "ANATOMY", 231, 241], ["gastrointestinal", "ANATOMY", 243, 259], ["renal", "ANATOMY", 265, 270], ["blood", "ANATOMY", 387, 392], ["steatosis", "DISEASE", 48, 57], ["liver damage", "DISEASE", 129, 141], ["SARS", "DISEASE", 170, 174], ["CoV\u20102", "CHEMICAL", 175, 180], ["infection", "DISEASE", 181, 190], ["Myocardial, gastrointestinal, and renal symptoms", "DISEASE", 231, 279], ["renin\u2013angiotensin\u2010aldosterone", "CHEMICAL", 483, 512], ["microvascular", "TISSUE", 34, 47], ["lobular", "PATHOLOGICAL_FORMATION", 68, 75], ["portal", "MULTI-TISSUE_STRUCTURE", 80, 86], ["patients", "ORGANISM", 105, 113], ["liver", "ORGAN", 129, 134], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 175, 180], ["liver", "ORGAN", 207, 212], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 231, 241], ["gastrointestinal", "ORGAN", 243, 259], ["renal", "ORGAN", 265, 270], ["electrolyte", "SIMPLE_CHEMICAL", 363, 374], ["blood", "ORGANISM_SUBSTANCE", 387, 392], ["ACE2", "GENE_OR_GENE_PRODUCT", 403, 407], ["renin\u2013angiotensin\u2010aldosterone", "SIMPLE_CHEMICAL", 483, 512], ["ACE2", "PROTEIN", 403, 407], ["patients", "SPECIES", 105, 113], ["moderate microvascular steatosis", "PROBLEM", 25, 57], ["mild lobular and portal activity in these patients", "PROBLEM", 63, 113], ["liver damage", "PROBLEM", 129, 141], ["SARS", "PROBLEM", 170, 174], ["CoV\u20102 infection", "PROBLEM", 175, 190], ["drug\u2010induced liver", "PROBLEM", 194, 212], ["Myocardial, gastrointestinal, and renal symptoms", "PROBLEM", 231, 279], ["electrolyte balance", "TEST", 363, 382], ["blood pressure", "TEST", 387, 401], ["ACE2", "TEST", 403, 407], ["moderate", "OBSERVATION_MODIFIER", 25, 33], ["microvascular", "ANATOMY", 34, 47], ["steatosis", "OBSERVATION", 48, 57], ["mild", "OBSERVATION_MODIFIER", 63, 67], ["lobular", "OBSERVATION", 68, 75], ["portal", "ANATOMY", 80, 86], ["activity", "OBSERVATION_MODIFIER", 87, 95], ["liver", "ANATOMY", 129, 134], ["damage", "OBSERVATION", 135, 141], ["infection", "OBSERVATION", 181, 190], ["liver", "ANATOMY", 207, 212], ["gastrointestinal", "ANATOMY", 243, 259], ["renal", "ANATOMY", 265, 270], ["electrolyte balance", "OBSERVATION", 363, 382]]], ["Upon infection, SARS\u2010CoV\u20102 binds ACE2.", [["infection", "DISEASE", 5, 14], ["SARS", "DISEASE", 16, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 33, 37], ["CoV\u20102", "PROTEIN", 21, 26], ["ACE2", "PROTEIN", 33, 37], ["SARS\u2010CoV", "SPECIES", 16, 24], ["infection", "PROBLEM", 5, 14], ["SARS", "PROBLEM", 16, 20], ["infection", "OBSERVATION", 5, 14]]], ["This results in degradation of ACE2, which subsequently dampens the counter\u2010effect of ACE2 on RAAS.", [["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["ACE2", "GENE_OR_GENE_PRODUCT", 86, 90], ["RAAS", "GENE_OR_GENE_PRODUCT", 94, 98], ["ACE2", "PROTEIN", 31, 35], ["ACE2", "PROTEIN", 86, 90], ["RAAS", "PROTEIN", 94, 98], ["ACE2", "TEST", 31, 35], ["ACE2 on RAAS", "TREATMENT", 86, 98]]], ["The final effect of ACE2 in an otherwise healthy adult is to increase reabsorption of sodium and the reciprocal excretion of potassium ions (K+).", [["sodium", "CHEMICAL", 86, 92], ["potassium", "CHEMICAL", 125, 134], ["K", "CHEMICAL", 141, 142], ["sodium", "CHEMICAL", 86, 92], ["potassium", "CHEMICAL", 125, 134], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["sodium", "SIMPLE_CHEMICAL", 86, 92], ["potassium ions", "SIMPLE_CHEMICAL", 125, 139], ["K+", "SIMPLE_CHEMICAL", 141, 143], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "TREATMENT", 20, 24], ["reabsorption of sodium", "TREATMENT", 70, 92], ["potassium ions", "TREATMENT", 125, 139], ["K", "TEST", 141, 142]]], ["The concomitant re\u2010uptake of water with sodium reabsorption prompts an increase in blood pressure (Weir & Rolfe, 2010).", [["blood", "ANATOMY", 83, 88], ["sodium", "CHEMICAL", 40, 46], ["increase in blood pressure", "DISEASE", 71, 97], ["sodium", "CHEMICAL", 40, 46], ["sodium", "SIMPLE_CHEMICAL", 40, 46], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["sodium reabsorption", "TREATMENT", 40, 59], ["blood pressure", "TEST", 83, 97], ["increase", "OBSERVATION_MODIFIER", 71, 79]]], ["Potassium is the predominant intracellular ion, that is majorly involved in regulation of cell membrane polarity.", [["intracellular", "ANATOMY", 29, 42], ["cell membrane", "ANATOMY", 90, 103], ["Potassium", "CHEMICAL", 0, 9], ["Potassium", "CHEMICAL", 0, 9], ["Potassium", "SIMPLE_CHEMICAL", 0, 9], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["cell membrane", "CELLULAR_COMPONENT", 90, 103], ["Potassium", "TEST", 0, 9], ["predominant", "OBSERVATION_MODIFIER", 17, 28], ["intracellular ion", "OBSERVATION", 29, 46], ["majorly", "OBSERVATION_MODIFIER", 56, 63], ["cell membrane polarity", "OBSERVATION", 90, 112]]], ["Too low levels of K+ in blood, known as hypokalemia, can result in cellular hyper\u2010polarity.", [["blood", "ANATOMY", 24, 29], ["cellular", "ANATOMY", 67, 75], ["K", "CHEMICAL", 18, 19], ["hypokalemia", "DISEASE", 40, 51], ["hyper\u2010polarity", "DISEASE", 76, 90], ["K+", "CHEMICAL", 18, 20], ["K+", "SIMPLE_CHEMICAL", 18, 20], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["cellular", "CELL", 67, 75], ["K", "PROTEIN", 18, 19], ["K+ in blood", "PROBLEM", 18, 29], ["hypokalemia", "PROBLEM", 40, 51], ["cellular hyper\u2010polarity", "PROBLEM", 67, 90], ["low levels", "OBSERVATION_MODIFIER", 4, 14], ["hypokalemia", "OBSERVATION", 40, 51], ["cellular hyper\u2010polarity", "OBSERVATION", 67, 90]]], ["A hyper\u2010polarized cell membrane tends to be depolarized faster than normal, causing aberrancy in the function of cardiac cells (Bielecka\u2010Dabrowa et al., 2012).Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes ::: PATHOGENESISIn a recent cohort study, patients diagnosed with COVID\u201019 were categorized into three groups: severe hypokalemia, hypokalemia, and normokalemia.", [["cell membrane", "ANATOMY", 18, 31], ["cardiac cells", "ANATOMY", 113, 126], ["Myocardial", "ANATOMY", 159, 169], ["gastrointestinal", "ANATOMY", 171, 187], ["renal", "ANATOMY", 193, 198], ["Myocardial, gastrointestinal, and renal symptoms", "DISEASE", 159, 207], ["hypokalemia", "DISEASE", 355, 366], ["hypokalemia", "DISEASE", 368, 379], ["normokalemia", "DISEASE", 385, 397], ["cell membrane", "CELLULAR_COMPONENT", 18, 31], ["cardiac cells", "CELL", 113, 126], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 159, 169], ["gastrointestinal", "ORGAN", 171, 187], ["renal", "ORGAN", 193, 198], ["patients", "ORGANISM", 279, 287], ["cardiac cells", "CELL_TYPE", 113, 126], ["patients", "SPECIES", 279, 287], ["A hyper\u2010polarized cell membrane", "PROBLEM", 0, 31], ["aberrancy", "PROBLEM", 84, 93], ["Myocardial, gastrointestinal, and renal symptoms", "PROBLEM", 159, 207], ["a recent cohort study", "TEST", 256, 277], ["COVID", "TEST", 303, 308], ["severe hypokalemia", "PROBLEM", 348, 366], ["hypokalemia", "PROBLEM", 368, 379], ["normokalemia", "PROBLEM", 385, 397], ["hyper\u2010polarized cell membrane", "OBSERVATION", 2, 31], ["cardiac cells", "ANATOMY", 113, 126], ["gastrointestinal", "ANATOMY", 171, 187], ["renal", "ANATOMY", 193, 198], ["severe", "OBSERVATION_MODIFIER", 348, 354], ["hypokalemia", "OBSERVATION", 355, 366], ["hypokalemia", "OBSERVATION", 368, 379]]], ["The study reported that 93% of patients with a severe clinical condition had hypokalemia.", [["hypokalemia", "DISEASE", 77, 88], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["The study", "TEST", 0, 9], ["a severe clinical condition", "PROBLEM", 45, 72], ["hypokalemia", "PROBLEM", 77, 88], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["hypokalemia", "OBSERVATION", 77, 88]]], ["Scientists did not find a direct link between gastrointestinal symptoms and hypokalemia among 108 patients with both severe or moderate hypokalemia.", [["gastrointestinal", "ANATOMY", 46, 62], ["gastrointestinal symptoms", "DISEASE", 46, 71], ["hypokalemia", "DISEASE", 76, 87], ["hypokalemia", "DISEASE", 136, 147], ["gastrointestinal", "ORGAN", 46, 62], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["gastrointestinal symptoms", "PROBLEM", 46, 71], ["hypokalemia", "PROBLEM", 76, 87], ["moderate hypokalemia", "PROBLEM", 127, 147], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["moderate", "OBSERVATION_MODIFIER", 127, 135], ["hypokalemia", "OBSERVATION", 136, 147]]], ["Further investigations established an association between parameters such as body temperature, creatine kinase (CK), creatine kinase myocardial band (CK\u2010MB), lactate dehydrogenase (LDH), and C\u2010reactive protein (CRP) with the severity of hypokalemia.", [["body", "ANATOMY", 77, 81], ["creatine", "CHEMICAL", 95, 103], ["creatine", "CHEMICAL", 117, 125], ["lactate", "CHEMICAL", 158, 165], ["hypokalemia", "DISEASE", 237, 248], ["creatine", "CHEMICAL", 95, 103], ["creatine", "CHEMICAL", 117, 125], ["lactate", "CHEMICAL", 158, 165], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 95, 110], ["CK", "GENE_OR_GENE_PRODUCT", 112, 114], ["creatine kinase myocardial band", "GENE_OR_GENE_PRODUCT", 117, 148], ["CK\u2010MB", "GENE_OR_GENE_PRODUCT", 150, 155], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 158, 179], ["LDH", "GENE_OR_GENE_PRODUCT", 181, 184], ["C\u2010reactive protein", "GENE_OR_GENE_PRODUCT", 191, 209], ["CRP", "GENE_OR_GENE_PRODUCT", 211, 214], ["creatine kinase", "PROTEIN", 95, 110], ["CK", "PROTEIN", 112, 114], ["creatine kinase", "PROTEIN", 117, 132], ["CK", "PROTEIN", 150, 152], ["lactate dehydrogenase", "PROTEIN", 158, 179], ["LDH", "PROTEIN", 181, 184], ["C\u2010reactive protein", "PROTEIN", 191, 209], ["CRP", "PROTEIN", 211, 214], ["Further investigations", "TEST", 0, 22], ["body temperature", "TEST", 77, 93], ["creatine kinase", "TEST", 95, 110], ["CK", "TEST", 112, 114], ["creatine kinase", "TEST", 117, 132], ["myocardial band", "TEST", 133, 148], ["CK\u2010MB", "TEST", 150, 155], ["lactate dehydrogenase (LDH)", "TEST", 158, 185], ["C\u2010reactive protein", "TEST", 191, 209], ["CRP", "TEST", 211, 214], ["hypokalemia", "PROBLEM", 237, 248], ["hypokalemia", "OBSERVATION", 237, 248]]], ["Reportedly, hypokalemia was most often observed with patients who had elevated levels of serum CK, CK\u2010MB, LDH, and CRP.", [["serum", "ANATOMY", 89, 94], ["hypokalemia", "DISEASE", 12, 23], ["patients", "ORGANISM", 53, 61], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["CK", "GENE_OR_GENE_PRODUCT", 95, 97], ["CK", "GENE_OR_GENE_PRODUCT", 99, 101], ["MB", "SIMPLE_CHEMICAL", 102, 104], ["LDH", "GENE_OR_GENE_PRODUCT", 106, 109], ["CRP", "GENE_OR_GENE_PRODUCT", 115, 118], ["serum CK", "PROTEIN", 89, 97], ["CK", "PROTEIN", 99, 101], ["LDH", "PROTEIN", 106, 109], ["CRP", "PROTEIN", 115, 118], ["patients", "SPECIES", 53, 61], ["hypokalemia", "PROBLEM", 12, 23], ["elevated levels", "PROBLEM", 70, 85], ["serum CK", "TEST", 89, 97], ["CK", "TEST", 99, 101], ["MB", "TEST", 102, 104], ["LDH", "TEST", 106, 109], ["CRP", "TEST", 115, 118], ["hypokalemia", "OBSERVATION", 12, 23], ["LDH", "ANATOMY", 106, 109]]], ["Potassium (K+) loss in the urine was determined to be the primary cause of hypokalemia.Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes ::: PATHOGENESISHypokalemia requires strenuous efforts to be corrected.", [["urine", "ANATOMY", 27, 32], ["Myocardial", "ANATOMY", 87, 97], ["gastrointestinal", "ANATOMY", 99, 115], ["renal", "ANATOMY", 121, 126], ["Potassium", "CHEMICAL", 0, 9], ["K", "CHEMICAL", 11, 12], ["hypokalemia", "DISEASE", 75, 86], ["Myocardial, gastrointestinal, and renal symptoms", "DISEASE", 87, 135], ["Potassium", "CHEMICAL", 0, 9], ["K+)", "CHEMICAL", 11, 14], ["Potassium", "SIMPLE_CHEMICAL", 0, 9], ["K+", "SIMPLE_CHEMICAL", 11, 13], ["urine", "ORGANISM_SUBSTANCE", 27, 32], ["Myocardial", "MULTI-TISSUE_STRUCTURE", 87, 97], ["gastrointestinal", "ORGAN", 99, 115], ["renal", "ORGAN", 121, 126], ["Potassium", "TEST", 0, 9], ["K", "TEST", 11, 12], ["loss in the urine", "PROBLEM", 15, 32], ["hypokalemia", "PROBLEM", 75, 86], ["Myocardial, gastrointestinal, and renal symptoms", "PROBLEM", 87, 135], ["homeostasis of electrolytes", "PROBLEM", 137, 164], ["PATHOGENESISHypokalemia", "PROBLEM", 169, 192], ["strenuous efforts", "TREATMENT", 202, 219], ["hypokalemia", "OBSERVATION", 75, 86], ["gastrointestinal", "ANATOMY", 99, 115], ["renal", "ANATOMY", 121, 126]]], ["This is chiefly due to the incessant loss of K+ in the urine, as a result of ACE2 degradation.", [["urine", "ANATOMY", 55, 60], ["K", "CHEMICAL", 45, 46], ["K+", "CHEMICAL", 45, 47], ["K+", "SIMPLE_CHEMICAL", 45, 47], ["urine", "ORGANISM_SUBSTANCE", 55, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["K", "PROTEIN", 45, 46], ["ACE2", "PROTEIN", 77, 81], ["the incessant loss of K+ in the urine", "PROBLEM", 23, 60], ["ACE2 degradation", "PROBLEM", 77, 93]]], ["In the case of COVID\u201019\u2010associated hypokalemia, however, the patients seemed to respond well to potassium supplements when the critical phase had passed [49].", [["hypokalemia", "DISEASE", 35, 46], ["potassium", "CHEMICAL", 96, 105], ["potassium", "CHEMICAL", 96, 105], ["patients", "ORGANISM", 61, 69], ["potassium", "SIMPLE_CHEMICAL", 96, 105], ["patients", "SPECIES", 61, 69], ["\u2010associated hypokalemia", "PROBLEM", 23, 46], ["potassium supplements", "TREATMENT", 96, 117], ["hypokalemia", "OBSERVATION", 35, 46]]], ["Therefore, one should consider the impact of hypokalemia in COVID\u201019 morbidity, and its effect on the outcomes of treatment.", [["hypokalemia", "DISEASE", 45, 56], ["COVID", "DISEASE", 60, 65], ["hypokalemia", "PROBLEM", 45, 56], ["treatment", "TREATMENT", 114, 123], ["hypokalemia", "OBSERVATION", 45, 56]]], ["This is a condition that must be carefully addressed for, as patients with COVID\u201019 are more inclined to develop dysfunctions in heart, lungs, and other vital organs (Li, Hu, Su, & Dai, 2020).Sex ::: POSSIBLE FACTORS CORRELATED WITH COVID\u201019Several studies have sought to compare the sex differences in the clinical findings of severe COVID\u201019.", [["heart", "ANATOMY", 129, 134], ["lungs", "ANATOMY", 136, 141], ["organs", "ANATOMY", 159, 165], ["COVID", "DISEASE", 335, 340], ["patients", "ORGANISM", 61, 69], ["heart", "ORGAN", 129, 134], ["lungs", "ORGAN", 136, 141], ["organs", "ORGAN", 159, 165], ["patients", "SPECIES", 61, 69], ["dysfunctions in heart, lungs, and other vital organs", "PROBLEM", 113, 165], ["19Several studies", "TEST", 239, 256], ["severe COVID\u2010", "PROBLEM", 328, 341], ["dysfunctions", "OBSERVATION", 113, 125], ["heart", "ANATOMY", 129, 134], ["lungs", "ANATOMY", 136, 141]]], ["In one study, scientists investigated 47 patients with COVID\u201019, 28 (59.6%) of whom were men.", [["COVID", "DISEASE", 55, 60], ["patients", "ORGANISM", 41, 49], ["men", "ORGANISM", 89, 92], ["patients", "SPECIES", 41, 49], ["men", "SPECIES", 89, 92], ["COVID", "TEST", 55, 60]]], ["Procalcitonin (PCT) level was reported to be higher in men than in women.", [["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["PCT", "GENE_OR_GENE_PRODUCT", 15, 18], ["men", "ORGANISM", 55, 58], ["women", "ORGANISM", 67, 72], ["PCT", "PROTEIN", 15, 18], ["men", "SPECIES", 55, 58], ["women", "SPECIES", 67, 72], ["Procalcitonin (PCT) level", "TEST", 0, 25]]], ["The results also showed higher amounts of serum N\u2010terminal\u2010pro brain natriuretic peptide, as increased levels of the molecule were detected in men 57.1% than women 26.3%.", [["serum", "ANATOMY", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 63, 88], ["men", "ORGANISM", 143, 146], ["women", "ORGANISM", 158, 163], ["men", "SPECIES", 143, 146], ["women", "SPECIES", 158, 163], ["higher amounts of serum N\u2010terminal\u2010pro brain natriuretic peptide", "PROBLEM", 24, 88], ["increased levels of the molecule", "PROBLEM", 93, 125]]], ["Furthermore, 17.9% of male patients were reported test\u2010positive for influenza A antibody, whereas no such records were registered for female patients.", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 141, 149], ["influenza A antibody", "PROTEIN", 68, 88], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 141, 149], ["influenza A antibody", "PROBLEM", 68, 88]]], ["During a 2\u2010week stay at the hospital, 17.9% of male, and 5.3% of female patients deteriorated, and hence were reassigned to the critical\u2010type group.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80]]], ["There was no mortality reports among women, whereas 3.6% of male patients had deceased due to COVID\u201019 complications.", [["COVID", "DISEASE", 94, 99], ["women", "ORGANISM", 37, 42], ["patients", "ORGANISM", 65, 73], ["women", "SPECIES", 37, 42], ["patients", "SPECIES", 65, 73], ["COVID\u201019 complications", "PROBLEM", 94, 116], ["no", "UNCERTAINTY", 10, 12]]], ["A total of 21.1% and 3.6% of female and male patients successfully recovered, and were discharged from the hospital.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Based on the current evidence, men are more likely to develop complications, and experience worse in\u2010hospital outcomes compared with women (Li, Zhang, et al., 2020).Pregnancy ::: POSSIBLE FACTORS CORRELATED WITH COVID\u201019A group of researchers led by Chen investigated the clinical characteristics of SARS\u2010CoV\u20102 infection in nine pregnant women.", [["SARS", "DISEASE", 300, 304], ["CoV\u20102 infection", "DISEASE", 305, 320], ["men", "ORGANISM", 31, 34], ["women", "ORGANISM", 133, 138], ["women", "ORGANISM", 338, 343], ["men", "SPECIES", 31, 34], ["women", "SPECIES", 133, 138], ["women", "SPECIES", 338, 343], ["SARS\u2010CoV\u20102", "SPECIES", 300, 310], ["complications", "PROBLEM", 62, 75], ["SARS", "PROBLEM", 300, 304], ["CoV\u20102 infection", "PROBLEM", 305, 320], ["more likely", "UNCERTAINTY", 39, 50], ["infection", "OBSERVATION", 311, 320]]], ["Their aim was to evaluate the likelihood of intrauterine/vertical transmission of SARS\u2010CoV\u20102 from mother to baby.", [["intrauterine", "ANATOMY", 44, 56], ["SARS", "DISEASE", 82, 86], ["intrauterine", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 56], ["CoV", "ORGANISM", 87, 90], ["SARS\u2010CoV", "SPECIES", 82, 90]]], ["All of the women who were being investigated had cesarean section in the third trimester of their previous pregnancies.", [["women", "ORGANISM", 11, 16], ["women", "SPECIES", 11, 16], ["cesarean section", "TREATMENT", 49, 65]]], ["Seven patients were febrile, and variably presented other symptoms such as cough, sore throat, myalgia, and malaise.", [["febrile", "DISEASE", 20, 27], ["cough", "DISEASE", 75, 80], ["sore throat", "DISEASE", 82, 93], ["myalgia", "DISEASE", 95, 102], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["febrile", "PROBLEM", 20, 27], ["other symptoms", "PROBLEM", 52, 66], ["cough", "PROBLEM", 75, 80], ["sore throat", "PROBLEM", 82, 93], ["myalgia", "PROBLEM", 95, 102], ["malaise", "PROBLEM", 108, 115], ["febrile", "OBSERVATION", 20, 27], ["sore throat", "ANATOMY", 82, 93], ["myalgia", "OBSERVATION", 95, 102], ["malaise", "OBSERVATION", 108, 115]]], ["Fetal distress was reported in two cases.", [["Fetal", "ANATOMY", 0, 5], ["Fetal distress", "DISEASE", 0, 14], ["Fetal", "ORGAN", 0, 5], ["Fetal distress", "PROBLEM", 0, 14], ["distress", "OBSERVATION", 6, 14]]], ["Lymphopenia and increased aminotransferase activity were observed in five and three patients, respectively.", [["Lymphopenia", "DISEASE", 0, 11], ["aminotransferase", "SIMPLE_CHEMICAL", 26, 42], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["Lymphopenia", "PROBLEM", 0, 11], ["increased aminotransferase activity", "PROBLEM", 16, 51], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["aminotransferase activity", "OBSERVATION", 26, 51]]], ["There was no mortality cases, as none of the patients in the study developed severe COVID\u201019\u2010associated pneumonia.", [["COVID", "DISEASE", 84, 89], ["pneumonia", "DISEASE", 104, 113], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["mortality cases", "PROBLEM", 13, 28], ["the study", "TEST", 57, 66], ["severe COVID\u201019\u2010associated pneumonia", "PROBLEM", 77, 113], ["no", "UNCERTAINTY", 10, 12], ["pneumonia", "OBSERVATION", 104, 113]]], ["The newborns displayed no signs of asphyxia.", [["asphyxia", "DISEASE", 35, 43], ["newborns", "ORGANISM", 4, 12], ["asphyxia", "PROBLEM", 35, 43], ["no signs of", "UNCERTAINTY", 23, 34], ["asphyxia", "OBSERVATION", 35, 43]]], ["A 1\u2010min Apgar score of 8\u20139, and a 5\u2010min Apgar score of 9\u201310 were calculated for all nine newborns.", [["newborns", "ORGANISM", 89, 97], ["A 1\u2010min Apgar score", "TEST", 0, 19], ["a 5\u2010min Apgar score", "TEST", 32, 51]]], ["Samples collected from six patients, including amniotic fluid, cord blood, neonatal throat swab, and breastmilk proved test\u2010negative for SARS\u2010CoV\u20102.", [["Samples", "ANATOMY", 0, 7], ["amniotic fluid", "ANATOMY", 47, 61], ["cord blood", "ANATOMY", 63, 73], ["throat swab", "ANATOMY", 84, 95], ["SARS", "DISEASE", 137, 141], ["patients", "ORGANISM", 27, 35], ["amniotic fluid", "ORGANISM_SUBSTANCE", 47, 61], ["cord blood", "ORGANISM_SUBSTANCE", 63, 73], ["throat", "ORGANISM_SUBDIVISION", 84, 90], ["swab", "ORGANISM_SUBSTANCE", 91, 95], ["patients", "SPECIES", 27, 35], ["SARS\u2010CoV", "SPECIES", 137, 145], ["Samples", "TEST", 0, 7], ["amniotic fluid", "TEST", 47, 61], ["cord blood", "TEST", 63, 73], ["neonatal throat swab", "TEST", 75, 95], ["breastmilk", "TREATMENT", 101, 111], ["SARS", "PROBLEM", 137, 141], ["amniotic fluid", "OBSERVATION", 47, 61], ["cord", "ANATOMY", 63, 67]]], ["The clinical features of COVID\u201019\u2010associated pneumonia observed in these pregnant women shared a great similarity to characteristics reported for COVID\u201019\u2010associated pneumonia in nonpregnant adult patients (Chen, Guo, et al., 2020).Blood type ::: POSSIBLE FACTORS CORRELATED WITH COVID\u201019In a recent investigation, scientists in China looked into the pattern of blood type distribution in 2,173 patients in three hospitals, who had been confirmed to have SARS\u2010CoV\u20102 infection.", [["Blood", "ANATOMY", 232, 237], ["blood", "ANATOMY", 362, 367], ["COVID", "DISEASE", 25, 30], ["pneumonia", "DISEASE", 45, 54], ["pneumonia", "DISEASE", 166, 175], ["SARS", "DISEASE", 455, 459], ["CoV\u20102 infection", "DISEASE", 460, 475], ["women", "ORGANISM", 82, 87], ["patients", "ORGANISM", 197, 205], ["Blood", "ORGANISM_SUBSTANCE", 232, 237], ["blood", "ORGANISM_SUBSTANCE", 362, 367], ["patients", "ORGANISM", 395, 403], ["women", "SPECIES", 82, 87], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 395, 403], ["COVID\u201019\u2010associated pneumonia", "PROBLEM", 25, 54], ["COVID\u201019\u2010associated pneumonia", "PROBLEM", 146, 175], ["a recent investigation", "TEST", 291, 313], ["SARS\u2010CoV\u20102 infection", "PROBLEM", 455, 475], ["pneumonia", "OBSERVATION", 45, 54], ["pneumonia", "OBSERVATION", 166, 175], ["blood type", "OBSERVATION", 362, 372], ["infection", "OBSERVATION", 466, 475]]], ["Accordingly, they compared their findings regarding the blood type of patients with that of the healthy population who lived in the same area as the patients in the study.", [["blood", "ANATOMY", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 149, 157], ["the study", "TEST", 161, 170]]], ["Apparently, there was a higher prevalence of blood type A among the patients with COVID\u201019 than in the normal population.", [["blood", "ANATOMY", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["type A", "CANCER", 51, 57], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["COVID\u2010", "TREATMENT", 82, 88], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["normal", "OBSERVATION", 103, 109]]], ["On the contrary, it seemed that individuals with O blood type were spared somehow, as there were fewer patients with this blood type in this study (both p < .001).", [["blood", "ANATOMY", 51, 56], ["blood", "ANATOMY", 122, 127], ["blood", "ORGANISM_SUBSTANCE", 51, 56], ["patients", "ORGANISM", 103, 111], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["patients", "SPECIES", 103, 111], ["O blood type", "TEST", 49, 61], ["this blood type", "PROBLEM", 117, 132], ["this study", "TEST", 136, 146]]], ["A series of meta\u2010analyses on the available data indicated a significantly higher risk for COVID\u201019 in people with blood type A, relative to individuals with non\u2010A blood types.", [["blood", "ANATOMY", 114, 119], ["blood", "ANATOMY", 163, 168], ["people", "ORGANISM", 102, 108], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["people", "SPECIES", 102, 108], ["the available data", "TEST", 29, 47], ["COVID", "TEST", 90, 95], ["blood type A", "PROBLEM", 114, 126], ["A blood types", "TEST", 161, 174]]], ["However, an opposite scenario seemed to be true for the blood type O community, since, according to the literature, are less susceptible for contracting infectious diseases such as COVID\u201019 (Zhao et al., 2020).Presumed asymptomatic carrier\u2010based transmission of COVID\u201019 ::: ETIOLOGY: SOURCES AND MODES OF TRANSMISSIONInvestigation on a familial cluster of five patients concluded that SARS\u2010CoV\u20102 might have actually been transmitted by an asymptomatic carrier in the family (Bai et al., 2020).", [["blood", "ANATOMY", 56, 61], ["infectious diseases", "DISEASE", 153, 172], ["SARS", "DISEASE", 386, 390], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["patients", "ORGANISM", 362, 370], ["patients", "SPECIES", 362, 370], ["SARS\u2010CoV", "SPECIES", 386, 394], ["an opposite scenario", "PROBLEM", 9, 29], ["contracting infectious diseases", "PROBLEM", 141, 172], ["SARS", "PROBLEM", 386, 390], ["infectious", "OBSERVATION", 153, 163]]], ["Surprisingly, the first reverse transcription polymerase chain reaction (RT\u2010PCR) test of the asymptomatic family member was reported negative; a noteworthy example of a false\u2010negative result.", [["the first reverse transcription polymerase chain reaction", "PROBLEM", 14, 71], ["RT\u2010PCR", "TEST", 73, 79], ["a false\u2010negative result", "PROBLEM", 167, 190]]], ["Unwanted false\u2010negative results are inevitably reported due to a number of factors, for example, quality of the test kit, sufficiency of the collected sample, or performance of the test by clinicians.", [["the test kit", "TEST", 108, 120], ["the collected sample", "TEST", 137, 157], ["the test", "TEST", 177, 185]]], ["To this date, RT\u2010PCR has widely been used as a reliable diagnostic method (Corman et al., 2020).", [["RT\u2010PCR", "TREATMENT", 14, 20]]], ["Thus, her second RT\u2010PCR result, reported positive, was unlikely to have been a false\u2010positive result; hence, it was accepted as the definite evidence that the suspected person had indeed been infected with SARS\u2010CoV\u20102 (Bai et al., 2020).Presumed asymptomatic carrier\u2010based transmission of COVID\u201019 ::: ETIOLOGY: SOURCES AND MODES OF TRANSMISSIONThere was also another study that reported an asymptomatic young boy with COVID\u201019 infection.", [["SARS", "DISEASE", 206, 210], ["infection", "DISEASE", 427, 436], ["person", "ORGANISM", 169, 175], ["boy", "ORGANISM", 409, 412], ["person", "SPECIES", 169, 175], ["boy", "SPECIES", 409, 412], ["her second RT\u2010PCR", "TEST", 6, 23], ["another study", "TEST", 359, 372], ["COVID\u201019 infection", "PROBLEM", 418, 436], ["infected", "OBSERVATION", 192, 200], ["infection", "OBSERVATION", 427, 436]]], ["However, CT scans obtained from the subject exhibited abnormalities, indicative of an on\u2010going pulmonary pathology (Chan et al., 2020).", [["pulmonary", "ANATOMY", 95, 104], ["pulmonary", "ORGAN", 95, 104], ["CT scans", "TEST", 9, 17], ["abnormalities", "PROBLEM", 54, 67], ["an on\u2010going pulmonary pathology", "PROBLEM", 83, 114], ["abnormalities", "OBSERVATION", 54, 67], ["indicative of", "UNCERTAINTY", 69, 82], ["pulmonary", "ANATOMY", 95, 104], ["pathology", "OBSERVATION", 105, 114]]], ["If we presume that the findings regarding asymptomatic carrier\u2010based transmission of COVID\u201019 can be replicated, this would prove COVID\u201019 an overwhelmingly challenging issue to be controlled (Bai et al., 2020).", [["COVID\u2010", "TREATMENT", 85, 91]]], ["The incubation period for the asymptomatic patient in the case of familial cluster was 19 days.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50]]], ["Despite being a long period, it still perfectly falls in the suggested incubation period of 0\u201324 days (Bai et al., 2020; Guan et al., 2020).Clinical symptom spectrum ::: DIAGNOSISUnderstanding the otherwise nonspecific clinical signs and symptoms of COVID\u201019 is a crucial step toward appropriate management of the disease.", [["COVID", "DISEASE", 250, 255], ["symptoms", "PROBLEM", 238, 246], ["the disease", "PROBLEM", 310, 321], ["nonspecific", "OBSERVATION_MODIFIER", 207, 218], ["disease", "OBSERVATION", 314, 321]]], ["Patients mostly complain of fever, non\u2010productive cough, and body ache or extreme tiredness.", [["body", "ANATOMY", 61, 65], ["fever", "DISEASE", 28, 33], ["cough", "DISEASE", 50, 55], ["body ache", "DISEASE", 61, 70], ["tiredness", "DISEASE", 82, 91], ["Patients", "ORGANISM", 0, 8], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["ache", "ORGANISM_SUBDIVISION", 66, 70], ["Patients", "SPECIES", 0, 8], ["fever", "PROBLEM", 28, 33], ["non\u2010productive cough", "PROBLEM", 35, 55], ["body ache", "PROBLEM", 61, 70], ["extreme tiredness", "PROBLEM", 74, 91], ["fever", "OBSERVATION", 28, 33], ["cough", "OBSERVATION", 50, 55]]], ["In some cases, diarrhea and nausea precede fever by a few days, suggesting that fever might not be the initial manifestation of infection.", [["diarrhea", "DISEASE", 15, 23], ["nausea", "DISEASE", 28, 34], ["fever", "DISEASE", 43, 48], ["fever", "DISEASE", 80, 85], ["infection", "DISEASE", 128, 137], ["diarrhea", "PROBLEM", 15, 23], ["nausea", "PROBLEM", 28, 34], ["fever", "PROBLEM", 43, 48], ["fever", "PROBLEM", 80, 85], ["infection", "PROBLEM", 128, 137], ["diarrhea", "OBSERVATION", 15, 23], ["fever", "OBSERVATION", 80, 85], ["infection", "OBSERVATION", 128, 137]]], ["A small number of patients reportedly had headache, or even developed hemoptysis (Guan et al., 2020; Wang, Hu, et al., 2020).", [["headache", "DISEASE", 42, 50], ["hemoptysis", "DISEASE", 70, 80], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["headache", "PROBLEM", 42, 50], ["hemoptysis", "PROBLEM", 70, 80], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["hemoptysis", "OBSERVATION", 70, 80]]], ["Some patients remained asymptomatic, despite being tested positive for the disease (Chan et al., 2020).", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["asymptomatic", "PROBLEM", 23, 35], ["the disease", "PROBLEM", 71, 82], ["asymptomatic", "OBSERVATION", 23, 35]]], ["According to several studies, infection with SARS\u2010CoV\u20102 in the elderly, especially the male community, is more likely to result in severe alveolar damage and respiratory failure (Chen, Zhou, et al., 2020).", [["alveolar", "ANATOMY", 138, 146], ["respiratory", "ANATOMY", 158, 169], ["infection", "DISEASE", 30, 39], ["SARS", "DISEASE", 45, 49], ["CoV\u20102", "CHEMICAL", 50, 55], ["alveolar damage", "DISEASE", 138, 153], ["respiratory failure", "DISEASE", 158, 177], ["alveolar", "TISSUE", 138, 146], ["several studies", "TEST", 13, 28], ["infection", "PROBLEM", 30, 39], ["SARS", "PROBLEM", 45, 49], ["severe alveolar damage", "PROBLEM", 131, 153], ["respiratory failure", "PROBLEM", 158, 177], ["infection", "OBSERVATION", 30, 39], ["more likely to", "UNCERTAINTY", 106, 120], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["alveolar", "ANATOMY_MODIFIER", 138, 146], ["damage", "OBSERVATION", 147, 153], ["respiratory failure", "OBSERVATION", 158, 177]]], ["Occasionally, the disease may be demonstrated with a fulminant natural history, rapidly progressing to organ dysfunction, and even death in critical cases.", [["organ", "ANATOMY", 103, 108], ["organ dysfunction", "DISEASE", 103, 120], ["death", "DISEASE", 131, 136], ["organ", "ORGAN", 103, 108], ["the disease", "PROBLEM", 14, 25], ["a fulminant natural history", "PROBLEM", 51, 78], ["organ dysfunction", "PROBLEM", 103, 120], ["disease", "OBSERVATION", 18, 25], ["fulminant", "OBSERVATION_MODIFIER", 53, 62]]], ["Organ dysfunction includes conditions such as shock, ARDS, acute cardiac injury, and acute kidney injury (Huang et al., 2020; Wang, Hu, et al., 2020).", [["Organ", "ANATOMY", 0, 5], ["cardiac", "ANATOMY", 65, 72], ["kidney", "ANATOMY", 91, 97], ["Organ dysfunction", "DISEASE", 0, 17], ["shock", "DISEASE", 46, 51], ["ARDS", "DISEASE", 53, 57], ["acute cardiac injury", "DISEASE", 59, 79], ["acute kidney injury", "DISEASE", 85, 104], ["cardiac", "ORGAN", 65, 72], ["kidney", "ORGAN", 91, 97], ["Organ dysfunction", "PROBLEM", 0, 17], ["shock", "PROBLEM", 46, 51], ["ARDS", "PROBLEM", 53, 57], ["acute cardiac injury", "PROBLEM", 59, 79], ["acute kidney injury", "PROBLEM", 85, 104], ["dysfunction", "OBSERVATION", 6, 17], ["shock", "OBSERVATION", 46, 51], ["ARDS", "OBSERVATION", 53, 57], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["cardiac", "ANATOMY", 65, 72], ["injury", "OBSERVATION", 73, 79], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["kidney", "ANATOMY", 91, 97], ["injury", "OBSERVATION", 98, 104]]], ["From a laboratory point of view, lymphopenia, thrombocytopenia, impaired prothrombin time (PT), and elevated serum levels of CRP stand among the findings that can be reported for patients with COVID\u201019 (Chen, Zhou, et al., 2020; Guan et al., 2020; Huang et al., 2020; Wang, Hu, et al., 2020).", [["serum", "ANATOMY", 109, 114], ["lymphopenia", "DISEASE", 33, 44], ["thrombocytopenia", "DISEASE", 46, 62], ["prothrombin", "GENE_OR_GENE_PRODUCT", 73, 84], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["CRP", "GENE_OR_GENE_PRODUCT", 125, 128], ["patients", "ORGANISM", 179, 187], ["CRP", "PROTEIN", 125, 128], ["patients", "SPECIES", 179, 187], ["view", "TEST", 27, 31], ["lymphopenia", "PROBLEM", 33, 44], ["thrombocytopenia", "PROBLEM", 46, 62], ["impaired prothrombin time", "PROBLEM", 64, 89], ["PT", "TEST", 91, 93], ["elevated serum levels", "PROBLEM", 100, 121], ["CRP stand", "TEST", 125, 134], ["lymphopenia", "OBSERVATION", 33, 44], ["thrombocytopenia", "OBSERVATION", 46, 62]]], ["Overall, any patient with fever and acute respiratory symptoms, who is reported to have lymphopenia or leukopenia on lab examination, should be suspected.", [["respiratory", "ANATOMY", 42, 53], ["fever", "DISEASE", 26, 31], ["acute respiratory symptoms", "DISEASE", 36, 62], ["lymphopenia", "DISEASE", 88, 99], ["leukopenia", "DISEASE", 103, 113], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["fever", "PROBLEM", 26, 31], ["acute respiratory symptoms", "PROBLEM", 36, 62], ["lymphopenia", "PROBLEM", 88, 99], ["leukopenia", "PROBLEM", 103, 113], ["lab examination", "TEST", 117, 132], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["respiratory", "ANATOMY", 42, 53], ["symptoms", "OBSERVATION", 54, 62], ["lymphopenia", "OBSERVATION", 88, 99], ["leukopenia", "OBSERVATION", 103, 113]]], ["A history of travel to Wuhan or having close contact with local residents is a strong indicator for careful management of the patient (Zu et al., 2020).", [["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 126, 133], ["careful management", "TREATMENT", 100, 118]]], ["Table 2 represents the criteria for diagnosis of COVID\u201019 infected patients (Committee, 2020b; Zu et al., 2020; WWW.ClinicalTrials.gov).Epidemiological history ::: DIAGNOSISShortly after the onset of the epidemic, The National Health Commission of China (Committee, 2020a; Organization, 2020a) initiated the Diagnosis and Treatment Program of COVID\u201019\u2010associated pneumonia, following the guidelines provided by WHO on SARS and MERS (Azhar & EI\u2010Kafrawy, 2014; Organization, 2017, 2020b).Epidemiological history ::: DIAGNOSISAccording to the newly formulated criteria, a \u201csuspected case\u201d is defined as a patient with epidemiological history, that is traveling and contact, and two clinical findings pertinent to the disease.", [["COVID", "DISEASE", 49, 54], ["pneumonia", "DISEASE", 363, 372], ["SARS", "DISEASE", 418, 422], ["patients", "ORGANISM", 67, 75], ["patient", "ORGANISM", 602, 609], ["patients", "SPECIES", 67, 75], ["patient", "SPECIES", 602, 609], ["COVID\u2010", "TREATMENT", 343, 349], ["pneumonia", "PROBLEM", 363, 372], ["pneumonia", "OBSERVATION", 363, 372]]], ["If, however, an epidemiological history is not confirmed, then the patient must present at least three clinical findings to be considered as a suspected case.", [["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74]]], ["Based on the Trial, Fifth Edition (Committee, 2020b), pathologic findings indicative of viral pneumonia on chest CT scans provide enough evidence for clinical diagnosis of COVID\u201019.", [["pneumonia", "DISEASE", 94, 103], ["COVID", "DISEASE", 172, 177], ["pathologic findings", "TEST", 54, 73], ["viral pneumonia", "PROBLEM", 88, 103], ["chest CT scans", "TEST", 107, 121], ["indicative of", "UNCERTAINTY", 74, 87], ["viral", "OBSERVATION_MODIFIER", 88, 93], ["pneumonia", "OBSERVATION", 94, 103], ["chest", "ANATOMY", 107, 112]]], ["Nonetheless, as of February 17, 2020, WHO does not approve of any diagnosis based solely on radiologic findings, without obtaining an RT\u2010PCR test from the patient (Organization, 2020c).", [["patient", "ORGANISM", 155, 162], ["patient", "SPECIES", 155, 162], ["radiologic findings", "TEST", 92, 111], ["an RT\u2010PCR test", "TEST", 131, 145]]], ["In the more recent revision of the Chinese Diagnosis and Treatment Program, 6th Edition, the term \u201cclinical diagnosis\u201d was removed and replaced with \u201cetiological diagnosis\u201d (Organization, 2020a).", [["revision", "OBSERVATION", 19, 27]]], ["According to the recent revision, it is imperative that an etiological diagnosis of COVID\u201019 is made at first, which can then be complemented by a positive real\u2010time RT\u2010PCR assay for SARS\u2010CoV\u20102, which is duly performed on the sputum or blood sample of the patient.", [["sputum", "ANATOMY", 226, 232], ["blood sample", "ANATOMY", 236, 248], ["COVID", "DISEASE", 84, 89], ["SARS", "DISEASE", 183, 187], ["sputum", "ORGANISM_SUBSTANCE", 226, 232], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["patient", "ORGANISM", 256, 263], ["patient", "SPECIES", 256, 263], ["SARS\u2010CoV", "SPECIES", 183, 191], ["SARS", "PROBLEM", 183, 187], ["the sputum", "TEST", 222, 232], ["blood sample", "TEST", 236, 248], ["revision", "OBSERVATION", 24, 32]]], ["After the final diagnosis is made, confirmed patients are categorized into mild, moderate, severe, and critical types, based on the severity of disease (Zu et al., 2020).Reverse transcriptase polymerase chain reaction ::: COVID\u201019 detection tests: Pathogenic laboratory testing, real\u2010time RT\u2010PCR, and sequencing of nucleic acid ::: DIAGNOSISDespite being the diagnostic gold standard, pathogenic lab testing is a rather time\u2010consuming procedure, with unavoidable false\u2010positive results (Wang, Kang, et al., 2020).", [["nucleic acid", "CHEMICAL", 315, 327], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["mild, moderate, severe, and critical types", "PROBLEM", 75, 117], ["disease", "PROBLEM", 144, 151], ["Reverse transcriptase polymerase chain reaction", "PROBLEM", 170, 217], ["detection tests", "TEST", 231, 246], ["Pathogenic laboratory testing", "TEST", 248, 277], ["real\u2010time RT\u2010PCR", "TEST", 279, 295], ["nucleic acid", "TEST", 315, 327], ["pathogenic lab testing", "TEST", 385, 407], ["a rather time\u2010consuming procedure", "TREATMENT", 411, 444], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["moderate", "OBSERVATION_MODIFIER", 81, 89], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["critical", "OBSERVATION_MODIFIER", 103, 111], ["types", "OBSERVATION_MODIFIER", 112, 117], ["disease", "OBSERVATION", 144, 151]]], ["It is recommended that lab testing should be performed, as soon as the patient is identified as a \u201cperson under investigation\u201d (PUI).", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["person", "SPECIES", 99, 105], ["lab testing", "TEST", 23, 34]]], ["Viral nucleic acid required for an RT\u2010PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., 2020; Corman et al., 2020).", [["secretions", "ANATOMY", 73, 83], ["lower respiratory tract", "ANATOMY", 91, 114], ["bronchoalveolar lavage", "ANATOMY", 129, 151], ["tracheal aspirate", "ANATOMY", 162, 179], ["sputum", "ANATOMY", 183, 189], ["nucleic acid", "CHEMICAL", 6, 18], ["secretions", "ORGANISM_SUBSTANCE", 73, 83], ["lower", "ORGANISM_SUBDIVISION", 91, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 129, 151], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 162, 179], ["sputum", "ORGANISM_SUBSTANCE", 183, 189], ["Viral nucleic acid", "TEST", 0, 18], ["an RT\u2010PCR test", "TEST", 32, 46], ["secretions of the lower respiratory tract", "PROBLEM", 73, 114], ["bronchoalveolar lavage", "TEST", 129, 151], ["tracheal aspirate", "TEST", 162, 179], ["sputum", "PROBLEM", 183, 189], ["nucleic acid", "OBSERVATION", 6, 18], ["lower", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114], ["bronchoalveolar lavage", "OBSERVATION", 129, 151], ["tracheal", "ANATOMY", 162, 170], ["aspirate", "OBSERVATION", 171, 179]]], ["Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits.", [["nucleic acid", "CHEMICAL", 99, 111], ["nucleic acid", "SIMPLE_CHEMICAL", 99, 111], ["nucleic acid testing", "TEST", 99, 119]]], ["In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., 2020), as the estimated detection rate of the test falls in an underwhelming range of 30\u201350% (Chu et al., 2020; Corman et al., 2020; Zhang et al., 2020).", [["the tests", "TEST", 22, 31], ["the test falls", "TEST", 133, 147]]], ["In spite of being a valuable asset, the undesirable false\u2010negative results of RT\u2010PCR have prompted careful clinical and etiological evaluation of COVID\u201019 in suspected cases as the first\u2010line diagnostic method (Zu et al., 2020).Computed tomography (CT) ::: COVID\u201019 detection tests: Pathogenic laboratory testing, real\u2010time RT\u2010PCR, and sequencing of nucleic acid ::: DIAGNOSISCT has proved to be of great value in diagnosis of the COVID\u201019\u2010associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods.", [["nucleic acid", "CHEMICAL", 350, 362], ["COVID", "DISEASE", 431, 436], ["pneumonia", "DISEASE", 451, 460], ["RT\u2010PCR", "TEST", 78, 84], ["etiological evaluation", "TEST", 120, 142], ["Computed tomography", "TEST", 228, 247], ["detection tests", "TEST", 266, 281], ["Pathogenic laboratory testing", "TEST", 283, 312], ["real\u2010time RT\u2010PCR", "TEST", 314, 330], ["nucleic acid", "TEST", 350, 362], ["the COVID\u201019\u2010associated pneumonia", "PROBLEM", 427, 460], ["alternative methods", "TREATMENT", 530, 549], ["pneumonia", "OBSERVATION", 451, 460]]], ["It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., 2020).", [["pulmonary", "ANATOMY", 161, 170], ["viral pneumonia", "DISEASE", 73, 88], ["pulmonary diseases", "DISEASE", 161, 179], ["pulmonary", "ORGAN", 161, 170], ["CT", "TEST", 16, 18], ["a reliable imaging modality", "TEST", 22, 49], ["viral pneumonia", "PROBLEM", 73, 88], ["many pulmonary diseases of inflammatory nature", "PROBLEM", 156, 202], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["pneumonia", "OBSERVATION", 79, 88], ["many", "OBSERVATION_MODIFIER", 156, 160], ["pulmonary", "ANATOMY", 161, 170], ["diseases", "OBSERVATION", 171, 179], ["inflammatory", "OBSERVATION_MODIFIER", 183, 195]]], ["The majority of patients with COVID\u201019 present with GGO in their chest CT, which later progress into multilobar consolidations.", [["chest", "ANATOMY", 65, 70], ["GGO", "DISEASE", 52, 55], ["patients", "ORGANISM", 16, 24], ["chest", "ORGAN", 65, 70], ["patients", "SPECIES", 16, 24], ["COVID\u2010", "TREATMENT", 30, 36], ["GGO", "PROBLEM", 52, 55], ["their chest CT", "TEST", 59, 73], ["multilobar consolidations", "PROBLEM", 101, 126], ["chest", "ANATOMY", 65, 70], ["multilobar", "OBSERVATION_MODIFIER", 101, 111], ["consolidations", "OBSERVATION", 112, 126]]], ["There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., 2020; Huang et al., 2020).", [["lung", "ANATOMY", 106, 110], ["opacities", "DISEASE", 43, 52], ["lung", "ORGAN", 106, 110], ["rounded opacities", "PROBLEM", 35, 52], ["rounded", "OBSERVATION_MODIFIER", 35, 42], ["opacities", "OBSERVATION", 43, 52], ["sometimes", "OBSERVATION_MODIFIER", 64, 73], ["peripherally", "OBSERVATION_MODIFIER", 74, 86], ["distributed", "OBSERVATION_MODIFIER", 87, 98], ["lung", "ANATOMY", 106, 110]]], ["In contrast to CT, plain chest radiography (CXR) has not been recommended as a first\u2010line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., 2020).", [["pulmonary", "ANATOMY", 211, 220], ["pulmonary infection", "DISEASE", 211, 230], ["pulmonary", "ORGAN", 211, 220], ["CT", "TEST", 15, 17], ["plain chest radiography", "TEST", 19, 42], ["CXR", "TEST", 44, 47], ["a first\u2010line imaging method", "TEST", 77, 104], ["CT scans", "TEST", 167, 175], ["pulmonary infection", "PROBLEM", 211, 230], ["chest", "ANATOMY", 25, 30], ["early stages", "OBSERVATION_MODIFIER", 195, 207], ["pulmonary", "ANATOMY", 211, 220], ["infection", "OBSERVATION", 221, 230]]], ["Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID\u201019, as the bilateral multifocal consolidations present in these patients are too dense to be missed.", [["COVID", "DISEASE", 98, 103], ["patients", "ORGANISM", 64, 72], ["consolidations", "CANCER", 136, 150], ["patients", "ORGANISM", 168, 176], ["CXR", "PROTEIN", 14, 17], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 168, 176], ["CXR", "TEST", 14, 17], ["recording pathologic changes", "PROBLEM", 32, 60], ["severely progressed COVID\u2010", "PROBLEM", 78, 104], ["the bilateral multifocal consolidations", "PROBLEM", 111, 150], ["bilateral", "ANATOMY_MODIFIER", 115, 124], ["multifocal", "OBSERVATION_MODIFIER", 125, 135], ["consolidations", "OBSERVATION", 136, 150]]], ["The notorious \u201cwhite lung\u201d appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., 2020).", [["lung", "ANATOMY", 21, 25], ["critically ill", "DISEASE", 73, 87], ["lung", "ORGAN", 21, 25], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["The notorious \u201cwhite lung\u201d appearance", "PROBLEM", 0, 37], ["CXRs", "TEST", 65, 69], ["notorious", "OBSERVATION_MODIFIER", 4, 13], ["white", "OBSERVATION_MODIFIER", 15, 20], ["lung", "ANATOMY", 21, 25]]], ["CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., 2020).", [["CT", "TEST", 0, 2]]], ["Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID\u201019 (Chan et al., 2020; Ng et al., 2020).Novel approaches: Artificial intelligence\u2010based technologies ::: COVID\u201019 detection tests: Pathogenic laboratory testing, real\u2010time RT\u2010PCR, and sequencing of nucleic acid ::: DIAGNOSISDepp learning, as a novel AI\u2010based modality might be able to analyze radiographic features of COVID\u201019, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., 2020).", [["pneumonia", "DISEASE", 95, 104], ["nucleic acid", "CHEMICAL", 326, 338], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["slice chest CT", "TEST", 11, 25], ["pneumonia", "PROBLEM", 95, 104], ["Pathogenic laboratory testing", "TEST", 259, 288], ["PCR", "TEST", 303, 306], ["nucleic acid", "TEST", 326, 338], ["chest", "ANATOMY", 17, 22], ["pneumonia", "OBSERVATION", 95, 104]]], ["As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis.", [["neural networks", "ANATOMY", 84, 99], ["neural networks", "MULTI-TISSUE_STRUCTURE", 84, 99], ["medical image analysis", "TEST", 133, 155], ["Neural Network", "OBSERVATION", 46, 60], ["deep", "ANATOMY_MODIFIER", 79, 83], ["neural networks", "OBSERVATION", 84, 99]]], ["To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., 2019; Kermany et al., 2018; Negassi, Suarez\u2010Ibarrola, Hein, Miernik, & Reiterer, 2020; Wang et al., 2018).Novel approaches: Artificial intelligence\u2010based technologies ::: COVID\u201019 detection tests: Pathogenic laboratory testing, real\u2010time RT\u2010PCR, and sequencing of nucleic acid ::: DIAGNOSISThe 21st century has seen many AI\u2010based models to be incorporated in several scientific fields, particularly imaging studies.", [["pulmonary nodules", "ANATOMY", 84, 101], ["pneumonia", "DISEASE", 138, 147], ["nucleic acid", "CHEMICAL", 495, 507], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 84, 101], ["children", "ORGANISM", 151, 159], ["children", "SPECIES", 151, 159], ["pulmonary nodules", "PROBLEM", 84, 101], ["CT images", "TEST", 114, 123], ["pneumonia", "PROBLEM", 138, 147], ["CXR", "TEST", 169, 172], ["image recognition", "TEST", 178, 195], ["cystoscopy", "TEST", 199, 209], ["Pathogenic laboratory testing", "TEST", 428, 457], ["real\u2010time RT\u2010PCR", "TEST", 459, 475], ["nucleic acid", "TEST", 495, 507], ["imaging studies", "TEST", 630, 645], ["pulmonary", "ANATOMY", 84, 93], ["nodules", "OBSERVATION", 94, 101], ["pneumonia", "OBSERVATION", 138, 147]]], ["Diagnostic AI\u2010based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time.", [["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181]]], ["Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI\u2010based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource\u2010wise admission of patients to the hospitals (Kim, 2020).PREDICTIONRecent studies focused on prognosis of COVID\u201019 concluded that the load of SARS\u2010CoV\u20102 RNA in blood (RNAemia) is correlated with Cytokine Release Storm (CRS) and poor prognosis of the disease.", [["blood", "ANATOMY", 369, 374], ["SARS", "DISEASE", 351, 355], ["human", "ORGANISM", 22, 27], ["patients", "ORGANISM", 228, 236], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 356, 361], ["blood", "ORGANISM_SUBSTANCE", 369, 374], ["Cytokine", "GENE_OR_GENE_PRODUCT", 404, 412], ["SARS\u2010CoV\u20102 RNA", "RNA", 351, 365], ["Cytokine", "PROTEIN", 404, 412], ["human", "SPECIES", 22, 27], ["patients", "SPECIES", 228, 236], ["human", "SPECIES", 22, 27], ["CXR", "TEST", 134, 137], ["CT scans", "TEST", 142, 150], ["PREDICTIONRecent studies", "TEST", 266, 290], ["SARS", "PROBLEM", 351, 355], ["Cytokine Release Storm", "TREATMENT", 404, 426], ["the disease", "PROBLEM", 455, 466], ["disease", "OBSERVATION", 459, 466]]], ["In one particular study, scientists used Generalized Linear Models to generate a prediction model for natural history of disease based on the Ct value of real\u2010time RT\u2010PCR results.", [["one particular study", "TEST", 3, 23], ["Generalized Linear Models", "PROBLEM", 41, 66], ["disease", "PROBLEM", 121, 128], ["the Ct value", "TEST", 138, 150], ["real\u2010time RT\u2010PCR", "TEST", 154, 170]]], ["They reported that traceable amounts of SARS\u2010CoV\u20102 RNA was detected in blood plasma of 15% of COVID\u201019 positive patients enrolled at the study.", [["blood plasma", "ANATOMY", 71, 83], ["SARS", "DISEASE", 40, 44], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 45, 50], ["blood plasma", "ORGANISM_SUBSTANCE", 71, 83], ["patients", "ORGANISM", 112, 120], ["SARS\u2010CoV\u20102 RNA", "RNA", 40, 54], ["patients", "SPECIES", 112, 120], ["SARS\u2010CoV\u20102 RNA", "TEST", 40, 54], ["blood plasma", "TEST", 71, 83], ["COVID", "TEST", 94, 99], ["the study", "TEST", 133, 142], ["amounts", "OBSERVATION_MODIFIER", 29, 36]]], ["Their findings drew a direct link between serum markers and disease severity, as RNAemia and high levels of IL\u20106 (nearly 10\u2010fold) were exclusively reported in critically ill patients.", [["serum", "ANATOMY", 42, 47], ["critically ill", "DISEASE", 159, 173], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 108, 112], ["patients", "ORGANISM", 174, 182], ["serum markers", "PROTEIN", 42, 55], ["IL\u20106", "PROTEIN", 108, 112], ["patients", "SPECIES", 174, 182], ["serum markers", "TEST", 42, 55], ["disease severity", "PROBLEM", 60, 76], ["RNAemia", "TEST", 81, 88], ["high", "OBSERVATION_MODIFIER", 93, 97]]], ["Interestingly, there was also an association between the extremely high levels of IL\u20106 with the incidence of RNAemia (R = 0.902) in patients.", [["RNAemia", "DISEASE", 109, 116], ["IL\u20106", "GENE_OR_GENE_PRODUCT", 82, 86], ["patients", "ORGANISM", 132, 140], ["IL\u20106", "PROTEIN", 82, 86], ["patients", "SPECIES", 132, 140], ["RNAemia", "TEST", 109, 116], ["extremely", "OBSERVATION_MODIFIER", 57, 66], ["high", "OBSERVATION_MODIFIER", 67, 71]]], ["Findings also suggested that vital signs of patients were also affected by high levels of both serum markers (R = 0.682).", [["serum", "ANATOMY", 95, 100], ["patients", "ORGANISM", 44, 52], ["serum", "ORGANISM_SUBSTANCE", 95, 100], ["serum markers", "PROTEIN", 95, 108], ["patients", "SPECIES", 44, 52], ["vital signs", "TEST", 29, 40], ["serum markers", "TEST", 95, 108]]], ["According to this study, IL\u20106 might be of clinical value in identification and treatment of patients with an excessive inflammatory response (Chen, Zhao, et al., 2020).", [["IL\u20106", "GENE_OR_GENE_PRODUCT", 25, 29], ["patients", "ORGANISM", 92, 100], ["IL\u20106", "PROTEIN", 25, 29], ["patients", "SPECIES", 92, 100], ["this study", "TEST", 13, 23], ["treatment", "TREATMENT", 79, 88], ["an excessive inflammatory response", "PROBLEM", 106, 140], ["excessive", "OBSERVATION_MODIFIER", 109, 118], ["inflammatory", "OBSERVATION", 119, 131]]], ["Table 3 (Chen, Zhao, et al., 2020; Yan et al., 2020) and Table 4 represent 2020 studies on prognosis of COVID\u201019 infected patients and related clinical trials, respectively.Chloroquine phosphate ::: THERAPYChloroquine phosphate is an old medicine, that has been widely used for treatment of malaria in endemic regions.", [["Chloroquine phosphate", "CHEMICAL", 173, 194], ["THERAPYChloroquine phosphate", "CHEMICAL", 199, 227], ["malaria", "DISEASE", 291, 298], ["Chloroquine phosphate", "CHEMICAL", 173, 194], ["THERAPYChloroquine phosphate", "CHEMICAL", 199, 227], ["patients", "ORGANISM", 122, 130], ["Chloroquine phosphate ::", "SIMPLE_CHEMICAL", 173, 197], ["THERAPYChloroquine phosphate", "SIMPLE_CHEMICAL", 199, 227], ["patients", "SPECIES", 122, 130], ["COVID\u2010", "TREATMENT", 104, 110], ["Chloroquine phosphate", "TREATMENT", 173, 194], ["THERAPYChloroquine phosphate", "TREATMENT", 199, 227], ["an old medicine", "TREATMENT", 231, 246], ["malaria in endemic regions", "PROBLEM", 291, 317], ["malaria", "OBSERVATION", 291, 298], ["endemic", "OBSERVATION_MODIFIER", 302, 309]]], ["It is also a salutary treatment of choice for certain progressive anti\u2010inflammatory diseases, for example, rheumatoid arthritis, and systemic lupus erythematosus.", [["anti\u2010inflammatory diseases", "DISEASE", 66, 92], ["rheumatoid arthritis", "DISEASE", 107, 127], ["systemic lupus erythematosus", "DISEASE", 133, 161], ["a salutary treatment", "TREATMENT", 11, 31], ["certain progressive anti\u2010inflammatory diseases", "PROBLEM", 46, 92], ["rheumatoid arthritis", "PROBLEM", 107, 127], ["systemic lupus erythematosus", "PROBLEM", 133, 161], ["progressive", "OBSERVATION_MODIFIER", 54, 65], ["anti\u2010inflammatory diseases", "OBSERVATION", 66, 92], ["rheumatoid arthritis", "OBSERVATION", 107, 127], ["systemic", "OBSERVATION_MODIFIER", 133, 141], ["lupus erythematosus", "OBSERVATION", 142, 161]]], ["Recently, an investigation in China reported that remdesivir and chloroquine phosphate were effective experimental agents for controlling SARS\u2010CoV\u20102 infection in the lab (Chen et al., 2013).", [["remdesivir", "CHEMICAL", 50, 60], ["chloroquine phosphate", "CHEMICAL", 65, 86], ["SARS", "DISEASE", 138, 142], ["infection", "DISEASE", 149, 158], ["remdesivir", "CHEMICAL", 50, 60], ["chloroquine phosphate", "CHEMICAL", 65, 86], ["remdesivir", "SIMPLE_CHEMICAL", 50, 60], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 65, 86], ["SARS\u2010CoV\u20102", "SPECIES", 138, 148], ["an investigation", "TEST", 10, 26], ["remdesivir", "TREATMENT", 50, 60], ["chloroquine phosphate", "TREATMENT", 65, 86], ["experimental agents", "TREATMENT", 102, 121], ["CoV\u20102 infection", "PROBLEM", 143, 158]]], ["Initial findings reported by a recent study on effectiveness of therapeutic agents in management of SARS\u2010CoV\u20102 infection, and suggested successful application of chloroquine phosphate in treatment of patients with COVID\u201019\u2010associated pneumonia.", [["SARS", "DISEASE", 100, 104], ["infection", "DISEASE", 111, 120], ["chloroquine phosphate", "CHEMICAL", 162, 183], ["COVID", "DISEASE", 214, 219], ["pneumonia", "DISEASE", 234, 243], ["chloroquine phosphate", "CHEMICAL", 162, 183], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 162, 183], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["a recent study", "TEST", 29, 43], ["therapeutic agents", "TREATMENT", 64, 82], ["management", "TREATMENT", 86, 96], ["SARS", "PROBLEM", 100, 104], ["CoV\u20102 infection", "PROBLEM", 105, 120], ["chloroquine phosphate", "TREATMENT", 162, 183], ["treatment", "TREATMENT", 187, 196], ["COVID\u201019\u2010associated pneumonia", "PROBLEM", 214, 243], ["infection", "OBSERVATION", 111, 120], ["pneumonia", "OBSERVATION", 234, 243]]], ["Following the promising results, scientists recommended chloroquine phosphate to be included in treatment regimen of COVID\u201019 patients with severe involvement of the lungs (Yu et al., 2013).", [["lungs", "ANATOMY", 166, 171], ["chloroquine phosphate", "CHEMICAL", 56, 77], ["chloroquine phosphate", "CHEMICAL", 56, 77], ["chloroquine", "SIMPLE_CHEMICAL", 56, 67], ["phosphate", "SIMPLE_CHEMICAL", 68, 77], ["patients", "ORGANISM", 126, 134], ["lungs", "ORGAN", 166, 171], ["patients", "SPECIES", 126, 134], ["chloroquine phosphate", "TREATMENT", 56, 77], ["treatment regimen", "TREATMENT", 96, 113], ["COVID\u2010", "TREATMENT", 117, 123], ["severe involvement of the lungs", "PROBLEM", 140, 171], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["involvement", "OBSERVATION", 147, 158], ["lungs", "ANATOMY", 166, 171]]], ["On February 15, 2020, participants from different organizations, including medical experts and authorities, made an agreement on potency of Chloroquine phosphate against SARS\u2010CoV\u20102 infection (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/).Chloroquine phosphate ::: THERAPYSo far, close monitoring of over 100 patients, who were under treatment of chloroquine phosphate, has provided further evidence regarding the effectiveness of this long\u2010known medicine.", [["Chloroquine phosphate", "CHEMICAL", 140, 161], ["SARS", "DISEASE", 170, 174], ["infection", "DISEASE", 181, 190], ["Chloroquine phosphate", "CHEMICAL", 266, 287], ["chloroquine phosphate", "CHEMICAL", 374, 395], ["Chloroquine phosphate", "CHEMICAL", 140, 161], ["Chloroquine phosphate", "CHEMICAL", 266, 287], ["chloroquine phosphate", "CHEMICAL", 374, 395], ["Chloroquine phosphate", "SIMPLE_CHEMICAL", 140, 161], ["CoV\u20102", "SIMPLE_CHEMICAL", 175, 180], ["Chloroquine", "SIMPLE_CHEMICAL", 266, 277], ["patients", "ORGANISM", 336, 344], ["chloroquine", "SIMPLE_CHEMICAL", 374, 385], ["participants", "SPECIES", 22, 34], ["patients", "SPECIES", 336, 344], ["Chloroquine phosphate", "TREATMENT", 140, 161], ["SARS", "PROBLEM", 170, 174], ["CoV\u20102 infection", "PROBLEM", 175, 190], ["Chloroquine phosphate", "TREATMENT", 266, 287], ["chloroquine phosphate", "TREATMENT", 374, 395], ["this long\u2010known medicine", "TREATMENT", 458, 482], ["infection", "OBSERVATION", 181, 190]]], ["Investigations indicated that chloroquine phosphate prevented exacerbation of pneumonia in these patients, improved their chest CT findings, and shortened the otherwise long natural course of the disease.", [["chest", "ANATOMY", 122, 127], ["chloroquine phosphate", "CHEMICAL", 30, 51], ["pneumonia", "DISEASE", 78, 87], ["chloroquine phosphate", "CHEMICAL", 30, 51], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 30, 51], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["Investigations", "TEST", 0, 14], ["chloroquine phosphate", "TREATMENT", 30, 51], ["pneumonia", "PROBLEM", 78, 87], ["their chest CT findings", "TEST", 116, 139], ["the disease", "PROBLEM", 192, 203], ["pneumonia", "OBSERVATION", 78, 87], ["chest", "ANATOMY", 122, 127], ["long natural", "OBSERVATION_MODIFIER", 169, 181], ["disease", "OBSERVATION", 196, 203]]], ["Importantly, there have been no records of severe reaction or hypersensitivity to this therapeutic agent.", [["hypersensitivity", "DISEASE", 62, 78], ["severe reaction", "PROBLEM", 43, 58], ["hypersensitivity", "PROBLEM", 62, 78], ["this therapeutic agent", "TREATMENT", 82, 104], ["no records of", "UNCERTAINTY", 29, 42], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["reaction", "OBSERVATION", 50, 58]]], ["It has been suggested that the broad\u2010spectrum antiviral activity of chloroquine phosphate lies within the complicated pharmacodynamics of the drug that results in a basic shift in the endosomal pH required for successful fusion of virus onto the host cell. chloroquine phosphate also seems to have disruptive effects on glycosylation of cellular receptors of SARS\u2010CoV (Yin & Wunderink, 2018; Zumla et al., 2020), rendering them nonfunctional.", [["endosomal", "ANATOMY", 184, 193], ["cell", "ANATOMY", 251, 255], ["cellular", "ANATOMY", 337, 345], ["chloroquine phosphate", "CHEMICAL", 68, 89], ["chloroquine phosphate", "CHEMICAL", 257, 278], ["SARS", "DISEASE", 359, 363], ["chloroquine phosphate", "CHEMICAL", 68, 89], ["chloroquine phosphate", "CHEMICAL", 257, 278], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 68, 89], ["endosomal", "CELLULAR_COMPONENT", 184, 193], ["host cell", "CELL", 246, 255], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 257, 278], ["cellular", "CELL", 337, 345], ["CoV", "ORGANISM", 364, 367], ["host cell", "CELL_TYPE", 246, 255], ["cellular receptors", "PROTEIN", 337, 355], ["the broad\u2010spectrum antiviral activity of chloroquine phosphate", "TREATMENT", 27, 89], ["a basic shift", "PROBLEM", 163, 176], ["the endosomal pH", "PROBLEM", 180, 196], ["successful fusion of virus", "TREATMENT", 210, 236], ["chloroquine phosphate", "TREATMENT", 257, 278], ["endosomal pH", "OBSERVATION", 184, 196], ["fusion", "OBSERVATION", 221, 227], ["host cell", "OBSERVATION", 246, 255], ["nonfunctional", "OBSERVATION", 428, 441]]], ["It also interferes with activation of p38 mitogen\u2010activated protein kinase, a signaling event involved in replication of HCoV\u2010229E (Kono et al., 2008).Lopinavir/ritonavir, leronlimab, galidesivir ::: THERAPYLopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID\u201019 in a number of reports (Kim et al., 2020).", [["Lopinavir/ritonavir", "CHEMICAL", 151, 170], ["leronlimab", "CHEMICAL", 172, 182], ["galidesivir", "CHEMICAL", 184, 195], ["THERAPYLopinavir", "CHEMICAL", 200, 216], ["Ritonavir", "CHEMICAL", 217, 226], ["HIV infection", "DISEASE", 259, 272], ["Lopinavir", "CHEMICAL", 151, 160], ["ritonavir", "CHEMICAL", 161, 170], ["leronlimab", "CHEMICAL", 172, 182], ["galidesivir", "CHEMICAL", 184, 195], ["THERAPYLopinavir", "CHEMICAL", 200, 216], ["Ritonavir", "CHEMICAL", 217, 226], ["p38 mitogen\u2010activated protein kinase", "GENE_OR_GENE_PRODUCT", 38, 74], ["Lopinavir", "SIMPLE_CHEMICAL", 151, 160], ["ritonavir", "SIMPLE_CHEMICAL", 161, 170], ["leronlimab", "SIMPLE_CHEMICAL", 172, 182], ["galidesivir", "SIMPLE_CHEMICAL", 184, 195], ["THERAPYLopinavir", "SIMPLE_CHEMICAL", 200, 216], ["Ritonavir", "SIMPLE_CHEMICAL", 217, 226], ["HIV", "ORGANISM", 259, 262], ["p38 mitogen\u2010activated protein kinase", "PROTEIN", 38, 74], ["HCoV\u2010229E", "SPECIES", 121, 130], ["HIV", "SPECIES", 259, 262], ["p38 mitogen\u2010activated protein kinase", "TEST", 38, 74], ["a signaling event", "PROBLEM", 76, 93], ["Lopinavir", "TREATMENT", 151, 160], ["ritonavir", "TREATMENT", 161, 170], ["leronlimab", "TREATMENT", 172, 182], ["galidesivir", "TREATMENT", 184, 195], ["THERAPYLopinavir", "TREATMENT", 200, 216], ["Ritonavir", "TREATMENT", 217, 226], ["HIV infection", "PROBLEM", 259, 272], ["infection", "OBSERVATION", 263, 272]]], ["Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS\u2010CoV, and improve the clinical status of patients with SARS (Chu et al., 2004).", [["Lopinavir", "CHEMICAL", 56, 65], ["Ritonavir", "CHEMICAL", 70, 79], ["SARS", "DISEASE", 128, 132], ["SARS", "DISEASE", 187, 191], ["Lopinavir", "CHEMICAL", 56, 65], ["Ritonavir", "CHEMICAL", 70, 79], ["Lopinavir", "SIMPLE_CHEMICAL", 56, 65], ["Ritonavir", "SIMPLE_CHEMICAL", 70, 79], ["CoV", "ORGANISM", 133, 136], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["CoV", "SPECIES", 133, 136], ["Previous studies", "TEST", 0, 16], ["Lopinavir", "TREATMENT", 56, 65], ["Ritonavir", "TREATMENT", 70, 79], ["SARS", "PROBLEM", 128, 132], ["CoV", "PROBLEM", 133, 136], ["SARS", "PROBLEM", 187, 191]]], ["This might also mean that the well\u2010known antiretroviral duo can also prove beneficial in treatment of COVID\u201019.Lopinavir/ritonavir, leronlimab, galidesivir ::: THERAPYOther candidates for possible management of SARS\u2010CoV\u20102 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients.", [["Lopinavir/ritonavir", "CHEMICAL", 111, 130], ["leronlimab", "CHEMICAL", 132, 142], ["galidesivir", "CHEMICAL", 144, 155], ["SARS", "DISEASE", 211, 215], ["CoV\u20102", "CHEMICAL", 216, 221], ["Leronlimab", "CHEMICAL", 230, 240], ["Galidesivir", "CHEMICAL", 245, 256], ["viral infections", "DISEASE", 330, 346], ["Lopinavir", "CHEMICAL", 111, 120], ["ritonavir", "CHEMICAL", 121, 130], ["leronlimab", "CHEMICAL", 132, 142], ["galidesivir", "CHEMICAL", 144, 155], ["Leronlimab", "CHEMICAL", 230, 240], ["Galidesivir", "CHEMICAL", 245, 256], ["Lopinavir", "SIMPLE_CHEMICAL", 111, 120], ["ritonavir", "SIMPLE_CHEMICAL", 121, 130], ["leronlimab", "SIMPLE_CHEMICAL", 132, 142], ["galidesivir", "SIMPLE_CHEMICAL", 144, 155], ["CoV\u20102", "SIMPLE_CHEMICAL", 216, 221], ["Leronlimab", "SIMPLE_CHEMICAL", 230, 240], ["Galidesivir", "SIMPLE_CHEMICAL", 245, 256], ["patients", "ORGANISM", 390, 398], ["patients", "SPECIES", 390, 398], ["the well\u2010known antiretroviral duo", "PROBLEM", 26, 59], ["COVID\u2010", "TREATMENT", 102, 108], ["Lopinavir", "TREATMENT", 111, 120], ["ritonavir", "TREATMENT", 121, 130], ["management", "TREATMENT", 197, 207], ["SARS", "PROBLEM", 211, 215], ["CoV\u20102", "TREATMENT", 216, 221], ["Leronlimab", "TREATMENT", 230, 240], ["Galidesivir", "TREATMENT", 245, 256], ["several fatal viral infections", "PROBLEM", 316, 346], ["several", "OBSERVATION_MODIFIER", 316, 323], ["fatal", "OBSERVATION_MODIFIER", 324, 329], ["viral infections", "OBSERVATION", 330, 346]]], ["Leronlimab is a humanized monoclonal antibody (CCR5 antagonist).", [["Leronlimab", "CHEMICAL", 0, 10], ["Leronlimab", "CHEMICAL", 0, 10], ["Leronlimab", "SIMPLE_CHEMICAL", 0, 10], ["CCR5", "GENE_OR_GENE_PRODUCT", 47, 51], ["humanized monoclonal antibody", "PROTEIN", 16, 45], ["CCR5", "PROTEIN", 47, 51], ["Leronlimab", "TREATMENT", 0, 10], ["a humanized monoclonal antibody (CCR5 antagonist", "TREATMENT", 14, 62]]], ["Galidesivir, on the other hand, belongs to the family of nucleoside RNA polymerase inhibitors (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/).", [["Galidesivir", "CHEMICAL", 0, 11], ["nucleoside", "CHEMICAL", 57, 67], ["Galidesivir", "CHEMICAL", 0, 11], ["nucleoside", "CHEMICAL", 57, 67], ["Galidesivir", "SIMPLE_CHEMICAL", 0, 11], ["nucleoside", "SIMPLE_CHEMICAL", 57, 67], ["nucleoside RNA polymerase", "PROTEIN", 57, 82], ["Galidesivir", "TREATMENT", 0, 11], ["nucleoside RNA polymerase inhibitors", "TREATMENT", 57, 93]]], ["In the absence of any specific therapeutic agents to quell SARs\u2010CoV\u20102, it might be a salutary strategy to repurpose the already available medicine, and include them in treatment of COVID\u201019 (Tian et al., 2020).Lopinavir/ritonavir, leronlimab, galidesivir ::: THERAPYSeveral clinical trials can be viewed at ClinicalTrials.gov, that are currently in progress.", [["Lopinavir/ritonavir", "CHEMICAL", 210, 229], ["leronlimab", "CHEMICAL", 231, 241], ["galidesivir", "CHEMICAL", 243, 254], ["Lopinavir", "CHEMICAL", 210, 219], ["ritonavir", "CHEMICAL", 220, 229], ["leronlimab", "CHEMICAL", 231, 241], ["galidesivir", "CHEMICAL", 243, 254], ["CoV\u20102", "SIMPLE_CHEMICAL", 64, 69], ["Lopinavir", "SIMPLE_CHEMICAL", 210, 219], ["ritonavir", "SIMPLE_CHEMICAL", 220, 229], ["leronlimab", "SIMPLE_CHEMICAL", 231, 241], ["galidesivir", "SIMPLE_CHEMICAL", 243, 254], ["Lopinavir", "TREATMENT", 210, 219], ["ritonavir", "TREATMENT", 220, 229], ["leronlimab", "TREATMENT", 231, 241], ["THERAPYSeveral clinical trials", "TREATMENT", 259, 289]]], ["These trials have specially focused on potency of Remdesivir, immunoglobulins, and combinational therapies, for example, Arbidol hydrochloride with interferon atomization, ASC09F and oseltamivir, ritonavir and oseltamivir, and lopinavir combined with ritonavir (https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=).RAAS inhibitors ::: THERAPYACE2 is a prominent regulatory arm in the RAAS axis, thus, a disruption in ACE\u2010Angiotensin II\u2010Angiotensin Type 1 Receptor (AT1R), and ACE2/Angiotensin\u2010(1\u20107)/Mas Receptor axes can result in multisystem inflammation.", [["Remdesivir", "CHEMICAL", 50, 60], ["Arbidol hydrochloride", "CHEMICAL", 121, 142], ["ASC09F", "CHEMICAL", 172, 178], ["oseltamivir", "CHEMICAL", 183, 194], ["ritonavir", "CHEMICAL", 196, 205], ["oseltamivir", "CHEMICAL", 210, 221], ["lopinavir", "CHEMICAL", 227, 236], ["ritonavir", "CHEMICAL", 251, 260], ["Angiotensin II", "CHEMICAL", 455, 469], ["Angiotensin", "CHEMICAL", 470, 481], ["multisystem inflammation", "DISEASE", 565, 589], ["Remdesivir", "CHEMICAL", 50, 60], ["Arbidol hydrochloride", "CHEMICAL", 121, 142], ["oseltamivir", "CHEMICAL", 183, 194], ["ritonavir", "CHEMICAL", 196, 205], ["oseltamivir", "CHEMICAL", 210, 221], ["lopinavir", "CHEMICAL", 227, 236], ["ritonavir", "CHEMICAL", 251, 260], ["Remdesivir", "SIMPLE_CHEMICAL", 50, 60], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 62, 77], ["Arbidol hydrochloride", "SIMPLE_CHEMICAL", 121, 142], ["interferon", "SIMPLE_CHEMICAL", 148, 158], ["ASC09F", "SIMPLE_CHEMICAL", 172, 178], ["oseltamivir", "SIMPLE_CHEMICAL", 183, 194], ["ritonavir", "SIMPLE_CHEMICAL", 196, 205], ["oseltamivir", "SIMPLE_CHEMICAL", 210, 221], ["lopinavir", "SIMPLE_CHEMICAL", 227, 236], ["ritonavir", "SIMPLE_CHEMICAL", 251, 260], ["RAAS", "GENE_OR_GENE_PRODUCT", 418, 422], ["ACE", "GENE_OR_GENE_PRODUCT", 451, 454], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 455, 469], ["Angiotensin Type 1 Receptor", "GENE_OR_GENE_PRODUCT", 470, 497], ["AT1R", "GENE_OR_GENE_PRODUCT", 499, 503], ["ACE2", "GENE_OR_GENE_PRODUCT", 510, 514], ["Angiotensin\u2010(1\u20107)", "GENE_OR_GENE_PRODUCT", 515, 532], ["Mas", "GENE_OR_GENE_PRODUCT", 533, 536], ["interferon", "PROTEIN", 148, 158], ["THERAPYACE2", "PROTEIN", 369, 380], ["ACE", "PROTEIN", 451, 454], ["Angiotensin II", "PROTEIN", 455, 469], ["Angiotensin Type 1 Receptor", "PROTEIN", 470, 497], ["AT1R", "PROTEIN", 499, 503], ["ACE2", "PROTEIN", 510, 514], ["Remdesivir", "TREATMENT", 50, 60], ["immunoglobulins", "TREATMENT", 62, 77], ["combinational therapies", "TREATMENT", 83, 106], ["Arbidol hydrochloride", "TREATMENT", 121, 142], ["interferon atomization", "TREATMENT", 148, 170], ["ASC09F", "TREATMENT", 172, 178], ["oseltamivir", "TREATMENT", 183, 194], ["ritonavir", "TREATMENT", 196, 205], ["oseltamivir", "TREATMENT", 210, 221], ["lopinavir", "TREATMENT", 227, 236], ["ritonavir (https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=).RAAS inhibitors", "TREATMENT", 251, 364], ["a disruption in ACE", "PROBLEM", 435, 454], ["Angiotensin Type 1 Receptor (AT1R)", "TREATMENT", 470, 504], ["ACE2/Angiotensin\u2010", "TREATMENT", 510, 527], ["Mas Receptor axes", "TREATMENT", 533, 550], ["multisystem inflammation", "PROBLEM", 565, 589], ["prominent", "OBSERVATION", 386, 395], ["arm", "ANATOMY", 407, 410], ["RAAS axis", "ANATOMY", 418, 427], ["multisystem", "OBSERVATION_MODIFIER", 565, 576], ["inflammation", "OBSERVATION", 577, 589]]], ["Increased levels of ACE and Angiotensin II in plasma are considered poor prognostic factors in severe pneumonia.", [["plasma", "ANATOMY", 46, 52], ["Angiotensin II", "CHEMICAL", 28, 42], ["pneumonia", "DISEASE", 102, 111], ["ACE", "GENE_OR_GENE_PRODUCT", 20, 23], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 28, 42], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["ACE", "PROTEIN", 20, 23], ["Angiotensin II", "PROTEIN", 28, 42], ["ACE and Angiotensin II in plasma", "TREATMENT", 20, 52], ["poor prognostic factors", "PROBLEM", 68, 91], ["severe pneumonia", "PROBLEM", 95, 111], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["pneumonia", "OBSERVATION", 102, 111]]], ["Several studies on animal models have reported effectiveness of RAAS inhibitors in alleviation of severe pneumonia and acute respiratory failure.", [["respiratory", "ANATOMY", 125, 136], ["pneumonia", "DISEASE", 105, 114], ["acute respiratory failure", "DISEASE", 119, 144], ["RAAS", "SIMPLE_CHEMICAL", 64, 68], ["Several studies", "TEST", 0, 15], ["RAAS inhibitors", "TREATMENT", 64, 79], ["severe pneumonia", "PROBLEM", 98, 114], ["acute respiratory failure", "PROBLEM", 119, 144], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["pneumonia", "OBSERVATION", 105, 114], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["respiratory failure", "OBSERVATION", 125, 144]]], ["In the aftermath of SARS\u2010CoV\u20102 and ACE2 binding, the enzyme is eventually degraded, hence, the inhibition of ACE2/Angiotensin\u2010(1\u20107)/Mas Receptor pathway.", [["SARS", "DISEASE", 20, 24], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 25, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["Angiotensin\u2010(1\u20107)", "GENE_OR_GENE_PRODUCT", 114, 131], ["Mas Receptor", "GENE_OR_GENE_PRODUCT", 132, 144], ["ACE2", "PROTEIN", 35, 39], ["ACE2", "PROTEIN", 109, 113], ["Mas Receptor", "PROTEIN", 132, 144], ["SARS", "PROBLEM", 20, 24], ["ACE2 binding", "PROBLEM", 35, 47], ["the enzyme", "TEST", 49, 59], ["ACE2/Angiotensin\u2010", "TREATMENT", 109, 126], ["Mas Receptor pathway", "TREATMENT", 132, 152], ["SARS", "OBSERVATION", 20, 24]]], ["Accordingly, it is assumed that ACE and AT1R inhibitors might be game\u2010changing agents that can especially be administered for COVID\u201019 patients who have serious impairments in their homeostasis.", [["ACE", "GENE_OR_GENE_PRODUCT", 32, 35], ["AT1R", "GENE_OR_GENE_PRODUCT", 40, 44], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["ACE and AT1R inhibitors", "TREATMENT", 32, 55], ["agents", "TREATMENT", 79, 85], ["serious impairments", "PROBLEM", 153, 172]]], ["Maintenance of homeostasis may ultimately result in suppression of the inflammatory response, mostly in the pulmonary tissue (Sun, Yang, Sun, & Su, 2020).Combination therapy ::: THERAPYCombination therapy is a more extensive and rigorous approach mainly aimed at correction of life\u2010threatening events such as shock, hypoxemia, secondary or super infection, and maintenance of homeostasis, that is, electrolyte, acid and base balance.", [["pulmonary tissue", "ANATOMY", 108, 124], ["shock", "DISEASE", 309, 314], ["hypoxemia", "DISEASE", 316, 325], ["infection", "DISEASE", 346, 355], ["pulmonary tissue", "TISSUE", 108, 124], ["homeostasis", "TREATMENT", 15, 26], ["the inflammatory response", "PROBLEM", 67, 92], ["THERAPYCombination therapy", "TREATMENT", 178, 204], ["rigorous approach", "TREATMENT", 229, 246], ["life\u2010threatening events", "PROBLEM", 277, 300], ["shock", "PROBLEM", 309, 314], ["hypoxemia", "PROBLEM", 316, 325], ["super infection", "PROBLEM", 340, 355], ["electrolyte, acid and base balance", "TEST", 398, 432], ["homeostasis", "OBSERVATION", 15, 26], ["inflammatory", "OBSERVATION_MODIFIER", 71, 83], ["pulmonary tissue", "ANATOMY", 108, 124], ["hypoxemia", "OBSERVATION", 316, 325], ["super", "OBSERVATION_MODIFIER", 340, 345], ["infection", "OBSERVATION", 346, 355]]], ["As a palliative practice, antiviral treatment in the early stages of COVID\u201019 might lessen the severity and prevent further progression of the disease.", [["a palliative practice", "TREATMENT", 3, 24], ["antiviral treatment", "TREATMENT", 26, 45], ["COVID\u2010", "TREATMENT", 69, 75], ["the disease", "PROBLEM", 139, 150], ["progression", "OBSERVATION_MODIFIER", 124, 135], ["disease", "OBSERVATION", 143, 150]]], ["Trials on combination therapy with lopinavir/ritonavir and arbidol (umifenovir) have reported satisfactory results in treatment of COVID\u201019.", [["lopinavir/ritonavir", "CHEMICAL", 35, 54], ["arbidol", "CHEMICAL", 59, 66], ["umifenovir", "CHEMICAL", 68, 78], ["lopinavir", "CHEMICAL", 35, 44], ["ritonavir", "CHEMICAL", 45, 54], ["arbidol", "CHEMICAL", 59, 66], ["umifenovir", "CHEMICAL", 68, 78], ["lopinavir", "SIMPLE_CHEMICAL", 35, 44], ["ritonavir", "SIMPLE_CHEMICAL", 45, 54], ["arbidol", "SIMPLE_CHEMICAL", 59, 66], ["umifenovir", "SIMPLE_CHEMICAL", 68, 78], ["combination therapy", "TREATMENT", 10, 29], ["lopinavir", "TREATMENT", 35, 44], ["ritonavir", "TREATMENT", 45, 54], ["arbidol (umifenovir", "TREATMENT", 59, 78], ["treatment of COVID\u2010", "TREATMENT", 118, 137]]], ["Alongside a proper antiviral treatment, patients may also benefit from an artificial liver blood purification system, which is capable of rapidly removing the inflammatory factors from blood, thus, halting the disastrous cytokine release syndrome.", [["liver blood", "ANATOMY", 85, 96], ["blood", "ANATOMY", 185, 190], ["patients", "ORGANISM", 40, 48], ["liver", "ORGAN", 85, 90], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["inflammatory factors", "PROTEIN", 159, 179], ["cytokine", "PROTEIN", 221, 229], ["patients", "SPECIES", 40, 48], ["a proper antiviral treatment", "TREATMENT", 10, 38], ["an artificial liver blood purification system", "TREATMENT", 71, 116], ["the inflammatory factors", "PROBLEM", 155, 179], ["the disastrous cytokine release syndrome", "PROBLEM", 206, 246], ["antiviral treatment", "OBSERVATION", 19, 38], ["liver", "ANATOMY", 85, 90], ["inflammatory", "OBSERVATION", 159, 171]]], ["This system can also facilitate the sustenance of critically ill patients by preserving the balance of bodily fluid.", [["bodily fluid", "ANATOMY", 103, 115], ["critically ill", "DISEASE", 50, 64], ["patients", "ORGANISM", 65, 73], ["bodily fluid", "ORGANISM_SUBSTANCE", 103, 115], ["patients", "SPECIES", 65, 73], ["bodily fluid", "PROBLEM", 103, 115]]], ["Administration of glucocorticoids in moderate doses is another intervention that has recently been indicated for patients with severe COVID\u201019\u2010associated pneumonia.", [["glucocorticoids", "CHEMICAL", 18, 33], ["COVID", "DISEASE", 134, 139], ["pneumonia", "DISEASE", 154, 163], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["glucocorticoids", "TREATMENT", 18, 33], ["another intervention", "TREATMENT", 55, 75], ["severe COVID\u201019\u2010associated pneumonia", "PROBLEM", 127, 163], ["moderate doses", "OBSERVATION_MODIFIER", 37, 51], ["pneumonia", "OBSERVATION", 154, 163]]], ["However, secondary fungal infection should be considered.", [["fungal infection", "DISEASE", 19, 35], ["secondary fungal infection", "PROBLEM", 9, 35], ["secondary", "OBSERVATION_MODIFIER", 9, 18], ["fungal", "OBSERVATION_MODIFIER", 19, 25], ["infection", "OBSERVATION", 26, 35]]], ["Patients with an oxygenation index of less than 200 mmHg might benefit more from oxygen therapy than noninvasive ventilation.", [["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 81, 87], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["Patients", "SPECIES", 0, 8], ["an oxygenation index", "TEST", 14, 34], ["oxygen therapy", "TREATMENT", 81, 95], ["noninvasive ventilation", "TREATMENT", 101, 124], ["oxygenation index", "OBSERVATION", 17, 34]]], ["A rational prescription of antimicrobial medicines has been cautioned only for patients with remittent fever and elevated antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever, and elevated PCT levels.", [["fever", "DISEASE", 103, 108], ["fever", "DISEASE", 262, 267], ["patients", "ORGANISM", 79, 87], ["patients", "ORGANISM", 215, 223], ["PCT", "GENE_OR_GENE_PRODUCT", 282, 285], ["PCT", "PROTEIN", 282, 285], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 215, 223], ["antimicrobial medicines", "TREATMENT", 27, 50], ["remittent fever", "PROBLEM", 93, 108], ["elevated antimicrobial prophylaxis", "TREATMENT", 113, 147], ["disease", "PROBLEM", 244, 251], ["repeated fever", "PROBLEM", 253, 267], ["elevated PCT levels", "PROBLEM", 273, 292], ["antimicrobial prophylaxis", "OBSERVATION", 122, 147]]], ["Ultimately, to maintain the balance of intestinal microbiota, oral intake of prebiotics or probiotics has been suggested.", [["intestinal", "ANATOMY", 39, 49], ["oral", "ANATOMY", 62, 66], ["intestinal microbiota", "MULTI-TISSUE_STRUCTURE", 39, 60], ["oral", "ORGANISM_SUBDIVISION", 62, 66], ["prebiotics", "TREATMENT", 77, 87], ["probiotics", "TREATMENT", 91, 101], ["intestinal microbiota", "ANATOMY", 39, 60]]], ["This can reduce the risk of secondary infections as a result of microbial translocation; however, effectiveness of such interventions on postinfection clearance pattern of SARS\u2010CoV\u20102 has not been studied (Xu et al., 2020).Convalescent blood therapy ::: Other future possible options ::: THERAPYA conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID\u201019.", [["blood", "ANATOMY", 235, 240], ["plasma", "ANATOMY", 365, 371], ["infections", "DISEASE", 38, 48], ["SARS", "DISEASE", 172, 176], ["CoV\u20102", "CHEMICAL", 177, 182], ["COVID", "DISEASE", 451, 456], ["blood", "ORGANISM_SUBSTANCE", 235, 240], ["human", "ORGANISM", 346, 351], ["convalescent", "ORGANISM", 352, 364], ["plasma", "ORGANISM_SUBSTANCE", 365, 371], ["human", "SPECIES", 346, 351], ["human", "SPECIES", 346, 351], ["secondary infections", "PROBLEM", 28, 48], ["microbial translocation", "PROBLEM", 64, 87], ["such interventions", "TREATMENT", 115, 133], ["postinfection clearance", "TEST", 137, 160], ["SARS", "PROBLEM", 172, 176], ["Convalescent blood therapy", "TREATMENT", 222, 248], ["human convalescent plasma", "TREATMENT", 346, 371], ["a beneficial strategy", "TREATMENT", 392, 413], ["treatment of COVID\u2010", "TREATMENT", 438, 457], ["secondary", "OBSERVATION_MODIFIER", 28, 37], ["infections", "OBSERVATION", 38, 48]]], ["The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin\u2010containing serum.", [["serum", "ANATOMY", 157, 162], ["patients", "ORGANISM", 90, 98], ["serum", "ORGANISM_SUBSTANCE", 157, 162], ["patients", "SPECIES", 90, 98]]], ["Although one still might argue the possibility of SARS\u2010CoV\u20102 infection via convalescent blood transfusion, no such incident with SARS\u2010CoV was reported by WHO amidst the outbreak of the disease in 2003.", [["blood", "ANATOMY", 88, 93], ["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 61, 70], ["SARS", "DISEASE", 129, 133], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 55, 60], ["convalescent", "ORGANISM", 75, 87], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["SARS\u2010CoV", "ORGANISM", 129, 137], ["SARS\u2010CoV", "SPECIES", 129, 137], ["SARS", "PROBLEM", 50, 54], ["CoV\u20102 infection", "PROBLEM", 55, 70], ["convalescent blood transfusion", "TREATMENT", 75, 105], ["SARS\u2010CoV", "PROBLEM", 129, 137], ["the disease", "PROBLEM", 181, 192], ["disease", "OBSERVATION", 185, 192]]], ["The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID\u201019 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, 2020; Cunningham, Goh, & Koh, 2020).Mesenchymal stem cell (MSC) therapy ::: Other future possible options ::: THERAPYA new therapeutic for treating immune\u2010mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID\u201019.", [["Mesenchymal stem cell", "ANATOMY", 335, 356], ["MSC", "ANATOMY", 358, 361], ["MSC", "ANATOMY", 473, 476], ["SARS", "DISEASE", 222, 226], ["MERS", "DISEASE", 228, 232], ["Mesenchymal stem cell", "CELL", 335, 356], ["MSC", "CELL", 358, 361], ["MSC", "CELL", 473, 476], ["cytokines", "PROTEIN", 553, 562], ["therapeutic strategies", "TREATMENT", 101, 123], ["SARS", "PROBLEM", 222, 226], ["Mesenchymal stem cell (MSC) therapy", "TREATMENT", 335, 370], ["treating immune\u2010mediated diseases", "PROBLEM", 438, 471], ["MSC therapy", "TREATMENT", 473, 484], ["cytokines in COVID\u2010", "TREATMENT", 553, 572], ["stem cell", "OBSERVATION", 347, 356]]], ["Through its anti\u2010inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury.", [["MSC", "ANATOMY", 39, 42], ["respiratory", "ANATOMY", 80, 91], ["lung", "ANATOMY", 129, 133], ["acute lung injury", "DISEASE", 123, 140], ["MSC", "CELL", 39, 42], ["murine", "ORGANISM", 104, 110], ["lung", "ORGAN", 129, 133], ["murine", "SPECIES", 104, 110], ["its anti\u2010inflammatory effects", "TREATMENT", 8, 37], ["MSC therapy", "TREATMENT", 39, 50], ["acute lung injury", "PROBLEM", 123, 140], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140]]], ["Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, 2018; Wang, Yao, Lv, Ling, & Li, 2017; Xiang et al., 2017).", [["MSCs", "ANATOMY", 23, 27], ["MSCs", "CELL", 23, 27], ["MSCs", "CELL_TYPE", 23, 27], ["inflammatory factors", "PROTEIN", 84, 104], ["MSCs", "PROBLEM", 23, 27], ["inflammatory factors", "PROBLEM", 84, 104], ["inflammatory", "OBSERVATION_MODIFIER", 84, 96], ["Lv", "ANATOMY", 132, 134], ["Ling", "ANATOMY", 136, 140]]], ["In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9\u2010induced ARDS.", [["MSCs", "ANATOMY", 79, 83], ["pneumonia", "DISEASE", 146, 155], ["ARDS", "DISEASE", 233, 237], ["MSCs", "CELL", 79, 83], ["MSCs", "CELL_TYPE", 79, 83], ["H7N9", "SPECIES", 220, 224], ["a study", "TEST", 15, 22], ["transplantation of MSCs", "TREATMENT", 60, 83], ["a novel approach", "TREATMENT", 107, 123], ["viral pneumonia", "PROBLEM", 140, 155], ["this method", "TREATMENT", 191, 202], ["management", "TREATMENT", 206, 216], ["H7N9", "PROBLEM", 220, 224], ["ARDS", "PROBLEM", 233, 237], ["viral", "OBSERVATION_MODIFIER", 140, 145], ["pneumonia", "OBSERVATION", 146, 155], ["ARDS", "OBSERVATION", 233, 237]]], ["Since H7N9 and SARS\u2010CoV\u20102 can result in similar complications, for example, ARDS and respiratory failure, MSC\u2010based therapy might lead to a new path in treatment of COVID\u201019\u2010associated pneumonia (Chen, Hu, et al., 2020).Nano drug delivery systems ::: Other future possible options ::: THERAPYIt has long been known that the traditional circulation\u2010based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard\u2010to\u2010reach tissues in human body.", [["respiratory", "ANATOMY", 85, 96], ["MSC", "ANATOMY", 106, 109], ["tissues", "ANATOMY", 509, 516], ["body", "ANATOMY", 526, 530], ["SARS", "DISEASE", 15, 19], ["ARDS", "DISEASE", 76, 80], ["respiratory failure", "DISEASE", 85, 104], ["COVID", "DISEASE", 165, 170], ["pneumonia", "DISEASE", 185, 194], ["SARS\u2010CoV\u20102", "ORGANISM", 15, 25], ["MSC", "CELL", 106, 109], ["hard\u2010to\u2010reach tissues", "TISSUE", 495, 516], ["human", "ORGANISM", 520, 525], ["body", "ORGANISM_SUBDIVISION", 526, 530], ["human", "SPECIES", 520, 525], ["H7N9", "SPECIES", 6, 10], ["SARS\u2010CoV", "SPECIES", 15, 23], ["human", "SPECIES", 520, 525], ["H7N9", "PROBLEM", 6, 10], ["similar complications", "PROBLEM", 40, 61], ["ARDS", "PROBLEM", 76, 80], ["respiratory failure", "PROBLEM", 85, 104], ["MSC\u2010based therapy", "TREATMENT", 106, 123], ["COVID\u201019\u2010associated pneumonia", "PROBLEM", 165, 194], ["Nano drug delivery systems", "TREATMENT", 220, 246], ["therapeutic agents", "TREATMENT", 366, 384], ["novel platforms", "TREATMENT", 450, 465], ["delivery of molecules", "TREATMENT", 470, 491], ["complications", "OBSERVATION", 48, 61], ["ARDS", "OBSERVATION", 76, 80], ["respiratory failure", "OBSERVATION", 85, 104], ["pneumonia", "OBSERVATION", 185, 194], ["human", "ANATOMY", 520, 525], ["body", "ANATOMY_MODIFIER", 526, 530]]], ["Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, 2017; Agarwal, Chhikara, Quiterio, Doncel, & Parang, 2012).", [["nucleoside", "CHEMICAL", 46, 56], ["HIV infection", "DISEASE", 147, 160], ["nucleoside", "CHEMICAL", 46, 56], ["nucleoside analogs", "SIMPLE_CHEMICAL", 46, 64], ["HIV", "ORGANISM", 147, 150], ["HIV", "SPECIES", 147, 150], ["HIV", "SPECIES", 147, 150], ["antiviral agents", "TREATMENT", 15, 31], ["nucleoside analogs", "TREATMENT", 46, 64], ["specific nanoparticles", "TREATMENT", 71, 93], ["resistant HIV infection", "PROBLEM", 137, 160], ["Agarwal", "TEST", 205, 212], ["antiviral agents", "OBSERVATION", 15, 31], ["resistant", "OBSERVATION_MODIFIER", 137, 146], ["HIV", "OBSERVATION_MODIFIER", 147, 150], ["infection", "OBSERVATION", 151, 160]]], ["Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID\u201019 (Chhikara & Varma, 2019) in hopes of shortening the course of the disease (Chhikara et al., 2020).Psychological interventions ::: Other future possible options ::: THERAPYProgression of COVID\u201019, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions.", [["patients", "ORGANISM", 446, 454], ["patients", "SPECIES", 446, 454], ["drug delivery platforms", "TREATMENT", 32, 55], ["custom therapeutic formulations", "TREATMENT", 131, 162], ["treatment of COVID\u2010", "TREATMENT", 167, 186], ["Chhikara & Varma", "TREATMENT", 190, 206], ["the disease", "PROBLEM", 251, 262], ["Psychological interventions", "TREATMENT", 287, 314], ["any other disease", "PROBLEM", 396, 413], ["psychological symptoms", "PROBLEM", 466, 488], ["special interventions", "TREATMENT", 509, 530], ["appreciable", "OBSERVATION_MODIFIER", 10, 21], ["number", "OBSERVATION_MODIFIER", 22, 28], ["disease", "OBSERVATION", 406, 413]]], ["It has been well\u2010established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders.", [["stress disorders", "DISEASE", 158, 174], ["disease outbreaks", "PROBLEM", 111, 128], ["stress disorders", "PROBLEM", 158, 174], ["variable degrees", "OBSERVATION_MODIFIER", 138, 154], ["stress disorders", "OBSERVATION", 158, 174]]], ["With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.)", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["psychological interventions", "TREATMENT", 122, 149], ["the disease", "PROBLEM", 177, 188]]], ["(Duan & Zhu, 2020).Psychological interventions ::: Other future possible options ::: THERAPYIn large\u2010scale outbreaks such as COVID\u201019 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease.", [["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["Psychological interventions", "TREATMENT", 19, 46], ["the disease", "PROBLEM", 249, 260], ["disease", "OBSERVATION", 253, 260]]], ["(Duan & Zhu, 2020).Psychological interventions ::: Other future possible options ::: THERAPYInterventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, 2009).PATIENTS RECOVERED FROM COVID\u201019The following criteria must be met in order for a patient to be discharged from hospital or released from quarantine: (a) having been afebrile for at least 3 consecutive days, (b) remission of respiratory distress, (c) regression of infiltrations/consolidations on chest CT images, and two consecutive negative reports of RT\u2010PCR test performed at least 1 day apart (d).", [["respiratory", "ANATOMY", 645, 656], ["impaired mental health", "DISEASE", 261, 283], ["panic", "DISEASE", 329, 334], ["respiratory distress", "DISEASE", 645, 665], ["patient", "ORGANISM", 502, 509], ["patient", "SPECIES", 502, 509], ["Psychological interventions", "TREATMENT", 19, 46], ["THERAPYInterventions", "TREATMENT", 85, 105], ["a thorough evaluation", "TEST", 148, 169], ["risk factors", "PROBLEM", 173, 185], ["panic", "PROBLEM", 329, 334], ["afebrile", "PROBLEM", 586, 594], ["respiratory distress", "PROBLEM", 645, 665], ["infiltrations", "PROBLEM", 685, 698], ["consolidations", "PROBLEM", 699, 713], ["chest CT images", "TEST", 717, 732], ["RT\u2010PCR test", "TEST", 774, 785], ["respiratory", "ANATOMY", 645, 656], ["distress", "OBSERVATION", 657, 665], ["infiltrations", "OBSERVATION", 685, 698], ["consolidations", "OBSERVATION", 699, 713], ["chest", "ANATOMY", 717, 722]]], ["Despite these thoroughly formulated criteria, one study reported positive RT\u2010PCR test results 5\u201313 days after hospital discharge for four patients with COVID\u201019, who met all of the criteria above before they were discharged.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["one study", "TEST", 46, 55], ["PCR test", "TEST", 77, 85]]], ["These findings are important in that they imply the slight possibility that even a fully recovered patient might still be a silent carrier of the virus.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["the virus", "PROBLEM", 142, 151], ["virus", "OBSERVATION", 146, 151]]], ["In this scenario, however, no family members were reported to be infected, since all of the four patients with bizarrely late positive tests were medical professional, and followed all of the guidelines while they were at home quarantine.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["bizarrely late positive tests", "PROBLEM", 111, 140]]], ["The number of confirmed cases is on the rise, and the seamless spread of the virus has become a plight for general population, and the entire medical community.", [["the virus", "PROBLEM", 73, 82], ["cases", "OBSERVATION", 24, 29]]], ["In spite of the extreme preventive measures while near a patient, clinicians are still at great risk for contracting the disease from the visitors.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["the extreme preventive measures", "TREATMENT", 12, 43], ["the disease", "PROBLEM", 117, 128]]], ["Else, it is vividly known that quarantine alone is not the optimal choice for containing of the virus.", [["the virus", "PROBLEM", 92, 101]]], ["On the other hand, the devastating potential impact of the outbreak is a much feared topic around the world.", [["devastating", "OBSERVATION_MODIFIER", 23, 34]]], ["Science has always been the ultimate arsenal of weaponry when it comes to battling obstinate pathogens; however, time is needed for conduction of proper investigations on human\u2010to\u2010human and animal\u2010to\u2010human transmission of SARS\u2010CoV\u20102.CONCLUSIONS AND FUTURE PERSPECTIVESWith no access to requisite information on the structure and life cycle of the novel Coronavirus, research and development programs on therapeutic agents become a far\u2010fetched milestone, rendering the tried\u2010and\u2010true primary prevention measures the only proper means to confront SARS\u2010CoV\u20102.", [["SARS", "DISEASE", 222, 226], ["SARS", "DISEASE", 545, 549], ["SARS\u2010CoV", "SPECIES", 222, 230], ["human\u2010to\u2010human", "TREATMENT", 171, 185], ["the novel Coronavirus", "PROBLEM", 343, 364], ["therapeutic agents", "TREATMENT", 403, 421], ["the tried\u2010and\u2010true primary prevention measures", "TREATMENT", 464, 510]]], ["As of today, few existing drugs have been considered for treatment of COVID\u201019, with scant reports on benevolence of the results.", [["COVID\u2010", "TEST", 70, 76]]], ["As our meager knowledge of SARS\u2010CoV\u20102 is advancing, one may speculate the advent of an effectual vaccine, alongside treatment options that might include antiviral agents, and even monoclonal antibodies.", [["SARS", "DISEASE", 27, 31], ["CoV\u20102", "CHEMICAL", 32, 37], ["monoclonal antibodies", "PROTEIN", 180, 201], ["an effectual vaccine", "TREATMENT", 84, 104], ["treatment options", "TREATMENT", 116, 133], ["antiviral agents", "TREATMENT", 153, 169]]], ["At the time of writing this manuscript, no definitive treatment option has been known for COVID\u201019; however, the unabating flow of investigations and clinical trials may soon lead us to the optimal therapy for COVID\u201019\u2010associated pneumonia.CONCLUSIONS AND FUTURE PERSPECTIVESNeedless to say, the fascinatingly high transmissibility of COVID\u201019 demands meticulous monitoring of the transmission routes and patterns to a reach a firm theory on adaptive mechanisms wielded by SARs\u2010CoV\u20102, thus, making an accurate prediction about the future outcomes regarding pathogenicity, transmissibility, and evolution of the virus.", [["COVID", "DISEASE", 210, 215], ["pneumonia", "DISEASE", 230, 239], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 478, 483], ["definitive treatment option", "TREATMENT", 43, 70], ["the optimal therapy", "TREATMENT", 186, 205], ["COVID\u201019\u2010associated pneumonia", "PROBLEM", 210, 239], ["meticulous monitoring", "TEST", 352, 373], ["pathogenicity", "PROBLEM", 557, 570], ["the virus", "PROBLEM", 607, 616], ["pneumonia", "OBSERVATION", 230, 239], ["firm", "OBSERVATION", 427, 431], ["virus", "OBSERVATION", 611, 616]]], ["These efforts will hopefully result in better prognosis and fewer mortalities.CONFLICT OF INTERESTSThe authors declare that they have no conflict of interest.AUTHOR CONTRIBUTIONSAll authors contributed to different parts of the study.", [["the study", "TEST", 224, 233]]]], "PMC7095465": [], "PMC7287038": [["IntroductionCoronavirus disease-19 (COVID-19) is caused by a novel coronavirus (CoV) that was originally reported in Wuhan, Hubei province, China in December 2019 (World Health Organization, 2020a).", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["coronavirus", "ORGANISM", 67, 78], ["CoV", "ORGANISM", 80, 83], ["coronavirus", "SPECIES", 67, 78], ["IntroductionCoronavirus disease-19 (COVID-19", "SPECIES", 0, 44], ["CoV", "SPECIES", 80, 83], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 36, 41], ["a novel coronavirus (CoV", "PROBLEM", 59, 83], ["coronavirus", "OBSERVATION", 67, 78]]], ["The International Committee on Taxonomy of Viruses named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 74, 112], ["SARS-CoV-2", "ORGANISM", 116, 126], ["virus severe acute respiratory syndrome coronavirus", "SPECIES", 61, 112], ["SARS-CoV-2", "SPECIES", 116, 126], ["Viruses", "TREATMENT", 43, 50], ["the virus severe acute respiratory syndrome coronavirus", "PROBLEM", 57, 112], ["SARS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["respiratory syndrome", "OBSERVATION", 80, 100]]], ["Infection by SARS-CoV-2 causes a respiratory illness that varies in severity from mild upper respiratory symptoms akin to the seasonal flu, to severe progressive respiratory failure that requires intensive care and can lead to death.", [["respiratory", "ANATOMY", 33, 44], ["respiratory", "ANATOMY", 93, 104], ["respiratory", "ANATOMY", 162, 173], ["SARS", "DISEASE", 13, 17], ["respiratory illness", "DISEASE", 33, 52], ["flu", "DISEASE", 135, 138], ["respiratory failure", "DISEASE", 162, 181], ["death", "DISEASE", 227, 232], ["SARS-CoV-2", "ORGANISM", 13, 23], ["CoV-2", "SPECIES", 18, 23], ["SARS-CoV-2", "SPECIES", 13, 23], ["Infection", "PROBLEM", 0, 9], ["SARS", "PROBLEM", 13, 17], ["a respiratory illness", "PROBLEM", 31, 52], ["mild upper respiratory symptoms", "PROBLEM", 82, 113], ["the seasonal flu", "PROBLEM", 122, 138], ["severe progressive respiratory failure", "PROBLEM", 143, 181], ["intensive care", "TREATMENT", 196, 210], ["death", "PROBLEM", 227, 232], ["respiratory illness", "OBSERVATION", 33, 52], ["mild", "OBSERVATION_MODIFIER", 82, 86], ["upper", "ANATOMY_MODIFIER", 87, 92], ["respiratory", "ANATOMY", 93, 104], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["progressive", "OBSERVATION_MODIFIER", 150, 161], ["respiratory failure", "OBSERVATION", 162, 181]]], ["Asymptomatic carriers of the virus have also been reported and pose a significant public health threat due to their ability to unknowingly spread the virus (Chan et al., 2020a).", [["Asymptomatic carriers", "PROBLEM", 0, 21], ["the virus", "PROBLEM", 25, 34]]], ["SARS-CoV-2 represents the third CoV in this millennium to cross species from animals to humans and cause a severe respiratory disease after Middle-East respiratory syndrome coronavirus (MERS-CoV) in 2012 (Zaki et al., 2012), and SARS-CoV in 2003 (Drosten et al., 2003; Ksiazek et al., 2003).", [["respiratory", "ANATOMY", 114, 125], ["SARS", "DISEASE", 0, 4], ["respiratory disease", "DISEASE", 114, 133], ["Middle-East respiratory syndrome coronavirus", "DISEASE", 140, 184], ["SARS-CoV", "DISEASE", 229, 237], ["SARS-CoV-2", "ORGANISM", 0, 10], ["CoV", "ORGANISM", 32, 35], ["humans", "ORGANISM", 88, 94], ["Middle-East respiratory syndrome coronavirus", "ORGANISM", 140, 184], ["MERS-CoV", "ORGANISM", 186, 194], ["SARS-CoV", "ORGANISM", 229, 237], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["Middle-East respiratory syndrome coronavirus", "SPECIES", 140, 184], ["MERS-CoV", "SPECIES", 186, 194], ["SARS-CoV", "SPECIES", 229, 237], ["SARS", "PROBLEM", 0, 4], ["the third CoV", "PROBLEM", 22, 35], ["a severe respiratory disease", "PROBLEM", 105, 133], ["East respiratory syndrome coronavirus", "PROBLEM", 147, 184], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["respiratory disease", "OBSERVATION", 114, 133], ["Middle", "ANATOMY_MODIFIER", 140, 146], ["respiratory syndrome", "OBSERVATION", 152, 172]]], ["This novel CoV has now been identified as the seventh CoV that is transmissible between humans (including HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) (Salata et al., 2019).", [["CoV", "GENE_OR_GENE_PRODUCT", 11, 14], ["CoV", "GENE_OR_GENE_PRODUCT", 54, 57], ["humans", "ORGANISM", 88, 94], ["HCoV-229E", "ORGANISM", 106, 115], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 117, 126], ["HCoV-NL63", "GENE_OR_GENE_PRODUCT", 128, 137], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["This novel CoV", "PROBLEM", 0, 14], ["HCoV", "TEST", 106, 110], ["HCoV", "TEST", 117, 121], ["OC43", "TEST", 122, 126], ["HCoV", "TEST", 128, 132], ["HCoV", "TEST", 143, 147]]], ["On 30th January 2020, the World Health Organization (WHO) declared the SARS-CoV-2 epidemic a public health emergency of international concern and was upgraded to a pandemic on 11th March 2020.", [["SARS-CoV-2 epidemic", "DISEASE", 71, 90], ["the SARS", "PROBLEM", 67, 75]]], ["At least 4,302,774 confirmed cases and 289,561 deaths worldwide were reported as of 12th May 2020 (worldometers.info/coronavirus/).", [["deaths", "DISEASE", 47, 53], ["coronavirus", "ORGANISM", 117, 128], ["info/coronavirus", "SPECIES", 112, 128]]], ["Diagnostic testing is critical during a pandemic as the ability to track the spread of SARS-CoV-2 is essential for effective disease management and control.IntroductionSARS-CoV-2 is a positive-sense, single-stranded RNA (ssRNA), group IV virus.", [["SARS", "DISEASE", 87, 91], ["SARS-CoV-2", "ORGANISM", 87, 97], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 156, 178], ["IntroductionSARS-CoV-2", "DNA", 156, 178], ["positive-sense, single-stranded RNA", "DNA", 184, 219], ["SARS-CoV", "SPECIES", 87, 95], ["Diagnostic testing", "TEST", 0, 18], ["a pandemic", "PROBLEM", 38, 48], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["effective disease management", "TREATMENT", 115, 143], ["IntroductionSARS", "TEST", 156, 172], ["CoV", "TEST", 173, 176], ["single-stranded RNA (ssRNA", "PROBLEM", 200, 226], ["group IV virus", "PROBLEM", 229, 243]]], ["The genome was sequenced from the bronchoalveolar lavage fluid of a patient (Genbank: MN908947) and shared through the Global Initiative on Sharing All Influenza Data (GISAID) platform on 12th January 2020 (Wu et al., 2020).", [["bronchoalveolar lavage fluid", "ANATOMY", 34, 62], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 34, 62], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["the bronchoalveolar lavage fluid", "TEST", 30, 62], ["bronchoalveolar lavage", "OBSERVATION", 34, 56]]], ["The ~30 k base pair genome is highly similar to the human SARS-CoV and bat CoV-SARS-like genomes with 14 open reading frames (ORFs) that encode structural, replication and non-structural accessory proteins, as depicted in Figure 1.", [["human", "ORGANISM", 52, 57], ["SARS-CoV", "ORGANISM", 58, 66], ["bat CoV-SARS", "ORGANISM", 71, 83], ["~30 k base pair genome", "DNA", 4, 26], ["human SARS-CoV and bat CoV-SARS-like genomes", "DNA", 52, 96], ["14 open reading frames", "DNA", 102, 124], ["ORFs", "DNA", 126, 130], ["non-structural accessory proteins", "PROTEIN", 172, 205], ["human", "SPECIES", 52, 57], ["bat CoV", "SPECIES", 71, 78], ["human SARS-CoV", "SPECIES", 52, 66], ["bat CoV", "SPECIES", 71, 78], ["The ~30 k base pair genome", "TEST", 0, 26], ["the human SARS", "TEST", 48, 62], ["CoV", "TEST", 63, 66], ["bat CoV", "TEST", 71, 78], ["SARS", "PROBLEM", 79, 83], ["non-structural accessory proteins", "PROBLEM", 172, 205]]], ["Molecular modeling studies demonstrate that like SARS-CoV, SARS-CoV-2 is surrounded by a lipid bilayer membrane, containing structural membrane (M) and envelope (E) proteins that interact to form the viral envelope (Durrant et al., 2020).", [["lipid bilayer membrane", "ANATOMY", 89, 111], ["membrane", "ANATOMY", 135, 143], ["SARS-CoV", "ORGANISM", 49, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["lipid", "CELLULAR_COMPONENT", 89, 94], ["bilayer membrane", "CELLULAR_COMPONENT", 95, 111], ["structural membrane", "CELLULAR_COMPONENT", 124, 143], ["envelope (E) proteins", "GENE_OR_GENE_PRODUCT", 152, 173], ["SARS-CoV-2", "DNA", 59, 69], ["structural membrane (M) and envelope (E) proteins", "PROTEIN", 124, 173], ["SARS-CoV", "SPECIES", 49, 57], ["Molecular modeling studies", "TEST", 0, 26], ["like SARS", "PROBLEM", 44, 53], ["CoV", "TEST", 54, 57], ["SARS", "PROBLEM", 59, 63], ["a lipid bilayer membrane", "PROBLEM", 87, 111], ["envelope (E) proteins", "PROBLEM", 152, 173], ["lipid bilayer membrane", "OBSERVATION", 89, 111], ["structural membrane", "OBSERVATION", 124, 143]]], ["This layer also contains spike glycoproteins (S) that give the characteristic \u201ccorona\u201d appearance of this family of viruses.", [["spike glycoproteins", "PROTEIN", 25, 44], ["S", "PROTEIN", 46, 47], ["spike glycoproteins", "PROBLEM", 25, 44], ["spike glycoproteins", "OBSERVATION", 25, 44], ["viruses", "OBSERVATION", 116, 123]]], ["The spike proteins bind specific host cell receptors to facilitate host cell attachment and entry (Graham and Baric, 2010).", [["cell", "ANATOMY", 38, 42], ["cell", "ANATOMY", 72, 76], ["cell", "CELL", 38, 42], ["host cell", "CELL", 67, 76], ["spike proteins", "PROTEIN", 4, 18], ["host cell receptors", "PROTEIN", 33, 52], ["The spike proteins bind", "PROBLEM", 0, 23], ["host cell receptors", "TREATMENT", 33, 52], ["host cell attachment", "OBSERVATION", 67, 87]]], ["The nucleic acid-associated protein binds the RNA genome and forms the nucleocapsid (N).", [["nucleic acid-associated protein", "PROTEIN", 4, 35], ["RNA genome", "DNA", 46, 56], ["nucleocapsid (N)", "PROTEIN", 71, 87], ["protein binds", "OBSERVATION", 28, 41], ["RNA genome", "OBSERVATION", 46, 56]]], ["Other proteins include replication and non-structural accessory proteins that are listed in Table 1.", [["non-structural accessory proteins", "PROTEIN", 39, 72], ["non-structural accessory proteins", "TREATMENT", 39, 72], ["non-structural", "OBSERVATION_MODIFIER", 39, 53], ["accessory proteins", "OBSERVATION", 54, 72]]], ["Reports of different strains of SARS-CoV-2 suggest an early split from the SARS-CoV-2 lineage and/or the virus is mutating.", [["SARS", "DISEASE", 32, 36], ["SARS", "DISEASE", 75, 79], ["SARS-CoV-2", "ORGANISM", 32, 42], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 32, 40], ["SARS-CoV", "SPECIES", 75, 83], ["different strains of SARS", "PROBLEM", 11, 36], ["an early split", "PROBLEM", 51, 65], ["the SARS", "TEST", 71, 79], ["CoV", "TEST", 80, 83], ["the virus", "PROBLEM", 101, 110], ["virus", "OBSERVATION", 105, 110]]], ["Ongoing research provides insight into the unique and conserved features of the genome and proteome of SARS-CoV-2 to track mutations and generates evidence about the evolution of the virus (Phan, 2020; Wang et al., 2020).", [["SARS-CoV-2", "ORGANISM", 103, 113], ["SARS-CoV", "SPECIES", 103, 111], ["SARS", "PROBLEM", 103, 107], ["CoV", "TEST", 108, 111], ["track mutations", "PROBLEM", 117, 132]]], ["This is important as these changes may affect key structural and non-structural components of SARS-CoV-2 that can render some diagnostic tests ineffective or less sensitive and can also impact the selection of epitopes for the development of new tests.IntroductionThe spread of SARS-CoV-2 is primarily by respiratory droplets that arise from individuals that harbor the virus.", [["respiratory droplets", "ANATOMY", 305, 325], ["SARS", "DISEASE", 94, 98], ["SARS", "DISEASE", 278, 282], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 94, 104], ["SARS-CoV-2", "ORGANISM", 278, 288], ["epitopes", "PROTEIN", 210, 218], ["SARS-CoV", "SPECIES", 94, 102], ["SARS-CoV", "SPECIES", 278, 286], ["some diagnostic tests", "TEST", 121, 142], ["new tests", "TEST", 242, 251], ["respiratory droplets", "PROBLEM", 305, 325], ["the virus", "PROBLEM", 366, 375], ["respiratory droplets", "OBSERVATION", 305, 325]]], ["Symptomatic individuals with the disease are one source of virus, but a major public health concern is transmission by mildly ill or asymptomatic individuals during the incubation period.", [["mildly ill", "DISEASE", 119, 129], ["Symptomatic individuals", "PROBLEM", 0, 23], ["the disease", "PROBLEM", 29, 40], ["virus", "PROBLEM", 59, 64], ["mildly ill", "PROBLEM", 119, 129], ["asymptomatic individuals", "PROBLEM", 133, 157], ["disease", "OBSERVATION", 33, 40], ["virus", "OBSERVATION", 59, 64]]], ["Rapid viral diagnostic testing for SARS-CoV-2 is critical to identify these individuals and facilitate the implementation of protective measures such as social distancing, quarantine and isolation that help to mitigate the spread of the virus in the community.", [["SARS", "DISEASE", 35, 39], ["SARS-CoV-2", "ORGANISM", 35, 45], ["SARS-CoV", "SPECIES", 35, 43], ["Rapid viral diagnostic testing", "TEST", 0, 30], ["SARS", "PROBLEM", 35, 39], ["protective measures", "TREATMENT", 125, 144], ["quarantine", "TREATMENT", 172, 182], ["isolation", "TREATMENT", 187, 196]]], ["The development of rapid and accurate tests that detect antibodies post-infection provide information about an individual's exposure to the virus and can be used to monitor the possibility of immunity, relapse or reinfection.", [["antibodies", "PROTEIN", 56, 66], ["rapid and accurate tests", "TEST", 19, 43], ["antibodies post-infection", "PROBLEM", 56, 81], ["the virus", "PROBLEM", 136, 145], ["relapse", "PROBLEM", 202, 209], ["reinfection", "PROBLEM", 213, 224], ["rapid", "OBSERVATION_MODIFIER", 19, 24], ["reinfection", "OBSERVATION", 213, 224]]], ["This supports interventions to protect higher risk populations from developing more severe illness and can be used to investigate the efficacy of passive antibody therapies for COVID-19 infection.", [["COVID-19", "CHEMICAL", 177, 185], ["infection", "DISEASE", 186, 195], ["COVID-19", "ORGANISM", 177, 185], ["COVID-19", "SPECIES", 177, 185], ["interventions", "TREATMENT", 14, 27], ["higher risk populations", "PROBLEM", 39, 62], ["more severe illness", "PROBLEM", 79, 98], ["passive antibody therapies", "TREATMENT", 146, 172], ["COVID-19 infection", "PROBLEM", 177, 195], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["illness", "OBSERVATION", 91, 98], ["infection", "OBSERVATION", 186, 195]]], ["This review describes the available testing methods for SARS-CoV-2 and brings to light the importance of laboratory testing to control this disease and prepare for possible future disease threats.RNA Isolation ::: Sample Collection ::: Detection of SARS-CoV-2 by Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)RNA is extracted from clinical specimens using approved viral isolation kits (Corman et al., 2020).Real-Time RT-PCR ::: Sample Collection ::: Detection of SARS-CoV-2 by Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)RNA is reverse transcribed to cDNA and subsequently amplified using a real-time quantitative PCR instrument.", [["specimens", "ANATOMY", 360, 369], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 249, 259], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 484, 494], ["cDNA", "DNA", 594, 598], ["SARS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 249, 257], ["SARS-CoV", "SPECIES", 484, 492], ["laboratory testing", "TEST", 105, 123], ["this disease", "PROBLEM", 135, 147], ["future disease threats", "PROBLEM", 173, 195], ["SARS", "TEST", 249, 253], ["CoV", "TEST", 254, 257], ["Transcriptase Polymerase Chain Reaction (RT-PCR)RNA", "TREATMENT", 281, 332], ["clinical specimens", "TEST", 351, 369], ["viral isolation kits", "TREATMENT", 385, 405], ["SARS", "TEST", 484, 488], ["CoV", "TEST", 489, 492], ["Transcriptase Polymerase Chain Reaction (RT-PCR)RNA", "TREATMENT", 516, 567]]], ["WHO announced various primer and probe sets for SARS-CoV-2 previously developed in China, Germany, Hong Kong, Japan, Thailand, and USA (World Health Organization, 2020b; Table 2).", [["SARS-CoV", "SPECIES", 48, 56], ["probe sets", "TEST", 33, 43], ["SARS", "PROBLEM", 48, 52], ["CoV", "TEST", 53, 56]]], ["Primers targeting different sections of the virus genetic sequence including the envelope E gene, the RNA-dependent RNA polymerase (RdRp) gene, and the N gene (Chu et al., 2020; Corman et al., 2020; World Health Organization, 2020b).", [["sections", "ANATOMY", 28, 36], ["envelope E", "GENE_OR_GENE_PRODUCT", 81, 91], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 102, 130], ["virus genetic sequence", "DNA", 44, 66], ["envelope E gene", "DNA", 81, 96], ["RNA-dependent RNA polymerase (RdRp) gene", "DNA", 102, 142], ["N gene", "DNA", 152, 158], ["the virus genetic sequence", "TREATMENT", 40, 66], ["the envelope E gene", "TREATMENT", 77, 96], ["the RNA-dependent RNA polymerase", "TREATMENT", 98, 130]]], ["Targeting the E gene is reported for highest sensitivity, followed by the RdRp gene for confirmation (Corman et al., 2020).", [["E", "GENE_OR_GENE_PRODUCT", 14, 15], ["E gene", "DNA", 14, 20], ["RdRp gene", "DNA", 74, 83]]], ["Some laboratories have multiplexed PCR tests consisting of multiple primer and probe sets located at different regions in the SARS-CoV-2 genome.", [["SARS-CoV-2 genome", "DNA", 126, 143], ["SARS-CoV", "SPECIES", 126, 134], ["Some laboratories", "TEST", 0, 17], ["multiplexed PCR tests", "TEST", 23, 44], ["multiple primer and probe sets", "PROBLEM", 59, 89], ["the SARS", "TEST", 122, 130], ["multiple", "OBSERVATION_MODIFIER", 59, 67], ["primer", "OBSERVATION", 68, 74], ["different", "OBSERVATION_MODIFIER", 101, 110], ["regions", "OBSERVATION_MODIFIER", 111, 118], ["SARS", "OBSERVATION", 126, 130], ["CoV", "OBSERVATION_MODIFIER", 131, 134], ["2 genome", "ANATOMY_MODIFIER", 135, 143]]], ["These assays can be designed to contain primer sets targeting multiple genes simultaneously (RdRp/hel, S, N) (Chan et al., 2020b), or to detect different regions in a single target such as the N gene (U.F.A.D. Administration, 2020Table 2).", [["multiple genes", "DNA", 62, 76], ["N gene", "DNA", 193, 199], ["These assays", "TEST", 0, 12]]], ["The use of multiplex assays is potentially beneficial as this can improve sensitivity in cases of loss or degradation of viral RNA during specimen collection and nucleic acid extraction, or in the event of mutation of the virus genome.", [["specimen", "ANATOMY", 138, 146], ["nucleic acid", "CHEMICAL", 162, 174], ["nucleic acid", "SIMPLE_CHEMICAL", 162, 174], ["viral RNA", "RNA", 121, 130], ["virus genome", "DNA", 222, 234], ["multiplex assays", "TEST", 11, 27], ["loss", "PROBLEM", 98, 102], ["viral RNA", "PROBLEM", 121, 130], ["specimen collection", "TEST", 138, 157], ["nucleic acid extraction", "TREATMENT", 162, 185], ["mutation of the virus genome", "PROBLEM", 206, 234], ["viral RNA", "OBSERVATION", 121, 130], ["virus genome", "OBSERVATION", 222, 234]]], ["These assays use in vitro synthesized RNA derived from transcripts (e.g., BetaCoV_Wuhan_WIV04_2019, GISAID Access number: EPI_ISL_402124) as positive controls and to generate standard curves.", [["These assays", "TEST", 0, 12]]], ["An internal control using RNAse P (RP) verifies the presence and quality of nucleic acid in samples and molecular grade nuclease-free water is used as a negative amplification control.", [["samples", "ANATOMY", 92, 99], ["nucleic acid", "CHEMICAL", 76, 88], ["RNAse", "GENE_OR_GENE_PRODUCT", 26, 31], ["nucleic acid", "SIMPLE_CHEMICAL", 76, 88], ["RNAse P", "PROTEIN", 26, 33], ["nuclease", "PROTEIN", 120, 128], ["An internal control", "TREATMENT", 0, 19], ["RNAse P (RP", "TREATMENT", 26, 37], ["nucleic acid in samples", "TEST", 76, 99], ["a negative amplification control", "TREATMENT", 151, 183]]], ["A negative patient sample serves both as a negative extraction control to monitor cross contamination across samples and to validate test reagents.Advantages ::: Detection of SARS-CoV-2 by Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)RT-PCR is the frontline diagnostic test for COVID-19 that is capable of analyzing thousands of specimens in a single day and shows a testing sensitivity of 95% (Corman et al., 2020).", [["samples", "ANATOMY", 109, 116], ["specimens", "ANATOMY", 350, 359], ["patient", "ORGANISM", 11, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 175, 185], ["patient", "SPECIES", 11, 18], ["SARS-CoV", "SPECIES", 175, 183], ["a negative extraction control", "TREATMENT", 41, 70], ["cross contamination across samples", "TEST", 82, 116], ["test reagents", "TEST", 133, 146], ["SARS", "TEST", 175, 179], ["CoV", "TEST", 180, 183], ["Chain Reaction", "TEST", 232, 246], ["RT-PCR", "TEST", 255, 261], ["COVID", "TEST", 299, 304], ["a testing sensitivity", "TEST", 386, 407], ["negative", "OBSERVATION", 2, 10]]], ["The anticipated limit of detection of the SARS-CoV-2 RT-PCR test is <10 copies/reaction (Chu et al., 2020) which allows early detection of low viral titers.", [["SARS-CoV", "SPECIES", 42, 50], ["the SARS", "TEST", 38, 46], ["CoV", "TEST", 47, 50], ["RT-PCR test", "TEST", 53, 64], ["low viral titers", "PROBLEM", 139, 155], ["low", "OBSERVATION_MODIFIER", 139, 142], ["viral titers", "OBSERVATION", 143, 155]]], ["Gene amplification indicates a positive result for the presence of SARS-CoV-2 RNA and should correlate with clinical observations, patient history, and epidemiological information.Disadvantages ::: Detection of SARS-CoV-2 by Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)False positive results could be generated by cross-reactivity of primers with nucleic acids arising from co-infection with other viruses or bacteria.", [["nucleic acids", "CHEMICAL", 369, 382], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["patient", "ORGANISM", 131, 138], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 211, 221], ["SARS-CoV-2 RNA", "RNA", 67, 81], ["patient", "SPECIES", 131, 138], ["SARS-CoV", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 211, 219], ["Gene amplification", "TEST", 0, 18], ["SARS", "PROBLEM", 67, 71], ["CoV-2 RNA", "PROBLEM", 72, 81], ["SARS", "TEST", 211, 215], ["CoV", "TEST", 216, 219], ["Transcriptase Polymerase Chain Reaction", "TEST", 243, 282], ["RT-PCR", "TEST", 284, 290], ["False positive results", "PROBLEM", 291, 313], ["nucleic acids", "PROBLEM", 369, 382], ["co-infection", "PROBLEM", 396, 408], ["other viruses", "PROBLEM", 414, 427], ["bacteria", "PROBLEM", 431, 439]]], ["In these cases, the agent detected may not be the definite cause of disease.", [["the agent", "TREATMENT", 16, 25], ["disease", "PROBLEM", 68, 75], ["may not be the definite", "UNCERTAINTY", 35, 58], ["disease", "OBSERVATION", 68, 75]]], ["Matching of the SARS-CoV-2 RT-PCR primers and probes using reliable libraries (e.g., BLAST) is necessary to ensure there is no homology with other CoVs like SARS-CoV from 2003 or other organisms such as Staphylococcus aureus and Candida albicans.", [["SARS", "DISEASE", 157, 161], ["Staphylococcus aureus", "DISEASE", 203, 224], ["CoVs", "GENE_OR_GENE_PRODUCT", 147, 151], ["SARS-CoV", "ORGANISM", 157, 165], ["Staphylococcus aureus", "ORGANISM", 203, 224], ["Candida albicans", "ORGANISM", 229, 245], ["SARS-CoV-2 RT-PCR primers", "DNA", 16, 41], ["Staphylococcus aureus", "SPECIES", 203, 224], ["Candida albicans", "SPECIES", 229, 245], ["SARS-CoV", "SPECIES", 157, 165], ["Staphylococcus aureus", "SPECIES", 203, 224], ["Candida albicans", "SPECIES", 229, 245], ["the SARS", "TEST", 12, 20], ["CoV", "TEST", 21, 24], ["PCR primers", "TEST", 30, 41], ["other CoVs", "PROBLEM", 141, 151], ["SARS", "PROBLEM", 157, 161], ["CoV", "PROBLEM", 162, 165], ["other organisms", "PROBLEM", 179, 194], ["Staphylococcus aureus", "PROBLEM", 203, 224], ["Candida albicans", "PROBLEM", 229, 245], ["SARS", "OBSERVATION", 16, 20], ["Staphylococcus aureus", "OBSERVATION", 203, 224], ["Candida albicans", "OBSERVATION", 229, 245]]], ["False positives can also occur if reagents in a laboratory become contaminated, which is a major concern, particularly with the high volume of testing encountered during a pandemic.", [["False positives", "PROBLEM", 0, 15], ["a pandemic", "PROBLEM", 170, 180]]], ["A negative patient sample is useful to identify this error in testing.Disadvantages ::: Detection of SARS-CoV-2 by Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)False-negative results could potentially arise from mutations occurring in the primer and probe target regions in the SARS-CoV-2 genome.", [["patient", "ORGANISM", 11, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 101, 111], ["primer and probe target regions", "DNA", 260, 291], ["SARS-CoV-2 genome", "DNA", 299, 316], ["patient", "SPECIES", 11, 18], ["SARS-CoV", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 299, 307], ["this error in testing", "TEST", 48, 69], ["SARS", "TEST", 101, 105], ["CoV", "TEST", 106, 109], ["Transcriptase Polymerase Chain Reaction", "TEST", 133, 172], ["RT-PCR", "TEST", 174, 180], ["False", "TEST", 181, 186], ["mutations", "PROBLEM", 233, 242], ["the SARS", "PROBLEM", 295, 303], ["negative", "OBSERVATION", 2, 10]]], ["Negative results do not preclude SARS-CoV-2 infection, and results should be validated with different primer sets against the same gene target and combined with patient history and other clinical data to accurately determine patient infection status.Key Logistics ::: Detection of SARS-CoV-2 by Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)Provisions for testing laboratories, the use of approved tests and validation of results with governing authorities to develop master protocols for use by multiple investigators must be in place to achieve rapid testing capacity.", [["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 233, 242], ["SARS-CoV-2", "ORGANISM", 33, 43], ["patient", "ORGANISM", 161, 168], ["patient", "ORGANISM", 225, 232], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 281, 291], ["patient", "SPECIES", 161, 168], ["patient", "SPECIES", 225, 232], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 281, 289], ["SARS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["2 infection", "PROBLEM", 42, 53], ["other clinical data", "TEST", 181, 200], ["patient infection status", "PROBLEM", 225, 249], ["SARS", "TEST", 281, 285], ["CoV", "TEST", 286, 289], ["Transcriptase Polymerase Chain Reaction", "TREATMENT", 313, 352], ["testing laboratories", "TEST", 376, 396], ["approved tests", "TEST", 409, 423], ["rapid testing capacity", "TEST", 567, 589], ["do not preclude", "UNCERTAINTY", 17, 32], ["infection", "OBSERVATION", 44, 53]]], ["The output for number of tests per day and number of individuals tested per day relies on the laboratory capacity, trained staff, reagents, supplies and equipment.", [["The output", "TEST", 0, 10], ["tests", "TEST", 25, 30], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["Large quantities of specific high-grade reagents are needed to perform tests and supplies can be quickly depleted in a pandemic.", [["Large quantities of specific high-grade reagents", "PROBLEM", 0, 48], ["tests", "TEST", 71, 76], ["quantities", "OBSERVATION_MODIFIER", 6, 16]]], ["This impacts the turnaround time for RT-PCR diagnostic testing that ranges between 2 and 5 days.", [["RT-PCR diagnostic testing", "TEST", 37, 62]]], ["Strategies to rapidly scale up testing for novel HCoVs must be considered for future diagnostic testing.Enzyme-Linked Immunosorbent Assay (ELISA) ::: Sample Collection ::: Detection of Antibodies Against SARS-CoV-2 Proteins by Enzyme Immunosorbent Assay (EIA)Purified rS or rN are immobilized to the surface of a multi-well-plate as capture antigens.", [["surface", "ANATOMY", 300, 307], ["HCoVs", "CANCER", 49, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 204, 214], ["rN", "SIMPLE_CHEMICAL", 274, 276], ["surface", "CELLULAR_COMPONENT", 300, 307], ["Antibodies", "PROTEIN", 185, 195], ["SARS-CoV-2 Proteins", "PROTEIN", 204, 223], ["rS", "PROTEIN", 268, 270], ["rN", "PROTEIN", 274, 276], ["multi-well-plate as capture antigens", "PROTEIN", 313, 349], ["SARS-CoV", "SPECIES", 204, 212], ["rapidly scale up testing", "TEST", 14, 38], ["novel HCoVs", "TEST", 43, 54], ["diagnostic testing", "TEST", 85, 103], ["Enzyme", "TEST", 104, 110], ["Antibodies", "TEST", 185, 195], ["SARS", "TEST", 204, 208], ["CoV", "TEST", 209, 212], ["Enzyme Immunosorbent Assay", "TEST", 227, 253]]], ["Controls and inactivated SARS-CoV-2 serum samples are incubated with the antigen for SARS-CoV-2 antibody-antigen binding.", [["serum samples", "ANATOMY", 36, 49], ["SARS-CoV", "ORGANISM", 25, 33], ["serum samples", "ORGANISM_SUBSTANCE", 36, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 85, 95], ["SARS-CoV-2 antibody", "PROTEIN", 85, 104], ["SARS-CoV", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 85, 93], ["inactivated SARS", "PROBLEM", 13, 29], ["CoV-2 serum samples", "TEST", 30, 49], ["the antigen", "TEST", 69, 80], ["SARS", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["antibody", "TEST", 96, 104]]], ["A labeled secondary antibody-conjugate (e.g., horseradish peroxidase) is bound to the SARS-CoV antibodies for signal detection by substrate addition, and quantification.Advantages ::: Detection of Antibodies Against SARS-CoV-2 Proteins by Enzyme Immunosorbent Assay (EIA)Antibody tests provide the advantage of a simple method of detection of SARS-CoV-2 antibodies and are convenient to compare multiple samples from a single patient.", [["samples", "ANATOMY", 404, 411], ["SARS", "DISEASE", 216, 220], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 46, 68], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 216, 226], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 343, 364], ["patient", "ORGANISM", 426, 433], ["horseradish peroxidase", "PROTEIN", 46, 68], ["SARS-CoV antibodies", "PROTEIN", 86, 105], ["Antibodies", "PROTEIN", 197, 207], ["SARS-CoV-2 Proteins", "PROTEIN", 216, 235], ["SARS-CoV-2 antibodies", "PROTEIN", 343, 364], ["horseradish", "SPECIES", 46, 57], ["patient", "SPECIES", 426, 433], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 216, 224], ["SARS-CoV", "SPECIES", 343, 351], ["A labeled secondary antibody", "TEST", 0, 28], ["the SARS", "TEST", 82, 90], ["CoV antibodies", "TEST", 91, 105], ["signal detection", "TEST", 110, 126], ["Antibodies", "TEST", 197, 207], ["SARS", "TEST", 216, 220], ["CoV", "TEST", 221, 224], ["Enzyme Immunosorbent Assay", "TEST", 239, 265], ["EIA", "TEST", 267, 270], ["Antibody tests", "TEST", 271, 285], ["SARS", "PROBLEM", 343, 347], ["CoV-2 antibodies", "TEST", 348, 364]]], ["Positive rates of detection for SARS-CoV-2 IgG in patients by ELISA measurements are 85.4% and 75.6\u201393.1% for IgM (Guo et al., 2020).", [["SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 32, 46], ["patients", "ORGANISM", 50, 58], ["IgG", "PROTEIN", 43, 46], ["IgM", "PROTEIN", 110, 113], ["patients", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 32, 40], ["detection", "TEST", 18, 27], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["ELISA measurements", "TEST", 62, 80], ["IgM", "TEST", 110, 113]]], ["Jin et al. (2020) reported sensitivities of serum IgM and IgG antibodies for detection were 48.1 and 88.9%, and specificities were 100 and 90.9% with the highest sensitivity for antibody tests recorded 2 weeks after first symptoms of disease.", [["serum", "ANATOMY", 44, 49], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["IgM", "GENE_OR_GENE_PRODUCT", 50, 53], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 58, 72], ["serum IgM", "PROTEIN", 44, 53], ["IgG antibodies", "PROTEIN", 58, 72], ["serum IgM", "TEST", 44, 53], ["IgG antibodies", "TEST", 58, 72], ["detection", "TEST", 77, 86], ["specificities", "TEST", 112, 125], ["antibody tests", "TEST", 178, 192], ["first symptoms of disease", "PROBLEM", 216, 241], ["disease", "OBSERVATION", 234, 241]]], ["The lower IgM sensitivity may be because the IgM response occurs early then decreases and does not offer a strong detectable signal, while IgG signals may be more readily detected and present beyond 20 days.", [["IgM", "GENE_OR_GENE_PRODUCT", 10, 13], ["IgM", "GENE_OR_GENE_PRODUCT", 45, 48], ["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["IgM", "PROTEIN", 10, 13], ["IgM", "PROTEIN", 45, 48], ["IgG", "PROTEIN", 139, 142], ["The lower IgM sensitivity", "TEST", 0, 25], ["the IgM response", "TEST", 41, 57], ["IgG signals", "TEST", 139, 150], ["lower", "ANATOMY_MODIFIER", 4, 9], ["IgM", "OBSERVATION", 10, 13]]], ["The incorporation of unique immunoglobulin labels may increase the sensitivity of rapid antibody tests for respiratory viruses (Li R. et al., 2018).", [["respiratory viruses", "DISEASE", 107, 126], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 28, 42], ["immunoglobulin labels", "PROTEIN", 28, 49], ["unique immunoglobulin labels", "TEST", 21, 49], ["rapid antibody tests", "TEST", 82, 102], ["respiratory viruses", "PROBLEM", 107, 126]]], ["Results from antibody testing could inform infection status and define previous exposure to SARS-CoV-2.", [["infection", "DISEASE", 43, 52], ["SARS", "DISEASE", 92, 96], ["CoV-2", "ORGANISM", 97, 102], ["SARS-CoV", "SPECIES", 92, 100], ["antibody testing", "TEST", 13, 29], ["infection status", "PROBLEM", 43, 59], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100]]], ["Antibody detection is also used to identify recovered patients as human donors for the generation of convalescent patient serum or plasma as an investigational treatment for critically ill patients (Shen et al., 2020).Disadvantages ::: Detection of Antibodies Against SARS-CoV-2 Proteins by Enzyme Immunosorbent Assay (EIA)The results of SARS-CoV-2 antibody tests may vary by apparent disease periods by time after symptom onset as well as on the reliability of diagnostic assays.", [["serum", "ANATOMY", 122, 127], ["plasma", "ANATOMY", 131, 137], ["critically ill", "DISEASE", 174, 188], ["patients", "ORGANISM", 54, 62], ["human", "ORGANISM", 66, 71], ["donors", "ORGANISM", 72, 78], ["patient", "ORGANISM", 114, 121], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["plasma", "ORGANISM_SUBSTANCE", 131, 137], ["patients", "ORGANISM", 189, 197], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 268, 278], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 338, 348], ["Antibodies", "PROTEIN", 249, 259], ["SARS-CoV-2 Proteins", "PROTEIN", 268, 287], ["patients", "SPECIES", 54, 62], ["human", "SPECIES", 66, 71], ["patient", "SPECIES", 114, 121], ["patients", "SPECIES", 189, 197], ["human", "SPECIES", 66, 71], ["SARS-CoV", "SPECIES", 268, 276], ["SARS-CoV", "SPECIES", 338, 346], ["Antibody detection", "TEST", 0, 18], ["human donors", "TREATMENT", 66, 78], ["convalescent patient serum", "TEST", 101, 127], ["plasma", "TREATMENT", 131, 137], ["an investigational treatment", "TREATMENT", 141, 169], ["Antibodies", "TEST", 249, 259], ["SARS", "TEST", 268, 272], ["CoV", "TEST", 273, 276], ["Enzyme Immunosorbent Assay", "TEST", 291, 317], ["EIA", "TEST", 319, 322], ["SARS", "TEST", 338, 342], ["CoV-2 antibody tests", "TEST", 343, 363], ["apparent disease periods", "PROBLEM", 376, 400], ["symptom onset", "PROBLEM", 415, 428], ["diagnostic assays", "TEST", 462, 479]]], ["It is not yet known when IgM or IgG antibodies specific to the SARS-CoV-2 virus will become detectable during an infection, how long antibodies persist following infection and the extent of protection of neutralizing antibodies against subsequent infection with the virus.Disadvantages ::: Detection of Antibodies Against SARS-CoV-2 Proteins by Enzyme Immunosorbent Assay (EIA)The overall sensitivity and specificity indicate the possibility of false negatives and false positives in this testing method.", [["SARS", "DISEASE", 63, 67], ["infection", "DISEASE", 113, 122], ["infection", "DISEASE", 162, 171], ["infection", "DISEASE", 247, 256], ["IgM", "GENE_OR_GENE_PRODUCT", 25, 28], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 32, 46], ["SARS-CoV-2 virus", "ORGANISM", 63, 79], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 322, 332], ["IgM", "PROTEIN", 25, 28], ["IgG antibodies", "PROTEIN", 32, 46], ["long antibodies", "PROTEIN", 128, 143], ["neutralizing antibodies", "PROTEIN", 204, 227], ["Antibodies", "PROTEIN", 303, 313], ["SARS-CoV-2 Proteins", "PROTEIN", 322, 341], ["CoV-2 virus", "SPECIES", 68, 79], ["SARS-CoV-2 virus", "SPECIES", 63, 79], ["SARS-CoV", "SPECIES", 322, 330], ["IgM", "TEST", 25, 28], ["IgG antibodies", "TEST", 32, 46], ["the SARS", "TEST", 59, 67], ["CoV", "TEST", 68, 71], ["virus", "PROBLEM", 74, 79], ["an infection", "PROBLEM", 110, 122], ["how long antibodies", "PROBLEM", 124, 143], ["infection", "PROBLEM", 162, 171], ["neutralizing antibodies", "TREATMENT", 204, 227], ["subsequent infection", "PROBLEM", 236, 256], ["the virus", "PROBLEM", 262, 271], ["Antibodies", "TEST", 303, 313], ["SARS", "TEST", 322, 326], ["CoV", "TEST", 327, 330], ["Enzyme Immunosorbent Assay", "TEST", 345, 371], ["EIA", "TEST", 373, 376], ["The overall sensitivity", "TEST", 377, 400], ["false negatives", "PROBLEM", 445, 460], ["false positives", "PROBLEM", 465, 480], ["this testing method", "TEST", 484, 503], ["infection", "OBSERVATION", 113, 122], ["infection", "OBSERVATION", 247, 256], ["false positives", "OBSERVATION", 465, 480]]], ["Since the risk for recurrent infection with SARS-CoV-2 is not known for COVID-19, detection of one or two antibodies (IgM and/or IgG) does not necessarily guarantee immunity against reinfection.", [["infection", "DISEASE", 29, 38], ["SARS", "DISEASE", 44, 48], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["IgM", "GENE_OR_GENE_PRODUCT", 118, 121], ["IgG", "GENE_OR_GENE_PRODUCT", 129, 132], ["antibodies", "PROTEIN", 106, 116], ["IgM", "PROTEIN", 118, 121], ["IgG", "PROTEIN", 129, 132], ["SARS-CoV", "SPECIES", 44, 52], ["recurrent infection", "PROBLEM", 19, 38], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["COVID", "TEST", 72, 77], ["two antibodies", "TEST", 102, 116], ["IgM", "TEST", 118, 121], ["IgG", "TEST", 129, 132], ["reinfection", "PROBLEM", 182, 193], ["risk for", "UNCERTAINTY", 10, 18], ["recurrent", "OBSERVATION_MODIFIER", 19, 28], ["infection", "OBSERVATION", 29, 38]]], ["Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus and positive results may be due to past or present infection with SARS-CoV (Guo et al., 2020) and possibly non-SARS-CoV strains (Gaunt et al., 2010).", [["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 168, 177], ["SARS", "DISEASE", 183, 187], ["SARS-CoV-2", "ORGANISM", 33, 43], ["SARS-CoV", "ORGANISM", 183, 191], ["non-SARS-CoV", "ORGANISM", 224, 236], ["SARS-CoV", "SPECIES", 183, 191], ["non-SARS-CoV", "SPECIES", 224, 236], ["SARS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["2 infection", "PROBLEM", 42, 53], ["the virus", "PROBLEM", 107, 116], ["present infection", "PROBLEM", 160, 177], ["SARS", "PROBLEM", 183, 187], ["non-SARS", "PROBLEM", 224, 232], ["CoV strains", "PROBLEM", 233, 244], ["infection", "OBSERVATION", 44, 53], ["infection", "OBSERVATION", 168, 177]]], ["It will be critical to conduct stringent evaluation of antibody diagnostic assays to determine the accuracy and reliability of results.Key Logistics ::: Detection of Antibodies Against SARS-CoV-2 Proteins by Enzyme Immunosorbent Assay (EIA)Recombinant systems are routinely used to express recombinant proteins to develop antibody assays.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 185, 195], ["Antibodies", "PROTEIN", 166, 176], ["SARS-CoV-2 Proteins", "PROTEIN", 185, 204], ["recombinant proteins", "PROTEIN", 290, 310], ["SARS-CoV", "SPECIES", 185, 193], ["stringent evaluation", "TEST", 31, 51], ["antibody diagnostic assays", "TEST", 55, 81], ["Antibodies", "TEST", 166, 176], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["Enzyme Immunosorbent Assay", "TEST", 208, 234], ["antibody assays", "TEST", 322, 337]]], ["However, protein-expression systems can result in significant discrepancies between recombinant and native viral proteins.", [["recombinant and native viral proteins", "PROTEIN", 84, 121], ["protein-expression systems", "PROBLEM", 9, 35], ["significant discrepancies between recombinant and native viral proteins", "PROBLEM", 50, 121], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["discrepancies", "OBSERVATION", 62, 75], ["viral proteins", "OBSERVATION", 107, 121]]], ["For example, the use of E. coli competent cells produces proteins that lack critical post-translational modifications in human cells (e.g., glycosylation) that can alter epitopes and protein conformation (Gupta and Shukla, 2018).", [["cells", "ANATOMY", 42, 47], ["cells", "ANATOMY", 127, 132], ["E. coli", "ORGANISM", 24, 31], ["cells", "CELL", 42, 47], ["human", "ORGANISM", 121, 126], ["cells", "CELL", 127, 132], ["E. coli competent cells", "CELL_LINE", 24, 47], ["human cells", "CELL_TYPE", 121, 132], ["epitopes", "PROTEIN", 170, 178], ["E. coli", "SPECIES", 24, 31], ["human", "SPECIES", 121, 126], ["E. coli", "SPECIES", 24, 31], ["human", "SPECIES", 121, 126], ["E. coli competent cells", "PROBLEM", 24, 47], ["translational modifications in human cells", "PROBLEM", 90, 132]]], ["Consequently, this can compromise sensitivity and specificity of antigens for diagnostic assays.", [["antigens", "PROTEIN", 65, 73], ["diagnostic assays", "TEST", 78, 95]]], ["The use of mammalian expression systems to express recombinant proteins will produce antigens with post-translation modifications that more closely resemble human native proteins (Bandaranayake and Almo, 2014) leading to higher sensitivity and specificity of assays.Key Logistics ::: Detection of Antibodies Against SARS-CoV-2 Proteins by Enzyme Immunosorbent Assay (EIA)Serological assays are currently under accelerated development for diagnosis of HCoV infections.", [["HCoV infections", "DISEASE", 451, 466], ["human", "ORGANISM", 157, 162], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 316, 326], ["HCoV", "ORGANISM", 451, 455], ["recombinant proteins", "PROTEIN", 51, 71], ["human native proteins", "PROTEIN", 157, 178], ["Antibodies", "PROTEIN", 297, 307], ["SARS-CoV-2 Proteins", "PROTEIN", 316, 335], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["SARS-CoV", "SPECIES", 316, 324], ["HCoV", "SPECIES", 451, 455], ["mammalian expression systems", "TREATMENT", 11, 39], ["recombinant proteins", "PROBLEM", 51, 71], ["post-translation modifications", "TREATMENT", 99, 129], ["higher sensitivity", "PROBLEM", 221, 239], ["assays", "TEST", 259, 265], ["Antibodies", "TEST", 297, 307], ["SARS", "TEST", 316, 320], ["CoV", "TEST", 321, 324], ["Enzyme Immunosorbent Assay", "TEST", 339, 365], ["EIA", "TEST", 367, 370], ["Serological assays", "TEST", 371, 389], ["HCoV infections", "PROBLEM", 451, 466], ["infections", "OBSERVATION", 456, 466]]], ["Commercial reagents need to be validated by clinical trials using samples from patients with confirmed infections of SARS-CoV-2, and approved by the regulatory review process.", [["samples", "ANATOMY", 66, 73], ["infections", "DISEASE", 103, 113], ["SARS", "DISEASE", 117, 121], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["SARS-CoV", "SPECIES", 117, 125], ["Commercial reagents", "TREATMENT", 0, 19], ["SARS", "PROBLEM", 117, 121]]], ["Nonetheless, a rapid and sensitive platform for identification of antibody titers will also support screening to identify and minimize the risk of viral spread to others, as well as for epidemiological studies and vaccine evaluation studies.", [["antibody titers", "PROBLEM", 66, 81], ["screening", "TEST", 100, 109], ["viral spread", "PROBLEM", 147, 159], ["epidemiological studies", "TEST", 186, 209], ["vaccine evaluation studies", "TEST", 214, 240], ["viral", "OBSERVATION", 147, 152]]], ["The US FDA allows the use of rapid antibody tests for SARS-CoV-2 under emergency use authorization (EUA).", [["SARS", "DISEASE", 54, 58], ["SARS-CoV", "SPECIES", 54, 62], ["The US FDA", "TEST", 0, 10], ["rapid antibody tests", "TEST", 29, 49], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62]]], ["This expedites the assessment and optimization of these diagnostic tests, with the expectation that any test is sufficiently experimentally validated before it is made available to patients.", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["the assessment", "TEST", 15, 29], ["these diagnostic tests", "TEST", 50, 72], ["any test", "TEST", 100, 108]]], ["If these tests do not provide accurate results, this can impair prevention efforts and delay appropriate treatment during the global pandemic response.Advantage ::: LFIA ::: Rapid Detection of SARS-CoV-2 by Lateral Flow Immunoassays (LFIA)Two drops of blood are sufficient for detection of SARS-CoV-2 and antibodies by this method.", [["blood", "ANATOMY", 252, 257], ["SARS", "DISEASE", 290, 294], ["Lateral Flow Immunoassays", "SIMPLE_CHEMICAL", 207, 232], ["blood", "ORGANISM_SUBSTANCE", 252, 257], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 290, 300], ["antibodies", "PROTEIN", 305, 315], ["SARS-CoV", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 290, 298], ["these tests", "TEST", 3, 14], ["delay appropriate treatment", "TREATMENT", 87, 114], ["SARS", "TEST", 193, 197], ["CoV", "TEST", 198, 201], ["Lateral Flow Immunoassays", "TEST", 207, 232], ["LFIA", "TEST", 234, 238], ["SARS", "TEST", 290, 294], ["CoV", "TEST", 295, 298], ["antibodies", "TEST", 305, 315], ["this method", "TEST", 319, 330], ["SARS", "OBSERVATION", 193, 197]]], ["This technique delivers results in ~15 min, and uses visual detection by the naked eye in comparison to RT-PCR (2\u20135 days).", [["eye", "ANATOMY", 83, 86], ["eye", "ORGAN", 83, 86], ["visual detection", "TEST", 53, 69], ["RT-PCR", "TEST", 104, 110], ["eye", "ANATOMY", 83, 86]]], ["Detection of antibodies shows previous viral exposure while detection of antigens indicates active carriers of SARS-CoV-2 virus.", [["SARS-CoV-2 virus", "ORGANISM", 111, 127], ["antibodies", "PROTEIN", 13, 23], ["antigens", "PROTEIN", 73, 81], ["CoV-2 virus", "SPECIES", 116, 127], ["SARS-CoV-2 virus", "SPECIES", 111, 127], ["Detection of antibodies", "TEST", 0, 23], ["previous viral exposure", "PROBLEM", 30, 53], ["antigens", "PROBLEM", 73, 81], ["SARS", "PROBLEM", 111, 115], ["CoV-2 virus", "PROBLEM", 116, 127], ["viral exposure", "OBSERVATION", 39, 53], ["active", "OBSERVATION_MODIFIER", 92, 98]]], ["The specificity and sensitivity of LIFAs are comparable for antibody and antigen assays.Disadvantage ::: LFIA ::: Rapid Detection of SARS-CoV-2 by Lateral Flow Immunoassays (LFIA)Tests to detect SARS-CoV-2 in patients by identifying viral antigens are more challenging to develop than tests to detect the neutralizing antibodies against SARS-CoV-2 (see below), as purified monoclonal antibodies must be generated against target antigens.", [["LIFAs", "SIMPLE_CHEMICAL", 35, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 133, 143], ["SARS-CoV-2", "ORGANISM", 195, 205], ["patients", "ORGANISM", 209, 217], ["SARS-CoV-2", "ORGANISM", 337, 347], ["LIFAs", "PROTEIN", 35, 40], ["viral antigens", "PROTEIN", 233, 247], ["neutralizing antibodies", "PROTEIN", 305, 328], ["purified monoclonal antibodies", "PROTEIN", 364, 394], ["target antigens", "PROTEIN", 421, 436], ["patients", "SPECIES", 209, 217], ["SARS-CoV", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 195, 203], ["SARS-CoV", "SPECIES", 337, 345], ["The specificity", "TEST", 0, 15], ["LIFAs", "TEST", 35, 40], ["antibody and antigen assays", "TEST", 60, 87], ["SARS", "TEST", 133, 137], ["CoV", "TEST", 138, 141], ["Lateral Flow Immunoassays", "TEST", 147, 172], ["LFIA", "TEST", 174, 178], ["Tests", "TEST", 179, 184], ["SARS", "PROBLEM", 195, 199], ["CoV", "TEST", 200, 203], ["viral antigens", "PROBLEM", 233, 247], ["tests", "TEST", 285, 290], ["the neutralizing antibodies", "TEST", 301, 328], ["SARS", "PROBLEM", 337, 341], ["CoV", "TEST", 342, 345], ["purified monoclonal antibodies", "PROBLEM", 364, 394], ["SARS", "OBSERVATION", 133, 137]]], ["Further, these assays need to be assessed and optimized using blood from infected patients.Key Logistics ::: LFIA ::: Rapid Detection of SARS-CoV-2 by Lateral Flow Immunoassays (LFIA)The rapid development of some antigens for assays are led by the use of \u201cprototype\u201d pathogens and in silico models of antibody\u2013antigen interactions that are used to generate artificial antibody libraries (Shao et al., 2007).", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["patients", "ORGANISM", 82, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 137, 147], ["antibody\u2013antigen", "GENE_OR_GENE_PRODUCT", 301, 317], ["antigens", "PROTEIN", 213, 221], ["patients", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 137, 145], ["these assays", "TEST", 9, 21], ["SARS", "TEST", 137, 141], ["CoV", "TEST", 142, 145], ["Lateral Flow Immunoassays", "TEST", 151, 176], ["some antigens for assays", "PROBLEM", 208, 232], ["\u201cprototype\u201d pathogens", "TREATMENT", 255, 276], ["antibody\u2013antigen interactions", "PROBLEM", 301, 330], ["SARS", "OBSERVATION", 137, 141]]], ["Antibody phage display technology can be applied to discover antibodies against antigens (Ledsgaard et al., 2018).", [["antibodies", "PROTEIN", 61, 71], ["antigens", "PROTEIN", 80, 88], ["Antibody phage", "TREATMENT", 0, 14]]], ["These can be rapidly generated to produce prototypes of diagnostic tests for validation studies that expedite assessment and optimization, before the final commercial diagnostic kits are available.", [["diagnostic tests", "TEST", 56, 72], ["validation studies", "TEST", 77, 95], ["expedite assessment", "TEST", 101, 120]]], ["Integrating fast, portable tests with epidemiological surveillance will also provide quick and reliable information to public health authorities monitoring the spread of SARS-CoV-2.SVN ::: Sample Collection ::: Serum Virus Neutralization Assay (SVN)Several cell lines are suitable for SARS-CoV-2 transduction including Vero (monkey kidney cell line), Huh7 (human hepatoma cell line), 293T (human kidney cell line) (Nie et al., 2020).", [["Serum", "ANATOMY", 211, 216], ["cell lines", "ANATOMY", 257, 267], ["kidney cell line", "ANATOMY", 332, 348], ["Huh7", "ANATOMY", 351, 355], ["hepatoma cell line", "ANATOMY", 363, 381], ["293T", "ANATOMY", 384, 388], ["kidney cell line", "ANATOMY", 396, 412], ["SARS", "DISEASE", 170, 174], ["Serum", "ORGANISM_SUBSTANCE", 211, 216], ["cell lines", "CELL", 257, 267], ["Vero", "CELL", 319, 323], ["monkey", "ORGANISM", 325, 331], ["kidney cell line", "CELL", 332, 348], ["Huh7", "CELL", 351, 355], ["human", "ORGANISM", 357, 362], ["hepatoma cell line)", "CELL", 363, 382], ["293T", "CELL", 384, 388], ["human", "ORGANISM", 390, 395], ["kidney cell line", "CELL", 396, 412], ["cell lines", "CELL_LINE", 257, 267], ["Vero (monkey kidney cell line", "CELL_LINE", 319, 348], ["Huh7", "CELL_LINE", 351, 355], ["human hepatoma cell line", "CELL_LINE", 357, 381], ["293T", "CELL_LINE", 384, 388], ["human kidney cell line", "CELL_LINE", 390, 412], ["human", "SPECIES", 357, 362], ["human", "SPECIES", 390, 395], ["SARS-CoV", "SPECIES", 170, 178], ["human", "SPECIES", 357, 362], ["human", "SPECIES", 390, 395], ["portable tests", "TEST", 18, 32], ["epidemiological surveillance", "TEST", 38, 66], ["CoV", "TEST", 175, 178], ["Sample Collection", "TEST", 189, 206], ["Serum Virus Neutralization Assay", "TEST", 211, 243], ["Several cell lines", "TREATMENT", 249, 267], ["SARS", "PROBLEM", 285, 289], ["CoV", "TEST", 290, 293], ["2 transduction", "TREATMENT", 294, 308], ["Vero (monkey kidney cell line", "TREATMENT", 319, 348], ["Huh7 (human hepatoma cell line", "TREATMENT", 351, 381], ["293T (human kidney cell line", "TREATMENT", 384, 412], ["cell lines", "OBSERVATION", 257, 267], ["kidney", "ANATOMY", 332, 338], ["cell line", "OBSERVATION", 339, 348], ["Huh7", "ANATOMY", 351, 355], ["hepatoma", "ANATOMY", 363, 371], ["cell line", "OBSERVATION", 372, 381], ["kidney", "ANATOMY", 396, 402], ["cell line", "OBSERVATION", 403, 412]]], ["Serial dilutions of patient convalescent serum are added to known strains of virus (BetaCoV/Shenzhen/SZTH-003/2020 strain virus, GISAID access number: EPI_ISL_406594) (Shen et al., 2020).", [["serum", "ANATOMY", 41, 46], ["patient", "ORGANISM", 20, 27], ["convalescent", "ORGANISM", 28, 40], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["BetaCoV/Shenzhen/SZTH-003/2020 strain virus", "ORGANISM", 84, 127], ["patient", "SPECIES", 20, 27], ["BetaCoV/Shenzhen/SZTH-003/2020 strain virus", "SPECIES", 84, 127], ["Serial dilutions", "TEST", 0, 16], ["patient convalescent serum", "TEST", 20, 46], ["known strains of virus", "PROBLEM", 60, 82], ["BetaCoV", "TEST", 84, 91], ["SZTH", "TEST", 101, 105], ["strain virus", "PROBLEM", 115, 127]]], ["The mixture is inoculated into a susceptible cell monolayer and incubated for virus adsorption.", [["cell monolayer", "ANATOMY", 45, 59], ["cell monolayer", "CELL", 45, 59], ["susceptible cell monolayer", "CELL_LINE", 33, 59], ["a susceptible cell monolayer", "TREATMENT", 31, 59], ["virus adsorption", "TREATMENT", 78, 94], ["susceptible cell monolayer", "OBSERVATION", 33, 59]]], ["The cytopathic effect can be measured by microscopic examination (Shen et al., 2020) after a 5-day incubation or fluorescence (Nie et al., 2020) or plaque formation, following 24 h of incubation.", [["plaque", "ANATOMY", 148, 154], ["plaque", "PATHOLOGICAL_FORMATION", 148, 154], ["The cytopathic effect", "PROBLEM", 0, 21], ["microscopic examination", "TEST", 41, 64], ["plaque formation", "PROBLEM", 148, 164], ["incubation", "TREATMENT", 184, 194], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["plaque", "OBSERVATION", 148, 154]]], ["The neutralizing antibody titer is the highest dilution of serum that reduces activity of SARS-CoV-2.Advantages ::: Serum Virus Neutralization Assay (SVN)The SVN assay is a highly robust and reproducible test that may be applied to detect SARS-CoV-2 neutralizing antibodies in convalescent plasma samples to identify the best candidates for treatment.", [["serum", "ANATOMY", 59, 64], ["Serum", "ANATOMY", 116, 121], ["plasma samples", "ANATOMY", 290, 304], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["Serum", "ORGANISM_SUBSTANCE", 116, 121], ["CoV-2", "GENE_OR_GENE_PRODUCT", 244, 249], ["convalescent", "ORGANISM", 277, 289], ["plasma samples", "ORGANISM_SUBSTANCE", 290, 304], ["SARS-CoV-2 neutralizing antibodies", "PROTEIN", 239, 273], ["SARS-CoV", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 239, 247], ["The neutralizing antibody titer", "TEST", 0, 31], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98], ["Serum Virus Neutralization Assay", "TEST", 116, 148], ["The SVN assay", "TEST", 154, 167], ["reproducible test", "TEST", 191, 208], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247], ["neutralizing antibodies", "TEST", 250, 273], ["convalescent plasma samples", "TEST", 277, 304], ["treatment", "TREATMENT", 341, 350], ["neutralizing", "OBSERVATION_MODIFIER", 4, 16], ["antibody titer", "OBSERVATION", 17, 31], ["SVN", "ANATOMY", 158, 161]]], ["Neutralizing activities along with viral load and antibody titers can be simultaneously monitored in paired plasma samples in patients receiving convalescence plasma, to establish algorithms for determining patient and donor factors that predict clinical efficacy.Disadvantages ::: Serum Virus Neutralization Assay (SVN)The accessibility of the live SARS-CoV-2 strain is regulated, which limits the development of laboratory testing by SVN.", [["plasma samples", "ANATOMY", 108, 122], ["plasma", "ANATOMY", 159, 165], ["Serum", "ANATOMY", 282, 287], ["SARS", "DISEASE", 350, 354], ["plasma samples", "ORGANISM_SUBSTANCE", 108, 122], ["patients", "ORGANISM", 126, 134], ["plasma", "ORGANISM_SUBSTANCE", 159, 165], ["patient", "ORGANISM", 207, 214], ["Serum", "ORGANISM_SUBSTANCE", 282, 287], ["SARS-CoV-2", "ORGANISM", 350, 360], ["SVN", "CANCER", 436, 439], ["patients", "SPECIES", 126, 134], ["patient", "SPECIES", 207, 214], ["Neutralizing activities", "PROBLEM", 0, 23], ["viral load", "TEST", 35, 45], ["antibody titers", "TEST", 50, 65], ["convalescence plasma", "TEST", 145, 165], ["algorithms", "TEST", 180, 190], ["Serum Virus Neutralization Assay", "TEST", 282, 314], ["the live SARS", "TEST", 341, 354], ["CoV-2 strain", "PROBLEM", 355, 367], ["laboratory testing", "TEST", 414, 432]]], ["While inexpensive, it is a manual assay and requires careful in-house standardization and quality control.Key Logistics ::: Serum Virus Neutralization Assay (SVN)The preliminary case report of positive responses of 5 severely ill patients with COVID-19 who were treated in the Shenzhen Third People's Hospital, China, using plasma from recovered individuals was recently published (Shen et al., 2020).", [["Serum", "ANATOMY", 124, 129], ["plasma", "ANATOMY", 324, 330], ["severely ill", "DISEASE", 217, 229], ["Serum", "ORGANISM_SUBSTANCE", 124, 129], ["patients", "ORGANISM", 230, 238], ["plasma", "ORGANISM_SUBSTANCE", 324, 330], ["patients", "SPECIES", 230, 238], ["a manual assay", "TEST", 25, 39], ["Serum Virus Neutralization Assay", "TEST", 124, 156]]], ["The convalescent plasma contained functional IgG and IgM anti\u2013SARS-CoV-2 neutralizing antibodies that inhibited viral growth in cell cultures.", [["plasma", "ANATOMY", 17, 23], ["cell cultures", "ANATOMY", 128, 141], ["plasma", "ORGANISM_SUBSTANCE", 17, 23], ["IgG", "GENE_OR_GENE_PRODUCT", 45, 48], ["IgM anti\u2013SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 72], ["cell cultures", "CELL", 128, 141], ["IgG", "PROTEIN", 45, 48], ["IgM anti\u2013SARS-CoV-2 neutralizing antibodies", "PROTEIN", 53, 96], ["cell cultures", "CELL_LINE", 128, 141], ["The convalescent plasma", "TEST", 0, 23], ["functional IgG", "TEST", 34, 48], ["IgM anti\u2013SARS", "TEST", 53, 66], ["CoV", "TEST", 67, 70], ["neutralizing antibodies", "TEST", 73, 96], ["viral growth in cell cultures", "PROBLEM", 112, 141]]], ["Notably, the SNV assay reliably measured the increases in the patients' neutralizing antibody titers between 1 and 12 days after plasma transfusion.", [["plasma", "ANATOMY", 129, 135], ["patients", "ORGANISM", 62, 70], ["plasma", "ORGANISM_SUBSTANCE", 129, 135], ["patients", "SPECIES", 62, 70], ["the SNV assay", "TEST", 9, 22], ["the patients' neutralizing antibody titers", "TEST", 58, 100], ["plasma transfusion", "TREATMENT", 129, 147], ["increases", "OBSERVATION_MODIFIER", 45, 54]]], ["This study was not evaluated in a randomized clinical trial and there are limitations to the data interpretation.", [["This study", "TEST", 0, 10], ["the data interpretation", "TEST", 89, 112]]], ["Nonetheless, these findings demonstrate the utility of the SVN assay for evaluating anti\u2013SARS-CoV-2 neutralizing antibodies for future convalescent plasma assessment in more rigorous clinical investigations involving a larger cohort of patients with severe COVID-19 illness.Isothermal Nucleic Acid Amplification ::: Emerging Methods for Diagnosis of SARS-CoV-2This method amplifies DNA or RNA target sequence in a streamlined and exponential manner for detection, and in contrast to PCR, does not require thermal cycling.", [["plasma", "ANATOMY", 148, 154], ["COVID", "DISEASE", 257, 262], ["illness", "DISEASE", 266, 273], ["SARS", "DISEASE", 350, 354], ["anti\u2013SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 84, 99], ["plasma", "ORGANISM_SUBSTANCE", 148, 154], ["patients", "ORGANISM", 236, 244], ["DNA", "CELLULAR_COMPONENT", 382, 385], ["anti\u2013SARS-CoV-2 neutralizing antibodies", "PROTEIN", 84, 123], ["RNA target sequence", "DNA", 389, 408], ["patients", "SPECIES", 236, 244], ["SARS-CoV", "SPECIES", 350, 358], ["the SVN assay", "TEST", 55, 68], ["anti\u2013SARS", "TEST", 84, 93], ["CoV", "TEST", 94, 97], ["2 neutralizing antibodies", "TREATMENT", 98, 123], ["future convalescent plasma assessment", "TEST", 128, 165], ["clinical investigations", "TEST", 183, 206], ["severe COVID-19 illness", "PROBLEM", 250, 273], ["SARS", "PROBLEM", 350, 354], ["CoV", "TEST", 355, 358], ["RNA target sequence", "TEST", 389, 408], ["PCR", "TEST", 483, 486], ["thermal cycling", "TREATMENT", 505, 520], ["severe", "OBSERVATION_MODIFIER", 250, 256]]], ["A wide variety of nucleic acid detection assays have been developed including loop-mediated isothermal amplification (LAMP), a single-tube technique for the amplification of DNA and reverse transcription-LAMP that combines reverse transcriptase and LAMP to detect RNA (RT-LAMP; Notomi et al., 2000), recombinase polymerase amplification (RPA; Li J. et al., 2018), helicase-dependent amplification (HDA; Vincent et al., 2004), strand displacement amplification (SDA; Walker et al., 1992), and nucleic acid sequence-based amplification (NASBA; Compton, 1991).", [["nucleic acid", "CHEMICAL", 18, 30], ["nucleic acid", "CHEMICAL", 492, 504], ["DNA", "CELLULAR_COMPONENT", 174, 177], ["reverse transcriptase", "PROTEIN", 223, 244], ["recombinase polymerase", "PROTEIN", 300, 322], ["helicase", "PROTEIN", 364, 372], ["nucleic acid detection assays", "TEST", 18, 47], ["loop-mediated isothermal amplification", "TREATMENT", 78, 116], ["a single-tube technique", "TREATMENT", 125, 148], ["the amplification of DNA", "TREATMENT", 153, 177], ["reverse transcription", "TREATMENT", 182, 203], ["LAMP", "TREATMENT", 204, 208], ["LAMP", "TEST", 249, 253], ["RNA", "TEST", 264, 267], ["strand displacement amplification", "PROBLEM", 426, 459], ["nucleic acid sequence", "TEST", 492, 513], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["These assays incorporate isothermal methods to enable primer binding followed by amplification using a polymerase with strand-displacement activity that separates the strand that is annealed to the target sequence for detection.", [["These assays", "TEST", 0, 12], ["isothermal methods", "TREATMENT", 25, 43], ["enable primer binding", "PROBLEM", 47, 68], ["a polymerase", "TEST", 101, 113], ["strand-displacement activity", "TREATMENT", 119, 147]]], ["Amplified gene products can be detected by photometry.", [["Amplified gene products", "TREATMENT", 0, 23]]], ["Isothermal nucleic acid amplification is utilized in several commercial molecular diagnostic platforms and is considered the fastest available molecular laboratory and point-of-care test for the detection of novel SARS-CoV-2.RT-LAMP ::: Emerging Methods for Diagnosis of SARS-CoV-2The RT-LAMP method has been shown to effectively detect SARS-CoV-2 in clinical samples from individuals with COVID-19 (Yan et al., 2020).", [["samples", "ANATOMY", 360, 367], ["nucleic acid", "CHEMICAL", 11, 23], ["SARS", "DISEASE", 214, 218], ["SARS", "DISEASE", 271, 275], ["SARS-CoV", "ORGANISM", 214, 222], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 337, 347], ["samples", "CANCER", 360, 367], ["SARS-CoV", "SPECIES", 214, 222], ["SARS-CoV", "SPECIES", 271, 279], ["SARS-CoV", "SPECIES", 337, 345], ["Isothermal nucleic acid amplification", "TREATMENT", 0, 37], ["novel SARS", "TEST", 208, 218], ["CoV", "TEST", 219, 222], ["SARS", "PROBLEM", 271, 275], ["CoV", "TEST", 276, 279], ["LAMP method", "TREATMENT", 288, 299], ["SARS", "PROBLEM", 337, 341], ["CoV", "TEST", 342, 345], ["clinical samples", "TEST", 351, 367], ["COVID", "TEST", 390, 395]]], ["Multiple loop primers targeting the ORF1ab gene and the S gene were used for DNA strand displacement activity and target amplification that achieved detection of 20 copies/reaction and 200 copies/reaction, respectively.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 36, 42], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["ORF1ab gene", "DNA", 36, 47], ["S gene", "DNA", 56, 62], ["Multiple loop primers", "TREATMENT", 0, 21], ["the ORF1ab gene", "TREATMENT", 32, 47], ["the S gene", "TREATMENT", 52, 62], ["DNA strand displacement activity", "PROBLEM", 77, 109], ["20 copies/reaction", "PROBLEM", 162, 180], ["loop primers", "OBSERVATION", 9, 21]]], ["These results were comparable to RT-PCR amplification.", [["RT-PCR amplification", "TEST", 33, 53]]], ["The reported 100% sensitivity and 100% specificity and the mean time for detection was under 30 min, demonstrates this is a definitive testing method.RPA ::: Emerging Methods for Diagnosis of SARS-CoV-2This method detected total viral RNA derived from cell culture supernatant and 19 nasopharyngeal swab samples (8 positive and 11 negative) for SARS-CoV-2 (Behrmann et al., 2020).", [["cell culture supernatant", "ANATOMY", 252, 276], ["nasopharyngeal swab samples", "ANATOMY", 284, 311], ["cell", "CELL", 252, 256], ["nasopharyngeal swab samples", "CANCER", 284, 311], ["viral RNA", "RNA", 229, 238], ["SARS-CoV", "SPECIES", 192, 200], ["SARS-CoV", "SPECIES", 345, 353], ["a definitive testing method", "TEST", 122, 149], ["SARS", "PROBLEM", 192, 196], ["CoV", "TEST", 197, 200], ["2This method", "TEST", 201, 213], ["total viral RNA", "PROBLEM", 223, 238], ["cell culture supernatant", "TEST", 252, 276], ["nasopharyngeal swab samples", "TEST", 284, 311], ["SARS", "PROBLEM", 345, 349], ["CoV", "TEST", 350, 353]]], ["This approach integrates isothermal methods for reverse transcription followed by recombinase activity that mediates primer (targeting the N gene) binding to the homologous sequence in dsDNA.", [["dsDNA", "CELLULAR_COMPONENT", 185, 190], ["N gene", "DNA", 139, 145], ["isothermal methods", "TREATMENT", 25, 43], ["reverse transcription", "TREATMENT", 48, 69]]], ["Subsequent amplification by polymerase mediated primer extension achieved 100% diagnostic sensitivity and specificity.", [["Subsequent amplification by polymerase mediated primer extension", "PROBLEM", 0, 64], ["diagnostic sensitivity", "TEST", 79, 101]]], ["This method offers potential advantages over RT-PCR for speed, scale and portability, allowing evidence-based clinical decisions to be made during a patient visit.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) ::: Emerging Methods for Diagnosis of SARS-CoV-2The CRISPR assay functionality is being applied for detection of DNA or RNA using nucleic acid pre-amplification combined with CRISPR-Cas enzymology for specific recognition of sequences.CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) ::: Emerging Methods for Diagnosis of SARS-CoV-2The CRISPR/Cas13a system is a recently discovered CRISPR-RNA (crRNA) guided detection method that is specific for RNA and is being applied for SARS-CoV-2 detection.", [["SARS", "DISEASE", 268, 272], ["nucleic acid", "CHEMICAL", 360, 372], ["SARS", "DISEASE", 570, 574], ["patient", "ORGANISM", 149, 156], ["DNA", "CELLULAR_COMPONENT", 343, 346], ["CRISPR-Cas", "GENE_OR_GENE_PRODUCT", 405, 415], ["CRISPR", "DNA", 163, 169], ["Clustered Regularly Interspaced Short Palindromic Repeats", "DNA", 171, 228], ["CRISPR", "DNA", 282, 288], ["CRISPR", "DNA", 405, 411], ["Cas", "PROTEIN", 412, 415], ["CRISPR", "DNA", 465, 471], ["Clustered Regularly Interspaced Short Palindromic Repeats", "DNA", 473, 530], ["CRISPR", "DNA", 584, 590], ["Cas13a system", "DNA", 591, 604], ["patient", "SPECIES", 149, 156], ["SARS-CoV", "SPECIES", 268, 276], ["SARS-CoV", "SPECIES", 570, 578], ["RT-PCR", "TREATMENT", 45, 51], ["SARS", "PROBLEM", 268, 272], ["CoV", "TEST", 273, 276], ["The CRISPR assay functionality", "TREATMENT", 278, 308], ["DNA", "PROBLEM", 343, 346], ["RNA", "PROBLEM", 350, 353], ["nucleic acid pre-amplification", "TREATMENT", 360, 390], ["SARS", "PROBLEM", 570, 574], ["CoV", "TEST", 575, 578], ["guided detection method", "TEST", 649, 672], ["RNA", "PROBLEM", 694, 697], ["SARS", "PROBLEM", 723, 727]]], ["A key feature of this approach is the Cas13a (formerly named C2c2) enzyme that recognizes and binds targeted RNAs in a sequence-specific manner followed by non-specific trans-endonuclease cleavage of non-targeted RNA (\u201ccollateral\u201d cleavage) for signal amplification and nucleic acid detection.", [["nucleic acid", "CHEMICAL", 270, 282], ["Cas13a", "GENE_OR_GENE_PRODUCT", 38, 44], ["C2c2", "GENE_OR_GENE_PRODUCT", 61, 65], ["nucleic acid", "SIMPLE_CHEMICAL", 270, 282], ["Cas13a (formerly named C2c2) enzyme", "PROTEIN", 38, 73], ["targeted RNAs", "RNA", 100, 113], ["non-targeted RNA", "RNA", 200, 216], ["non-targeted RNA", "TREATMENT", 200, 216], ["collateral\u201d cleavage", "TREATMENT", 219, 239], ["signal amplification", "TEST", 245, 265], ["nucleic acid detection", "TEST", 270, 292]]], ["The Cas13a assay can be paired with target nucleic acid amplification for more sensitive results using an isothermal exponential amplification technique, most commonly RPA.", [["nucleic acid", "CHEMICAL", 43, 55], ["Cas13a", "GENE_OR_GENE_PRODUCT", 4, 10], ["RPA", "GENE_OR_GENE_PRODUCT", 168, 171], ["Cas13a", "PROTEIN", 4, 10], ["RPA", "PROTEIN", 168, 171], ["The Cas13a assay", "TEST", 0, 16], ["target nucleic acid amplification", "TEST", 36, 69], ["an isothermal exponential amplification technique", "TREATMENT", 103, 152]]], ["This coupled technique is termed SHERLOCK (Specific High-Sensitivity Enzymatic Reporter unLOCKing) and allows fluorescence, colorimetric, lateral flow, and other readout approaches to enable the rapid detection of a variety of targets (Kellner et al., 2019).Cas13a Assay ::: Emerging Methods for Diagnosis of SARS-CoV-2Unlike in vivo CRISPR tools, the Cas13a protein must be recombinantly expressed and purified.", [["Cas13a", "GENE_OR_GENE_PRODUCT", 352, 358], ["Cas13a protein", "PROTEIN", 352, 366], ["SARS-CoV", "SPECIES", 309, 317], ["fluorescence", "TEST", 110, 122], ["colorimetric, lateral flow", "TEST", 124, 150], ["the rapid detection", "TEST", 191, 210], ["SARS", "PROBLEM", 309, 313], ["CoV", "PROBLEM", 314, 317], ["the Cas13a protein", "TREATMENT", 348, 366]]], ["The endonuclease activity of purified Cas13a uses crRNA targeting sequences in the S gene and ORF1ab in SARS-CoV-2 RNA.", [["Cas13a", "GENE_OR_GENE_PRODUCT", 38, 44], ["crRNA", "GENE_OR_GENE_PRODUCT", 50, 55], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 94, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["endonuclease", "PROTEIN", 4, 16], ["Cas13a", "PROTEIN", 38, 44], ["crRNA targeting sequences", "DNA", 50, 75], ["S gene", "DNA", 83, 89], ["ORF1ab", "DNA", 94, 100], ["SARS-CoV-2 RNA", "RNA", 104, 118], ["SARS-CoV", "SPECIES", 104, 112], ["ORF1ab", "TEST", 94, 100], ["SARS", "TEST", 104, 108]]], ["Target site-recognition activates trans-cleavage of reporter probes resulting in increases in fluorescence output signals and confirming the presence of viral RNA.", [["reporter probes", "DNA", 52, 67], ["viral RNA", "RNA", 153, 162], ["reporter probes", "TREATMENT", 52, 67], ["fluorescence output signals", "TEST", 94, 121], ["viral RNA", "PROBLEM", 153, 162], ["increases", "OBSERVATION_MODIFIER", 81, 90], ["viral RNA", "OBSERVATION", 153, 162]]], ["Using synthetic SARS-CoV-2 the reported performance of this method for detection of target sequences is 20\u2013200 aM (Kellner et al., 2019).", [["target sequences", "DNA", 84, 100], ["target sequences", "TEST", 84, 100]]], ["The Cas13a/crRNA platform has been adapted for lateral-flow assays and could have wide applications as a SARS-CoV2 detector in both research and in the clinic.", [["Cas13a", "GENE_OR_GENE_PRODUCT", 4, 10], ["crRNA", "GENE_OR_GENE_PRODUCT", 11, 16], ["Cas13a/crRNA platform", "DNA", 4, 25], ["The Cas13a/crRNA platform", "TEST", 0, 25], ["lateral-flow assays", "TEST", 47, 66], ["a SARS", "TEST", 103, 109]]], ["Assays can be designed as a paper dipstick test that delivers signals in 30\u201360 min using.", [["a paper dipstick test", "TEST", 26, 47]]], ["This is a very promising technology and these positive advances in science offer immense hope for future disease control.Sample Preparation ::: Next Generation Sequencing ::: Emerging Methods for Diagnosis of SARS-CoV-2RNA is extracted from clinical specimens, as for RT-PCR, and further purified to remove human cytoplasmic and ribosomal rRNA.Biosafety ::: Library Preparation ::: Next Generation Sequencing ::: Emerging Methods for Diagnosis of SARS-CoV-2Regulating authorities provide interim guidance on the handling of specimens associated with SARS-CoV-2 (CDC, 2020b).", [["specimens", "ANATOMY", 250, 259], ["cytoplasmic", "ANATOMY", 313, 324], ["ribosomal", "ANATOMY", 329, 338], ["specimens", "ANATOMY", 524, 533], ["SARS", "DISEASE", 209, 213], ["SARS", "DISEASE", 447, 451], ["SARS", "DISEASE", 550, 554], ["human", "ORGANISM", 307, 312], ["cytoplasmic", "ORGANISM_SUBSTANCE", 313, 324], ["ribosomal", "CELLULAR_COMPONENT", 329, 338], ["rRNA", "CELLULAR_COMPONENT", 339, 343], ["SARS-CoV-2RNA", "DNA", 209, 222], ["human cytoplasmic and ribosomal rRNA", "DNA", 307, 343], ["human", "SPECIES", 307, 312], ["SARS-CoV-2RNA", "SPECIES", 209, 222], ["human", "SPECIES", 307, 312], ["SARS-CoV", "SPECIES", 550, 558], ["future disease control", "TREATMENT", 98, 120], ["SARS", "PROBLEM", 209, 213], ["CoV", "PROBLEM", 214, 217], ["2RNA", "PROBLEM", 218, 222], ["clinical specimens", "TEST", 241, 259], ["RT-PCR", "TEST", 268, 274], ["human cytoplasmic and ribosomal rRNA", "TREATMENT", 307, 343], ["SARS", "PROBLEM", 447, 451], ["CoV", "PROBLEM", 452, 455], ["SARS", "PROBLEM", 550, 554], ["CoV", "TEST", 555, 558], ["ribosomal rRNA", "OBSERVATION", 329, 343]]], ["Samples for testing can be performed in a BSL-2 laboratory with unidirectional airflow and BSL-3 precautions, and respiratory protection and a designated area for personal protective equipment changes are recommended.", [["Samples", "ANATOMY", 0, 7], ["Samples for testing", "TEST", 0, 19], ["unidirectional airflow", "TREATMENT", 64, 86], ["BSL-3 precautions", "TREATMENT", 91, 108], ["respiratory protection", "TREATMENT", 114, 136], ["personal protective equipment changes", "TREATMENT", 163, 200]]], ["Isolation of SARS-CoV-2 in cell culture and initial characterization of viral agents recovered in cultures of patient samples should be conducted at Biosafety Level 3 (BSL-3), with regulatory approval and guidance.ConclusionFigure 2 and Table 3 summarize the main laboratory tests for detection of components of SARS-CoV-2 and the humoral response to the virus, and depict key features of these approaches.", [["cell", "ANATOMY", 27, 31], ["samples", "ANATOMY", 118, 125], ["SARS", "DISEASE", 312, 316], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["cell", "CELL", 27, 31], ["patient", "ORGANISM", 110, 117], ["SARS-CoV-2", "ORGANISM", 312, 322], ["patient", "SPECIES", 110, 117], ["SARS-CoV", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 312, 320], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["cell culture", "TEST", 27, 39], ["viral agents", "TREATMENT", 72, 84], ["cultures", "TEST", 98, 106], ["patient samples", "TEST", 110, 125], ["ConclusionFigure", "TEST", 214, 230], ["SARS", "PROBLEM", 312, 316], ["CoV", "TEST", 317, 320], ["the virus", "PROBLEM", 351, 360], ["SARS", "OBSERVATION", 13, 17]]], ["Given the public health emergency that the expanding COVID-19 outbreak presents, more widespread testing is needed to investigate the disease (e.g., prevalence in the population, severity in age groups), and to identify individuals who are infected but have few or no symptoms.", [["the expanding COVID", "TEST", 39, 58], ["widespread testing", "TEST", 86, 104], ["the disease", "PROBLEM", 130, 141], ["symptoms", "PROBLEM", 268, 276], ["infected", "OBSERVATION", 240, 248]]], ["Detailed epidemiological data sets will better establish the rates of severe infection and death among infected populations.ConclusionOngoing research is critical to optimize existing antibody tests to determine whether immunity prevents recurrent infection and to investigate the efficacy of passive antibody therapies for COVID-19 infection.", [["infection", "DISEASE", 77, 86], ["death", "DISEASE", 91, 96], ["infection", "DISEASE", 248, 257], ["COVID-19", "CHEMICAL", 324, 332], ["infection", "DISEASE", 333, 342], ["COVID-19", "ORGANISM", 324, 332], ["COVID-19", "SPECIES", 324, 332], ["severe infection", "PROBLEM", 70, 86], ["death", "PROBLEM", 91, 96], ["infected populations", "PROBLEM", 103, 123], ["existing antibody tests", "TEST", 175, 198], ["recurrent infection", "PROBLEM", 238, 257], ["passive antibody therapies", "TREATMENT", 293, 319], ["COVID-19 infection", "PROBLEM", 324, 342], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["infection", "OBSERVATION", 77, 86], ["infection", "OBSERVATION", 248, 257], ["infection", "OBSERVATION", 333, 342]]], ["The identification of novel disease biomarkers may be valuable for understanding what makes people susceptible to COVID-19 infection and in predicting the severity and progression of disease, Researchers could request approval to analyze stored samples of human blood or in animals that might be a natural reservoir of the virus.", [["samples", "ANATOMY", 245, 252], ["blood", "ANATOMY", 262, 267], ["infection", "DISEASE", 123, 132], ["people", "ORGANISM", 92, 98], ["COVID-19", "ORGANISM", 114, 122], ["human", "ORGANISM", 256, 261], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["people", "SPECIES", 92, 98], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["novel disease biomarkers", "PROBLEM", 22, 46], ["COVID-19 infection", "PROBLEM", 114, 132], ["disease", "PROBLEM", 183, 190], ["human blood", "PROBLEM", 256, 267], ["the virus", "PROBLEM", 319, 328], ["infection", "OBSERVATION", 123, 132], ["progression", "OBSERVATION_MODIFIER", 168, 179], ["disease", "OBSERVATION", 183, 190]]], ["Specifically, guidance would be needed to direct blood and plasma collection centers to allow access of samples from COVID-19 patients.ConclusionThe COVID-19 pandemic showcases how quickly information needs to be shared as responders address rapidly evolving situations.", [["blood", "ANATOMY", 49, 54], ["plasma", "ANATOMY", 59, 65], ["samples", "ANATOMY", 104, 111], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["blood and plasma collection centers", "TEST", 49, 84], ["COVID", "TEST", 117, 122]]], ["Establishing communication across laboratories worldwide helps to develop master protocols and establish reference panels for use by multiple investigators.", [["master protocols", "TREATMENT", 74, 90]]], ["Having a range of tests also puts less pressure on one manufacturer or supply chain, as different suppliers may use different materials.", [["a range of tests", "TEST", 7, 23]]], ["This could help alleviate difficult decisions to limit testing to the most vulnerable patients which can have great public health consequences.Author ContributionsRD'C and VS contributed to concept and writing of manuscript.", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]]], "8b878724474a69d5e72831f637e49c6f7f1483a0": [["As cases of COVID-19, the disease caused by the novel coronavirus (SARS-CoV-2), continue to spread globally, public health experts have warned about the devastating impact this pandemic may have on society's most vulnerable [1] .", [["COVID-19", "CHEMICAL", 12, 20], ["SARS-CoV-2", "ORGANISM", 67, 77], ["COVID", "TEST", 12, 17], ["the disease", "PROBLEM", 22, 33], ["the novel coronavirus", "PROBLEM", 44, 65], ["disease", "OBSERVATION", 26, 33]]], ["In other parts of the world, the use of opiates and opioids has remained relatively stable; however, in Eastern Europe, Russia and Central Asia opiate use has increased [4] .", [["opiates", "SIMPLE_CHEMICAL", 40, 47], ["opioids", "SIMPLE_CHEMICAL", 52, 59], ["opiates", "TREATMENT", 40, 47], ["opioids", "TREATMENT", 52, 59], ["Central Asia opiate", "TREATMENT", 131, 150], ["stable", "OBSERVATION_MODIFIER", 84, 90]]], ["In these regions, the prevalence of injection drug use is high, as is prevalence of HIV among people who inject drugsover 40% in major Russian cities according to recent estimates [5] .", [["HIV", "DISEASE", 84, 87], ["HIV", "ORGANISM", 84, 87], ["people", "ORGANISM", 94, 100], ["HIV", "SPECIES", 84, 87], ["people", "SPECIES", 94, 100], ["HIV", "SPECIES", 84, 87], ["injection drug", "TREATMENT", 36, 50]]], ["Worldwide nearly half a million people died as a result of drug misuse in 2015; 168,000 of those deaths were due to overdose [6] .", [["deaths", "DISEASE", 97, 103], ["overdose", "DISEASE", 116, 124], ["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38]]], ["People living with HIV (PLWH) face higher risk of opioid misuse than HIV-negative people, in part because PLWH are more likely to suffer chronic pain and receive opioid analgesic treatment for symptom relief [7, 8] .", [["HIV", "DISEASE", 19, 22], ["PLWH", "DISEASE", 24, 28], ["chronic pain", "DISEASE", 137, 149], ["People", "ORGANISM", 0, 6], ["HIV", "ORGANISM", 69, 72], ["people", "ORGANISM", 82, 88], ["People", "SPECIES", 0, 6], ["HIV", "SPECIES", 19, 22], ["HIV", "SPECIES", 69, 72], ["people", "SPECIES", 82, 88], ["HIV", "SPECIES", 19, 22], ["HIV", "SPECIES", 69, 72], ["chronic pain", "PROBLEM", 137, 149], ["opioid analgesic treatment", "TREATMENT", 162, 188], ["symptom relief", "PROBLEM", 193, 207]]]], "741cd6e1645b4579030643494ca5518b38463b45": [["To the Editor, Since the coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) first emerged in Wuhan, China, in December 2019, the outbreak of COVID-19 epidemic has become an increasingly serious global health concern.", [["coronavirus disease", "DISEASE", 25, 44], ["COVID-19", "CHEMICAL", 51, 59], ["SARS-CoV-2", "DISEASE", 71, 81], ["acute respiratory syndrome coronavirus", "DISEASE", 90, 128], ["COVID-19", "CHEMICAL", 197, 205], ["coronavirus", "ORGANISM", 25, 36], ["COVID-19", "ORGANISM", 51, 59], ["SARS-CoV-2", "ORGANISM", 71, 81], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 83, 128], ["CoV-2", "SPECIES", 76, 81], ["coronavirus disease 2019 (COVID-19", "SPECIES", 25, 59], ["SARS-CoV-2 (severe acute respiratory syndrome coronavirus", "SPECIES", 71, 128], ["COVID-19", "SPECIES", 197, 205], ["the coronavirus disease", "PROBLEM", 21, 44], ["COVID", "TEST", 51, 56], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 83, 128], ["COVID", "TEST", 197, 202], ["coronavirus", "ANATOMY", 25, 36], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116], ["increasingly", "OBSERVATION_MODIFIER", 229, 241], ["serious", "OBSERVATION_MODIFIER", 242, 249]]], ["Currently, over 150 countries have reported COVID-19 cases, and the situation has progressed to a pandemic associated with substantial morbidity and mortality.", [["COVID", "TEST", 44, 49], ["a pandemic", "PROBLEM", 96, 106], ["substantial morbidity", "PROBLEM", 123, 144], ["substantial", "OBSERVATION_MODIFIER", 123, 134], ["morbidity", "OBSERVATION", 135, 144]]], ["1 At present, rRT-PCR (real-time reverse transcription-polymerase chain reaction) assay is the most common and only direct method of SARS-CoV-2 detection for the diagnosis of COVID-19.", [["rRT", "DNA", 14, 17], ["COVID-19", "DNA", 175, 183], ["SARS-CoV", "SPECIES", 133, 141], ["rRT", "TEST", 14, 17], ["PCR", "TEST", 18, 21], ["polymerase chain reaction", "TEST", 55, 80], ["COVID", "TEST", 175, 180]]], ["2 However, false-negative results due to laboratory errors or improper collection of the specimens may inevitably lead to an important percentage of undiagnosed COVID-19 patients.", [["specimens", "ANATOMY", 89, 98], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["laboratory errors", "PROBLEM", 41, 58], ["improper collection of the specimens", "PROBLEM", 62, 98]]], ["Some patients with suspected COVID-19 have initial negative result of the rRT-PCR test 3, 4 or low viral concentration of SARS-CoV-2 at the sampling site in the early stages of the disease.", [["patients", "ORGANISM", 5, 13], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 122, 132], ["patients", "SPECIES", 5, 13], ["COVID", "TEST", 29, 34], ["the rRT", "TEST", 70, 77], ["PCR test", "TEST", 78, 86], ["low viral concentration of SARS", "PROBLEM", 95, 126], ["CoV", "TEST", 127, 130], ["the disease", "PROBLEM", 177, 188], ["early stages", "OBSERVATION_MODIFIER", 161, 173], ["disease", "OBSERVATION", 181, 188]]], ["5 This study aims to compare the clinical and laboratory characteristics of eventually confirmed COVID-19 patients with initial positive and negative SARS-CoV-2 nucleic acid test results.", [["nucleic acid", "CHEMICAL", 161, 173], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["This study", "TEST", 2, 12], ["COVID", "TEST", 97, 102], ["CoV", "TEST", 155, 158], ["nucleic acid test", "TEST", 161, 178]]]], "PMC7151932": [["IntroductionBioterrorism, once limited to military-directed biowarfare, has developed considerable prominence due to increasing world threats and the anthrax outbreak in the United States in 2001.", [["IntroductionBioterrorism", "CHEMICAL", 0, 24], ["anthrax", "DISEASE", 150, 157], ["IntroductionBioterrorism", "TREATMENT", 0, 24], ["considerable prominence", "PROBLEM", 86, 109], ["increasing world threats", "PROBLEM", 117, 141], ["considerable", "OBSERVATION_MODIFIER", 86, 98], ["prominence", "OBSERVATION", 99, 109], ["increasing", "OBSERVATION_MODIFIER", 117, 127]]], ["Clinicians and public health officials have become more aware of these rare diseases as local, state, and national programs increase detection, therapeutic options, and responses to the causative agents.IntroductionEarly recognition of bioterrorism agents can be difficult since the early prodromal phase of most agents is similar and often indistinguishable from other causes of febrile respiratory illnesses.", [["respiratory", "ANATOMY", 388, 399], ["febrile respiratory illnesses", "DISEASE", 380, 409], ["these rare diseases", "PROBLEM", 65, 84], ["therapeutic options", "TREATMENT", 144, 163], ["the causative agents", "TREATMENT", 182, 202], ["bioterrorism agents", "TREATMENT", 236, 255], ["febrile respiratory illnesses", "PROBLEM", 380, 409], ["febrile", "OBSERVATION_MODIFIER", 380, 387], ["respiratory illnesses", "OBSERVATION", 388, 409]]], ["Febrile respiratory illnesses and respiratory failure can signify a natural outbreak (e.g., severe acute respiratory syndrome, plague, tularemia, or a novel strain of influenza) or a bioterrorism event.1, 2 Most cases of febrile respiratory illnesses admitted to intensive care units (ICUs) are caused by community-acquired pneumonia, and respiratory failure and acute respiratory distress syndrome (ARDS) subsequently develop in up to 11% of these community-acquired pneumonia cases.3, 4 Although most cases of community-acquired pneumonia are recognizable, the rare and contagious causes (e.g., plague) can have a large impact on the health care and public health systems.2, 5 Thus, early recognition of these infections becomes important for two reasons.", [["respiratory", "ANATOMY", 8, 19], ["respiratory", "ANATOMY", 34, 45], ["respiratory", "ANATOMY", 229, 240], ["respiratory", "ANATOMY", 339, 350], ["respiratory", "ANATOMY", 369, 380], ["Febrile respiratory illnesses", "DISEASE", 0, 29], ["respiratory failure", "DISEASE", 34, 53], ["acute respiratory syndrome", "DISEASE", 99, 125], ["plague", "DISEASE", 127, 133], ["tularemia", "DISEASE", 135, 144], ["influenza", "DISEASE", 167, 176], ["febrile respiratory illnesses", "DISEASE", 221, 250], ["pneumonia", "DISEASE", 324, 333], ["respiratory failure", "DISEASE", 339, 358], ["acute respiratory distress syndrome", "DISEASE", 363, 398], ["ARDS", "DISEASE", 400, 404], ["pneumonia", "DISEASE", 468, 477], ["pneumonia", "DISEASE", 531, 540], ["infections", "DISEASE", 712, 722], ["Febrile respiratory illnesses", "PROBLEM", 0, 29], ["respiratory failure", "PROBLEM", 34, 53], ["a natural outbreak", "PROBLEM", 66, 84], ["severe acute respiratory syndrome", "PROBLEM", 92, 125], ["plague", "PROBLEM", 127, 133], ["tularemia", "PROBLEM", 135, 144], ["influenza", "PROBLEM", 167, 176], ["a bioterrorism event", "PROBLEM", 181, 201], ["febrile respiratory illnesses", "PROBLEM", 221, 250], ["community-acquired pneumonia", "PROBLEM", 305, 333], ["respiratory failure", "PROBLEM", 339, 358], ["acute respiratory distress syndrome", "PROBLEM", 363, 398], ["ARDS", "PROBLEM", 400, 404], ["these community-acquired pneumonia cases", "PROBLEM", 443, 483], ["community-acquired pneumonia", "PROBLEM", 512, 540], ["these infections", "PROBLEM", 706, 722], ["respiratory", "ANATOMY", 8, 19], ["illnesses", "OBSERVATION", 20, 29], ["respiratory failure", "OBSERVATION", 34, 53], ["natural", "OBSERVATION_MODIFIER", 68, 75], ["outbreak", "OBSERVATION_MODIFIER", 76, 84], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory syndrome", "OBSERVATION", 105, 125], ["tularemia", "OBSERVATION", 135, 144], ["febrile", "OBSERVATION_MODIFIER", 221, 228], ["respiratory illnesses", "OBSERVATION", 229, 250], ["pneumonia", "OBSERVATION", 324, 333], ["respiratory failure", "OBSERVATION", 339, 358], ["acute", "OBSERVATION_MODIFIER", 363, 368], ["respiratory distress", "OBSERVATION", 369, 389], ["pneumonia", "OBSERVATION", 468, 477], ["pneumonia", "OBSERVATION", 531, 540], ["contagious", "OBSERVATION_MODIFIER", 572, 582], ["large", "OBSERVATION_MODIFIER", 616, 621], ["impact", "OBSERVATION_MODIFIER", 622, 628], ["infections", "OBSERVATION", 712, 722]]], ["First, early infection control and public health preparedness strategies must be implemented to reduce spread to health care workers and the public, particularly in the acute stages of disease when patients are most contagious and most likely to undergo aerosol-generating diagnostic procedures.", [["infection", "DISEASE", 13, 22], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["early infection control", "PROBLEM", 7, 30], ["public health preparedness strategies", "TREATMENT", 35, 72], ["disease", "PROBLEM", 185, 192], ["aerosol", "TREATMENT", 254, 261], ["diagnostic procedures", "TREATMENT", 273, 294], ["early", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22]]], ["Therefore, early suspicion of a bioterrorism or outbreak event, along with early protective measures and public health contact, will reduce the likelihood of transmission to health care workers, visitors, patients, and the community.IntroductionBioterrorism involves the deliberate release of viruses, bacteria, or their products (e.g., toxins) to cause morbidity and mortality in humans, animals, or plants.6, 7 All bioterrorism agents are naturally occurring organisms or toxins that can cause sporadic disease under ordinary circumstances, but on occasion, an agent has been manipulated to increase resistance to antibiotics or increase organism virulence.7 This chapter provides an overview of the major agents of bioterrorism and highly lethal disease outbreaks along with clues for detection, steps for public health response, and infection control interventions.Bioterrorism: A Historical PerspectiveBioterrorism has existed for centuries, from ancient Mesopotamia to current times.7, 8 The initial goal was to incapacitate the enemy through death or stir panic in the population, leading to surrender.", [["Bioterrorism", "DISEASE", 245, 257], ["infection", "DISEASE", 837, 846], ["death", "DISEASE", 1049, 1054], ["panic", "DISEASE", 1063, 1068], ["patients", "ORGANISM", 205, 213], ["humans", "ORGANISM", 381, 387], ["patients", "SPECIES", 205, 213], ["humans", "SPECIES", 381, 387], ["humans", "SPECIES", 381, 387], ["a bioterrorism", "PROBLEM", 30, 44], ["viruses", "PROBLEM", 293, 300], ["bacteria", "PROBLEM", 302, 310], ["morbidity", "PROBLEM", 354, 363], ["mortality in humans", "PROBLEM", 368, 387], ["naturally occurring organisms", "PROBLEM", 441, 470], ["toxins", "PROBLEM", 474, 480], ["sporadic disease", "PROBLEM", 496, 512], ["an agent", "TREATMENT", 560, 568], ["antibiotics", "TREATMENT", 616, 627], ["increase organism virulence", "PROBLEM", 631, 658], ["bioterrorism", "PROBLEM", 718, 730], ["highly lethal disease outbreaks", "PROBLEM", 735, 766], ["infection control interventions", "TREATMENT", 837, 868], ["stir panic", "PROBLEM", 1058, 1068], ["bioterrorism", "OBSERVATION", 32, 44], ["viruses", "OBSERVATION", 293, 300], ["infection", "OBSERVATION", 837, 846]]], ["For example, in the 14th century, the Tartars catapulted plague-infected corpses into Kaffa, leading to disease spread and defeat of the city (also starting the second wave of the Black Death in Europe).9 In the New World, smallpox-contaminated blankets may have been distributed by early settlers to natives in an effort to overcome the siege of Fort Pitt.", [["corpses", "ANATOMY", 73, 80], ["plague-infected corpses", "DISEASE", 57, 80], ["Kaffa", "CHEMICAL", 86, 91], ["Death", "DISEASE", 186, 191], ["smallpox", "DISEASE", 223, 231], ["disease spread", "PROBLEM", 104, 118], ["smallpox-contaminated blankets", "TREATMENT", 223, 253], ["disease", "OBSERVATION", 104, 111]]], ["However, bioterrorism took form in the last 100 years with extensive biowarfare units in World War I and II.7, 8 Notably, Unit 731 of the Japanese army in World War II used anthrax, plague, cholera, and typhoid on Chinese prisoners with high mortality, but the transition to the battlefield was less successful.7, 8, 9 The Cold War saw both the United States and the former Soviet Union develop bioweapon stockpiles that have since been dismantled.", [["anthrax", "DISEASE", 173, 180], ["plague", "DISEASE", 182, 188], ["cholera", "DISEASE", 190, 197], ["typhoid", "DISEASE", 203, 210], ["extensive biowarfare units", "TREATMENT", 59, 85], ["anthrax", "PROBLEM", 173, 180], ["plague", "PROBLEM", 182, 188], ["cholera", "PROBLEM", 190, 197], ["typhoid", "PROBLEM", 203, 210], ["bioweapon stockpiles", "PROBLEM", 395, 415]]], ["However, over the past 25 years, there has been an increase in individual-initiated bioterrorism, culminating in the anthrax outbreak in 2001 that used the postal service for distribution, causing 22 cases.7, 8, 10", [["anthrax", "DISEASE", 117, 124], ["bioterrorism", "PROBLEM", 84, 96], ["increase", "OBSERVATION_MODIFIER", 51, 59], ["bioterrorism", "OBSERVATION", 84, 96]]]], "PMC7491522": [["IntroductionAs of September 2020, SARS-CoV-2 has infected over 25 million people globally.", [["SARS", "DISEASE", 34, 38], ["SARS-CoV-2", "ORGANISM", 34, 44], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["SARS-CoV", "SPECIES", 34, 42], ["infected", "OBSERVATION_MODIFIER", 49, 57]]], ["While a majority of COVID-19 patients present with respiratory symptoms, neurological involvement, including impaired consciousness and headache, have been reported in patients (Mao et al., 2020).", [["respiratory", "ANATOMY", 51, 62], ["neurological", "ANATOMY", 73, 85], ["respiratory symptoms", "DISEASE", 51, 71], ["impaired consciousness", "DISEASE", 109, 131], ["headache", "DISEASE", 136, 144], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 168, 176], ["respiratory symptoms", "PROBLEM", 51, 71], ["neurological involvement", "PROBLEM", 73, 97], ["impaired consciousness", "PROBLEM", 109, 131], ["headache", "PROBLEM", 136, 144], ["respiratory", "ANATOMY", 51, 62]]], ["To date, human autopsy studies have identified viral RNA transcripts in brain tissues (Puelles et al., 2020; Solomon et al., 2020) and viral proteins in the endothelial cells within the olfactory bulb (Cantuti-Castelvetri et al., 2020) in a handful of people who succumbed to COVID-19.", [["brain tissues", "ANATOMY", 72, 85], ["endothelial cells", "ANATOMY", 157, 174], ["olfactory bulb", "ANATOMY", 186, 200], ["COVID-19", "CHEMICAL", 276, 284], ["human", "ORGANISM", 9, 14], ["brain tissues", "TISSUE", 72, 85], ["endothelial cells", "CELL", 157, 174], ["olfactory bulb", "TISSUE", 186, 200], ["people", "ORGANISM", 252, 258], ["viral RNA transcripts", "RNA", 47, 68], ["viral proteins", "PROTEIN", 135, 149], ["endothelial cells", "CELL_TYPE", 157, 174], ["human", "SPECIES", 9, 14], ["people", "SPECIES", 252, 258], ["human", "SPECIES", 9, 14], ["human autopsy studies", "TEST", 9, 30], ["viral RNA transcripts in brain tissues", "PROBLEM", 47, 85], ["viral proteins in the endothelial cells", "PROBLEM", 135, 174], ["viral RNA transcripts", "OBSERVATION", 47, 68], ["brain tissues", "ANATOMY", 72, 85], ["viral proteins", "OBSERVATION", 135, 149], ["endothelial cells", "OBSERVATION", 157, 174], ["olfactory bulb", "ANATOMY", 186, 200]]], ["However, the potential of SARS-CoV-2 to infect neurons in the CNS is unknown.", [["neurons", "ANATOMY", 47, 54], ["CNS", "ANATOMY", 62, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["neurons", "CELL", 47, 54], ["CNS", "ANATOMICAL_SYSTEM", 62, 65], ["SARS", "PROBLEM", 26, 30], ["infect neurons", "PROBLEM", 40, 54], ["CNS", "ANATOMY", 62, 65]]], ["Understanding the full extent of viral invasion is crucial to treating patients, as we begin try to figure out the long-term consequences of COVID-19, many of which are predicted to have possible central nervous system involvement (De Felice et al., 2020; Heneka et al., 2020; Pereira, 2020; Zhang et al., 2020).IntroductionBecause the central nervous system is not the primary organ affected by SARS-CoV-2, studying the neurological disease in COVID-19 patients systemically provides several challenges, including, having only a subset of the population of patients with neuroinvasion, lack of technology to sample CNS tissues directly, and being able to distinguish direct neuroinvasion vs. systemic viremia within the brain.", [["central nervous system", "ANATOMY", 196, 218], ["central nervous system", "ANATOMY", 336, 358], ["organ", "ANATOMY", 378, 383], ["neurological", "ANATOMY", 421, 433], ["CNS tissues", "ANATOMY", 616, 627], ["brain", "ANATOMY", 721, 726], ["SARS", "DISEASE", 396, 400], ["neurological disease", "DISEASE", 421, 441], ["COVID", "DISEASE", 445, 450], ["neuroinvasion", "DISEASE", 572, 585], ["neuroinvasion", "DISEASE", 675, 688], ["viremia", "DISEASE", 702, 709], ["patients", "ORGANISM", 71, 79], ["nervous system", "ANATOMICAL_SYSTEM", 204, 218], ["central nervous system", "ANATOMICAL_SYSTEM", 336, 358], ["organ", "ORGAN", 378, 383], ["SARS-CoV-2", "ORGANISM", 396, 406], ["patients", "ORGANISM", 454, 462], ["patients", "ORGANISM", 558, 566], ["CNS tissues", "TISSUE", 616, 627], ["brain", "ORGAN", 721, 726], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 454, 462], ["patients", "SPECIES", 558, 566], ["SARS-CoV", "SPECIES", 396, 404], ["viral invasion", "PROBLEM", 33, 47], ["COVID", "TEST", 141, 146], ["central nervous system involvement", "PROBLEM", 196, 230], ["CoV", "TEST", 401, 404], ["the neurological disease", "PROBLEM", 417, 441], ["COVID", "TEST", 445, 450], ["neuroinvasion", "PROBLEM", 572, 585], ["direct neuroinvasion", "PROBLEM", 668, 688], ["systemic viremia within the brain", "PROBLEM", 693, 726], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["invasion", "OBSERVATION", 39, 47], ["central", "ANATOMY_MODIFIER", 196, 203], ["nervous system", "ANATOMY", 204, 218], ["central", "ANATOMY_MODIFIER", 336, 343], ["nervous", "ANATOMY", 344, 351], ["neurological disease", "OBSERVATION", 421, 441], ["viremia", "OBSERVATION", 702, 709], ["brain", "ANATOMY", 721, 726]]], ["Therefore, robust, reliable model systems are required to answer the questions underlying SARS-CoV-2 neuropathology.", [["SARS-CoV", "SPECIES", 90, 98], ["neuropathology", "PROBLEM", 101, 115]]], ["During the Zika virus (ZIKV) pandemic, several groups utilized human brain organoids to answer key questions regarding ZIKV neuroinvasion and its subsequent consequences (Garcez et al., 2016; Qian et al., 2016; Xu et al., 2019).", [["brain organoids", "ANATOMY", 69, 84], ["Zika virus (ZIKV) pandemic", "DISEASE", 11, 37], ["neuroinvasion", "DISEASE", 124, 137], ["Zika virus", "ORGANISM", 11, 21], ["human", "ORGANISM", 63, 68], ["brain organoids", "CELL", 69, 84], ["ZIKV", "ORGANISM", 119, 123], ["human brain organoids", "CELL_TYPE", 63, 84], ["human", "SPECIES", 63, 68], ["Zika virus", "SPECIES", 11, 21], ["ZIKV", "SPECIES", 23, 27], ["human", "SPECIES", 63, 68], ["ZIKV", "SPECIES", 119, 123], ["the Zika virus", "PROBLEM", 7, 21], ["pandemic", "PROBLEM", 29, 37], ["human brain organoids", "TREATMENT", 63, 84], ["ZIKV neuroinvasion", "PROBLEM", 119, 137]]], ["Using a similarly well characterized human brain organoid model (Lancaster and Knoblich, 2014; Lancaster et al., 2013), here, we test the infection capacity of SARS-CoV-2 in central nervous system tissue.", [["brain organoid", "ANATOMY", 43, 57], ["central nervous system tissue", "ANATOMY", 174, 203], ["infection", "DISEASE", 138, 147], ["SARS", "DISEASE", 160, 164], ["human", "ORGANISM", 37, 42], ["brain organoid", "TISSUE", 43, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 160, 170], ["central nervous system tissue", "TISSUE", 174, 203], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["SARS-CoV", "SPECIES", 160, 168], ["the infection capacity", "PROBLEM", 134, 156], ["SARS", "PROBLEM", 160, 164], ["CoV", "TEST", 165, 168], ["brain organoid", "ANATOMY", 43, 57], ["infection", "OBSERVATION", 138, 147], ["central", "ANATOMY_MODIFIER", 174, 181], ["nervous system", "ANATOMY", 182, 196]]], ["Utilizing single cell RNA-sequencing, we uncover the transcriptional changes caused by SARS-CoV-2 infection of neurons.IntroductionBeyond the neuroinvasive potential of SARS-CoV-2, the question remains whether or not ACE2 is the main route of entry of SARS-CoV-2 into neuronal cells and what strategies might block viral infection.", [["cell", "ANATOMY", 17, 21], ["neurons", "ANATOMY", 111, 118], ["neuronal cells", "ANATOMY", 268, 282], ["SARS", "DISEASE", 169, 173], ["SARS", "DISEASE", 252, 256], ["viral infection", "DISEASE", 315, 330], ["cell", "CELL", 17, 21], ["SARS-CoV-2", "ORGANISM", 87, 97], ["neurons", "CELL", 111, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 169, 179], ["ACE2", "GENE_OR_GENE_PRODUCT", 217, 221], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 252, 262], ["neuronal cells", "CELL", 268, 282], ["ACE2", "PROTEIN", 217, 221], ["neuronal cells", "CELL_TYPE", 268, 282], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 169, 177], ["single cell RNA", "TREATMENT", 10, 25], ["the transcriptional changes", "PROBLEM", 49, 76], ["SARS", "PROBLEM", 87, 91], ["CoV-2 infection of neurons", "PROBLEM", 92, 118], ["SARS", "PROBLEM", 169, 173], ["SARS", "PROBLEM", 252, 256], ["CoV", "TEST", 257, 260], ["block viral infection", "PROBLEM", 309, 330], ["infection", "OBSERVATION", 98, 107], ["neurons", "ANATOMY", 111, 118], ["viral", "OBSERVATION_MODIFIER", 315, 320], ["infection", "OBSERVATION", 321, 330]]], ["ACE2 expression in the CNS, and in neurons in particular, is still unclear (Xia and Lazartigues, 2008).", [["CNS", "ANATOMY", 23, 26], ["neurons", "ANATOMY", 35, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["CNS", "ANATOMICAL_SYSTEM", 23, 26], ["neurons", "CELL", 35, 42], ["ACE2", "PROTEIN", 0, 4], ["ACE2 expression in the CNS", "PROBLEM", 0, 26], ["expression", "OBSERVATION", 5, 15], ["CNS", "ANATOMY", 23, 26], ["neurons", "ANATOMY", 35, 42]]], ["Moreover, in addition to ACE2, other cofactors such as TMPRSS2 (Hoffmann et al., 2020) and Neuropilin-1 (Cantuti-Castelvetri et al., 2020; Daly et al., 2020) seem to affect infection rates, but it is unclear if these are also required for neuronal infection.", [["neuronal", "ANATOMY", 239, 247], ["infection", "DISEASE", 173, 182], ["neuronal infection", "DISEASE", 239, 257], ["ACE2", "GENE_OR_GENE_PRODUCT", 25, 29], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 55, 62], ["Neuropilin-1", "GENE_OR_GENE_PRODUCT", 91, 103], ["neuronal", "CELL", 239, 247], ["ACE2", "PROTEIN", 25, 29], ["ACE2", "TEST", 25, 29], ["other cofactors", "PROBLEM", 31, 46], ["TMPRSS2", "TEST", 55, 62], ["Neuropilin", "TEST", 91, 101], ["infection rates", "PROBLEM", 173, 188], ["neuronal infection", "PROBLEM", 239, 257], ["infection", "OBSERVATION", 173, 182], ["infection", "OBSERVATION", 248, 257]]], ["Thus, we use transcriptional profiling along with blocking antibody studies to demonstrate the requirement of ACE2 and SARS-CoV-2 spike protein to infect neurons.IntroductionTo gain in vivo relevance of these findings, we examine the neuroinvasive potential SARS-CoV-2 using mouse models of SARS-CoV-2, and observe significant vascular remodeling in infected regions, independent of vascular infection, providing a valuable tool that can be used to dissect out the consequences of CNS infection.", [["neurons", "ANATOMY", 154, 161], ["vascular", "ANATOMY", 327, 335], ["vascular", "ANATOMY", 383, 391], ["CNS", "ANATOMY", 481, 484], ["SARS", "DISEASE", 291, 295], ["vascular infection", "DISEASE", 383, 401], ["infection", "DISEASE", 485, 494], ["ACE2", "GENE_OR_GENE_PRODUCT", 110, 114], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 119, 129], ["neurons", "CELL", 154, 161], ["CoV-2", "GENE_OR_GENE_PRODUCT", 263, 268], ["mouse", "ORGANISM", 275, 280], ["SARS-CoV-2", "ORGANISM", 291, 301], ["vascular", "MULTI-TISSUE_STRUCTURE", 327, 335], ["vascular", "MULTI-TISSUE_STRUCTURE", 383, 391], ["CNS", "ANATOMICAL_SYSTEM", 481, 484], ["ACE2", "PROTEIN", 110, 114], ["SARS-CoV-2 spike protein", "PROTEIN", 119, 143], ["mouse", "SPECIES", 275, 280], ["mouse", "SPECIES", 275, 280], ["SARS-CoV", "SPECIES", 291, 299], ["transcriptional profiling", "TEST", 13, 38], ["blocking antibody studies", "TEST", 50, 75], ["ACE2", "TEST", 110, 114], ["SARS", "TEST", 119, 123], ["CoV", "TEST", 124, 127], ["infect neurons", "PROBLEM", 147, 161], ["CoV", "TEST", 263, 266], ["SARS", "TEST", 291, 295], ["CoV", "TEST", 296, 299], ["significant vascular remodeling in infected regions", "PROBLEM", 315, 366], ["vascular infection", "PROBLEM", 383, 401], ["CNS infection", "PROBLEM", 481, 494], ["significant", "OBSERVATION_MODIFIER", 315, 326], ["vascular", "ANATOMY", 327, 335], ["remodeling", "OBSERVATION", 336, 346], ["infected", "OBSERVATION", 350, 358], ["vascular", "ANATOMY", 383, 391], ["infection", "OBSERVATION", 392, 401], ["CNS", "ANATOMY", 481, 484], ["infection", "OBSERVATION", 485, 494]]], ["Finally, by examining post-mortem COVID-19 patient brain tissues, we provide evidence of neuroinvasion by SARS-CoV-2 and identify associations between infection and ischemic infarcts in localized brain regions.Modeling SARS-CoV-2 neuroinvasion and cellular death using human brain organoids ::: ResultsTo dissect the mode and consequences of infection, we first established the neuroinvasive potential of SARS-CoV-2 in a human brain model system.", [["brain tissues", "ANATOMY", 51, 64], ["brain", "ANATOMY", 196, 201], ["cellular", "ANATOMY", 248, 256], ["brain organoids", "ANATOMY", 275, 290], ["brain", "ANATOMY", 427, 432], ["neuroinvasion", "DISEASE", 89, 102], ["SARS", "DISEASE", 106, 110], ["infection", "DISEASE", 151, 160], ["ischemic infarcts", "DISEASE", 165, 182], ["death", "DISEASE", 257, 262], ["infection", "DISEASE", 342, 351], ["patient", "ORGANISM", 43, 50], ["brain tissues", "TISSUE", 51, 64], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 106, 116], ["brain", "ORGAN", 196, 201], ["cellular", "CELL", 248, 256], ["human", "ORGANISM", 269, 274], ["brain organoids", "CELL", 275, 290], ["SARS-CoV-2", "CELL", 405, 415], ["human", "ORGANISM", 421, 426], ["brain", "ORGAN", 427, 432], ["human brain organoids", "CELL_TYPE", 269, 290], ["patient", "SPECIES", 43, 50], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 421, 426], ["SARS-CoV", "SPECIES", 106, 114], ["human", "SPECIES", 269, 274], ["SARS-CoV", "SPECIES", 405, 413], ["human", "SPECIES", 421, 426], ["post-mortem COVID", "TEST", 22, 39], ["neuroinvasion", "PROBLEM", 89, 102], ["SARS", "PROBLEM", 106, 110], ["CoV", "TEST", 111, 114], ["infection", "PROBLEM", 151, 160], ["ischemic infarcts in localized brain regions", "PROBLEM", 165, 209], ["Modeling SARS", "PROBLEM", 210, 223], ["neuroinvasion", "PROBLEM", 230, 243], ["cellular death", "PROBLEM", 248, 262], ["infection", "PROBLEM", 342, 351], ["SARS", "PROBLEM", 405, 409], ["CoV", "TEST", 410, 413], ["brain tissues", "ANATOMY", 51, 64], ["neuroinvasion", "OBSERVATION", 89, 102], ["infection", "OBSERVATION", 151, 160], ["ischemic", "OBSERVATION_MODIFIER", 165, 173], ["infarcts", "OBSERVATION", 174, 182], ["localized", "ANATOMY_MODIFIER", 186, 195], ["brain", "ANATOMY", 196, 201], ["regions", "ANATOMY_MODIFIER", 202, 209], ["cellular death", "OBSERVATION", 248, 262], ["infection", "OBSERVATION", 342, 351], ["human brain", "ANATOMY", 421, 432]]], ["We utilized human induced pluripotent stem cell (hiPSC) lines (Y1 and Y6), derived from healthy individuals (Figure S1), to generate forebrain-specific human neural progenitor cells (hNPCs).", [["pluripotent stem cell", "ANATOMY", 26, 47], ["hiPSC) lines", "ANATOMY", 49, 61], ["Y1", "ANATOMY", 63, 65], ["Y6", "ANATOMY", 70, 72], ["forebrain", "ANATOMY", 133, 142], ["neural progenitor cells", "ANATOMY", 158, 181], ["hNPCs", "ANATOMY", 183, 188], ["human", "ORGANISM", 12, 17], ["induced pluripotent stem cell (hiPSC) lines", "CELL", 18, 61], ["Y1", "CELL", 63, 65], ["Y6", "CELL", 70, 72], ["human", "ORGANISM", 152, 157], ["neural progenitor cells", "CELL", 158, 181], ["hNPCs", "CELL", 183, 188], ["human induced pluripotent stem cell (hiPSC) lines", "CELL_LINE", 12, 61], ["Y1", "CELL_LINE", 63, 65], ["Y6", "CELL_LINE", 70, 72], ["human neural progenitor cells", "CELL_TYPE", 152, 181], ["hNPCs", "CELL_TYPE", 183, 188], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 152, 157], ["human induced pluripotent stem cell (hiPSC) lines", "TREATMENT", 12, 61], ["pluripotent stem cell", "OBSERVATION", 26, 47], ["forebrain", "ANATOMY", 133, 142], ["neural progenitor cells", "OBSERVATION", 158, 181]]], ["In culture, we observed replication of SARS-CoV-2 in two-week-old hNPCs, with peak viral titers as early as 12 h post infection (hpi) (Figure S2A and B).", [["hNPCs", "ANATOMY", 66, 71], ["infection", "DISEASE", 118, 127], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["hNPCs", "PATHOLOGICAL_FORMATION", 66, 71], ["SARS-CoV", "SPECIES", 39, 47], ["culture", "TEST", 3, 10], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47], ["old hNPCs", "PROBLEM", 62, 71], ["peak viral titers", "PROBLEM", 78, 95], ["infection", "PROBLEM", 118, 127], ["infection", "OBSERVATION", 118, 127]]], ["In addition, TUNEL staining indicated increased cell death (Figure S2A).", [["cell", "ANATOMY", 48, 52], ["death", "DISEASE", 53, 58], ["cell", "CELL", 48, 52], ["TUNEL staining", "TEST", 13, 27], ["increased cell death", "PROBLEM", 38, 58], ["TUNEL staining", "OBSERVATION", 13, 27], ["increased cell death", "OBSERVATION", 38, 58]]], ["Next, we generated hiPSC-derived brain organoids (Amin and Pasca, 2018; Pellegrini et al., 2020; Qian et al., 2016; Velasco et al., 2019) to model the SARS-CoV-2 infection of neuronal cells in 3D.", [["hiPSC-derived brain organoids", "ANATOMY", 19, 48], ["neuronal cells", "ANATOMY", 175, 189], ["SARS", "DISEASE", 151, 155], ["infection", "DISEASE", 162, 171], ["hiPSC", "CELL", 19, 24], ["brain organoids", "CELL", 33, 48], ["Amin", "CELL", 50, 54], ["CoV-2", "GENE_OR_GENE_PRODUCT", 156, 161], ["neuronal cells", "CELL", 175, 189], ["hiPSC", "CELL_TYPE", 19, 24], ["neuronal cells", "CELL_TYPE", 175, 189], ["SARS-CoV", "SPECIES", 151, 159], ["the SARS", "TEST", 147, 155], ["CoV", "TEST", 156, 159], ["neuronal cells", "PROBLEM", 175, 189], ["brain", "ANATOMY", 33, 38], ["neuronal cells", "OBSERVATION", 175, 189]]], ["Similar to a recent report (Ramani et al., 2020), we observed infection of neuronal cells in nine-week-old organoids as early as 24 hpi, with significantly increased number of SARS-CoV-2 positive cells at 96 hpi (Figure 1A\u2013C, Figure S2C).", [["neuronal cells", "ANATOMY", 75, 89], ["organoids", "ANATOMY", 107, 116], ["cells", "ANATOMY", 196, 201], ["infection", "DISEASE", 62, 71], ["neuronal cells", "CELL", 75, 89], ["organoids", "CELL", 107, 116], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 176, 186], ["cells", "CELL", 196, 201], ["neuronal cells", "CELL_TYPE", 75, 89], ["SARS-CoV-2 positive cells", "CELL_LINE", 176, 201], ["infection of neuronal cells", "PROBLEM", 62, 89], ["old organoids", "PROBLEM", 103, 116], ["significantly increased number of SARS", "PROBLEM", 142, 180], ["CoV", "TEST", 181, 184], ["infection", "OBSERVATION", 62, 71], ["neuronal cells", "OBSERVATION", 75, 89]]], ["Although the majority of the SARS-CoV-2 infected cells were localized within MAP2 positive cellular fields of mature neurons (Figure 1B.2, Figure S2C), we also observed infection of SOX2-positive neural stem cells with bipolar morphology and cells localized around the neural tube-like structures (Figure 1B.1).", [["cells", "ANATOMY", 49, 54], ["cellular fields", "ANATOMY", 91, 106], ["neurons", "ANATOMY", 117, 124], ["neural stem cells", "ANATOMY", 196, 213], ["cells", "ANATOMY", 242, 247], ["neural tube-like structures", "ANATOMY", 269, 296], ["SARS", "DISEASE", 29, 33], ["infection", "DISEASE", 169, 178], ["bipolar", "DISEASE", 219, 226], ["SARS-CoV-2", "ORGANISM", 29, 39], ["cells", "CELL", 49, 54], ["MAP2", "GENE_OR_GENE_PRODUCT", 77, 81], ["cellular", "CELL", 91, 99], ["neurons", "CELL", 117, 124], ["SOX2", "GENE_OR_GENE_PRODUCT", 182, 186], ["neural stem cells", "CELL", 196, 213], ["cells", "CELL", 242, 247], ["neural tube-like structures", "TISSUE", 269, 296], ["MAP2", "PROTEIN", 77, 81], ["mature neurons", "CELL_TYPE", 110, 124], ["SOX2", "PROTEIN", 182, 186], ["positive neural stem cells", "CELL_TYPE", 187, 213], ["SARS-CoV", "SPECIES", 29, 37], ["the SARS", "TEST", 25, 33], ["CoV", "TEST", 34, 37], ["2 infected cells", "PROBLEM", 38, 54], ["Figure", "TEST", 126, 132], ["infection of SOX2-positive neural stem cells", "PROBLEM", 169, 213], ["bipolar morphology and cells", "PROBLEM", 219, 247], ["infected cells", "OBSERVATION", 40, 54], ["cellular fields", "OBSERVATION", 91, 106], ["infection", "OBSERVATION", 169, 178], ["positive neural stem cells", "OBSERVATION", 187, 213], ["bipolar morphology", "OBSERVATION", 219, 237], ["neural tube", "OBSERVATION", 269, 280]]], ["We observed an increase in SARS-CoV-2 positive cells 96 hpi compared to 24 hpi (Figure 1C, Figure S2C\u2013E).", [["cells", "ANATOMY", 47, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["SARS-CoV", "SPECIES", 27, 35], ["an increase in SARS", "PROBLEM", 12, 31], ["CoV", "TEST", 32, 35], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["SARS", "OBSERVATION", 27, 31]]], ["At 96 hpi we observed a wide spread infection mostly limited to the regions with high cortical cell density in the organoid (Figure 1D).", [["cortical cell", "ANATOMY", 86, 99], ["organoid", "ANATOMY", 115, 123], ["infection", "DISEASE", 36, 45], ["cortical cell", "CELL", 86, 99], ["organoid", "TISSUE", 115, 123], ["a wide spread infection", "PROBLEM", 22, 45], ["high cortical cell density", "PROBLEM", 81, 107], ["wide", "OBSERVATION_MODIFIER", 24, 28], ["spread", "OBSERVATION_MODIFIER", 29, 35], ["infection", "OBSERVATION", 36, 45], ["high", "OBSERVATION_MODIFIER", 81, 85], ["cortical cell density", "OBSERVATION", 86, 107], ["organoid", "ANATOMY", 115, 123]]], ["Using electron microscopy, we visualized viral particles within the organoid (Figure 1E, Figure S3), with discrete regions of high-density virus accumulation (Figure 1E.1) and other regions showing viral budding from endoplasmic reticulum-like structures (Figure 1E.2\u20134), suggesting SARS-CoV-2 is able to utilize the neuronal cell machinery to replicate.", [["organoid", "ANATOMY", 68, 76], ["endoplasmic reticulum-like structures", "ANATOMY", 217, 254], ["neuronal cell", "ANATOMY", 317, 330], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 217, 238], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 283, 293], ["neuronal cell", "CELL", 317, 330], ["electron microscopy", "TEST", 6, 25], ["visualized viral particles", "PROBLEM", 30, 56], ["high-density virus accumulation", "PROBLEM", 126, 157], ["viral budding from endoplasmic reticulum", "PROBLEM", 198, 238], ["Figure", "TEST", 256, 262], ["SARS", "PROBLEM", 283, 287], ["the neuronal cell machinery", "TREATMENT", 313, 340], ["viral particles", "OBSERVATION", 41, 56], ["organoid", "ANATOMY_MODIFIER", 68, 76], ["discrete", "OBSERVATION_MODIFIER", 106, 114], ["high", "OBSERVATION_MODIFIER", 126, 130], ["-density", "OBSERVATION_MODIFIER", 130, 138], ["virus accumulation", "OBSERVATION", 139, 157], ["viral budding", "OBSERVATION", 198, 211], ["endoplasmic reticulum", "OBSERVATION", 217, 238]]], ["Organoid infection resulted in extensive neuronal cell death; strikingly, however, the majority of TUNEL-positive cells were SARS-CoV-2 negative (Figure 1F and G, Figure S2F), and only ~15% of the cells infected with SARS-CoV-2 were TUNEL-positive (Figure 1H).", [["neuronal cell", "ANATOMY", 41, 54], ["TUNEL-positive cells", "ANATOMY", 99, 119], ["cells", "ANATOMY", 197, 202], ["infection", "DISEASE", 9, 18], ["neuronal cell death", "DISEASE", 41, 60], ["SARS", "DISEASE", 217, 221], ["neuronal cell", "CELL", 41, 54], ["cells", "CELL", 114, 119], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 125, 135], ["cells", "CELL", 197, 202], ["SARS-CoV-2", "ORGANISM", 217, 227], ["TUNEL-positive cells", "CELL_LINE", 99, 119], ["SARS-CoV", "SPECIES", 217, 225], ["Organoid infection", "PROBLEM", 0, 18], ["extensive neuronal cell death", "PROBLEM", 31, 60], ["TUNEL", "TEST", 99, 104], ["SARS", "TEST", 125, 129], ["CoV", "TEST", 130, 133], ["Figure", "TEST", 146, 152], ["G", "TEST", 160, 161], ["Figure S2F", "TEST", 163, 173], ["SARS", "TEST", 217, 221], ["CoV", "TEST", 222, 225], ["TUNEL", "TEST", 233, 238], ["infection", "OBSERVATION", 9, 18], ["extensive", "OBSERVATION_MODIFIER", 31, 40], ["neuronal cell death", "OBSERVATION", 41, 60], ["positive cells", "OBSERVATION", 105, 119]]], ["Increased cell death was correlated with a higher density of SARS-CoV-2 positive cells (Figure 1I), which however, were not overtly dying (Figure 1G and H).", [["cell", "ANATOMY", 10, 14], ["cells", "ANATOMY", 81, 86], ["death", "DISEASE", 15, 20], ["cell", "CELL", 10, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["positive cells", "CELL_TYPE", 72, 86], ["SARS-CoV", "SPECIES", 61, 69], ["Increased cell death", "PROBLEM", 0, 20], ["a higher density of SARS", "PROBLEM", 41, 65], ["CoV", "TEST", 66, 69], ["2 positive cells", "PROBLEM", 70, 86], ["cell death", "OBSERVATION", 10, 20], ["higher density", "OBSERVATION_MODIFIER", 43, 57]]], ["Even within a single plane, we noticed high density SARS-CoV-2 area to have more TUNEL-positive cells (Figure 1J yellow box) compared to low-density SARS-CoV-2 regions (Figure 1J white box).", [["TUNEL-positive cells", "ANATOMY", 81, 101], ["TUNEL-positive cells", "CELL_LINE", 81, 101], ["SARS-CoV-2 regions", "DNA", 149, 167], ["Figure 1J white box", "DNA", 169, 188], ["high density SARS", "PROBLEM", 39, 56], ["more TUNEL-positive cells", "PROBLEM", 76, 101], ["Figure", "TEST", 103, 109], ["low-density SARS", "PROBLEM", 137, 153], ["CoV", "TEST", 154, 157], ["high density", "OBSERVATION_MODIFIER", 39, 51], ["SARS", "OBSERVATION", 52, 56], ["more TUNEL", "OBSERVATION_MODIFIER", 76, 86], ["positive cells", "OBSERVATION", 87, 101], ["low-density", "OBSERVATION_MODIFIER", 137, 148], ["SARS", "OBSERVATION", 149, 153]]], ["Together, these data indicated that SARS-CoV-2 can infect cells of neural origin, and suggested that infected cells can promote death of nearby cells.Single-cell level profiling of human brain organoid ::: ResultsWe hypothesized that the cellular heterogeneity of brain organoids may be leading to certain cells being more susceptible to infection and others to death and that this system would provide an ideal platform to understand the cellular tropism of SARS-CoV-2 in the CNS and elucidate the consequences of SARS-CoV-2 neuroinvasion.", [["cells", "ANATOMY", 58, 63], ["neural", "ANATOMY", 67, 73], ["cells", "ANATOMY", 110, 115], ["cells", "ANATOMY", 144, 149], ["cell", "ANATOMY", 157, 161], ["brain organoid", "ANATOMY", 187, 201], ["cellular", "ANATOMY", 238, 246], ["brain organoids", "ANATOMY", 264, 279], ["cells", "ANATOMY", 306, 311], ["cellular", "ANATOMY", 439, 447], ["CNS", "ANATOMY", 477, 480], ["death", "DISEASE", 128, 133], ["infection", "DISEASE", 338, 347], ["death", "DISEASE", 362, 367], ["SARS", "DISEASE", 459, 463], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 46], ["cells", "CELL", 58, 63], ["cells", "CELL", 110, 115], ["cells", "CELL", 144, 149], ["cell", "CELL", 157, 161], ["human", "ORGANISM", 181, 186], ["brain organoid", "CANCER", 187, 201], ["cellular", "CELL", 238, 246], ["brain organoids", "TISSUE", 264, 279], ["cells", "CELL", 306, 311], ["cellular", "CELL", 439, 447], ["SARS-CoV-2", "ORGANISM", 459, 469], ["CNS", "ANATOMICAL_SYSTEM", 477, 480], ["SARS-CoV-2", "ORGANISM", 515, 525], ["infected cells", "CELL_TYPE", 101, 115], ["nearby cells", "CELL_TYPE", 137, 149], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["SARS-CoV", "SPECIES", 459, 467], ["SARS-CoV", "SPECIES", 515, 523], ["these data", "TEST", 10, 20], ["SARS", "PROBLEM", 36, 40], ["CoV", "TEST", 41, 44], ["infected cells", "PROBLEM", 101, 115], ["Single-cell level", "TEST", 150, 167], ["the cellular heterogeneity of brain organoids", "PROBLEM", 234, 279], ["certain cells", "PROBLEM", 298, 311], ["infection", "PROBLEM", 338, 347], ["SARS", "PROBLEM", 459, 463], ["CoV", "TEST", 464, 467], ["SARS", "PROBLEM", 515, 519], ["neuroinvasion", "PROBLEM", 526, 539], ["neural origin", "ANATOMY", 67, 80], ["infected cells", "OBSERVATION", 101, 115], ["nearby cells", "OBSERVATION", 137, 149], ["human brain", "ANATOMY", 181, 192], ["cellular heterogeneity", "OBSERVATION", 238, 260], ["brain", "ANATOMY", 264, 269], ["organoids", "OBSERVATION", 270, 279], ["infection", "OBSERVATION", 338, 347], ["CNS", "ANATOMY", 477, 480]]], ["To address these questions, we performed single-cell RNA sequencing to dissect the cellular states and transcriptional changes occurring after SARS-CoV-2 infection in both infected and non-infected cells within the organoid.", [["cellular", "ANATOMY", 83, 91], ["cells", "ANATOMY", 198, 203], ["organoid", "ANATOMY", 215, 223], ["infection", "DISEASE", 154, 163], ["cellular", "CELL", 83, 91], ["SARS-CoV-2", "ORGANISM", 143, 153], ["cells", "CELL", 198, 203], ["organoid", "CANCER", 215, 223], ["infected and non-infected cells", "CELL_TYPE", 172, 203], ["SARS-CoV", "SPECIES", 143, 151], ["single-cell RNA", "TREATMENT", 41, 56], ["the cellular states", "PROBLEM", 79, 98], ["transcriptional changes", "PROBLEM", 103, 126], ["SARS", "PROBLEM", 143, 147], ["CoV", "PROBLEM", 148, 151], ["2 infection", "PROBLEM", 152, 163], ["cellular states", "OBSERVATION", 83, 98], ["infection", "OBSERVATION", 154, 163], ["both", "OBSERVATION_MODIFIER", 167, 171], ["infected", "OBSERVATION", 172, 180], ["non-infected cells", "OBSERVATION", 185, 203], ["organoid", "ANATOMY_MODIFIER", 215, 223]]], ["We analyzed 60-day-old organoids that were either mock infected or infected with SARS-CoV-2 and collected at 2, 24, and 96 hpi (n = 2 for each time point); 96,205 cells were used to create 31 distinct clusters (Figure S4A).", [["organoids", "ANATOMY", 23, 32], ["cells", "ANATOMY", 163, 168], ["organoids", "CELL", 23, 32], ["SARS-CoV-2", "ORGANISM", 81, 91], ["cells", "CELL", 163, 168], ["SARS-CoV", "SPECIES", 81, 89], ["old organoids", "PROBLEM", 19, 32], ["SARS", "PROBLEM", 81, 85], ["CoV", "TEST", 86, 89]]], ["Annotations from previous studies (Cakir et al., 2019; Kanton et al., 2019; Velasco et al., 2019) allowed us to characterize the identity of each cluster (Figure S4A\u2013C).", [["previous studies", "TEST", 17, 33]]], ["Monocle trajectory further classified these clusters into four major cellular states; Neural progenitors/outer radial glia, intermediate progenitor/interneurons, neurons, and cortical neurons (Figure S4B\u2013D).", [["cellular", "ANATOMY", 69, 77], ["Neural progenitors", "ANATOMY", 86, 104], ["outer radial glia", "ANATOMY", 105, 122], ["intermediate progenitor", "ANATOMY", 124, 147], ["interneurons", "ANATOMY", 148, 160], ["neurons", "ANATOMY", 162, 169], ["cortical neurons", "ANATOMY", 175, 191], ["cellular", "CELL", 69, 77], ["Neural progenitors", "CELL", 86, 104], ["outer radial glia", "CELL", 105, 122], ["progenitor", "CELL", 137, 147], ["interneurons", "CELL", 148, 160], ["neurons", "CELL", 162, 169], ["cortical neurons", "CELL", 175, 191], ["Neural progenitors", "CELL_TYPE", 86, 104], ["outer radial glia", "CELL_TYPE", 105, 122], ["intermediate progenitor/interneurons, neurons", "CELL_TYPE", 124, 169], ["cortical neurons", "CELL_TYPE", 175, 191], ["Neural progenitors", "OBSERVATION", 86, 104], ["outer", "ANATOMY_MODIFIER", 105, 110], ["radial glia", "ANATOMY", 111, 122], ["intermediate progenitor", "OBSERVATION", 124, 147], ["interneurons", "ANATOMY", 148, 160], ["neurons", "ANATOMY", 162, 169], ["cortical neurons", "ANATOMY", 175, 191]]], ["To confirm the cell-types we found in the single cell sequencing, we used additional staining with dorsal cortical markers CTIP2, PAX6, TBR1 and observed infection primarily overlapping with CTIP2 positive, PAX6 negative cells or CTIP2/TBR1 double positive, Pax6 negative cells, which are neuronal cells with a deep-layer (layers 5/6) fate.Single-cell level profiling of human brain organoid ::: ResultsComparing global UMAP clusters in specimens collected before and after infection, we were able to identify cellular population changes during infection (Figure 2B, S4F and S5).", [["cell", "ANATOMY", 15, 19], ["cell", "ANATOMY", 49, 53], ["dorsal cortical", "ANATOMY", 99, 114], ["cells", "ANATOMY", 221, 226], ["Pax6 negative cells", "ANATOMY", 258, 277], ["neuronal cells", "ANATOMY", 289, 303], ["cell", "ANATOMY", 347, 351], ["brain organoid", "ANATOMY", 377, 391], ["specimens", "ANATOMY", 437, 446], ["cellular", "ANATOMY", 510, 518], ["infection", "DISEASE", 154, 163], ["infection", "DISEASE", 474, 483], ["infection", "DISEASE", 545, 554], ["cell", "CELL", 15, 19], ["cell", "CELL", 49, 53], ["CTIP2", "GENE_OR_GENE_PRODUCT", 123, 128], ["PAX6", "GENE_OR_GENE_PRODUCT", 130, 134], ["TBR1", "GENE_OR_GENE_PRODUCT", 136, 140], ["CTIP2", "GENE_OR_GENE_PRODUCT", 191, 196], ["PAX6", "GENE_OR_GENE_PRODUCT", 207, 211], ["CTIP2", "GENE_OR_GENE_PRODUCT", 230, 235], ["TBR1", "GENE_OR_GENE_PRODUCT", 236, 240], ["Pax6", "GENE_OR_GENE_PRODUCT", 258, 262], ["neuronal cells", "CELL", 289, 303], ["cell", "CELL", 347, 351], ["human", "ORGANISM", 371, 376], ["brain organoid", "CANCER", 377, 391], ["specimens", "CANCER", 437, 446], ["cellular", "CELL", 510, 518], ["dorsal cortical markers", "PROTEIN", 99, 122], ["CTIP2", "PROTEIN", 123, 128], ["PAX6", "PROTEIN", 130, 134], ["TBR1", "PROTEIN", 136, 140], ["CTIP2 positive, PAX6 negative cells", "CELL_LINE", 191, 226], ["CTIP2/TBR1 double positive, Pax6 negative cells", "CELL_LINE", 230, 277], ["neuronal cells", "CELL_TYPE", 289, 303], ["UMAP clusters", "DNA", 420, 433], ["human", "SPECIES", 371, 376], ["human", "SPECIES", 371, 376], ["additional staining", "TEST", 74, 93], ["dorsal cortical markers CTIP2", "TEST", 99, 128], ["PAX6", "PROBLEM", 130, 134], ["TBR1", "TREATMENT", 136, 140], ["observed infection", "PROBLEM", 145, 163], ["CTIP2", "TEST", 191, 196], ["PAX6 negative cells", "PROBLEM", 207, 226], ["CTIP2", "TEST", 230, 235], ["TBR1", "TEST", 236, 240], ["Pax6 negative cells", "PROBLEM", 258, 277], ["neuronal cells", "PROBLEM", 289, 303], ["Single-cell level", "TEST", 340, 357], ["infection", "PROBLEM", 474, 483], ["cellular population changes during infection", "PROBLEM", 510, 554], ["dorsal", "ANATOMY_MODIFIER", 99, 105], ["cortical markers", "OBSERVATION", 106, 122], ["infection", "OBSERVATION", 154, 163], ["PAX6 negative cells", "OBSERVATION", 207, 226], ["Pax6 negative cells", "OBSERVATION", 258, 277], ["neuronal cells", "OBSERVATION", 289, 303], ["deep", "OBSERVATION_MODIFIER", 311, 315], ["layer", "OBSERVATION_MODIFIER", 316, 321], ["human brain", "ANATOMY", 371, 382], ["infection", "OBSERVATION", 545, 554]]], ["With an added SARS-CoV-2 annotation, SARS-CoV-2 transcript reads were localized to a variety of cell clusters (Figure 2A and Figure S4G), demonstrating the widespread infectivity of SARS-CoV-2 in neurons, radial glia and neuronal progenitor cells.", [["cell", "ANATOMY", 96, 100], ["neurons", "ANATOMY", 196, 203], ["radial glia", "ANATOMY", 205, 216], ["neuronal progenitor cells", "ANATOMY", 221, 246], ["SARS", "DISEASE", 182, 186], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["cell", "CELL", 96, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 182, 192], ["neurons", "CELL", 196, 203], ["radial glia", "CELL", 205, 216], ["neuronal progenitor cells", "CELL", 221, 246], ["SARS-CoV-2", "DNA", 14, 24], ["SARS-CoV-2 transcript reads", "RNA", 37, 64], ["radial glia", "CELL_TYPE", 205, 216], ["neuronal progenitor cells", "CELL_TYPE", 221, 246], ["SARS-CoV", "SPECIES", 182, 190], ["an added SARS", "TEST", 5, 18], ["CoV", "TEST", 19, 22], ["SARS", "PROBLEM", 37, 41], ["SARS", "PROBLEM", 182, 186], ["CoV", "TEST", 187, 190], ["widespread", "OBSERVATION_MODIFIER", 156, 166], ["infectivity", "OBSERVATION", 167, 178], ["neurons", "ANATOMY", 196, 203], ["radial glia", "ANATOMY", 205, 216], ["neuronal", "OBSERVATION", 221, 229], ["progenitor cells", "OBSERVATION", 230, 246]]], ["Several cell clusters\u2014defined in Figure S4\u2014 showed large changes in their representation within the organoid, such as cluster 1 (from 5% to roughly 20% of the population), or cluster 7 (from ~10% to nearly 0%) (Figure 2B).", [["cell", "ANATOMY", 8, 12], ["organoid", "ANATOMY", 100, 108], ["cell", "CELL", 8, 12], ["organoid", "CANCER", 100, 108], ["Several cell clusters", "TEST", 0, 21], ["large changes", "PROBLEM", 51, 64], ["cell clusters", "OBSERVATION", 8, 21], ["large", "OBSERVATION_MODIFIER", 51, 56], ["changes", "OBSERVATION", 57, 64], ["organoid", "OBSERVATION_MODIFIER", 100, 108]]], ["However, this was not uniformly seen with all infected clusters, as cells in cluster 11 showed high infection rates (Figure 2A), but with little change in population representation (Figure 2B, Figure S4H).", [["cells", "ANATOMY", 68, 73], ["infection", "DISEASE", 100, 109], ["cells", "CELL", 68, 73], ["all infected clusters", "PROBLEM", 42, 63], ["cells in cluster", "TEST", 68, 84], ["high infection rates", "PROBLEM", 95, 115], ["infected", "OBSERVATION", 46, 54], ["high", "OBSERVATION_MODIFIER", 95, 99], ["infection", "OBSERVATION", 100, 109], ["little", "OBSERVATION_MODIFIER", 138, 144], ["change", "OBSERVATION_MODIFIER", 145, 151]]], ["This is consistent with findings from TUNEL staining (Figure 1E\u2013G), which demonstrated minimal overlap between SARS-CoV-2 infected cells and those undergoing cell death.Single-cell level profiling of human brain organoid ::: ResultsNext, we compared the changes in the transcriptome of SARS-CoV-2 infected organoids with another well-studied neurotropic virus\u2014Zika virus (ZIKV).", [["cells", "ANATOMY", 131, 136], ["cell", "ANATOMY", 158, 162], ["cell", "ANATOMY", 176, 180], ["brain organoid", "ANATOMY", 206, 220], ["organoids", "ANATOMY", 306, 315], ["death", "DISEASE", 163, 168], ["SARS", "DISEASE", 286, 290], ["cells", "CELL", 131, 136], ["cell", "CELL", 158, 162], ["cell", "CELL", 176, 180], ["human", "ORGANISM", 200, 205], ["brain organoid", "CANCER", 206, 220], ["SARS-CoV-2", "ORGANISM", 286, 296], ["organoids", "CELL", 306, 315], ["neurotropic virus", "ORGANISM", 342, 359], ["Zika virus", "ORGANISM", 360, 370], ["human", "SPECIES", 200, 205], ["Zika virus", "SPECIES", 360, 370], ["SARS-CoV", "SPECIES", 111, 119], ["human", "SPECIES", 200, 205], ["SARS-CoV", "SPECIES", 286, 294], ["Zika virus", "SPECIES", 360, 370], ["ZIKV", "SPECIES", 372, 376], ["TUNEL staining", "TEST", 38, 52], ["Figure 1E\u2013G", "TEST", 54, 65], ["minimal overlap between SARS", "PROBLEM", 87, 115], ["2 infected cells", "PROBLEM", 120, 136], ["cell death", "PROBLEM", 158, 168], ["Single-cell level", "TEST", 169, 186], ["SARS", "PROBLEM", 286, 290], ["CoV", "TEST", 291, 294], ["infected organoids", "PROBLEM", 297, 315], ["Zika virus", "PROBLEM", 360, 370], ["consistent with", "UNCERTAINTY", 8, 23], ["TUNEL staining", "OBSERVATION", 38, 52], ["minimal", "OBSERVATION_MODIFIER", 87, 94], ["overlap", "OBSERVATION_MODIFIER", 95, 102], ["infected cells", "OBSERVATION", 122, 136], ["cell death", "OBSERVATION", 158, 168], ["human brain", "ANATOMY", 200, 211]]], ["Differentially expressed genes (DEGs) after a brain organoid infection with ZIKV (Watanabe et al., 2017) showed almost no overlap with DEGs from SARS-CoV-2 infected organoids (Figure 2D).", [["brain organoid", "ANATOMY", 46, 60], ["organoids", "ANATOMY", 165, 174], ["organoid infection", "DISEASE", 52, 70], ["SARS", "DISEASE", 145, 149], ["SARS-CoV-2", "ORGANISM", 145, 155], ["organoids", "CELL", 165, 174], ["DEGs", "DNA", 32, 36], ["DEGs", "DNA", 135, 139], ["ZIKV", "SPECIES", 76, 80], ["SARS-CoV", "SPECIES", 145, 153], ["Differentially expressed genes (DEGs)", "PROBLEM", 0, 37], ["a brain organoid infection", "PROBLEM", 44, 70], ["DEGs", "PROBLEM", 135, 139], ["SARS", "PROBLEM", 145, 149], ["CoV", "TEST", 150, 153], ["2 infected organoids", "PROBLEM", 154, 174], ["brain", "ANATOMY", 46, 51], ["organoid", "ANATOMY_MODIFIER", 52, 60], ["infection", "OBSERVATION", 61, 70]]], ["In both cases the transcriptome showed evidence of viral infection and invasion (Figure 2E).", [["viral infection", "DISEASE", 51, 66], ["viral infection", "PROBLEM", 51, 66], ["evidence of", "UNCERTAINTY", 39, 50], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["infection", "OBSERVATION", 57, 66], ["invasion", "OBSERVATION_MODIFIER", 71, 79]]], ["However, unique processes were enriched in each of the infections.", [["infections", "DISEASE", 55, 65], ["the infections", "PROBLEM", 51, 65], ["infections", "OBSERVATION", 55, 65]]], ["SARS-CoV-2 infected brain organoid upregulated pathways related to cell division, organelle fission and metabolic processes, while ZIKV showed enrichment in type I interferon pathways (Figure 2E).", [["brain organoid", "ANATOMY", 20, 34], ["cell", "ANATOMY", 67, 71], ["organelle", "ANATOMY", 82, 91], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["brain organoid", "CELL", 20, 34], ["cell", "CELL", 67, 71], ["organelle", "CELLULAR_COMPONENT", 82, 91], ["type I interferon", "GENE_OR_GENE_PRODUCT", 157, 174], ["ZIKV", "PROTEIN", 131, 135], ["type I interferon", "PROTEIN", 157, 174], ["SARS", "TEST", 0, 4], ["infected brain organoid upregulated pathways", "PROBLEM", 11, 55], ["cell division", "PROBLEM", 67, 80], ["organelle fission", "PROBLEM", 82, 99], ["metabolic processes", "PROBLEM", 104, 123], ["ZIKV", "PROBLEM", 131, 135], ["brain", "ANATOMY", 20, 25], ["organoid upregulated", "OBSERVATION", 26, 46], ["cell division", "OBSERVATION", 67, 80], ["metabolic processes", "OBSERVATION", 104, 123]]], ["SARS-Cov-2 induced a unique transcriptional state within neurons compared to ZIKV \u2014consistent with the fact that SARS-CoV-2 induces a moderate interferon-stimulate gene (ISG) response in other tissues (Blanco-Melo et al., 2020), and previous reports of specific virus replication being controlled by alternative pathways by neurons (Daniels et al., 2019; Yordy et al., 2012).Single-cell level profiling of human brain organoid ::: ResultsTo understand the impact of SARS-CoV-2 infection on the brain organoid at the cellular level, we characterized cells that were infected with SARS-CoV-2 versus neighboring uninfected cells without the presence of SARS-CoV-2 transcript, in a cluster comprising the highest number of infected cells at 96 hpi.", [["neurons", "ANATOMY", 57, 64], ["tissues", "ANATOMY", 193, 200], ["neurons", "ANATOMY", 324, 331], ["cell", "ANATOMY", 382, 386], ["brain organoid", "ANATOMY", 412, 426], ["brain organoid", "ANATOMY", 494, 508], ["cellular", "ANATOMY", 516, 524], ["cells", "ANATOMY", 549, 554], ["cells", "ANATOMY", 620, 625], ["cells", "ANATOMY", 728, 733], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 466, 470], ["infection", "DISEASE", 477, 486], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["neurons", "CELL", 57, 64], ["SARS-CoV-2", "ORGANISM", 113, 123], ["ISG", "GENE_OR_GENE_PRODUCT", 170, 173], ["tissues", "TISSUE", 193, 200], ["neurons", "CELL", 324, 331], ["cell", "CELL", 382, 386], ["human", "ORGANISM", 406, 411], ["brain organoid", "CANCER", 412, 426], ["SARS-CoV-2", "ORGANISM", 466, 476], ["brain organoid", "CANCER", 494, 508], ["cellular", "CELL", 516, 524], ["cells", "CELL", 549, 554], ["SARS-CoV-2", "ORGANISM", 579, 589], ["cells", "CELL", 620, 625], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 650, 660], ["cells", "CELL", 728, 733], ["SARS-Cov-2", "DNA", 0, 10], ["interferon", "PROTEIN", 143, 153], ["ISG", "DNA", 170, 173], ["uninfected cells", "CELL_TYPE", 609, 625], ["SARS-CoV-2 transcript", "RNA", 650, 671], ["infected cells", "CELL_TYPE", 719, 733], ["human", "SPECIES", 406, 411], ["ZIKV", "SPECIES", 77, 81], ["human", "SPECIES", 406, 411], ["SARS-CoV", "SPECIES", 579, 587], ["SARS-CoV", "SPECIES", 650, 658], ["SARS", "PROBLEM", 0, 4], ["ZIKV", "PROBLEM", 77, 81], ["SARS", "PROBLEM", 113, 117], ["CoV", "TEST", 118, 121], ["a moderate interferon", "TREATMENT", 132, 153], ["specific virus replication", "PROBLEM", 253, 279], ["Single-cell level", "TEST", 375, 392], ["SARS", "PROBLEM", 466, 470], ["CoV-2 infection on the brain organoid", "PROBLEM", 471, 508], ["SARS", "PROBLEM", 579, 583], ["CoV", "TEST", 584, 587], ["neighboring uninfected cells", "PROBLEM", 597, 625], ["SARS", "PROBLEM", 650, 654], ["infected cells", "PROBLEM", 719, 733], ["virus replication", "OBSERVATION", 262, 279], ["human brain", "ANATOMY", 406, 417], ["SARS", "OBSERVATION", 466, 470], ["infection", "OBSERVATION", 477, 486], ["brain", "ANATOMY", 494, 499], ["organoid", "ANATOMY_MODIFIER", 500, 508], ["infected cells", "OBSERVATION", 719, 733]]], ["SARS-CoV-2-positive cells showed enrichment of genes corresponding to viral transcription, along with enrichment for metabolic processes including electron transport coupled proton transport, cytochrome c to oxygen, and NADH to ubiquinone (Figure 2F top panel).", [["cells", "ANATOMY", 20, 25], ["SARS", "DISEASE", 0, 4], ["oxygen", "CHEMICAL", 208, 214], ["NADH", "CHEMICAL", 220, 224], ["ubiquinone", "CHEMICAL", 228, 238], ["oxygen", "CHEMICAL", 208, 214], ["NADH", "CHEMICAL", 220, 224], ["ubiquinone", "CHEMICAL", 228, 238], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["electron", "SIMPLE_CHEMICAL", 147, 155], ["proton", "SIMPLE_CHEMICAL", 174, 180], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 192, 204], ["oxygen", "SIMPLE_CHEMICAL", 208, 214], ["NADH", "SIMPLE_CHEMICAL", 220, 224], ["ubiquinone", "SIMPLE_CHEMICAL", 228, 238], ["SARS-CoV-2-positive cells", "CELL_LINE", 0, 25], ["cytochrome c", "PROTEIN", 192, 204], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["positive cells", "PROBLEM", 11, 25], ["enrichment of genes", "PROBLEM", 33, 52], ["viral transcription", "PROBLEM", 70, 89], ["metabolic processes", "PROBLEM", 117, 136], ["proton transport", "TREATMENT", 174, 190], ["cytochrome c to oxygen", "TREATMENT", 192, 214], ["NADH", "TREATMENT", 220, 224], ["ubiquinone (Figure 2F top panel", "TREATMENT", 228, 259], ["viral transcription", "OBSERVATION", 70, 89]]], ["Conversely, SARS-CoV-2-negative cells showed a mitochondrial catabolic state with the upregulation of alcohol metabolism, cholesterol synthesis, and regulation of cell death (Figure 2F bottom panel).", [["cells", "ANATOMY", 32, 37], ["mitochondrial", "ANATOMY", 47, 60], ["cell", "ANATOMY", 163, 167], ["alcohol", "CHEMICAL", 102, 109], ["cholesterol", "CHEMICAL", 122, 133], ["alcohol", "CHEMICAL", 102, 109], ["cholesterol", "CHEMICAL", 122, 133], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["cells", "CELL", 32, 37], ["mitochondrial", "CELLULAR_COMPONENT", 47, 60], ["alcohol", "SIMPLE_CHEMICAL", 102, 109], ["cholesterol", "SIMPLE_CHEMICAL", 122, 133], ["cell", "CELL", 163, 167], ["SARS-CoV-2-negative cells", "CELL_LINE", 12, 37], ["SARS-CoV", "TEST", 12, 20], ["a mitochondrial catabolic state", "PROBLEM", 45, 76], ["alcohol metabolism", "PROBLEM", 102, 120], ["cholesterol synthesis", "PROBLEM", 122, 143], ["cell death", "PROBLEM", 163, 173], ["Figure 2F bottom panel", "TEST", 175, 197], ["mitochondrial", "OBSERVATION", 47, 60], ["catabolic state", "OBSERVATION", 61, 76], ["alcohol metabolism", "OBSERVATION", 102, 120], ["cell death", "OBSERVATION", 163, 173]]], ["These two cell populations displayed antagonizing pathway enrichment, with the infected cells responding to hyperoxia and the bystander cells responding to hypoxia (Figure 2F highlight in yellow).", [["cell", "ANATOMY", 10, 14], ["cells", "ANATOMY", 88, 93], ["cells", "ANATOMY", 136, 141], ["hypoxia", "DISEASE", 156, 163], ["cell populations", "CELL", 10, 26], ["cells", "CELL", 88, 93], ["bystander cells", "CELL", 126, 141], ["infected cells", "CELL_TYPE", 79, 93], ["bystander cells", "CELL_TYPE", 126, 141], ["These two cell populations", "PROBLEM", 0, 26], ["antagonizing pathway enrichment", "PROBLEM", 37, 68], ["the infected cells", "PROBLEM", 75, 93], ["hyperoxia", "PROBLEM", 108, 117], ["the bystander cells", "PROBLEM", 122, 141], ["hypoxia", "PROBLEM", 156, 163], ["two cell", "OBSERVATION", 6, 14], ["antagonizing", "OBSERVATION_MODIFIER", 37, 49], ["pathway enrichment", "OBSERVATION", 50, 68], ["infected cells", "OBSERVATION", 79, 93]]], ["The hypermetabolic state is unique to the SARS-CoV-2 infected cells (Figure 2G) and highlights the ability of SARS-CoV-2 to hijack the host neuron machinery to replicate (Figure 1D).", [["cells", "ANATOMY", 62, 67], ["neuron", "ANATOMY", 140, 146], ["SARS", "DISEASE", 42, 46], ["cells", "CELL", 62, 67], ["Figure 2G", "CELL", 69, 78], ["SARS-CoV-2", "ORGANISM", 110, 120], ["SARS-CoV-2 infected cells", "CELL_LINE", 42, 67], ["SARS-CoV", "SPECIES", 42, 50], ["the SARS", "TEST", 38, 46], ["CoV", "TEST", 47, 50], ["infected cells", "PROBLEM", 53, 67], ["hypermetabolic state", "OBSERVATION", 4, 24]]], ["Finally, we confirmed that infection by SARS-CoV-2 induced a locally hypoxic environment in neuronal regions by staining for HIF1\u03b1 (Figure 2H and 2I) in mock infected and SARS-CoV-2 infected organoids.", [["neuronal regions", "ANATOMY", 92, 108], ["organoids", "ANATOMY", 191, 200], ["infection", "DISEASE", 27, 36], ["SARS", "DISEASE", 40, 44], ["SARS-CoV-2", "ORGANISM", 40, 50], ["neuronal", "CELL", 92, 100], ["HIF1\u03b1", "GENE_OR_GENE_PRODUCT", 125, 130], ["Figure 2H", "GENE_OR_GENE_PRODUCT", 132, 141], ["SARS-CoV-2", "ORGANISM", 171, 181], ["organoids", "CELL", 191, 200], ["HIF1\u03b1", "PROTEIN", 125, 130], ["Figure 2H and 2I", "PROTEIN", 132, 148], ["SARS-CoV", "SPECIES", 40, 48], ["SARS-CoV", "SPECIES", 171, 179], ["infection", "PROBLEM", 27, 36], ["SARS", "PROBLEM", 40, 44], ["CoV", "TEST", 45, 48], ["a locally hypoxic environment", "PROBLEM", 59, 88], ["HIF1\u03b1", "TEST", 125, 130], ["SARS", "PROBLEM", 171, 175], ["2 infected organoids", "PROBLEM", 180, 200], ["infection", "OBSERVATION", 27, 36], ["locally", "OBSERVATION_MODIFIER", 61, 68], ["hypoxic environment", "OBSERVATION", 69, 88], ["infected organoids", "OBSERVATION", 182, 200]]], ["Together these results indicate the potential of SARS-CoV-2 in manipulating host metabolic programming, that may create a resource-restricted environment for cells.Host ACE2 receptor is required for infection of neurons ::: ResultsOne of the main arguments against SARS-CoV-2 neuroinvasion lies in the fact that the mRNA levels of ACE2 appear to be very low in the CNS (Li et al., 2020; Qi et al., 2020; Sungnak et al., 2020).", [["cells", "ANATOMY", 158, 163], ["neurons", "ANATOMY", 212, 219], ["CNS", "ANATOMY", 365, 368], ["infection", "DISEASE", 199, 208], ["SARS", "DISEASE", 265, 269], ["SARS-CoV-2", "ORGANISM", 49, 59], ["cells", "CELL", 158, 163], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 169, 182], ["neurons", "CELL", 212, 219], ["SARS-CoV-2", "ORGANISM", 265, 275], ["ACE2", "GENE_OR_GENE_PRODUCT", 331, 335], ["CNS", "ANATOMICAL_SYSTEM", 365, 368], ["Host ACE2 receptor", "PROTEIN", 164, 182], ["ACE2", "PROTEIN", 331, 335], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["Host ACE2 receptor", "TREATMENT", 164, 182], ["infection", "PROBLEM", 199, 208], ["SARS", "PROBLEM", 265, 269], ["CoV", "PROBLEM", 270, 273], ["2 neuroinvasion", "PROBLEM", 274, 289], ["the mRNA levels", "TEST", 312, 327], ["ACE2", "TEST", 331, 335], ["main", "OBSERVATION_MODIFIER", 242, 246], ["CNS", "ANATOMY", 365, 368]]], ["Indeed, our single cell RNA-seq data set demonstrated low levels of ACE2; it was, however, detectable in many clusters (Figure S6A).", [["cell", "ANATOMY", 19, 23], ["cell", "CELL", 19, 23], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["ACE2", "PROTEIN", 68, 72], ["our single cell RNA", "TEST", 8, 27], ["seq data", "TEST", 28, 36], ["low levels of ACE2", "PROBLEM", 54, 72], ["low levels", "OBSERVATION_MODIFIER", 54, 64]]], ["In addition, we did not observe a correlation between the percentage of cells infected in each cluster to either ACE2, TMPRSS2 or Neuropilin-1 expression (Figure S6B).", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 113, 117], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 119, 126], ["Neuropilin-1", "GENE_OR_GENE_PRODUCT", 130, 142], ["ACE2", "PROTEIN", 113, 117], ["TMPRSS2", "PROTEIN", 119, 126], ["Neuropilin", "PROTEIN", 130, 140], ["cells infected", "PROBLEM", 72, 86], ["ACE2", "TEST", 113, 117], ["TMPRSS2", "TEST", 119, 126], ["Neuropilin", "TEST", 130, 140], ["cells infected", "OBSERVATION", 72, 86]]], ["However, it remained possible that ACE2 protein may be expressed on the cell surface to promote viral entry.", [["cell surface", "ANATOMY", 72, 84], ["ACE2", "GENE_OR_GENE_PRODUCT", 35, 39], ["cell surface", "CELLULAR_COMPONENT", 72, 84], ["ACE2", "PROTEIN", 35, 39], ["ACE2 protein", "PROBLEM", 35, 47], ["the cell surface", "TREATMENT", 68, 84], ["viral entry", "OBSERVATION", 96, 107]]], ["Consistent with this idea, we found widespread expression of ACE2 protein in both MAP2-positive neurons and cells in the neural tube-like structures of the organoids (Figure 3A), indicating that the mRNA level of ACE2 does not accurately reflect ACE2 protein expression.", [["MAP2-positive neurons", "ANATOMY", 82, 103], ["cells", "ANATOMY", 108, 113], ["neural tube-like structures", "ANATOMY", 121, 148], ["organoids", "ANATOMY", 156, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["MAP2", "GENE_OR_GENE_PRODUCT", 82, 86], ["cells", "CELL", 108, 113], ["neural tube-like structures", "TISSUE", 121, 148], ["organoids", "TISSUE", 156, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 213, 217], ["ACE2", "GENE_OR_GENE_PRODUCT", 246, 250], ["ACE2 protein", "PROTEIN", 61, 73], ["MAP2", "PROTEIN", 82, 86], ["ACE2", "PROTEIN", 213, 217], ["ACE2", "PROTEIN", 246, 250], ["ACE2 protein", "TEST", 61, 73], ["the mRNA level of ACE2", "TEST", 195, 217], ["ACE2 protein expression", "PROBLEM", 246, 269], ["ACE2 protein", "OBSERVATION", 61, 73], ["positive neurons", "OBSERVATION", 87, 103], ["neural tube", "OBSERVATION", 121, 132], ["protein expression", "OBSERVATION", 251, 269]]], ["In addition, we used post-mortem human brain tissue to stain for neurons and ACE2 and found that neurons in the cortical grey matter co-localized with ACE2 staining (yellow arrow, Figure S6C), and found other cells in the vicinity that also stained for ACE2 (white arrow, Figure S6C).", [["brain tissue", "ANATOMY", 39, 51], ["neurons", "ANATOMY", 65, 72], ["neurons", "ANATOMY", 97, 104], ["cortical grey matter", "ANATOMY", 112, 132], ["cells", "ANATOMY", 209, 214], ["human", "ORGANISM", 33, 38], ["brain tissue", "TISSUE", 39, 51], ["neurons", "CELL", 65, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["neurons", "CELL", 97, 104], ["ACE2", "GENE_OR_GENE_PRODUCT", 151, 155], ["cells", "CELL", 209, 214], ["ACE2", "GENE_OR_GENE_PRODUCT", 253, 257], ["ACE2", "PROTEIN", 77, 81], ["ACE2", "PROTEIN", 151, 155], ["ACE2", "PROTEIN", 253, 257], ["Figure S6C", "PROTEIN", 272, 282], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["ACE2", "TEST", 77, 81], ["neurons in the cortical grey matter", "PROBLEM", 97, 132], ["ACE2 staining", "TEST", 151, 164], ["other cells", "PROBLEM", 203, 214], ["ACE2", "TEST", 253, 257], ["cortical", "ANATOMY_MODIFIER", 112, 120], ["grey matter", "ANATOMY", 121, 132]]], ["To test the requirement of ACE2 for SARS-CoV-2 infection, we incubated organoids with an anti-ACE2 blocking monoclonal antibody prior to infection with SARS-CoV-2.", [["organoids", "ANATOMY", 71, 80], ["infection", "DISEASE", 47, 56], ["infection", "DISEASE", 137, 146], ["ACE2", "GENE_OR_GENE_PRODUCT", 27, 31], ["SARS-CoV-2", "ORGANISM", 36, 46], ["organoids", "CELL", 71, 80], ["anti-ACE2", "SIMPLE_CHEMICAL", 89, 98], ["SARS-CoV-2", "ORGANISM", 152, 162], ["ACE2", "PROTEIN", 27, 31], ["anti-ACE2 blocking monoclonal antibody", "PROTEIN", 89, 127], ["SARS-CoV-2", "SPECIES", 36, 46], ["SARS-CoV", "SPECIES", 152, 160], ["ACE2", "TEST", 27, 31], ["SARS", "PROBLEM", 36, 40], ["CoV-2 infection", "PROBLEM", 41, 56], ["an anti-ACE2 blocking monoclonal antibody", "TREATMENT", 86, 127], ["infection", "PROBLEM", 137, 146], ["SARS", "TEST", 152, 156], ["CoV", "TEST", 157, 160], ["infection", "OBSERVATION", 47, 56]]], ["We detected significant inhibition of SARS-CoV-2 infection upon pre-treatment with ACE2 antibody compared with isotype control, indicating the requirement of ACE2 for infection of brain organoids (Figure 3B and 3F, Figure S6C).Host ACE2 receptor is required for infection of neurons ::: ResultsNext, we investigated whether there are humoral antibody responses against SARS-CoV-2 in the CNS of infected patients, and whether antibodies present in the CNS can prevent infection of neurons.", [["brain organoids", "ANATOMY", 180, 195], ["neurons", "ANATOMY", 275, 282], ["CNS", "ANATOMY", 387, 390], ["CNS", "ANATOMY", 451, 454], ["neurons", "ANATOMY", 480, 487], ["infection", "DISEASE", 49, 58], ["infection", "DISEASE", 167, 176], ["infection", "DISEASE", 262, 271], ["infection", "DISEASE", 467, 476], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["ACE2", "GENE_OR_GENE_PRODUCT", 158, 162], ["brain organoids", "CELL", 180, 195], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 232, 245], ["neurons", "CELL", 275, 282], ["SARS-CoV-2", "ORGANISM", 369, 379], ["CNS", "ANATOMICAL_SYSTEM", 387, 390], ["patients", "ORGANISM", 403, 411], ["CNS", "ANATOMICAL_SYSTEM", 451, 454], ["neurons", "CELL", 480, 487], ["ACE2 antibody", "PROTEIN", 83, 96], ["ACE2", "PROTEIN", 158, 162], ["brain organoids", "CELL_TYPE", 180, 195], ["Host ACE2 receptor", "PROTEIN", 227, 245], ["antibodies", "PROTEIN", 425, 435], ["patients", "SPECIES", 403, 411], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 369, 377], ["SARS", "PROBLEM", 38, 42], ["CoV-2 infection", "PROBLEM", 43, 58], ["ACE2 antibody", "TREATMENT", 83, 96], ["isotype control", "TREATMENT", 111, 126], ["infection of brain organoids", "PROBLEM", 167, 195], ["Host ACE2 receptor", "TREATMENT", 227, 245], ["infection", "PROBLEM", 262, 271], ["humoral antibody responses", "PROBLEM", 334, 360], ["SARS", "PROBLEM", 369, 373], ["CoV", "TEST", 374, 377], ["antibodies", "PROBLEM", 425, 435], ["infection of neurons", "PROBLEM", 467, 487], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["inhibition", "OBSERVATION_MODIFIER", 24, 34], ["SARS", "OBSERVATION", 38, 42], ["infection", "OBSERVATION", 49, 58], ["infection", "OBSERVATION", 167, 176], ["infected", "OBSERVATION", 394, 402], ["infection", "OBSERVATION", 467, 476]]], ["We analyzed cerebrospinal fluid (CSF) from a patient hospitalized with COVID-19 and acute encephalopathy (Figure 3C) and from a healthy control volunteer by performing ELISA against the spike protein of SARS-CoV-2 (Figure 3D).", [["cerebrospinal fluid", "ANATOMY", 12, 31], ["encephalopathy", "DISEASE", 90, 104], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 12, 31], ["CSF", "ORGANISM_SUBSTANCE", 33, 36], ["patient", "ORGANISM", 45, 52], ["spike protein", "PROTEIN", 186, 199], ["patient", "SPECIES", 45, 52], ["SARS-CoV", "SPECIES", 203, 211], ["cerebrospinal fluid (CSF", "TEST", 12, 36], ["COVID", "TEST", 71, 76], ["acute encephalopathy", "PROBLEM", 84, 104], ["performing ELISA", "TEST", 157, 173], ["the spike protein of SARS", "PROBLEM", 182, 207], ["CoV", "TEST", 208, 211], ["cerebrospinal fluid", "OBSERVATION", 12, 31], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["encephalopathy", "OBSERVATION", 90, 104]]], ["We detected IgG antibodies specific to the spike protein in the patient CSF even at 100x dilutions (Figure 3D).", [["IgG antibodies", "GENE_OR_GENE_PRODUCT", 12, 26], ["patient", "ORGANISM", 64, 71], ["CSF", "ORGANISM_SUBSTANCE", 72, 75], ["IgG antibodies", "PROTEIN", 12, 26], ["spike protein", "PROTEIN", 43, 56], ["patient", "SPECIES", 64, 71], ["IgG antibodies", "TEST", 12, 26], ["the spike protein", "TEST", 39, 56], ["the patient CSF", "TEST", 60, 75]]], ["Using this patient\u2019s CSF, we performed a neutralization assay against SARS-CoV-2 and validated its efficacy in preventing brain organoid infection (Figure 3E).", [["brain organoid", "ANATOMY", 122, 136], ["brain organoid infection", "DISEASE", 122, 146], ["patient", "ORGANISM", 11, 18], ["CSF", "GENE_OR_GENE_PRODUCT", 21, 24], ["SARS-CoV-2", "ORGANISM", 70, 80], ["brain organoid", "CANCER", 122, 136], ["patient", "SPECIES", 11, 18], ["SARS-CoV", "SPECIES", 70, 78], ["a neutralization assay", "TEST", 39, 61], ["SARS", "PROBLEM", 70, 74], ["brain organoid infection", "PROBLEM", 122, 146], ["brain", "ANATOMY", 122, 127], ["organoid", "ANATOMY_MODIFIER", 128, 136], ["infection", "OBSERVATION", 137, 146]]], ["CSF-containing antiviral antibodies blocked SARS-CoV-2 infection in organoids (Figure 3E and F, Figure S6D), highlighting the potential of SARS-CoV-2 neuroinvasion and subsequent immune response in the CNS.Mouse models of COVID-19 confirm the neuroinvasive potential of SARS-CoV-2 ::: ResultsIn order to examine the consequences of SARS-CoV-2 infection in a more physiologically complete system, we examined the neuroinvasive potential of SARS-CoV-2 in vivo by using transgenic mice expressing human ACE2 under the K18 promoter (K18-hACE2) (McCray et al., 2007).", [["organoids", "ANATOMY", 68, 77], ["CNS", "ANATOMY", 202, 205], ["infection", "DISEASE", 55, 64], ["SARS", "DISEASE", 270, 274], ["SARS", "DISEASE", 332, 336], ["infection", "DISEASE", 343, 352], ["CSF", "GENE_OR_GENE_PRODUCT", 0, 3], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["organoids", "CELL", 68, 77], ["SARS-CoV-2", "ORGANISM", 139, 149], ["CNS", "ANATOMICAL_SYSTEM", 202, 205], ["Mouse", "ORGANISM", 206, 211], ["SARS-CoV-2", "ORGANISM", 332, 342], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 439, 449], ["mice", "ORGANISM", 478, 482], ["human", "ORGANISM", 494, 499], ["ACE2", "GENE_OR_GENE_PRODUCT", 500, 504], ["K18", "GENE_OR_GENE_PRODUCT", 515, 518], ["K18", "GENE_OR_GENE_PRODUCT", 529, 532], ["CSF", "PROTEIN", 0, 3], ["antiviral antibodies", "PROTEIN", 15, 35], ["human ACE2", "PROTEIN", 494, 504], ["K18 promoter", "DNA", 515, 527], ["K18", "PROTEIN", 529, 532], ["hACE2", "DNA", 533, 538], ["Mouse", "SPECIES", 206, 211], ["mice", "SPECIES", 478, 482], ["human", "SPECIES", 494, 499], ["SARS-CoV-2", "SPECIES", 44, 54], ["SARS-CoV", "SPECIES", 139, 147], ["SARS-CoV", "SPECIES", 332, 340], ["SARS-CoV", "SPECIES", 439, 447], ["mice", "SPECIES", 478, 482], ["human", "SPECIES", 494, 499], ["CSF", "TEST", 0, 3], ["antiviral antibodies", "TEST", 15, 35], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["2 infection", "PROBLEM", 53, 64], ["SARS", "PROBLEM", 139, 143], ["CoV", "PROBLEM", 144, 147], ["neuroinvasion", "PROBLEM", 150, 163], ["COVID", "TEST", 222, 227], ["SARS", "PROBLEM", 270, 274], ["SARS", "PROBLEM", 332, 336], ["CoV-2 infection", "PROBLEM", 337, 352], ["SARS", "PROBLEM", 439, 443], ["CoV", "TEST", 444, 447], ["transgenic mice expressing human ACE2 under the K18 promoter", "TREATMENT", 467, 527], ["antiviral antibodies", "OBSERVATION", 15, 35], ["infection", "OBSERVATION", 55, 64], ["SARS", "OBSERVATION", 139, 143], ["immune response", "OBSERVATION", 179, 194], ["CNS", "ANATOMY", 202, 205], ["infection", "OBSERVATION", 343, 352]]], ["Similar to previous reports of SARS-CoV showing neurotropism (McCray et al., 2007; Netland et al., 2008), we observed increasing viral titers in the brain of mice after intranasal administration of SARS-CoV-2 (Figure 4A and B).", [["brain", "ANATOMY", 149, 154], ["SARS", "DISEASE", 31, 35], ["SARS-CoV", "ORGANISM", 31, 39], ["brain", "ORGAN", 149, 154], ["mice", "ORGANISM", 158, 162], ["B", "CELL", 224, 225], ["mice", "SPECIES", 158, 162], ["SARS-CoV", "SPECIES", 31, 39], ["mice", "SPECIES", 158, 162], ["SARS-CoV", "SPECIES", 198, 206], ["SARS", "PROBLEM", 31, 35], ["neurotropism", "PROBLEM", 48, 60], ["increasing viral titers", "PROBLEM", 118, 141], ["intranasal administration", "TREATMENT", 169, 194], ["SARS", "PROBLEM", 198, 202], ["CoV", "TEST", 203, 206], ["increasing", "OBSERVATION_MODIFIER", 118, 128], ["viral titers", "OBSERVATION", 129, 141], ["brain", "ANATOMY", 149, 154]]], ["We next analyzed the distribution of the virus in the whole brain by immunolabeling against the nucleocapsid protein, clearing and light sheet microscopy imaging using iDISCO+ (Renier et al., 2014) (Figure 4, Supplementary Movie 1).", [["brain", "ANATOMY", 60, 65], ["brain", "ORGAN", 60, 65], ["nucleocapsid protein", "PROTEIN", 96, 116], ["the virus in the whole brain", "PROBLEM", 37, 65], ["the nucleocapsid protein", "TEST", 92, 116], ["light sheet microscopy imaging", "TEST", 131, 161], ["virus", "OBSERVATION", 41, 46], ["whole brain", "ANATOMY", 54, 65]]], ["At 7 days after infection, the virus was widely present in neural cells throughout the forebrain (Figure 4C).", [["neural cells", "ANATOMY", 59, 71], ["forebrain", "ANATOMY", 87, 96], ["infection", "DISEASE", 16, 25], ["neural cells", "CELL", 59, 71], ["forebrain", "ORGAN", 87, 96], ["neural cells", "CELL_TYPE", 59, 71], ["infection", "PROBLEM", 16, 25], ["the virus", "PROBLEM", 27, 36], ["infection", "OBSERVATION", 16, 25], ["neural cells", "OBSERVATION", 59, 71], ["forebrain", "ANATOMY", 87, 96]]], ["The cortex was unevenly infected, as the infected cells were visible in columnar patches and in sensory regions, while the layer 4 was mostly devoid of infection (Figure 4C and D).", [["cortex", "ANATOMY", 4, 10], ["cells", "ANATOMY", 50, 55], ["columnar patches", "ANATOMY", 72, 88], ["sensory regions", "ANATOMY", 96, 111], ["layer 4", "ANATOMY", 123, 130], ["infection", "DISEASE", 152, 161], ["cortex", "CANCER", 4, 10], ["cells", "CELL", 50, 55], ["infected cells", "CELL_TYPE", 41, 55], ["unevenly infected", "PROBLEM", 15, 32], ["the infected cells", "PROBLEM", 37, 55], ["infection", "PROBLEM", 152, 161], ["cortex", "ANATOMY", 4, 10], ["unevenly", "OBSERVATION_MODIFIER", 15, 23], ["infected", "OBSERVATION", 24, 32], ["infected cells", "OBSERVATION", 41, 55], ["visible", "OBSERVATION_MODIFIER", 61, 68], ["columnar patches", "OBSERVATION", 72, 88], ["sensory", "ANATOMY_MODIFIER", 96, 103], ["regions", "ANATOMY_MODIFIER", 104, 111], ["layer", "OBSERVATION_MODIFIER", 123, 128], ["infection", "OBSERVATION", 152, 161]]], ["We mapped the density of infected cells using ClearMap (Renier et al., 2016) and confirmed that most brain regions contained high density of infected cells, to the notable exception of the cerebellum (Figure 4E).", [["cells", "ANATOMY", 34, 39], ["brain", "ANATOMY", 101, 106], ["cells", "ANATOMY", 150, 155], ["cerebellum", "ANATOMY", 189, 199], ["cells", "CELL", 34, 39], ["brain", "ORGAN", 101, 106], ["cells", "CELL", 150, 155], ["cerebellum", "ORGAN", 189, 199], ["infected cells", "CELL_TYPE", 25, 39], ["infected cells", "CELL_TYPE", 141, 155], ["infected cells", "PROBLEM", 25, 39], ["high density of infected cells", "PROBLEM", 125, 155], ["density", "OBSERVATION_MODIFIER", 14, 21], ["infected cells", "OBSERVATION", 25, 39], ["brain", "ANATOMY", 101, 106], ["high density", "OBSERVATION", 125, 137], ["infected cells", "OBSERVATION", 141, 155], ["notable", "OBSERVATION_MODIFIER", 164, 171], ["cerebellum", "ANATOMY", 189, 199]]], ["Other regions also contained relatively low density of infected cells, for instance the dentate gyrus, the globus pallidus and cortical layer 4.", [["cells", "ANATOMY", 64, 69], ["dentate gyrus", "ANATOMY", 88, 101], ["globus pallidus", "ANATOMY", 107, 122], ["cortical layer", "ANATOMY", 127, 141], ["cells", "CELL", 64, 69], ["dentate gyrus", "MULTI-TISSUE_STRUCTURE", 88, 101], ["globus pallidus", "MULTI-TISSUE_STRUCTURE", 107, 122], ["infected cells", "CELL_TYPE", 55, 69], ["relatively low density of infected cells", "PROBLEM", 29, 69], ["relatively", "OBSERVATION_MODIFIER", 29, 39], ["low density", "OBSERVATION_MODIFIER", 40, 51], ["infected cells", "OBSERVATION", 55, 69], ["dentate gyrus", "ANATOMY", 88, 101], ["globus pallidus", "ANATOMY", 107, 122], ["cortical", "ANATOMY_MODIFIER", 127, 135], ["layer", "ANATOMY_MODIFIER", 136, 141]]], ["Of note, the whole brain analysis of the virus distribution didn\u2019t detect the presence of the virus in the vascular endothelium.", [["brain", "ANATOMY", 19, 24], ["vascular endothelium", "ANATOMY", 107, 127], ["brain", "ORGAN", 19, 24], ["vascular endothelium", "TISSUE", 107, 127], ["the whole brain analysis", "TEST", 9, 33], ["the virus distribution", "PROBLEM", 37, 59], ["the virus in the vascular endothelium", "PROBLEM", 90, 127], ["virus", "OBSERVATION", 94, 99], ["vascular endothelium", "ANATOMY", 107, 127]]], ["To explore the possibility that the viral expression by neural cells could indirectly affect the organization of the vascular network, we double labeled brains for the nucleocapsid protein and the vascular endothelium with CD31 and Podocalyxin, and used again ClearMap to reconstruct the whole brain vascular network 7 days after infection (Figure 4F) (Kirst et al. Cell 2020).", [["neural cells", "ANATOMY", 56, 68], ["vascular network", "ANATOMY", 117, 133], ["brains", "ANATOMY", 153, 159], ["vascular endothelium", "ANATOMY", 197, 217], ["brain vascular network", "ANATOMY", 294, 316], ["Cell", "ANATOMY", 366, 370], ["infection", "DISEASE", 330, 339], ["neural cells", "CELL", 56, 68], ["vascular network", "MULTI-TISSUE_STRUCTURE", 117, 133], ["brains", "ORGAN", 153, 159], ["vascular endothelium", "TISSUE", 197, 217], ["CD31", "GENE_OR_GENE_PRODUCT", 223, 227], ["Podocalyxin", "GENE_OR_GENE_PRODUCT", 232, 243], ["brain vascular network", "MULTI-TISSUE_STRUCTURE", 294, 316], ["Cell", "CELL", 366, 370], ["neural cells", "CELL_TYPE", 56, 68], ["nucleocapsid protein", "PROTEIN", 168, 188], ["CD31", "PROTEIN", 223, 227], ["Podocalyxin", "PROTEIN", 232, 243], ["ClearMap", "PROTEIN", 260, 268], ["the viral expression by neural cells", "PROBLEM", 32, 68], ["the nucleocapsid protein", "TEST", 164, 188], ["Podocalyxin", "TREATMENT", 232, 243], ["ClearMap", "TREATMENT", 260, 268], ["infection", "PROBLEM", 330, 339], ["neural cells", "OBSERVATION", 56, 68], ["vascular", "ANATOMY", 117, 125], ["vascular endothelium", "ANATOMY", 197, 217], ["vascular", "ANATOMY", 300, 308]]], ["We focused on the organization of the cortical vasculature.", [["cortical vasculature", "ANATOMY", 38, 58], ["cortical vasculature", "MULTI-TISSUE_STRUCTURE", 38, 58], ["cortical", "ANATOMY_MODIFIER", 38, 46], ["vasculature", "ANATOMY", 47, 58]]], ["In infected brains, we focused on hot spots of infections represented as the number of detected infected cells and measured the density and orientation of all blood vessels.", [["brains", "ANATOMY", 12, 18], ["cells", "ANATOMY", 105, 110], ["blood vessels", "ANATOMY", 159, 172], ["infections", "DISEASE", 47, 57], ["brains", "ORGAN", 12, 18], ["cells", "CELL", 105, 110], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 159, 172], ["infected cells", "CELL_TYPE", 96, 110], ["infected brains", "PROBLEM", 3, 18], ["hot spots of infections", "PROBLEM", 34, 57], ["infected cells", "PROBLEM", 96, 110], ["infected", "OBSERVATION", 3, 11], ["brains", "ANATOMY", 12, 18], ["infections", "OBSERVATION", 47, 57], ["infected cells", "OBSERVATION", 96, 110], ["density", "OBSERVATION", 128, 135], ["all", "ANATOMY_MODIFIER", 155, 158], ["blood vessels", "ANATOMY", 159, 172]]], ["In many instances, the expression of the virus coincided with a disruption in the normal vascular topology expected in the cortex, with an important loss of the normal enrichment in radially oriented vessels in upper layers.", [["vascular", "ANATOMY", 89, 97], ["cortex", "ANATOMY", 123, 129], ["vessels", "ANATOMY", 200, 207], ["upper layers", "ANATOMY", 211, 223], ["vascular", "MULTI-TISSUE_STRUCTURE", 89, 97], ["cortex", "CANCER", 123, 129], ["vessels", "MULTI-TISSUE_STRUCTURE", 200, 207], ["upper layers", "TISSUE", 211, 223], ["the virus", "PROBLEM", 37, 46], ["a disruption", "PROBLEM", 62, 74], ["virus", "OBSERVATION", 41, 46], ["normal", "OBSERVATION", 82, 88], ["vascular topology", "ANATOMY", 89, 106], ["cortex", "ANATOMY_MODIFIER", 123, 129], ["important", "OBSERVATION_MODIFIER", 139, 148], ["loss", "OBSERVATION_MODIFIER", 149, 153], ["normal", "OBSERVATION_MODIFIER", 161, 167], ["enrichment", "OBSERVATION_MODIFIER", 168, 178], ["radially", "OBSERVATION_MODIFIER", 182, 190], ["oriented", "OBSERVATION_MODIFIER", 191, 199], ["vessels", "ANATOMY", 200, 207], ["upper", "ANATOMY_MODIFIER", 211, 216], ["layers", "ANATOMY_MODIFIER", 217, 223]]], ["This analysis suggests that an important vascular remodeling accompanies the expression of the virus by neural cells, presumably reorienting the normal blood flow towards metabolically active hot spots.Mouse models of COVID-19 confirm the neuroinvasive potential of SARS-CoV-2 ::: ResultsTo dissect the consequences of SARS-CoV-2 infection in the CNS versus the respiratory system, we directed expression of human ACE2 using an adeno-associated virus vector (AAV-hACE2) (Israelow et al., 2020) to the lungs via intratracheal (IT) delivery or to the brain via intracisternal (IC) delivery (Figure 4H).", [["vascular", "ANATOMY", 41, 49], ["neural cells", "ANATOMY", 104, 116], ["blood", "ANATOMY", 152, 157], ["CNS", "ANATOMY", 347, 350], ["respiratory system", "ANATOMY", 362, 380], ["lungs", "ANATOMY", 501, 506], ["brain", "ANATOMY", 549, 554], ["SARS", "DISEASE", 266, 270], ["infection", "DISEASE", 330, 339], ["COVID-19", "CHEMICAL", 218, 226], ["vascular", "MULTI-TISSUE_STRUCTURE", 41, 49], ["neural cells", "CELL", 104, 116], ["blood", "ORGANISM_SUBSTANCE", 152, 157], ["Mouse", "ORGANISM", 202, 207], ["COVID-19", "CELL", 218, 226], ["SARS-CoV-2", "ORGANISM", 319, 329], ["CNS", "ANATOMICAL_SYSTEM", 347, 350], ["human", "ORGANISM", 408, 413], ["ACE2", "GENE_OR_GENE_PRODUCT", 414, 418], ["adeno-associated virus", "ORGANISM", 428, 450], ["AAV", "ORGANISM", 459, 462], ["-hACE2", "ORGANISM", 462, 468], ["lungs", "ORGAN", 501, 506], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 511, 524], ["brain", "ORGAN", 549, 554], ["intracisternal", "IMMATERIAL_ANATOMICAL_ENTITY", 559, 573], ["neural cells", "CELL_TYPE", 104, 116], ["human ACE2", "PROTEIN", 408, 418], ["Mouse", "SPECIES", 202, 207], ["human", "SPECIES", 408, 413], ["human", "SPECIES", 408, 413], ["This analysis", "TEST", 0, 13], ["an important vascular remodeling", "PROBLEM", 28, 60], ["the virus by neural cells", "PROBLEM", 91, 116], ["COVID", "TEST", 218, 223], ["SARS", "PROBLEM", 266, 270], ["SARS", "PROBLEM", 319, 323], ["CoV", "PROBLEM", 324, 327], ["2 infection", "PROBLEM", 328, 339], ["human ACE2", "TREATMENT", 408, 418], ["an adeno-associated virus vector", "TREATMENT", 425, 457], ["intratracheal (IT) delivery", "TREATMENT", 511, 538], ["intracisternal (IC) delivery", "TREATMENT", 559, 587], ["vascular", "ANATOMY", 41, 49], ["remodeling", "OBSERVATION", 50, 60], ["virus", "OBSERVATION", 95, 100], ["neural cells", "OBSERVATION", 104, 116], ["normal blood flow", "OBSERVATION", 145, 162], ["active", "OBSERVATION_MODIFIER", 185, 191], ["hot spots", "OBSERVATION", 192, 201], ["infection", "OBSERVATION", 330, 339], ["CNS", "ANATOMY", 347, 350], ["respiratory system", "ANATOMY", 362, 380], ["lungs", "ANATOMY", 501, 506], ["intratracheal", "ANATOMY", 511, 524], ["brain", "ANATOMY", 549, 554]]], ["Then, the mice were infected with SARS-CoV-2 respectively, either intranasally or intraventricularly.", [["intranasally", "ANATOMY", 66, 78], ["mice", "ORGANISM", 10, 14], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["SARS-CoV-2", "SPECIES", 34, 44], ["infected", "OBSERVATION", 20, 28]]], ["Intranasally infected mice showed signs of lung pathology (Israelow et al., 2020) but no weight loss or death (Figure 4I and J).", [["lung", "ANATOMY", 43, 47], ["weight loss", "DISEASE", 89, 100], ["death", "DISEASE", 104, 109], ["mice", "ORGANISM", 22, 26], ["lung", "ORGAN", 43, 47], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["lung pathology", "PROBLEM", 43, 57], ["weight loss", "PROBLEM", 89, 100], ["death", "PROBLEM", 104, 109], ["lung", "ANATOMY", 43, 47], ["pathology", "OBSERVATION", 48, 57], ["no", "UNCERTAINTY", 86, 88]]], ["However, intraventricular administration of SARS-CoV-2 resulted in significant weight loss and death, even at the challenge virus dose 100-fold lower than that used for intranasal infection (Figure 4I and J).", [["intraventricular", "ANATOMY", 9, 25], ["SARS-CoV-2", "CHEMICAL", 44, 54], ["weight loss", "DISEASE", 79, 90], ["death", "DISEASE", 95, 100], ["infection", "DISEASE", 180, 189], ["intraventricular", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 25], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["SARS", "PROBLEM", 44, 48], ["significant weight loss", "PROBLEM", 67, 90], ["death", "PROBLEM", 95, 100], ["the challenge virus dose", "TREATMENT", 110, 134], ["intranasal infection", "PROBLEM", 169, 189], ["intraventricular", "ANATOMY_MODIFIER", 9, 25], ["significant", "OBSERVATION_MODIFIER", 67, 78], ["weight loss", "OBSERVATION", 79, 90], ["infection", "OBSERVATION", 180, 189]]], ["Altogether, this highlights the neuro-replicative potential and lethal consequences of SARS-CoV-2 CNS infection in mice.Evidence of SARS-CoV-2 neuroinvasion in COVID-19 patient brain autopsies ::: ResultsFinally, to determine whether there is evidence of SARS-CoV-2 CNS infection in COVID-19 patient, we examined paraffin embedded formalin fixed sections of three patients who died after suffering from severe COVID-19-related complications.", [["brain", "ANATOMY", 177, 182], ["CNS", "ANATOMY", 266, 269], ["sections", "ANATOMY", 346, 354], ["SARS", "DISEASE", 87, 91], ["infection", "DISEASE", 102, 111], ["infection", "DISEASE", 270, 279], ["paraffin", "CHEMICAL", 313, 321], ["formalin", "CHEMICAL", 331, 339], ["SARS-CoV-2 CNS", "ORGANISM", 87, 101], ["mice", "ORGANISM", 115, 119], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 132, 142], ["COVID", "CANCER", 160, 165], ["patient", "ORGANISM", 169, 176], ["brain", "ORGAN", 177, 182], ["SARS-CoV-2 CNS", "ORGANISM", 255, 269], ["patient", "ORGANISM", 292, 299], ["patients", "ORGANISM", 364, 372], ["mice", "SPECIES", 115, 119], ["patient", "SPECIES", 169, 176], ["patient", "SPECIES", 292, 299], ["patients", "SPECIES", 364, 372], ["SARS-CoV", "SPECIES", 87, 95], ["mice", "SPECIES", 115, 119], ["SARS-CoV", "SPECIES", 132, 140], ["SARS-CoV", "SPECIES", 255, 263], ["SARS", "PROBLEM", 87, 91], ["CoV", "PROBLEM", 92, 95], ["CNS infection", "PROBLEM", 98, 111], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["neuroinvasion", "PROBLEM", 143, 156], ["COVID", "TEST", 160, 165], ["SARS", "PROBLEM", 255, 259], ["CoV", "TEST", 260, 263], ["2 CNS infection", "PROBLEM", 264, 279], ["severe COVID-19-related complications", "PROBLEM", 403, 440], ["CNS", "ANATOMY", 98, 101], ["infection", "OBSERVATION", 102, 111], ["SARS", "OBSERVATION", 132, 136], ["brain", "ANATOMY", 177, 182], ["evidence of", "UNCERTAINTY", 243, 254], ["SARS", "OBSERVATION", 255, 259], ["CNS", "ANATOMY", 266, 269], ["infection", "OBSERVATION", 270, 279]]], ["All patients had been admitted to the ICU, they were sedated and ventilated due to respiratory failure (days 3, 10 and 18; patient 3, 1 and 2 respectively), and their difficulty to be weaned from mechanical ventilation indicated the severity and highly pathogenic nature of the disease course (Supplementary Table 1).", [["respiratory", "ANATOMY", 83, 94], ["respiratory failure", "DISEASE", 83, 102], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 123, 130], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 123, 130], ["sedated", "TREATMENT", 53, 60], ["ventilated", "TREATMENT", 65, 75], ["respiratory failure", "PROBLEM", 83, 102], ["mechanical ventilation", "TREATMENT", 196, 218], ["the severity", "PROBLEM", 229, 241], ["respiratory", "ANATOMY", 83, 94], ["failure", "OBSERVATION", 95, 102]]], ["We sampled several regions of the brain and stained for both, Hematoxylin and Eosin (H&E) and for SARS-CoV-2 spike protein with a validated protocol and antibody we have used previously (Hosier et al., 2020).", [["brain", "ANATOMY", 34, 39], ["Hematoxylin", "CHEMICAL", 62, 73], ["Eosin", "CHEMICAL", 78, 83], ["brain", "ORGAN", 34, 39], ["Hematoxylin", "SIMPLE_CHEMICAL", 62, 73], ["Eosin", "GENE_OR_GENE_PRODUCT", 78, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["SARS-CoV-2 spike protein", "PROTEIN", 98, 122], ["SARS-CoV", "SPECIES", 98, 106], ["Hematoxylin", "TREATMENT", 62, 73], ["Eosin", "TREATMENT", 78, 83], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["a validated protocol", "TEST", 128, 148], ["antibody", "TREATMENT", 153, 161], ["brain", "ANATOMY", 34, 39]]], ["While in control slides there was no positive immunohistochemical staining for the SARS-CoV-2 spike protein, samples from COVID-19 patients showed distinct, and specific spike protein staining, albeit to different degrees (Figure 5, Figure S7).", [["samples", "ANATOMY", 109, 116], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["samples", "CANCER", 109, 116], ["patients", "ORGANISM", 131, 139], ["SARS-CoV-2 spike protein", "PROTEIN", 83, 107], ["patients", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 83, 91], ["positive immunohistochemical staining", "PROBLEM", 37, 74], ["the SARS", "TEST", 79, 87], ["CoV", "TEST", 88, 91], ["spike protein", "TEST", 94, 107], ["samples", "TEST", 109, 116], ["COVID", "TEST", 122, 127], ["specific spike protein staining", "PROBLEM", 161, 192], ["Figure", "TEST", 223, 229], ["no", "UNCERTAINTY", 34, 36]]], ["Neuropathological evaluations identified staining with anti-spike antibodies in cortical neurons (Figure 5A, B upper panel, D black arrows) along with signal in endothelial cells (Figure 5B lower panel) in patient 1 medium spiny neurons in the basal ganglia, however, did not show staining, similar to substantia nigra neurons in the midbrain which were also negative for the SARS-CoV-2 spike protein (Figure S8).", [["cortical neurons", "ANATOMY", 80, 96], ["endothelial cells", "ANATOMY", 161, 178], ["spiny neurons", "ANATOMY", 223, 236], ["basal ganglia", "ANATOMY", 244, 257], ["substantia nigra neurons", "ANATOMY", 302, 326], ["midbrain", "ANATOMY", 334, 342], ["cortical neurons", "CELL", 80, 96], ["endothelial cells", "CELL", 161, 178], ["patient", "ORGANISM", 206, 213], ["spiny neurons", "CELL", 223, 236], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 244, 257], ["substantia nigra neurons", "CELL", 302, 326], ["midbrain", "ORGAN", 334, 342], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 376, 386], ["Figure S8", "GENE_OR_GENE_PRODUCT", 402, 411], ["anti-spike antibodies", "PROTEIN", 55, 76], ["cortical neurons", "CELL_TYPE", 80, 96], ["endothelial cells", "CELL_TYPE", 161, 178], ["substantia nigra neurons", "CELL_TYPE", 302, 326], ["SARS-CoV-2 spike protein", "PROTEIN", 376, 400], ["Figure S8", "PROTEIN", 402, 411], ["patient", "SPECIES", 206, 213], ["Neuropathological evaluations", "TEST", 0, 29], ["staining", "TEST", 41, 49], ["anti-spike antibodies in cortical neurons", "PROBLEM", 55, 96], ["Figure 5A", "TEST", 98, 107], ["B upper panel", "TEST", 109, 122], ["D black arrows", "PROBLEM", 124, 138], ["signal in endothelial cells", "PROBLEM", 151, 178], ["Figure 5B lower panel", "TEST", 180, 201], ["staining", "PROBLEM", 281, 289], ["substantia nigra neurons in the midbrain", "PROBLEM", 302, 342], ["the SARS", "TEST", 372, 380], ["CoV", "TEST", 381, 384], ["cortical neurons", "ANATOMY", 80, 96], ["endothelial cells", "ANATOMY", 161, 178], ["basal ganglia", "ANATOMY", 244, 257], ["midbrain", "ANATOMY", 334, 342]]], ["The cellular staining pattern showed diffuse cytoplasmic and perinuclear staining, along with concentrated regions within the cells\u2014consistent with our findings using electron microscopy in the organoids, which demonstrated localized hotspots within the infected cell.", [["cellular", "ANATOMY", 4, 12], ["cytoplasmic", "ANATOMY", 45, 56], ["perinuclear", "ANATOMY", 61, 72], ["cells", "ANATOMY", 126, 131], ["organoids", "ANATOMY", 194, 203], ["cell", "ANATOMY", 263, 267], ["cellular", "CELL", 4, 12], ["cytoplasmic", "ORGANISM_SUBSTANCE", 45, 56], ["perinuclear", "ORGANISM_SUBSTANCE", 61, 72], ["cells", "CELL", 126, 131], ["organoids", "CELL", 194, 203], ["cell", "CELL", 263, 267], ["infected cell", "CELL_TYPE", 254, 267], ["The cellular staining pattern", "TEST", 0, 29], ["diffuse cytoplasmic and perinuclear staining", "PROBLEM", 37, 81], ["electron microscopy", "TEST", 167, 186], ["localized hotspots within the infected cell", "PROBLEM", 224, 267], ["cellular staining", "OBSERVATION", 4, 21], ["diffuse", "OBSERVATION_MODIFIER", 37, 44], ["cytoplasmic", "OBSERVATION_MODIFIER", 45, 56], ["perinuclear staining", "OBSERVATION", 61, 81], ["cells", "ANATOMY", 126, 131], ["consistent with", "UNCERTAINTY", 132, 147], ["infected cell", "OBSERVATION", 254, 267]]], ["Patient 3, who failed to regain consciousness after cessation of sedation, was diagnosed with severe global encephalopathy and was noted with multiple diffuse micro bleeds as demonstrated by diagnostic imaging (MRI).", [["encephalopathy", "DISEASE", 108, 122], ["micro bleeds", "DISEASE", 159, 171], ["Patient", "SPECIES", 0, 7], ["sedation", "TREATMENT", 65, 73], ["severe global encephalopathy", "PROBLEM", 94, 122], ["multiple diffuse micro bleeds", "PROBLEM", 142, 171], ["diagnostic imaging", "TEST", 191, 209], ["MRI", "TEST", 211, 214], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["global", "OBSERVATION_MODIFIER", 101, 107], ["encephalopathy", "OBSERVATION", 108, 122], ["multiple", "OBSERVATION_MODIFIER", 142, 150], ["diffuse", "OBSERVATION_MODIFIER", 151, 158], ["micro bleeds", "OBSERVATION", 159, 171]]], ["Upon histologic examination, we found multiple microscopic ischemic infarcts in the subcortical white matter, ranging from acute to subacute, and with focal hemorrhagic conversion (Figure 5C, Figure S9A).", [["subcortical white matter", "ANATOMY", 84, 108], ["ischemic infarcts", "DISEASE", 59, 76], ["hemorrhagic", "DISEASE", 157, 168], ["histologic examination", "TEST", 5, 27], ["multiple microscopic ischemic infarcts in the subcortical white matter", "PROBLEM", 38, 108], ["focal hemorrhagic conversion", "PROBLEM", 151, 179], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["microscopic", "OBSERVATION_MODIFIER", 47, 58], ["ischemic", "OBSERVATION_MODIFIER", 59, 67], ["infarcts", "OBSERVATION", 68, 76], ["subcortical", "ANATOMY_MODIFIER", 84, 95], ["white matter", "ANATOMY", 96, 108], ["ranging", "OBSERVATION_MODIFIER", 110, 117], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["subacute", "OBSERVATION_MODIFIER", 132, 140], ["focal", "OBSERVATION_MODIFIER", 151, 156], ["hemorrhagic", "OBSERVATION_MODIFIER", 157, 168]]], ["These varying stages of infarction indicated a temporal sequence of continued ischemic events.", [["infarction", "DISEASE", 24, 34], ["infarction", "PROBLEM", 24, 34], ["continued ischemic events", "PROBLEM", 68, 93], ["varying", "OBSERVATION_MODIFIER", 6, 13], ["infarction", "OBSERVATION", 24, 34], ["temporal", "OBSERVATION_MODIFIER", 47, 55], ["ischemic", "OBSERVATION", 78, 86]]], ["Most infarcts showed signs of tissue damage and localized cell death, and positive viral staining was present predominately around the edges of the infarct and to a lesser degree within the center.", [["infarcts", "ANATOMY", 5, 13], ["tissue", "ANATOMY", 30, 36], ["cell", "ANATOMY", 58, 62], ["infarcts", "DISEASE", 5, 13], ["tissue damage", "DISEASE", 30, 43], ["death", "DISEASE", 63, 68], ["infarct", "DISEASE", 148, 155], ["tissue", "TISSUE", 30, 36], ["cell", "CELL", 58, 62], ["Most infarcts", "PROBLEM", 0, 13], ["tissue damage", "PROBLEM", 30, 43], ["localized cell death", "PROBLEM", 48, 68], ["positive viral staining", "PROBLEM", 74, 97], ["the infarct", "PROBLEM", 144, 155], ["infarcts", "OBSERVATION", 5, 13], ["signs of", "UNCERTAINTY", 21, 29], ["tissue", "ANATOMY", 30, 36], ["damage", "OBSERVATION", 37, 43], ["localized", "OBSERVATION_MODIFIER", 48, 57], ["cell death", "OBSERVATION", 58, 68], ["positive", "OBSERVATION_MODIFIER", 74, 82], ["viral staining", "OBSERVATION", 83, 97], ["edges", "OBSERVATION_MODIFIER", 135, 140], ["infarct", "OBSERVATION", 148, 155], ["lesser degree", "OBSERVATION_MODIFIER", 165, 178]]], ["At the hyperacute stage of infarction, viral proteins were present in endothelium.", [["endothelium", "ANATOMY", 70, 81], ["infarction", "DISEASE", 27, 37], ["endothelium", "TISSUE", 70, 81], ["viral proteins", "PROTEIN", 39, 53], ["infarction", "PROBLEM", 27, 37], ["viral proteins", "PROBLEM", 39, 53], ["hyperacute", "OBSERVATION_MODIFIER", 7, 17], ["stage", "OBSERVATION_MODIFIER", 18, 23], ["infarction", "OBSERVATION", 27, 37], ["viral proteins", "OBSERVATION", 39, 53], ["endothelium", "ANATOMY", 70, 81]]], ["These infarcts are present predominately in subcortical white matter, not within the cortex.", [["infarcts", "ANATOMY", 6, 14], ["subcortical white matter", "ANATOMY", 44, 68], ["cortex", "ANATOMY", 85, 91], ["infarcts", "DISEASE", 6, 14], ["subcortical white matter", "CANCER", 44, 68], ["cortex", "CANCER", 85, 91], ["These infarcts", "PROBLEM", 0, 14], ["infarcts", "OBSERVATION", 6, 14], ["predominately", "OBSERVATION_MODIFIER", 27, 40], ["subcortical", "ANATOMY_MODIFIER", 44, 55], ["white matter", "ANATOMY", 56, 68], ["cortex", "ANATOMY_MODIFIER", 85, 91]]], ["In other samples, we found suspected viral staining in locally ischemic regions (Figure 5D, Figure S9B and C).", [["samples", "ANATOMY", 9, 16], ["viral staining in locally ischemic regions", "PROBLEM", 37, 79], ["viral staining", "OBSERVATION", 37, 51], ["locally", "OBSERVATION_MODIFIER", 55, 62], ["ischemic", "OBSERVATION_MODIFIER", 63, 71]]], ["Remarkably, all the regions of positive viral staining showed no lymphocyte or leukocyte infiltration.", [["lymphocyte", "ANATOMY", 65, 75], ["leukocyte", "ANATOMY", 79, 88], ["lymphocyte", "CELL", 65, 75], ["leukocyte", "CELL", 79, 88], ["positive viral staining", "PROBLEM", 31, 54], ["lymphocyte", "PROBLEM", 65, 75], ["leukocyte infiltration", "PROBLEM", 79, 101], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["viral staining", "OBSERVATION", 40, 54], ["no", "UNCERTAINTY", 62, 64], ["lymphocyte", "OBSERVATION", 65, 75], ["leukocyte infiltration", "OBSERVATION", 79, 101]]], ["This is in contrast to other neurotropic viruses\u2014Zika virus, rabies virus, herpes virus\u2014 in which the infection is typically accompanied by large number of immune cell infiltrates, including T cells.", [["immune cell infiltrates", "ANATOMY", 156, 179], ["T cells", "ANATOMY", 191, 198], ["rabies virus", "DISEASE", 61, 73], ["herpes virus\u2014", "DISEASE", 75, 88], ["infection", "DISEASE", 102, 111], ["Zika virus", "ORGANISM", 49, 59], ["rabies virus", "ORGANISM", 61, 73], ["herpes virus\u2014", "ORGANISM", 75, 88], ["immune cell", "CELL", 156, 167], ["T cells", "CELL", 191, 198], ["immune cell infiltrates", "CELL_TYPE", 156, 179], ["T cells", "CELL_TYPE", 191, 198], ["Zika virus", "SPECIES", 49, 59], ["rabies virus", "SPECIES", 61, 73], ["Zika virus", "SPECIES", 49, 59], ["rabies virus", "SPECIES", 61, 73], ["Zika virus", "PROBLEM", 49, 59], ["rabies virus", "PROBLEM", 61, 73], ["herpes virus\u2014", "PROBLEM", 75, 88], ["the infection", "PROBLEM", 98, 111], ["immune cell infiltrates", "PROBLEM", 156, 179], ["T cells", "PROBLEM", 191, 198], ["infection", "OBSERVATION", 102, 111], ["large", "OBSERVATION_MODIFIER", 140, 145], ["number", "OBSERVATION_MODIFIER", 146, 152], ["immune cell infiltrates", "OBSERVATION", 156, 179]]], ["These findings suggest that, although SARS-CoV-2 has neurotropic properties and can infect neurons in patients, it did not invoke an immune response typical of other neurotropic virus in this particular case.DiscussionWe examined the potential for SARS-CoV-2 to infect neural tissues of both mice and human origin and demonstrate potential consequences of its neuroinvasion.", [["neurons", "ANATOMY", 91, 98], ["neural tissues", "ANATOMY", 269, 283], ["SARS", "DISEASE", 38, 42], ["SARS-CoV-2", "ORGANISM", 38, 48], ["neurons", "CELL", 91, 98], ["patients", "ORGANISM", 102, 110], ["neurotropic virus", "ORGANISM", 166, 183], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 248, 258], ["neural tissues", "TISSUE", 269, 283], ["mice", "ORGANISM", 292, 296], ["human", "ORGANISM", 301, 306], ["patients", "SPECIES", 102, 110], ["mice", "SPECIES", 292, 296], ["human", "SPECIES", 301, 306], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 248, 256], ["mice", "SPECIES", 292, 296], ["human", "SPECIES", 301, 306], ["SARS", "TEST", 38, 42], ["neurotropic properties", "TREATMENT", 53, 75], ["other neurotropic virus", "PROBLEM", 160, 183], ["SARS", "PROBLEM", 248, 252], ["CoV", "TEST", 253, 256], ["its neuroinvasion", "PROBLEM", 356, 373], ["neurotropic virus", "OBSERVATION", 166, 183], ["neural tissues", "ANATOMY", 269, 283], ["neuroinvasion", "OBSERVATION", 360, 373]]], ["Our results suggest that neurologic symptoms associated with COVID-19 may be related to consequences of direct viral invasion of the CNS.", [["neurologic", "ANATOMY", 25, 35], ["CNS", "ANATOMY", 133, 136], ["neurologic symptoms", "DISEASE", 25, 44], ["COVID-19", "CHEMICAL", 61, 69], ["COVID-19", "CHEMICAL", 61, 69], ["COVID-19", "GENE_OR_GENE_PRODUCT", 61, 69], ["CNS", "ANATOMICAL_SYSTEM", 133, 136], ["neurologic symptoms", "PROBLEM", 25, 44], ["COVID", "TEST", 61, 66], ["direct viral invasion of the CNS", "PROBLEM", 104, 136], ["CNS", "ANATOMY", 133, 136]]], ["Specifically, our work experimentally demonstrates that the brain is a site for high replicative potential for SARS-CoV-2.", [["brain", "ANATOMY", 60, 65], ["brain", "ORGAN", 60, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["SARS-CoV", "SPECIES", 111, 119], ["SARS", "TEST", 111, 115], ["CoV", "TEST", 116, 119], ["brain", "ANATOMY", 60, 65]]], ["We further show that SARS-CoV-2 causes significant neuronal death in human brain organoids.", [["neuronal", "ANATOMY", 51, 59], ["brain organoids", "ANATOMY", 75, 90], ["SARS", "DISEASE", 21, 25], ["neuronal death", "DISEASE", 51, 65], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 21, 31], ["neuronal", "CELL", 51, 59], ["human", "ORGANISM", 69, 74], ["brain organoids", "CELL", 75, 90], ["human brain organoids", "CELL_TYPE", 69, 90], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["significant neuronal death in human brain organoids", "PROBLEM", 39, 90], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["neuronal death", "OBSERVATION", 51, 65], ["human brain", "ANATOMY", 69, 80]]], ["Using electron microscopy, we identified viral particles budding from the endoplasmic reticulum, indicating the virus\u2019s ability to use the neuron cell machinery to replicate.", [["endoplasmic reticulum", "ANATOMY", 74, 95], ["neuron cell", "ANATOMY", 139, 150], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 74, 95], ["neuron cell", "CELL", 139, 150], ["electron microscopy", "TEST", 6, 25], ["viral particles budding", "PROBLEM", 41, 64], ["the virus", "PROBLEM", 108, 117], ["the neuron cell machinery", "TREATMENT", 135, 160], ["viral particles", "OBSERVATION", 41, 56], ["endoplasmic reticulum", "ANATOMY", 74, 95]]], ["Similar to neuronal loss observed in patient autopsies (Solomon et al., 2020), we noticed large numbers of cells dying in the organoid, however, this neuronal death did not colocalize directly with virus infection.", [["neuronal", "ANATOMY", 11, 19], ["cells", "ANATOMY", 107, 112], ["organoid", "ANATOMY", 126, 134], ["neuronal", "ANATOMY", 150, 158], ["neuronal loss", "DISEASE", 11, 24], ["neuronal death", "DISEASE", 150, 164], ["infection", "DISEASE", 204, 213], ["neuronal", "CELL", 11, 19], ["patient", "ORGANISM", 37, 44], ["cells", "CELL", 107, 112], ["organoid", "CELL", 126, 134], ["neuronal", "CELL", 150, 158], ["patient", "SPECIES", 37, 44], ["neuronal loss", "PROBLEM", 11, 24], ["large numbers of cells", "PROBLEM", 90, 112], ["this neuronal death", "PROBLEM", 145, 164], ["virus infection", "PROBLEM", 198, 213], ["neuronal loss", "OBSERVATION", 11, 24], ["large", "OBSERVATION_MODIFIER", 90, 95], ["numbers", "OBSERVATION_MODIFIER", 96, 103], ["cells", "OBSERVATION", 107, 112], ["organoid", "ANATOMY", 126, 134]]], ["Single-cell RNA sequencing of the infected organoids showed metabolic changes in neurons without interferon or ISG signatures, indicating the neuroinvasive consequence of SARS-CoV-2 is unique compared to other neurotropic viruses such as ZIKV.", [["organoids", "ANATOMY", 43, 52], ["neurons", "ANATOMY", 81, 88], ["SARS", "DISEASE", 171, 175], ["organoids", "CELL", 43, 52], ["neurons", "CELL", 81, 88], ["interferon", "GENE_OR_GENE_PRODUCT", 97, 107], ["ISG", "GENE_OR_GENE_PRODUCT", 111, 114], ["SARS-CoV-2", "ORGANISM", 171, 181], ["interferon", "PROTEIN", 97, 107], ["SARS-CoV", "SPECIES", 171, 179], ["ZIKV", "SPECIES", 238, 242], ["Single-cell RNA", "TEST", 0, 15], ["the infected organoids", "PROBLEM", 30, 52], ["metabolic changes in neurons", "PROBLEM", 60, 88], ["interferon or ISG signatures", "PROBLEM", 97, 125], ["SARS", "PROBLEM", 171, 175], ["ZIKV", "PROBLEM", 238, 242], ["infected organoids", "OBSERVATION", 34, 52], ["metabolic changes", "OBSERVATION", 60, 77], ["neurons", "ANATOMY", 81, 88], ["without", "UNCERTAINTY", 89, 96]]], ["Closer examination showed diverging metabolic changes in infected versus neighboring cells, suggesting that the infected cells can cause local changes to their microenvironment affecting survival of nearby cells.", [["cells", "ANATOMY", 85, 90], ["cells", "ANATOMY", 121, 126], ["cells", "ANATOMY", 206, 211], ["cells", "CELL", 85, 90], ["cells", "CELL", 121, 126], ["cells", "CELL", 206, 211], ["infected versus neighboring cells", "CELL_TYPE", 57, 90], ["infected cells", "CELL_TYPE", 112, 126], ["nearby cells", "CELL_TYPE", 199, 211], ["Closer examination", "TEST", 0, 18], ["diverging metabolic changes in infected versus neighboring cells", "PROBLEM", 26, 90], ["the infected cells", "PROBLEM", 108, 126], ["local changes", "PROBLEM", 137, 150], ["diverging", "OBSERVATION_MODIFIER", 26, 35], ["metabolic changes", "OBSERVATION", 36, 53], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["neighboring cells", "OBSERVATION", 73, 90], ["infected cells", "OBSERVATION", 112, 126], ["nearby cells", "OBSERVATION", 199, 211]]], ["It is possible that viral infection induces locally hypoxic regions which aids in lowering the threshold for tissue damage in the context of an already oxygen deprived state.DiscussionWhile ACE2 expression levels in the human brain are still being investigated, we showed that ACE2 is expressed at the protein level and is functionally required for SARS-CoV-2 infection in human brain organoids.", [["tissue", "ANATOMY", 109, 115], ["brain", "ANATOMY", 226, 231], ["brain organoids", "ANATOMY", 379, 394], ["viral infection", "DISEASE", 20, 35], ["oxygen", "CHEMICAL", 152, 158], ["oxygen", "CHEMICAL", 152, 158], ["tissue", "TISSUE", 109, 115], ["oxygen", "SIMPLE_CHEMICAL", 152, 158], ["ACE2", "GENE_OR_GENE_PRODUCT", 190, 194], ["human", "ORGANISM", 220, 225], ["brain", "ORGAN", 226, 231], ["ACE2", "GENE_OR_GENE_PRODUCT", 277, 281], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 349, 359], ["human", "ORGANISM", 373, 378], ["brain organoids", "CELL", 379, 394], ["ACE2", "PROTEIN", 190, 194], ["ACE2", "PROTEIN", 277, 281], ["human brain organoids", "CELL_TYPE", 373, 394], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 373, 378], ["viral infection", "PROBLEM", 20, 35], ["locally hypoxic regions", "PROBLEM", 44, 67], ["tissue damage", "PROBLEM", 109, 122], ["an already oxygen deprived state", "PROBLEM", 141, 173], ["ACE2 expression levels", "TEST", 190, 212], ["ACE2", "TEST", 277, 281], ["the protein level", "TEST", 298, 315], ["SARS", "PROBLEM", 349, 353], ["CoV", "TEST", 354, 357], ["2 infection in human brain organoids", "PROBLEM", 358, 394], ["possible that", "UNCERTAINTY", 6, 19], ["viral", "OBSERVATION_MODIFIER", 20, 25], ["infection", "OBSERVATION", 26, 35], ["locally", "OBSERVATION_MODIFIER", 44, 51], ["hypoxic", "OBSERVATION_MODIFIER", 52, 59], ["damage", "OBSERVATION", 116, 122], ["oxygen deprived", "OBSERVATION", 152, 167], ["human brain", "ANATOMY", 220, 231], ["infection", "OBSERVATION", 360, 369], ["human brain", "ANATOMY", 373, 384]]], ["Further, we detected robust antiviral antibody presence in the CSF of a COVID-19 patient, who presented with acute neurologic symptoms.", [["neurologic", "ANATOMY", 115, 125], ["acute neurologic symptoms", "DISEASE", 109, 134], ["CSF", "ORGANISM_SUBSTANCE", 63, 66], ["patient", "ORGANISM", 81, 88], ["antiviral antibody", "PROTEIN", 28, 46], ["patient", "SPECIES", 81, 88], ["robust antiviral antibody presence", "PROBLEM", 21, 55], ["acute neurologic symptoms", "PROBLEM", 109, 134], ["robust", "OBSERVATION_MODIFIER", 21, 27], ["antiviral antibody", "OBSERVATION", 28, 46], ["acute", "OBSERVATION_MODIFIER", 109, 114]]], ["This finding suggests that, at least in some patients with COVID-19 and neurological symptoms, there is robust antibody response against the virus within the CSF.", [["neurological", "ANATOMY", 72, 84], ["neurological symptoms", "DISEASE", 72, 93], ["patients", "ORGANISM", 45, 53], ["CSF", "GENE_OR_GENE_PRODUCT", 158, 161], ["patients", "SPECIES", 45, 53], ["COVID", "TEST", 59, 64], ["neurological symptoms", "PROBLEM", 72, 93], ["robust antibody response", "PROBLEM", 104, 128], ["the virus", "PROBLEM", 137, 146], ["antibody response", "OBSERVATION", 111, 128], ["CSF", "ANATOMY", 158, 161]]], ["Although we did not find induction of ISGs in brain organoids, or leukocyte infiltration in the post-mortem COVID-19 brain tissues, the neuroinflammatory consequences of SARS-CoV-2 cannot be excluded given the amount of cell death we observed.", [["brain organoids", "ANATOMY", 46, 61], ["leukocyte", "ANATOMY", 66, 75], ["post-mortem COVID-19 brain tissues", "ANATOMY", 96, 130], ["cell", "ANATOMY", 220, 224], ["SARS", "DISEASE", 170, 174], ["death", "DISEASE", 225, 230], ["brain organoids", "CELL", 46, 61], ["leukocyte", "CELL", 66, 75], ["COVID-19 brain tissues", "TISSUE", 108, 130], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 170, 180], ["cell", "CELL", 220, 224], ["ISGs", "DNA", 38, 42], ["ISGs in brain organoids", "PROBLEM", 38, 61], ["leukocyte infiltration", "PROBLEM", 66, 88], ["the post-mortem COVID", "TEST", 92, 113], ["SARS", "PROBLEM", 170, 174], ["cell death", "PROBLEM", 220, 230], ["ISGs", "OBSERVATION", 38, 42], ["brain", "ANATOMY", 46, 51], ["organoids", "OBSERVATION", 52, 61], ["leukocyte infiltration", "OBSERVATION", 66, 88], ["brain tissues", "ANATOMY", 117, 130], ["neuroinflammatory", "OBSERVATION_MODIFIER", 136, 153], ["cell death", "OBSERVATION", 220, 230]]], ["In the in vivo setting of the CNS with vasculature and immune cells, neuronal death could have cascading downstream effects in causing and amplifying CNS inflammation.DiscussionAlthough our rodent model does not utilize the endogenous ACE2 expression, it has been previously reported that even mouse adapted SARS-CoV is still neurotropic in wild type mice and SARS-CoV-2 is neurotropic in mice with hACE2 expression from the endogenous locus (Roberts et al., 2007; Sun et al., 2020).", [["CNS", "ANATOMY", 30, 33], ["vasculature", "ANATOMY", 39, 50], ["immune cells", "ANATOMY", 55, 67], ["neuronal", "ANATOMY", 69, 77], ["CNS", "ANATOMY", 150, 153], ["neuronal death", "DISEASE", 69, 83], ["inflammation", "DISEASE", 154, 166], ["SARS", "DISEASE", 308, 312], ["CNS", "ANATOMICAL_SYSTEM", 30, 33], ["vasculature", "MULTI-TISSUE_STRUCTURE", 39, 50], ["immune cells", "CELL", 55, 67], ["neuronal", "CELL", 69, 77], ["CNS", "ANATOMICAL_SYSTEM", 150, 153], ["ACE2", "GENE_OR_GENE_PRODUCT", 235, 239], ["mouse", "ORGANISM", 294, 299], ["SARS-CoV", "ORGANISM", 308, 316], ["wild type mice", "ORGANISM", 341, 355], ["SARS-CoV-2", "ORGANISM", 360, 370], ["mice", "ORGANISM", 389, 393], ["hACE2", "GENE_OR_GENE_PRODUCT", 399, 404], ["immune cells", "CELL_TYPE", 55, 67], ["ACE2", "PROTEIN", 235, 239], ["hACE2", "PROTEIN", 399, 404], ["mouse", "SPECIES", 294, 299], ["mice", "SPECIES", 351, 355], ["mice", "SPECIES", 389, 393], ["mouse", "SPECIES", 294, 299], ["SARS-CoV", "SPECIES", 308, 316], ["mice", "SPECIES", 351, 355], ["SARS-CoV", "SPECIES", 360, 368], ["mice", "SPECIES", 389, 393], ["immune cells", "PROBLEM", 55, 67], ["neuronal death", "PROBLEM", 69, 83], ["CNS inflammation", "PROBLEM", 150, 166], ["CNS", "ANATOMY", 30, 33], ["vasculature", "ANATOMY", 39, 50], ["immune cells", "OBSERVATION", 55, 67], ["CNS", "ANATOMY", 150, 153], ["inflammation", "OBSERVATION", 154, 166]]], ["Using mouse models, we demonstrate for the first time that SARS-CoV-2 neuroinvasion in mice can have significant remodeling of brain vasculature, providing a link between the hypoxia and what we see in both the human organoid and the patient brains.DiscussionSimilar to previous reports of acute hypoxic ischemic damage without microthrombi in post-mortem brain of COVID-19 patients (Solomon et al., 2020), we also found presence of ischemic damage and micro infarcts in our post-mortem brain samples of COVID-19 patients.", [["brain vasculature", "ANATOMY", 127, 144], ["organoid", "ANATOMY", 217, 225], ["brains", "ANATOMY", 242, 248], ["brain", "ANATOMY", 356, 361], ["brain samples", "ANATOMY", 487, 500], ["hypoxia", "DISEASE", 175, 182], ["ischemic damage", "DISEASE", 304, 319], ["ischemic damage", "DISEASE", 433, 448], ["micro infarcts", "DISEASE", 453, 467], ["mouse", "ORGANISM", 6, 11], ["SARS-CoV-2", "ORGANISM", 59, 69], ["mice", "ORGANISM", 87, 91], ["brain vasculature", "MULTI-TISSUE_STRUCTURE", 127, 144], ["human", "ORGANISM", 211, 216], ["organoid", "CANCER", 217, 225], ["patient", "ORGANISM", 234, 241], ["brains", "ORGAN", 242, 248], ["brain", "ORGAN", 356, 361], ["patients", "ORGANISM", 374, 382], ["brain samples", "CANCER", 487, 500], ["patients", "ORGANISM", 513, 521], ["mouse", "SPECIES", 6, 11], ["mice", "SPECIES", 87, 91], ["human", "SPECIES", 211, 216], ["patient", "SPECIES", 234, 241], ["patients", "SPECIES", 374, 382], ["patients", "SPECIES", 513, 521], ["mouse", "SPECIES", 6, 11], ["mice", "SPECIES", 87, 91], ["human", "SPECIES", 211, 216], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["significant remodeling of brain vasculature", "PROBLEM", 101, 144], ["the hypoxia", "PROBLEM", 171, 182], ["acute hypoxic ischemic damage", "PROBLEM", 290, 319], ["microthrombi", "PROBLEM", 328, 340], ["ischemic damage", "PROBLEM", 433, 448], ["micro infarcts", "PROBLEM", 453, 467], ["COVID", "TEST", 504, 509], ["significant", "OBSERVATION_MODIFIER", 101, 112], ["remodeling", "OBSERVATION", 113, 123], ["brain vasculature", "ANATOMY", 127, 144], ["hypoxia", "OBSERVATION", 175, 182], ["human organoid", "ANATOMY", 211, 225], ["brains", "ANATOMY", 242, 248], ["acute", "OBSERVATION_MODIFIER", 290, 295], ["hypoxic", "OBSERVATION_MODIFIER", 296, 303], ["ischemic", "OBSERVATION_MODIFIER", 304, 312], ["damage", "OBSERVATION", 313, 319], ["without", "UNCERTAINTY", 320, 327], ["microthrombi", "OBSERVATION", 328, 340], ["ischemic", "OBSERVATION_MODIFIER", 433, 441], ["damage", "OBSERVATION", 442, 448], ["micro infarcts", "OBSERVATION", 453, 467]]], ["In our study, we observed evidence of SARS-CoV-2 infection within the regions of micro ischemic infarcts suggesting the possibility of neuroinvasion associated ischemia and vascular anomalies, consistent with what we observe in mice.", [["vascular", "ANATOMY", 173, 181], ["infection", "DISEASE", 49, 58], ["ischemic infarcts", "DISEASE", 87, 104], ["neuroinvasion", "DISEASE", 135, 148], ["ischemia", "DISEASE", 160, 168], ["vascular anomalies", "DISEASE", 173, 191], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["vascular", "MULTI-TISSUE_STRUCTURE", 173, 181], ["mice", "ORGANISM", 228, 232], ["mice", "SPECIES", 228, 232], ["SARS-CoV", "SPECIES", 38, 46], ["mice", "SPECIES", 228, 232], ["our study", "TEST", 3, 12], ["SARS", "PROBLEM", 38, 42], ["CoV-2 infection", "PROBLEM", 43, 58], ["micro ischemic infarcts", "PROBLEM", 81, 104], ["neuroinvasion associated ischemia", "PROBLEM", 135, 168], ["vascular anomalies", "PROBLEM", 173, 191], ["evidence of", "UNCERTAINTY", 26, 37], ["SARS", "OBSERVATION", 38, 42], ["CoV", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 49, 58], ["micro ischemic infarcts", "OBSERVATION", 81, 104], ["suggesting the possibility of", "UNCERTAINTY", 105, 134], ["neuroinvasion", "OBSERVATION", 135, 148], ["ischemia", "OBSERVATION", 160, 168], ["vascular", "ANATOMY", 173, 181], ["anomalies", "OBSERVATION", 182, 191], ["consistent with", "UNCERTAINTY", 193, 208]]], ["However, a limitation of our study is that autopsy samples from only a small number of patients were examined.", [["samples", "ANATOMY", 51, 58], ["autopsy samples", "CANCER", 43, 58], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["our study", "TEST", 25, 34], ["autopsy samples", "TEST", 43, 58], ["small", "OBSERVATION_MODIFIER", 71, 76]]], ["Future studies are needed to examine whether there are other cases of neuroinvasion in the CNS, and the predisposition for such infection.", [["CNS", "ANATOMY", 91, 94], ["neuroinvasion", "DISEASE", 70, 83], ["infection", "DISEASE", 128, 137], ["CNS", "ANATOMICAL_SYSTEM", 91, 94], ["Future studies", "TEST", 0, 14], ["neuroinvasion", "PROBLEM", 70, 83], ["such infection", "PROBLEM", 123, 137], ["neuroinvasion", "OBSERVATION", 70, 83], ["CNS", "ANATOMY", 91, 94], ["infection", "OBSERVATION", 128, 137]]], ["Although we are unable to determine the exact relationship between neuroinvasion and ischemic infarcts, we pose a possible hypothesis from our findings in the patients, mice, and infections of human brain organoids; that SARS-CoV-2 neuroinvasion may cause locally hypoxic regions and disturbance of vasculature, and the disruption of brain vasculature can make vulnerable ischemic infarcts and regions more susceptible to viral invasion (Figure S10).", [["brain organoids", "ANATOMY", 199, 214], ["vasculature", "ANATOMY", 299, 310], ["brain vasculature", "ANATOMY", 334, 351], ["neuroinvasion", "DISEASE", 67, 80], ["ischemic infarcts", "DISEASE", 85, 102], ["infections", "DISEASE", 179, 189], ["SARS", "DISEASE", 221, 225], ["ischemic infarcts", "DISEASE", 372, 389], ["patients", "ORGANISM", 159, 167], ["mice", "ORGANISM", 169, 173], ["human", "ORGANISM", 193, 198], ["brain organoids", "CELL", 199, 214], ["SARS-CoV-2", "ORGANISM", 221, 231], ["vasculature", "MULTI-TISSUE_STRUCTURE", 299, 310], ["brain vasculature", "MULTI-TISSUE_STRUCTURE", 334, 351], ["ischemic infarcts", "PATHOLOGICAL_FORMATION", 372, 389], ["patients", "SPECIES", 159, 167], ["mice", "SPECIES", 169, 173], ["human", "SPECIES", 193, 198], ["mice", "SPECIES", 169, 173], ["human", "SPECIES", 193, 198], ["neuroinvasion and ischemic infarcts", "PROBLEM", 67, 102], ["infections of human brain organoids", "PROBLEM", 179, 214], ["SARS", "PROBLEM", 221, 225], ["CoV-2 neuroinvasion", "PROBLEM", 226, 245], ["locally hypoxic regions", "PROBLEM", 256, 279], ["disturbance of vasculature", "PROBLEM", 284, 310], ["the disruption of brain vasculature", "PROBLEM", 316, 351], ["vulnerable ischemic infarcts", "PROBLEM", 361, 389], ["viral invasion", "PROBLEM", 422, 436], ["ischemic", "OBSERVATION_MODIFIER", 85, 93], ["infarcts", "OBSERVATION", 94, 102], ["brain", "ANATOMY", 199, 204], ["may cause", "UNCERTAINTY", 246, 255], ["locally", "OBSERVATION_MODIFIER", 256, 263], ["hypoxic", "OBSERVATION", 264, 271], ["vasculature", "ANATOMY", 299, 310], ["brain", "ANATOMY_MODIFIER", 334, 339], ["vasculature", "ANATOMY", 340, 351], ["vulnerable", "OBSERVATION_MODIFIER", 361, 371], ["ischemic", "OBSERVATION_MODIFIER", 372, 380], ["infarcts", "OBSERVATION", 381, 389], ["viral", "OBSERVATION_MODIFIER", 422, 427], ["invasion", "OBSERVATION", 428, 436]]], ["Our findings expand the utility of human brain organoids, beyond modeling fetal brains, and highlight the importance of using a variety of approaches to best model physiology of the human brain.DiscussionIn future studies, identifying the route of SARS-CoV-2 invasion into the brain in addition to determining the sequence of infection in different cell types in the central nervous system will help validate the temporal relationship between SARS-CoV-2 and ischemic infarcts in patients.", [["brain organoids", "ANATOMY", 41, 56], ["fetal brains", "ANATOMY", 74, 86], ["brain", "ANATOMY", 188, 193], ["brain", "ANATOMY", 277, 282], ["cell", "ANATOMY", 349, 353], ["central nervous system", "ANATOMY", 367, 389], ["SARS", "DISEASE", 248, 252], ["infection", "DISEASE", 326, 335], ["ischemic infarcts", "DISEASE", 458, 475], ["human", "ORGANISM", 35, 40], ["brain organoids", "CELL", 41, 56], ["fetal brains", "MULTI-TISSUE_STRUCTURE", 74, 86], ["human", "ORGANISM", 182, 187], ["brain", "ORGAN", 188, 193], ["brain", "ORGAN", 277, 282], ["cell", "CELL", 349, 353], ["central nervous system", "ANATOMICAL_SYSTEM", 367, 389], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 443, 453], ["ischemic infarcts", "PATHOLOGICAL_FORMATION", 458, 475], ["patients", "ORGANISM", 479, 487], ["human brain organoids", "CELL_TYPE", 35, 56], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 182, 187], ["patients", "SPECIES", 479, 487], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 182, 187], ["human brain organoids", "PROBLEM", 35, 56], ["modeling fetal brains", "PROBLEM", 65, 86], ["future studies", "TEST", 207, 221], ["SARS", "PROBLEM", 248, 252], ["CoV-2 invasion into the brain", "PROBLEM", 253, 282], ["infection", "PROBLEM", 326, 335], ["SARS-CoV-2 and ischemic infarcts", "PROBLEM", 443, 475], ["human brain organoids", "OBSERVATION", 35, 56], ["fetal brains", "ANATOMY", 74, 86], ["human brain", "ANATOMY", 182, 193], ["brain", "ANATOMY", 277, 282], ["infection", "OBSERVATION", 326, 335], ["different cell types", "OBSERVATION", 339, 359], ["central", "ANATOMY_MODIFIER", 367, 374], ["nervous", "ANATOMY", 375, 382], ["ischemic", "OBSERVATION_MODIFIER", 458, 466], ["infarcts", "OBSERVATION", 467, 475]]], ["It may be through the nasal cavity to CNS connection through the cribriform plate, olfactory epithelium and nerve, or viremia, but regardless, the brain should be considered a high-risk organ system upon respiratory exposure (Baig and Sanders, 2020; Coolen et al., 2020).DiscussionAltogether, our study provides clear demonstration that neurons can become a target of SARS-CoV-2 infection, with devastating consequences of localized ischemia in the brain and cell death, highlighting SARS-CoV-2 neurotropism and guiding rational approaches to treatment of patients with neuronal disorders.Mice. :::Six to twelve-week-old mixed sex C57Bl/6 (B6J) purchased from Jackson laboratories, and B6.Cg-Tg(K18-ACE2)2Prlmn/J(K18-hACE2) mice (gift from Jackson Laboratories) were subsequently bred and housed at Yale University.", [["nasal cavity", "ANATOMY", 22, 34], ["CNS", "ANATOMY", 38, 41], ["cribriform plate", "ANATOMY", 65, 81], ["olfactory epithelium", "ANATOMY", 83, 103], ["nerve", "ANATOMY", 108, 113], ["brain", "ANATOMY", 147, 152], ["organ", "ANATOMY", 186, 191], ["respiratory", "ANATOMY", 204, 215], ["neurons", "ANATOMY", 337, 344], ["brain", "ANATOMY", 449, 454], ["cell", "ANATOMY", 459, 463], ["neuronal", "ANATOMY", 570, 578], ["viremia", "DISEASE", 118, 125], ["SARS", "DISEASE", 368, 372], ["infection", "DISEASE", 379, 388], ["ischemia", "DISEASE", 433, 441], ["death", "DISEASE", 464, 469], ["neuronal disorders", "DISEASE", 570, 588], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 22, 34], ["CNS", "ANATOMICAL_SYSTEM", 38, 41], ["cribriform plate", "TISSUE", 65, 81], ["olfactory epithelium", "TISSUE", 83, 103], ["nerve", "MULTI-TISSUE_STRUCTURE", 108, 113], ["brain", "ORGAN", 147, 152], ["organ", "ORGAN", 186, 191], ["neurons", "CELL", 337, 344], ["SARS-CoV-2", "ORGANISM", 368, 378], ["brain", "ORGAN", 449, 454], ["cell", "CELL", 459, 463], ["patients", "ORGANISM", 556, 564], ["neuronal", "CELL", 570, 578], ["Mice", "ORGANISM", 589, 593], ["C57Bl/6", "ORGANISM", 631, 638], ["B6J", "CELL", 640, 643], ["K18", "GENE_OR_GENE_PRODUCT", 695, 698], ["K18", "GENE_OR_GENE_PRODUCT", 713, 716], ["K18", "PROTEIN", 695, 698], ["ACE2", "PROTEIN", 699, 703], ["2Prlmn", "PROTEIN", 704, 710], ["K18", "PROTEIN", 713, 716], ["hACE2", "PROTEIN", 717, 722], ["patients", "SPECIES", 556, 564], ["Mice", "SPECIES", 589, 593], ["mice", "SPECIES", 724, 728], ["SARS-CoV", "SPECIES", 368, 376], ["mice", "SPECIES", 724, 728], ["olfactory epithelium and nerve", "PROBLEM", 83, 113], ["viremia", "PROBLEM", 118, 125], ["our study", "TEST", 293, 302], ["SARS", "PROBLEM", 368, 372], ["CoV-2 infection", "PROBLEM", 373, 388], ["localized ischemia in the brain", "PROBLEM", 423, 454], ["cell death", "PROBLEM", 459, 469], ["SARS", "PROBLEM", 484, 488], ["neurotropism", "PROBLEM", 495, 507], ["neuronal disorders", "PROBLEM", 570, 588], ["B6", "TEST", 686, 688], ["Tg", "TEST", 692, 694], ["K18", "TEST", 695, 698], ["ACE2", "TEST", 699, 703], ["may be", "UNCERTAINTY", 3, 9], ["nasal cavity", "ANATOMY", 22, 34], ["cribriform plate", "ANATOMY", 65, 81], ["olfactory", "ANATOMY_MODIFIER", 83, 92], ["epithelium", "ANATOMY_MODIFIER", 93, 103], ["nerve", "ANATOMY", 108, 113], ["viremia", "OBSERVATION", 118, 125], ["brain", "ANATOMY", 147, 152], ["respiratory exposure", "OBSERVATION", 204, 224], ["localized", "OBSERVATION_MODIFIER", 423, 432], ["ischemia", "OBSERVATION", 433, 441], ["brain", "ANATOMY", 449, 454], ["cell death", "OBSERVATION", 459, 469]]], ["All procedures used in this study (sex-matched, age-matched) complied with federal guidelines and the institutional policies of the Yale School of Medicine Animal Care and Use Committee.Intratracheal injection. ::: AAV infection (Intratracheal and Intracisternal magna injection). :::Animals were anaesthetized using a mixture of ketamine (50 mg kg\u22121) and xylazine (5 mg kg\u22121), injected intraperitoneally.", [["Intratracheal", "ANATOMY", 186, 199], ["AAV infection", "DISEASE", 215, 228], ["ketamine", "CHEMICAL", 330, 338], ["xylazine", "CHEMICAL", 356, 364], ["ketamine", "CHEMICAL", 330, 338], ["xylazine", "CHEMICAL", 356, 364], ["Intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 186, 199], ["AAV", "ORGANISM", 215, 218], ["Animals", "ORGANISM", 284, 291], ["ketamine", "SIMPLE_CHEMICAL", 330, 338], ["xylazine", "SIMPLE_CHEMICAL", 356, 364], ["AAV", "SPECIES", 215, 218], ["All procedures", "TREATMENT", 0, 14], ["this study", "TEST", 23, 33], ["Intratracheal injection", "TREATMENT", 186, 209], ["AAV infection", "PROBLEM", 215, 228], ["Intratracheal and Intracisternal magna injection", "TREATMENT", 230, 278], ["ketamine", "TREATMENT", 330, 338], ["xylazine", "TREATMENT", 356, 364], ["infection", "OBSERVATION", 219, 228], ["Intratracheal", "ANATOMY", 230, 243], ["Intracisternal magna", "ANATOMY", 248, 268]]], ["The rostral neck was shaved and disinfected.", [["rostral neck", "ANATOMY", 4, 16], ["rostral neck", "MULTI-TISSUE_STRUCTURE", 4, 16], ["rostral", "ANATOMY_MODIFIER", 4, 11], ["neck", "ANATOMY", 12, 16], ["shaved", "OBSERVATION", 21, 27], ["disinfected", "OBSERVATION", 32, 43]]], ["A 5mm incision was made and the salivary glands were retracted, and trachea was visualized.", [["salivary glands", "ANATOMY", 32, 47], ["trachea", "ANATOMY", 68, 75], ["salivary glands", "ORGAN", 32, 47], ["trachea", "ORGAN", 68, 75], ["A 5mm incision", "TREATMENT", 0, 14], ["5mm", "OBSERVATION_MODIFIER", 2, 5], ["incision", "OBSERVATION", 6, 14], ["salivary glands", "ANATOMY", 32, 47], ["retracted", "OBSERVATION", 53, 62], ["trachea", "ANATOMY", 68, 75]]], ["Using a 500\u03bcL insulin syringe a 50\u03bcL bolus injection of 1011GC of AAV-CMV-hACE2 was injected into the trachea.", [["trachea", "ANATOMY", 102, 109], ["AAV-CMV-hACE2", "CHEMICAL", 66, 79], ["insulin", "GENE_OR_GENE_PRODUCT", 14, 21], ["AAV", "ORGANISM", 66, 69], ["CMV", "ORGANISM", 70, 73], ["hACE2", "ORGANISM", 74, 79], ["trachea", "ORGAN", 102, 109], ["AAV-CMV-hACE2", "DNA", 66, 79], ["a 500\u03bcL insulin syringe", "TREATMENT", 6, 29], ["a 50\u03bcL bolus injection", "TREATMENT", 30, 52], ["AAV-CMV-hACE2", "TREATMENT", 66, 79], ["trachea", "ANATOMY", 102, 109]]], ["The incision was closed with VetBond skin glue.", [["skin", "ANATOMY", 37, 41], ["skin", "ORGAN", 37, 41], ["The incision", "PROBLEM", 0, 12], ["VetBond skin glue", "TREATMENT", 29, 46], ["incision", "OBSERVATION", 4, 12], ["closed", "OBSERVATION", 17, 23], ["skin", "ANATOMY", 37, 41], ["glue", "OBSERVATION", 42, 46]]], ["Following intramuscular administration of analgesic (Meloxicam and buprenorphine, 1 mg kg\u22121), animals were placed in a heated cage until full recovery.Intracisternal magna injection. ::: AAV infection (Intratracheal and Intracisternal magna injection). :::Mice were anesthetized using ketamine and xylazine, and the dorsal neck was shaved and sterilized.", [["intramuscular", "ANATOMY", 10, 23], ["dorsal neck", "ANATOMY", 316, 327], ["Meloxicam", "CHEMICAL", 53, 62], ["buprenorphine", "CHEMICAL", 67, 80], ["AAV infection", "DISEASE", 187, 200], ["ketamine", "CHEMICAL", 285, 293], ["xylazine", "CHEMICAL", 298, 306], ["Meloxicam", "CHEMICAL", 53, 62], ["buprenorphine", "CHEMICAL", 67, 80], ["ketamine", "CHEMICAL", 285, 293], ["xylazine", "CHEMICAL", 298, 306], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["Meloxicam", "SIMPLE_CHEMICAL", 53, 62], ["buprenorphine", "SIMPLE_CHEMICAL", 67, 80], ["animals", "ORGANISM", 94, 101], ["AAV", "ORGANISM", 187, 190], ["Mice", "ORGANISM", 256, 260], ["ketamine", "SIMPLE_CHEMICAL", 285, 293], ["xylazine", "SIMPLE_CHEMICAL", 298, 306], ["dorsal neck", "ORGAN", 316, 327], ["Mice", "SPECIES", 256, 260], ["Mice", "SPECIES", 256, 260], ["analgesic (Meloxicam", "TREATMENT", 42, 62], ["buprenorphine", "TREATMENT", 67, 80], ["a heated cage", "TREATMENT", 117, 130], ["Intracisternal magna injection", "TREATMENT", 151, 181], ["AAV infection", "PROBLEM", 187, 200], ["Intratracheal and Intracisternal magna injection", "TREATMENT", 202, 250], ["ketamine", "TREATMENT", 285, 293], ["xylazine", "TREATMENT", 298, 306], ["magna", "OBSERVATION", 166, 171], ["infection", "OBSERVATION", 191, 200], ["Intratracheal", "ANATOMY", 202, 215], ["Intracisternal magna", "ANATOMY", 220, 240], ["dorsal", "ANATOMY_MODIFIER", 316, 322], ["neck", "ANATOMY", 323, 327], ["shaved", "OBSERVATION", 332, 338]]], ["A 2 cm incision was made at the base of the skull, and the dorsal neck muscles were separated using forceps.", [["skull", "ANATOMY", 44, 49], ["dorsal neck muscles", "ANATOMY", 59, 78], ["skull", "ORGAN", 44, 49], ["dorsal neck muscles", "ORGAN", 59, 78], ["A 2 cm incision", "TREATMENT", 0, 15], ["forceps", "TREATMENT", 100, 107], ["2 cm", "OBSERVATION_MODIFIER", 2, 6], ["incision", "OBSERVATION", 7, 15], ["base", "ANATOMY_MODIFIER", 32, 36], ["skull", "ANATOMY", 44, 49], ["dorsal", "ANATOMY_MODIFIER", 59, 65], ["neck muscles", "ANATOMY", 66, 78]]], ["After visualization of the cisterna magna, a Hamilton syringe with a 15 degree 33 gauge needle was used to puncture the dura.", [["cisterna magna", "ANATOMY", 27, 41], ["dura", "ANATOMY", 120, 124], ["cisterna magna", "MULTI-TISSUE_STRUCTURE", 27, 41], ["dura", "TISSUE", 120, 124], ["a Hamilton syringe", "TREATMENT", 43, 61], ["a 15 degree 33 gauge needle", "TREATMENT", 67, 94], ["cisterna magna", "ANATOMY", 27, 41], ["dura", "ANATOMY", 120, 124]]], ["3\u03bcL of AAV9 (3.1012 viral particles/mouse) or mRNA (4\u20135 \u03bcg) was administered per mouse at a rate of 1\u03bcL min\u22121.", [["AAV9", "CHEMICAL", 7, 11], ["AAV9", "GENE_OR_GENE_PRODUCT", 7, 11], ["mouse", "ORGANISM", 36, 41], ["mouse", "ORGANISM", 81, 86], ["AAV9 (3.1012 viral particles", "RNA", 7, 35], ["mRNA", "RNA", 46, 50], ["mouse", "SPECIES", 36, 41], ["mouse", "SPECIES", 81, 86], ["mouse", "SPECIES", 36, 41], ["mouse", "SPECIES", 81, 86], ["AAV9", "TEST", 7, 11], ["viral particles/mouse)", "TREATMENT", 20, 42], ["mRNA", "TEST", 46, 50]]], ["Upon completion of the injection, needle was left in to prevent backflow for an additional 3 minutes.", [["the injection", "TREATMENT", 19, 32], ["needle", "TREATMENT", 34, 40], ["backflow", "OBSERVATION", 64, 72]]], ["The skin was stapled, disinfected and same post-operative procedures as intratracheal injections were performed.Generation of SARS-CoV-2 virus. :::To generate SARS-CoV-2 viral stocks, Huh7.5 cells were inoculated with SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources #NR-52281) to generate a P1 stock.", [["skin", "ANATOMY", 4, 8], ["intratracheal", "ANATOMY", 72, 85], ["Huh7.5 cells", "ANATOMY", 184, 196], ["NR-52281", "CHEMICAL", 266, 274], ["skin", "ORGAN", 4, 8], ["SARS-CoV-2 virus", "ORGANISM", 126, 142], ["SARS-CoV-2", "ORGANISM", 159, 169], ["Huh7.5 cells", "CELL", 184, 196], ["Huh7.5 cells", "CELL_LINE", 184, 196], ["CoV-2 virus", "SPECIES", 131, 142], ["SARS-CoV-2 virus", "SPECIES", 126, 142], ["SARS-CoV-2 isolate USA-WA1/2020 (BEI Resources #NR-52281", "SPECIES", 218, 274], ["stapled", "TREATMENT", 13, 20], ["same post-operative procedures", "TREATMENT", 38, 68], ["intratracheal injections", "TREATMENT", 72, 96], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134], ["SARS", "TEST", 159, 163], ["CoV", "TEST", 164, 167], ["viral stocks", "TEST", 170, 182], ["SARS", "TEST", 218, 222], ["CoV", "TEST", 223, 226], ["NR", "TEST", 266, 268], ["a P1 stock", "TREATMENT", 288, 298], ["skin", "ANATOMY", 4, 8], ["stapled", "OBSERVATION", 13, 20], ["SARS", "OBSERVATION", 126, 130], ["SARS", "OBSERVATION", 159, 163]]], ["To generate a working stock, VeroE6 cells were infected at a MOI 0.01 for four days.", [["VeroE6 cells", "ANATOMY", 29, 41], ["VeroE6 cells", "CELL", 29, 41], ["VeroE6 cells", "CELL_LINE", 29, 41], ["a working stock, VeroE6 cells", "TREATMENT", 12, 41]]], ["Supernatant was clarified by centrifugation (450g \u00d7 5min) and filtered through a 0.45 micron filter.", [["Supernatant", "ANATOMY", 0, 11], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["a 0.45 micron filter", "TREATMENT", 79, 99]]], ["To concentrate virus, one volume of cold (4 \u00b0C) 4x PEG-it Virus Precipitation Solution (40% (w/v) PEG-8000 and 1.2M NaCl) was added to three volumes of virus-containing supernatant.", [["supernatant", "ANATOMY", 169, 180], ["PEG", "CHEMICAL", 51, 54], ["PEG", "CHEMICAL", 98, 101], ["NaCl", "CHEMICAL", 116, 120], ["PEG", "CHEMICAL", 51, 54], ["PEG", "CHEMICAL", 98, 101], ["NaCl", "CHEMICAL", 116, 120], ["Virus", "ORGANISM", 58, 63], ["cold (4 \u00b0C)", "TREATMENT", 36, 47], ["PEG", "TREATMENT", 51, 54], ["it Virus Precipitation Solution", "TREATMENT", 55, 86], ["w/v) PEG", "TREATMENT", 93, 101], ["1.2M NaCl)", "TREATMENT", 111, 121], ["virus", "TREATMENT", 152, 157], ["virus", "OBSERVATION", 15, 20], ["one volume", "OBSERVATION_MODIFIER", 22, 32]]], ["The solution was mixed by inverting the tubes several times and then incubated at 4 \u00b0C overnight.", [["The solution", "TREATMENT", 0, 12], ["inverting the tubes", "TREATMENT", 26, 45], ["tubes", "OBSERVATION", 40, 45]]], ["The precipitated virus was harvested by centrifugation at 1,500 00 g for 60 minutes at 4 \u00b0C. The pelleted virus was then resuspended in PBS then aliquoted for storage at \u221280\u00b0C. Virus titer was determined by plaque assay using Vero E6 cells.SARS-CoV-2 infection of organoids. :::Brain organoids in low adhesion plates were infected with SARS-CoV-2 at a MOI of 1.SARS-CoV-2 infection (intranasal). :::Mice were anesthetized using 30% v/v Isoflurane diluted in propylene glycol.", [["plaque", "ANATOMY", 207, 213], ["Vero E6 cells", "ANATOMY", 226, 239], ["organoids", "ANATOMY", 264, 273], ["Brain organoids", "ANATOMY", 278, 293], ["SARS", "DISEASE", 240, 244], ["infection", "DISEASE", 251, 260], ["infection", "DISEASE", 372, 381], ["Isoflurane", "CHEMICAL", 436, 446], ["propylene glycol", "CHEMICAL", 458, 474], ["Isoflurane", "CHEMICAL", 436, 446], ["propylene glycol", "CHEMICAL", 458, 474], ["Virus", "ORGANISM", 177, 182], ["Vero E6 cells", "CELL", 226, 239], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 240, 250], ["organoids", "CELL", 264, 273], ["Brain organoids", "CELL", 278, 293], ["SARS-CoV-2", "ORGANISM", 361, 371], ["Mice", "ORGANISM", 399, 403], ["v/v Isoflurane", "SIMPLE_CHEMICAL", 432, 446], ["propylene glycol", "SIMPLE_CHEMICAL", 458, 474], ["Vero E6 cells", "CELL_LINE", 226, 239], ["Mice", "SPECIES", 399, 403], ["Vero E6", "SPECIES", 226, 233], ["SARS-CoV", "SPECIES", 336, 344], ["Mice", "SPECIES", 399, 403], ["The precipitated virus", "PROBLEM", 0, 22], ["The pelleted virus", "TREATMENT", 93, 111], ["Virus titer", "TEST", 177, 188], ["plaque assay", "TEST", 207, 219], ["Vero E6 cells", "TREATMENT", 226, 239], ["SARS", "PROBLEM", 240, 244], ["2 infection of organoids", "PROBLEM", 249, 273], ["Brain organoids in low adhesion plates", "PROBLEM", 278, 316], ["SARS", "TEST", 336, 340], ["CoV", "TEST", 341, 344], ["SARS", "PROBLEM", 361, 365], ["CoV-2 infection (intranasal)", "PROBLEM", 366, 394], ["30% v/v Isoflurane", "TREATMENT", 428, 446], ["propylene glycol", "TREATMENT", 458, 474], ["virus", "OBSERVATION", 17, 22], ["virus", "OBSERVATION", 106, 111], ["E6 cells", "OBSERVATION", 231, 239], ["CoV", "OBSERVATION_MODIFIER", 245, 248], ["infection", "OBSERVATION", 251, 260], ["low adhesion", "OBSERVATION_MODIFIER", 297, 309], ["CoV", "OBSERVATION_MODIFIER", 366, 369], ["infection", "OBSERVATION", 372, 381]]], ["Using a pipette, 50\u03bcL of SARS-CoV-2 (3\u00d7107 PFU/ml) was delivered intranasally.SARS-CoV-2 infection (intraventricular). :::Animals were anaesthetized using a mixture of ketamine (50 mg kg\u22121) and xylazine (5 mg kg\u22121), injected intraperitoneally.", [["intranasally", "ANATOMY", 65, 77], ["SARS-CoV-2", "CHEMICAL", 25, 35], ["infection", "DISEASE", 89, 98], ["ketamine", "CHEMICAL", 168, 176], ["xylazine", "CHEMICAL", 194, 202], ["ketamine", "CHEMICAL", 168, 176], ["xylazine", "CHEMICAL", 194, 202], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 78, 88], ["Animals", "ORGANISM", 122, 129], ["ketamine", "SIMPLE_CHEMICAL", 168, 176], ["xylazine", "SIMPLE_CHEMICAL", 194, 202], ["SARS-CoV", "SPECIES", 78, 86], ["a pipette", "TREATMENT", 6, 15], ["SARS-CoV", "TREATMENT", 25, 33], ["SARS", "PROBLEM", 78, 82], ["CoV-2 infection (intraventricular)", "PROBLEM", 83, 117], ["ketamine", "TREATMENT", 168, 176], ["xylazine", "TREATMENT", 194, 202], ["CoV", "OBSERVATION_MODIFIER", 83, 86], ["infection", "OBSERVATION", 89, 98]]], ["After sterilization of the scalp with alcohol and betadine, a midline scalp incision was made to expose the coronal and sagittal sutures, and a burr holes were drilled 1 mm lateral to the sagittal suture and 0.5 mm posterior to the bregma.", [["scalp", "ANATOMY", 27, 32], ["scalp", "ANATOMY", 70, 75], ["coronal", "ANATOMY", 108, 115], ["alcohol", "CHEMICAL", 38, 45], ["betadine", "CHEMICAL", 50, 58], ["alcohol", "CHEMICAL", 38, 45], ["betadine", "CHEMICAL", 50, 58], ["scalp", "ORGAN", 27, 32], ["alcohol", "SIMPLE_CHEMICAL", 38, 45], ["betadine", "SIMPLE_CHEMICAL", 50, 58], ["coronal", "ORGAN", 108, 115], ["sterilization of the scalp", "TREATMENT", 6, 32], ["alcohol", "TREATMENT", 38, 45], ["betadine", "TREATMENT", 50, 58], ["a midline scalp incision", "TREATMENT", 60, 84], ["a burr holes", "TREATMENT", 142, 154], ["scalp", "ANATOMY", 27, 32], ["midline", "ANATOMY_MODIFIER", 62, 69], ["scalp", "ANATOMY", 70, 75], ["incision", "OBSERVATION", 76, 84], ["burr holes", "OBSERVATION", 144, 154], ["bregma", "ANATOMY", 232, 238]]], ["A 10 \u03bcl Hamilton syringe loaded with virus, and was inserted into the burr hole at a depth of 2 mm from the surface of the brain and left to equilibrate for 1 min before infusion.", [["surface", "ANATOMY", 108, 115], ["brain", "ANATOMY", 123, 128], ["brain", "ORGAN", 123, 128], ["A 10 \u03bcl Hamilton syringe", "TREATMENT", 0, 24], ["virus", "TREATMENT", 37, 42], ["the burr hole", "TREATMENT", 66, 79], ["burr hole", "OBSERVATION", 70, 79], ["surface", "ANATOMY_MODIFIER", 108, 115], ["brain", "ANATOMY", 123, 128], ["left", "ANATOMY_MODIFIER", 133, 137]]], ["Once the infusion was finished, the syringe was left in place for another minute before removal of the syringe.", [["the infusion", "TREATMENT", 5, 17], ["the syringe", "TREATMENT", 32, 43], ["removal of the syringe", "TREATMENT", 88, 110]]], ["Bone wax was used to fill the burr hole and skin was stapled and cleaned.", [["Bone", "ANATOMY", 0, 4], ["skin", "ANATOMY", 44, 48], ["Bone", "TISSUE", 0, 4], ["skin", "ORGAN", 44, 48], ["Bone wax", "TREATMENT", 0, 8], ["the burr hole", "TREATMENT", 26, 39], ["stapled", "TREATMENT", 53, 60], ["burr hole", "OBSERVATION", 30, 39], ["skin", "ANATOMY", 44, 48], ["stapled", "OBSERVATION", 53, 60]]], ["Following intramuscular administration of analgesic (Meloxicam and buprenorphine, 1 mg kg\u22121), animals were placed in a heated cage until full recovery.", [["intramuscular", "ANATOMY", 10, 23], ["Meloxicam", "CHEMICAL", 53, 62], ["buprenorphine", "CHEMICAL", 67, 80], ["Meloxicam", "CHEMICAL", 53, 62], ["buprenorphine", "CHEMICAL", 67, 80], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["Meloxicam", "SIMPLE_CHEMICAL", 53, 62], ["buprenorphine", "SIMPLE_CHEMICAL", 67, 80], ["animals", "ORGANISM", 94, 101], ["analgesic (Meloxicam", "TREATMENT", 42, 62], ["buprenorphine", "TREATMENT", 67, 80], ["a heated cage", "TREATMENT", 117, 130]]], ["For high condition, 5\u03bcL of SARS-CoV-2 (3\u00d7107 PFU/ml) and for low condition 5\u03bcL of SARS-CoV-2 (3\u00d7106 PFU/ml) was used.Samples staining and iDISCO+ clearing. :::Whole brain vasculature staining was performed following the iDISCO+ protocol previously described (Renier et al., 2016) with minimal modifications.", [["Samples", "ANATOMY", 117, 124], ["brain vasculature", "ANATOMY", 165, 182], ["SARS-CoV-2", "CHEMICAL", 27, 37], ["SARS-CoV-2", "CHEMICAL", 82, 92], ["brain vasculature", "MULTI-TISSUE_STRUCTURE", 165, 182], ["SARS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["low condition", "PROBLEM", 61, 74], ["SARS", "TEST", 82, 86], ["CoV", "TEST", 87, 90], ["Samples staining", "TEST", 117, 133], ["iDISCO", "TEST", 138, 144], ["Whole brain vasculature staining", "TEST", 159, 191], ["the iDISCO+ protocol", "TREATMENT", 216, 236], ["clearing", "OBSERVATION_MODIFIER", 146, 154], ["vasculature", "ANATOMY", 171, 182], ["minimal", "OBSERVATION_MODIFIER", 285, 292], ["modifications", "OBSERVATION", 293, 306]]], ["All the steps of the protocol were done at room temperature with gentle shaking unless otherwise specified.", [["the protocol", "TREATMENT", 17, 29], ["gentle shaking", "PROBLEM", 65, 79]]], ["All the buffers were supplemented with 0,01% Sodium Azide (Sigma-Aldrich, Germany) to prevent bacterial and fungi growth.", [["Sodium Azide", "CHEMICAL", 45, 57], ["Sodium Azide", "CHEMICAL", 45, 57], ["Sodium Azide", "SIMPLE_CHEMICAL", 45, 57], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 59, 72], ["All the buffers", "TREATMENT", 0, 15], ["0,01% Sodium Azide", "TREATMENT", 39, 57], ["Sigma-Aldrich, Germany)", "TREATMENT", 59, 82], ["bacterial and fungi growth", "PROBLEM", 94, 120], ["bacterial", "OBSERVATION", 94, 103], ["fungi growth", "OBSERVATION", 108, 120]]], ["Brains were dehydrated in an increasing series of methanol (Sigma-Aldrich, France) dilutions in water (washes of 1 hour in methanol 20%, 40%, 60%, 80% and 100%).", [["Brains", "ANATOMY", 0, 6], ["methanol", "CHEMICAL", 50, 58], ["methanol", "CHEMICAL", 50, 58], ["methanol", "CHEMICAL", 123, 131], ["Brains", "ORGAN", 0, 6], ["methanol", "SIMPLE_CHEMICAL", 50, 58], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 60, 73], ["dehydrated", "PROBLEM", 12, 22], ["methanol (Sigma-Aldrich, France) dilutions", "TREATMENT", 50, 92], ["methanol", "TREATMENT", 123, 131], ["dehydrated", "OBSERVATION", 12, 22]]], ["An additional wash of 2 hours in methanol 100% was done to remove residual water.", [["methanol", "CHEMICAL", 33, 41], ["methanol", "CHEMICAL", 33, 41], ["methanol", "SIMPLE_CHEMICAL", 33, 41], ["methanol", "TREATMENT", 33, 41]]], ["Once dehydrated, samples were incubated overnight in a solution containing a 66% dichloromethane (Sigma-Aldrich, Germany) in methanol, and then washed twice in methanol 100% (4 hours each wash).", [["samples", "ANATOMY", 17, 24], ["dichloromethane", "CHEMICAL", 81, 96], ["dichloromethane", "CHEMICAL", 81, 96], ["methanol", "CHEMICAL", 125, 133], ["methanol", "CHEMICAL", 160, 168], ["dichloromethane", "SIMPLE_CHEMICAL", 81, 96], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 98, 111], ["methanol", "SIMPLE_CHEMICAL", 125, 133], ["dehydrated", "PROBLEM", 5, 15], ["a 66% dichloromethane", "TREATMENT", 75, 96], ["methanol", "TREATMENT", 125, 133], ["methanol", "TREATMENT", 160, 168]]], ["Samples were then bleached overnight at 4\u00b0C in methanol containing a 5% of hydrogen peroxide (Sigma-Aldrich).", [["Samples", "ANATOMY", 0, 7], ["methanol", "CHEMICAL", 47, 55], ["hydrogen peroxide", "CHEMICAL", 75, 92], ["methanol", "CHEMICAL", 47, 55], ["hydrogen peroxide", "CHEMICAL", 75, 92], ["C", "SIMPLE_CHEMICAL", 42, 43], ["methanol", "SIMPLE_CHEMICAL", 47, 55], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 75, 92], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 94, 107], ["Samples", "TEST", 0, 7], ["methanol", "TREATMENT", 47, 55], ["hydrogen peroxide", "TREATMENT", 75, 92]]], ["Rehydration was done by incubating the samples in methanol 60%, 40% and 20% (1 hour each wash).", [["samples", "ANATOMY", 39, 46], ["methanol", "CHEMICAL", 50, 58], ["methanol", "SIMPLE_CHEMICAL", 50, 58], ["Rehydration", "TREATMENT", 0, 11], ["methanol", "TREATMENT", 50, 58]]], ["After methanol pretreatment, samples were washed in PBS twice 15 minutes and 1 hour in PBS containing a 0,2% of Triton X-100 (Sigma-Aldrich) and further permeabilized by a 24 hours incubation at 37\u00b0C in Permeabilization Solution, composed by 20% dimethyl sulfoxide (Sigma-Aldrich), 2,3% Glycine (Sigma-Aldrich, USA) in PBS-T.", [["samples", "ANATOMY", 29, 36], ["methanol", "CHEMICAL", 6, 14], ["Triton X-100", "CHEMICAL", 112, 124], ["Sigma-Aldrich", "CHEMICAL", 126, 139], ["dimethyl sulfoxide", "CHEMICAL", 246, 264], ["methanol", "CHEMICAL", 6, 14], ["Triton X-100", "CHEMICAL", 112, 124], ["dimethyl sulfoxide", "CHEMICAL", 246, 264], ["methanol", "SIMPLE_CHEMICAL", 6, 14], ["Triton X-100", "SIMPLE_CHEMICAL", 112, 124], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 126, 139], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 246, 264], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 266, 279], ["2,3% Glycine", "SIMPLE_CHEMICAL", 282, 294], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 296, 309], ["methanol pretreatment", "TREATMENT", 6, 27], ["samples", "TEST", 29, 36], ["Permeabilization Solution", "TREATMENT", 203, 228], ["dimethyl sulfoxide (Sigma-Aldrich)", "TREATMENT", 246, 280]]], ["In order to start the immunostaining, samples were first blocked with 0,2% gelatin (Sigma-Aldrich) in PBS-T for 24 hours at 37\u00b0C, the same blocking buffer was used to prepare antibody solutions.", [["samples", "ANATOMY", 38, 45], ["gelatin", "CHEMICAL", 75, 82], ["Sigma-Aldrich", "CHEMICAL", 84, 97], ["gelatin", "SIMPLE_CHEMICAL", 75, 82], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 84, 97], ["PBS-T", "SIMPLE_CHEMICAL", 102, 107], ["the immunostaining", "TREATMENT", 18, 36], ["samples", "TEST", 38, 45], ["0,2% gelatin", "TREATMENT", 70, 82], ["the same blocking buffer", "TREATMENT", 130, 154], ["antibody solutions", "TREATMENT", 175, 193]]], ["A combination of primary antibodies targeting different components of the vessel\u2019s walls were used to achieve continuous immunostaining.", [["vessel\u2019s walls", "ANATOMY", 74, 88], ["vessel\u2019s walls", "MULTI-TISSUE_STRUCTURE", 74, 88], ["primary antibodies", "PROTEIN", 17, 35], ["primary antibodies", "TREATMENT", 17, 35], ["continuous immunostaining", "TEST", 110, 135], ["primary", "OBSERVATION_MODIFIER", 17, 24], ["antibodies", "OBSERVATION", 25, 35], ["vessel", "ANATOMY", 74, 80]]], ["Antibodies to Podocalyxin and CD31 were combined with antibodies against the nucleocapsid (N) from GeneTex (Antibodies\u2019 references and concentrations are provided in Sup.", [["Podocalyxin", "GENE_OR_GENE_PRODUCT", 14, 25], ["CD31", "GENE_OR_GENE_PRODUCT", 30, 34], ["Podocalyxin", "PROTEIN", 14, 25], ["CD31", "PROTEIN", 30, 34], ["antibodies", "PROTEIN", 54, 64], ["nucleocapsid (N)", "PROTEIN", 77, 93], ["GeneTex", "PROTEIN", 99, 106], ["Antibodies", "PROTEIN", 108, 118], ["Antibodies", "TEST", 0, 10], ["Podocalyxin", "TEST", 14, 25], ["CD31", "TEST", 30, 34], ["antibodies", "TREATMENT", 54, 64], ["the nucleocapsid", "PROBLEM", 73, 89]]], ["Primary antibodies were incubated for 10 days at 37\u00b0C with gentle shaking, then washed in PBS-T (twice 1 hour and then overnight), and finally newly incubated for 10 days with secondary antibodies.", [["secondary antibodies", "PROTEIN", 176, 196], ["Primary antibodies", "TEST", 0, 18], ["gentle shaking", "PROBLEM", 59, 73], ["secondary antibodies", "PROBLEM", 176, 196]]], ["Secondary antibodies conjugated to Alexa 647 were used to detect Podocalyxin and CD31, while the Nucleocapsid protein was stained with a secondary antibody conjugated to Alexa 555.", [["Alexa 647", "CHEMICAL", 35, 44], ["Alexa 555", "CHEMICAL", 170, 179], ["Alexa 647", "CHEMICAL", 35, 44], ["Alexa 555", "CHEMICAL", 170, 179], ["Alexa 647", "SIMPLE_CHEMICAL", 35, 44], ["Podocalyxin", "GENE_OR_GENE_PRODUCT", 65, 76], ["CD31", "GENE_OR_GENE_PRODUCT", 81, 85], ["Nucleocapsid", "GENE_OR_GENE_PRODUCT", 97, 109], ["Alexa 555", "SIMPLE_CHEMICAL", 170, 179], ["antibodies", "PROTEIN", 10, 20], ["Alexa 647", "PROTEIN", 35, 44], ["Podocalyxin", "PROTEIN", 65, 76], ["CD31", "PROTEIN", 81, 85], ["Nucleocapsid protein", "PROTEIN", 97, 117], ["secondary antibody", "PROTEIN", 137, 155], ["Alexa 555", "PROTEIN", 170, 179], ["Secondary antibodies", "PROBLEM", 0, 20], ["Alexa", "TEST", 35, 40], ["Podocalyxin", "TEST", 65, 76], ["CD31", "TEST", 81, 85], ["the Nucleocapsid protein", "TEST", 93, 117]]], ["After immunostaining, the samples were washed in PBS-T (twice 1 hour and then overnight), dehydrated in a methanol/water increasing concentration series (20%, 40%, 60%, 80%, 100% one hour each and then methanol 100% overnight), followed by a wash in 66% dichloromethane \u2013 33% methanol for 3 hours.", [["samples", "ANATOMY", 26, 33], ["dichloromethane", "CHEMICAL", 254, 269], ["methanol", "CHEMICAL", 276, 284], ["methanol", "CHEMICAL", 106, 114], ["methanol", "CHEMICAL", 202, 210], ["dichloromethane", "CHEMICAL", 254, 269], ["methanol", "CHEMICAL", 276, 284], ["methanol", "SIMPLE_CHEMICAL", 106, 114], ["dichloromethane", "SIMPLE_CHEMICAL", 254, 269], ["methanol", "SIMPLE_CHEMICAL", 276, 284], ["immunostaining", "TEST", 6, 20], ["the samples", "TEST", 22, 33], ["a methanol/water increasing concentration series", "TREATMENT", 104, 152], ["methanol", "TREATMENT", 202, 210]]], ["Methanol was washed out with two final washes in dichloromethane 100% (15 min each) and finally the samples were cleared and stored in dibenzyl ether (Sigma-Aldrich) until light sheet imaging.Light sheet imaging. :::We imaged with a 4X 0.35NA objective cropped elongated field of view (600 \u00d7 2200\u03bcm) covering the narrow waist of the light sheet at 1.63\u03bcm/pixel of lateral resolution at 1.6\u03bcm spacing.", [["samples", "ANATOMY", 100, 107], ["Methanol", "CHEMICAL", 0, 8], ["dichloromethane", "CHEMICAL", 49, 64], ["dibenzyl ether", "CHEMICAL", 135, 149], ["Methanol", "CHEMICAL", 0, 8], ["dichloromethane", "CHEMICAL", 49, 64], ["dibenzyl ether", "CHEMICAL", 135, 149], ["Methanol", "SIMPLE_CHEMICAL", 0, 8], ["dichloromethane", "SIMPLE_CHEMICAL", 49, 64], ["dibenzyl ether", "SIMPLE_CHEMICAL", 135, 149], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 151, 164], ["Methanol", "TREATMENT", 0, 8], ["dichloromethane", "TREATMENT", 49, 64], ["the samples", "TEST", 96, 107], ["light sheet imaging", "TEST", 172, 191], ["Light sheet imaging", "TEST", 192, 211], ["lateral resolution at 1.6\u03bcm spacing", "PROBLEM", 364, 399], ["lateral", "OBSERVATION_MODIFIER", 364, 371], ["resolution", "OBSERVATION_MODIFIER", 372, 382]]], ["A reference channel for the registration to the annotated atlas using the sample autofluorescence was acquired at 5\u03bcm/pixel.", [["the sample autofluorescence", "TEST", 70, 97]]], ["The acquisitions were done on a LaVision Ultramicroscope II equipped with infinity-corrected objectives.", [["The acquisitions", "TEST", 0, 16], ["a LaVision Ultramicroscope II", "TREATMENT", 30, 59]]], ["The microscope was installed on an active vibration filtration device, itself put on a marble compressed-air table.", [["The microscope", "TREATMENT", 0, 14], ["an active vibration filtration device", "TREATMENT", 32, 69], ["a marble compressed-air table", "TREATMENT", 85, 114], ["active", "OBSERVATION_MODIFIER", 35, 41], ["vibration filtration", "OBSERVATION", 42, 62]]], ["Imaging was done with the following filters: 595/40 for Alexa Fluor-555, and \u2212680/30 for Alexa Fluor-647.", [["Alexa Fluor-647", "CHEMICAL", 89, 104], ["Alexa Fluor-555", "CHEMICAL", 56, 71], ["Alexa Fluor-647", "CHEMICAL", 89, 104], ["Alexa Fluor-555", "SIMPLE_CHEMICAL", 56, 71], ["Alexa Fluor-647", "SIMPLE_CHEMICAL", 89, 104], ["Alexa Fluor-647", "PROTEIN", 89, 104], ["Alexa Fluor-555", "SPECIES", 56, 71], ["Alexa Fluor-647", "SPECIES", 89, 104], ["Imaging", "TEST", 0, 7], ["Alexa Fluor", "TEST", 56, 67], ["Alexa Fluor", "TEST", 89, 100]]], ["The microscope was equipped with the following laser lines: OBIS-561nm 100mW, OBIS-639nm 70mW, and used the 2nd generation LaVision beam combiner.", [["laser lines", "CELL_LINE", 47, 58], ["OBIS-639nm 70mW", "CELL_LINE", 78, 93], ["The microscope", "TEST", 0, 14], ["OBIS", "TEST", 60, 64], ["OBIS", "TEST", 78, 82], ["the 2nd generation LaVision beam combiner", "TREATMENT", 104, 145]]], ["The images were acquired with an Andor CMOS sNEO camera.", [["Andor CMOS sNEO camera", "DNA", 33, 55], ["The images", "TEST", 0, 10], ["an Andor CMOS sNEO camera", "TREATMENT", 30, 55]]], ["Main acquisitions were done with the LVMI-Fluor 4X/O.3 WD6 LaVision Biotec objective.", [["LVMI-Fluor 4X", "CHEMICAL", 37, 50], ["LVMI", "PROTEIN", 37, 41], ["WD6", "PROTEIN", 55, 58], ["Main acquisitions", "TEST", 0, 17], ["the LVMI", "TEST", 33, 41]]], ["The brain was positioned in sagittal orientation, cortex side facing the light sheet.", [["brain", "ANATOMY", 4, 9], ["cortex", "ANATOMY", 50, 56], ["brain", "ORGAN", 4, 9], ["brain", "ANATOMY", 4, 9]]], ["A field of view of 400 \u00d7 1300 pixels was cropped at the center of the camera sensor.", [["A field of view", "TEST", 0, 15], ["pixels", "TEST", 30, 36]]], ["The light sheet numerical aperture was set to the NA (0.1).", [["The light sheet numerical aperture", "TEST", 0, 34]]], ["Beam width was set to the maximum.", [["Beam width", "TEST", 0, 10]]], ["Only the center-left light sheet was used.", [["left", "ANATOMY_MODIFIER", 16, 20]]], ["Laser powers were set to 100% (639nm) or 10% (561nm).", [["Laser powers", "TREATMENT", 0, 12]]], ["The acquisition routine was set to 1) Z-drive -> Save ome.tif stack 2) Filter change -> Z-drive -> Save ome.tif stack 3) Change X position -> repeat 1,2 12 times 4) Change y position -> repeat 1,2,3 6 times.", [["Filter change", "TREATMENT", 71, 84], ["Change X position", "TREATMENT", 121, 138], ["Filter", "OBSERVATION", 71, 77]]], ["At the end of the acquisition, the objective is changed to a MI PLAN 1.1X/0.1 for the reference scan at 488nm excitation (tissue autofluorescence).", [["tissue", "ANATOMY", 122, 128], ["MI", "DISEASE", 61, 63], ["tissue", "TISSUE", 122, 128], ["the reference scan", "TEST", 82, 100], ["tissue autofluorescence", "TEST", 122, 145]]], ["The field of view is cropped to the size of the brain, and the z-steps are set to 6\u03bcm, and light sheet numerical aperture to 0.03 NA.Viral RNA analysis. :::At indicated time points mice were euthanized in 100% Isoflurane.", [["brain", "ANATOMY", 48, 53], ["Isoflurane", "CHEMICAL", 210, 220], ["Isoflurane", "CHEMICAL", 210, 220], ["brain", "ORGAN", 48, 53], ["mice", "ORGANISM", 181, 185], ["Isoflurane", "SIMPLE_CHEMICAL", 210, 220], ["Viral RNA", "RNA", 133, 142], ["mice", "SPECIES", 181, 185], ["mice", "SPECIES", 181, 185], ["light sheet numerical aperture", "TEST", 91, 121], ["Viral RNA analysis", "TEST", 133, 151], ["Isoflurane", "TREATMENT", 210, 220], ["size", "OBSERVATION_MODIFIER", 36, 40], ["brain", "ANATOMY", 48, 53]]], ["Brain tissue was placed in a bead homogenizer tube with 1ml of PBS+2%FBS.", [["Brain tissue", "ANATOMY", 0, 12], ["FBS", "ANATOMY", 69, 72], ["Brain tissue", "TISSUE", 0, 12], ["FBS", "ORGANISM_SUBSTANCE", 69, 72], ["Brain tissue", "PROBLEM", 0, 12], ["a bead homogenizer tube", "TREATMENT", 27, 50], ["PBS", "TREATMENT", 63, 66], ["tissue", "OBSERVATION", 6, 12]]], ["After homogenization 250ul of this mixture was placed in 750ul Trizol LS (Invitrogen), and RNA was extracted with RNeasy mini kit (Qiagen) per manufacturer protocol.", [["this mixture", "TREATMENT", 30, 42], ["Trizol LS", "TREATMENT", 63, 72], ["RNeasy mini kit", "TREATMENT", 114, 129]]], ["To quantify SARS-CoV-2 RNA levels, RT-qPCR was performed using Luna Universal Probe Onestep RT-qPCR kits (New England Biolabs) with 1 ug of RNA, with the US CDC real-time RT-PCR primer/probe sets for 2019-nCoV_N1.Viral titer. :::Brain homogenates were centrifuged at 3900g for 10 minutes and supernatant was taken for plaque assays.", [["Brain homogenates", "ANATOMY", 229, 246], ["supernatant", "ANATOMY", 292, 303], ["plaque", "ANATOMY", 318, 324], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 12, 22], ["Brain homogenates", "ORGANISM_SUBSTANCE", 229, 246], ["SARS-CoV-2 RNA", "RNA", 12, 26], ["US CDC real-time RT-PCR primer", "DNA", 154, 184], ["2019-nCoV_N1", "DNA", 200, 212], ["SARS", "TEST", 12, 16], ["CoV", "TEST", 17, 20], ["RNA levels", "TEST", 23, 33], ["RT-qPCR", "TEST", 35, 42], ["the US CDC", "TEST", 150, 160], ["PCR primer", "TEST", 174, 184], ["Viral titer", "TEST", 213, 224], ["Brain homogenates", "TEST", 229, 246], ["plaque assays", "PROBLEM", 318, 331], ["titer", "OBSERVATION", 219, 224], ["plaque", "OBSERVATION", 318, 324]]], ["Supernatant at limiting dilutions were incubated on Vero E6 cells in MEM supplemented NaHCO3, 4% FBS 0.6% Avicel RC-581.", [["Supernatant", "ANATOMY", 0, 11], ["cells", "ANATOMY", 60, 65], ["MEM", "CHEMICAL", 69, 72], ["NaHCO3", "CHEMICAL", 86, 92], ["Avicel RC-581", "CHEMICAL", 106, 119], ["NaHCO3", "CHEMICAL", 86, 92], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["Vero E6 cells", "CELL", 52, 65], ["NaHCO3", "SIMPLE_CHEMICAL", 86, 92], ["FBS", "ORGANISM_SUBSTANCE", 97, 100], ["Avicel RC-581", "SIMPLE_CHEMICAL", 106, 119], ["Vero E6 cells", "CELL_LINE", 52, 65], ["Vero E6", "SPECIES", 52, 59], ["Supernatant at limiting dilutions", "PROBLEM", 0, 33], ["Vero E6 cells", "TREATMENT", 52, 65], ["MEM supplemented NaHCO3", "TREATMENT", 69, 92], ["FBS", "TEST", 97, 100], ["Avicel RC", "TEST", 106, 115]]], ["Plaques were resolved at 48hrs post infection by fixing in 10% formaldehyde for 1 hour followed by staining for 1 hour in 0.5% crystal violet in 20% ethanol.Stem cell culture. :::Human Y6 and Y1 iPS lines were obtained from Yale Stem Cell Center and New York Cell Stem Foundation respectively.", [["Plaques", "ANATOMY", 0, 7], ["Stem cell", "ANATOMY", 157, 166], ["Y6", "ANATOMY", 185, 187], ["iPS lines", "ANATOMY", 195, 204], ["Cell", "ANATOMY", 234, 238], ["infection", "DISEASE", 36, 45], ["formaldehyde", "CHEMICAL", 63, 75], ["crystal violet", "CHEMICAL", 127, 141], ["ethanol", "CHEMICAL", 149, 156], ["formaldehyde", "CHEMICAL", 63, 75], ["ethanol", "CHEMICAL", 149, 156], ["formaldehyde", "SIMPLE_CHEMICAL", 63, 75], ["ethanol", "SIMPLE_CHEMICAL", 149, 156], ["Stem cell", "CELL", 157, 166], ["Human", "ORGANISM", 179, 184], ["Y6", "CELL", 185, 187], ["Y1 iPS lines", "CELL", 192, 204], ["Stem cell culture", "CELL_LINE", 157, 174], ["Human Y6 and Y1 iPS lines", "CELL_LINE", 179, 204], ["Human", "SPECIES", 179, 184], ["Human", "SPECIES", 179, 184], ["Plaques", "PROBLEM", 0, 7], ["infection", "PROBLEM", 36, 45], ["Stem cell culture", "TEST", 157, 174], ["Human Y6 and Y1 iPS lines", "TREATMENT", 179, 204], ["infection", "OBSERVATION", 36, 45], ["iPS lines", "OBSERVATION", 195, 204], ["New", "OBSERVATION_MODIFIER", 250, 253], ["York Cell Stem", "OBSERVATION", 254, 268]]], ["Cells were verified as being pluripotent, having normal karyotype, mycoplasma free and cultured in feeder-free conditions on matrigel-coated plates with mTeSR Plus culture media (Stem Cell Technologies) and passaged using ReLeSR (Stem Cell Technologies).Teratoma formation. :::1\u00d7106 Y6 iPSC cells were collected by collagenase treatment, and resuspended in 100 ml of DMEM/F12, collagen, and matrigel mix (2:1:1 ratio).", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 184, 188], ["Cell", "ANATOMY", 235, 239], ["Teratoma", "ANATOMY", 254, 262], ["::1\u00d7106 Y6 iPSC cells", "ANATOMY", 275, 296], ["matrigel", "ANATOMY", 391, 399], ["Teratoma", "DISEASE", 254, 262], ["Cells", "CELL", 0, 5], ["Teratoma", "CANCER", 254, 262], ["::1\u00d7106 Y6 iPSC cells", "CELL", 275, 296], ["collagenase", "GENE_OR_GENE_PRODUCT", 315, 326], ["F12", "CELL", 372, 375], ["collagen", "GENE_OR_GENE_PRODUCT", 377, 385], ["::1\u00d7106 Y6 iPSC cells", "CELL_LINE", 275, 296], ["collagenase", "PROTEIN", 315, 326], ["collagen", "PROTEIN", 377, 385], ["Cells", "TEST", 0, 5], ["mycoplasma", "PROBLEM", 67, 77], ["matrigel-coated plates", "TREATMENT", 125, 147], ["mTeSR", "TREATMENT", 153, 158], ["culture media", "TREATMENT", 164, 177], ["Stem Cell Technologies", "TREATMENT", 179, 201], ["Teratoma formation", "PROBLEM", 254, 272], ["iPSC cells", "TEST", 286, 296], ["collagenase treatment", "TREATMENT", 315, 336], ["DMEM/F12", "TREATMENT", 367, 375], ["collagen", "TREATMENT", 377, 385]]], ["Cells were intramuscularly injected into immunodeficient Rag2\u2212/\u2212GammaC\u2212/\u2212 mouse.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Rag2\u2212", "GENE_OR_GENE_PRODUCT", 57, 62], ["GammaC", "GENE_OR_GENE_PRODUCT", 64, 70], ["GammaC", "PROTEIN", 64, 70], ["mouse", "SPECIES", 74, 79], ["mouse", "SPECIES", 74, 79], ["Cells", "TEST", 0, 5]]], ["After 8 weeks, teratomas were harvested, fixed, and subjected to paraffin-embedding and haematoxylin and eosin (H/E) staining.G-band staining for Karyotype analysis. :::Y6 iPSC small clumps were seeded on glass slide pre-coated with Matrigel and fed with mTESR medium for three days.", [["teratomas", "ANATOMY", 15, 24], ["iPSC", "ANATOMY", 172, 176], ["paraffin", "CHEMICAL", 65, 73], ["haematoxylin", "CHEMICAL", 88, 100], ["eosin", "CHEMICAL", 105, 110], ["teratomas", "CANCER", 15, 24], ["haematoxylin", "SIMPLE_CHEMICAL", 88, 100], ["Y6 iPSC small clumps", "CELL_LINE", 169, 189], ["teratomas", "PROBLEM", 15, 24], ["haematoxylin", "TREATMENT", 88, 100], ["band staining", "TEST", 128, 141], ["Karyotype analysis", "TEST", 146, 164], ["iPSC small clumps", "PROBLEM", 172, 189], ["Matrigel", "TREATMENT", 233, 241], ["mTESR medium", "TREATMENT", 255, 267], ["teratomas", "OBSERVATION", 15, 24], ["harvested", "OBSERVATION", 30, 39], ["small", "OBSERVATION_MODIFIER", 177, 182], ["clumps", "OBSERVATION", 183, 189]]], ["Then, medium were switched to DMEM basal medium supplemented with 10% of FBS for another 3 days.", [["FBS", "ANATOMY", 73, 76], ["FBS", "ORGANISM_SUBSTANCE", 73, 76], ["DMEM basal medium", "TREATMENT", 30, 47], ["FBS", "TREATMENT", 73, 76]]], ["Then the slide was transferred to Yale Cytogenetic laboratory for G-band staining.Neural Progenitor Cell culture. :::Y6 iPS lines were differentiated to NPCs on matrigel-coated plates using the monolayer protocol of the StemDiff SMADI Neural Induction kit (Catalog #08581, Stem Cell Technologies) for two passages and then maintained in StemDiff Neural Progenitor media (Catalog #05833, Stem Cell Technologies).", [["Cell", "ANATOMY", 100, 104], ["Y6 iPS lines", "ANATOMY", 117, 129], ["NPCs", "ANATOMY", 153, 157], ["Cell", "ANATOMY", 278, 282], ["Cell", "ANATOMY", 392, 396], ["Neural Progenitor Cell", "CELL", 82, 104], [":::Y6 iPS lines", "CELL", 114, 129], ["NPCs", "CELL", 153, 157], ["matrigel", "CELL", 161, 169], ["Neural Progenitor Cell culture", "CELL_LINE", 82, 112], ["Y6 iPS lines", "CELL_LINE", 117, 129], ["NPCs", "CELL_TYPE", 153, 157], ["band staining", "PROBLEM", 68, 81], ["Neural Progenitor Cell culture", "TEST", 82, 112], ["Y6 iPS lines", "TREATMENT", 117, 129], ["matrigel-coated plates", "TREATMENT", 161, 183], ["the monolayer protocol", "TREATMENT", 190, 212], ["the StemDiff SMADI", "TREATMENT", 216, 234], ["Stem Cell Technologies", "TREATMENT", 273, 295], ["Stem Cell Technologies", "TREATMENT", 387, 409], ["Progenitor Cell culture", "OBSERVATION", 89, 112], ["iPS lines", "OBSERVATION", 120, 129], ["Neural Progenitor", "ANATOMY", 346, 363], ["Stem Cell", "OBSERVATION", 387, 396]]], ["Twelve-day NPCs were used for all experiments.Cerebral organoid culture. :::For preparation of embryoid bodies, 9000 single cells were seeded in each well of low attachment 96-well U-bottom plate and 10 \u03bcM Y-27632 ROCK inhibitor for one day.", [["NPCs", "ANATOMY", 11, 15], ["Cerebral organoid culture", "ANATOMY", 46, 71], ["embryoid bodies", "ANATOMY", 95, 110], ["cells", "ANATOMY", 124, 129], ["Y-27632", "CHEMICAL", 206, 213], ["Y-27632", "CHEMICAL", 206, 213], ["NPCs", "CELL", 11, 15], ["embryoid bodies", "CELL", 95, 110], ["single cells", "CELL", 117, 129], ["Y-27632 ROCK", "GENE_OR_GENE_PRODUCT", 206, 218], ["NPCs", "CELL_TYPE", 11, 15], ["9000 single cells", "CELL_LINE", 112, 129], ["Twelve-day NPCs", "TREATMENT", 0, 15], ["Cerebral organoid culture", "TEST", 46, 71], ["preparation of embryoid bodies", "TREATMENT", 80, 110], ["single cells", "TREATMENT", 117, 129], ["bottom plate", "TREATMENT", 183, 195], ["ROCK inhibitor", "TREATMENT", 214, 228], ["embryoid bodies", "OBSERVATION", 95, 110]]], ["Cerebral organoids were generated following exactly the previously established protocol(Lancaster and Knoblich, 2014; Lancaster et al., 2013), using an orbital shaker for agitation.Immunostaining. :::Brains of infected mice and organoids were collected and fixed in 4% PFA.", [["Cerebral organoids", "ANATOMY", 0, 18], ["Brains", "ANATOMY", 200, 206], ["organoids", "ANATOMY", 228, 237], ["agitation", "DISEASE", 171, 180], ["PFA", "CHEMICAL", 269, 272], ["Cerebral organoids", "CELL", 0, 18], ["mice", "ORGANISM", 219, 223], ["organoids", "CELL", 228, 237], ["PFA", "SIMPLE_CHEMICAL", 269, 272], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 219, 223], ["an orbital shaker", "TREATMENT", 149, 166], ["agitation", "PROBLEM", 171, 180], ["Immunostaining", "TEST", 181, 195], ["orbital", "ANATOMY", 152, 159], ["infected", "OBSERVATION", 210, 218]]], ["Samples were then dehydrated in a 30% sucrose solution.", [["Samples", "ANATOMY", 0, 7], ["sucrose", "CHEMICAL", 38, 45], ["sucrose", "CHEMICAL", 38, 45], ["sucrose", "SIMPLE_CHEMICAL", 38, 45], ["Samples", "TEST", 0, 7], ["a 30% sucrose solution", "TREATMENT", 32, 54]]], ["Cryostat sections were blocked in 0.1 M Tris-HCl buffer with 0.3% Triton and 1% FBS before staining.", [["Cryostat sections", "ANATOMY", 0, 17], ["FBS", "ANATOMY", 80, 83], ["Tris-HCl", "CHEMICAL", 40, 48], ["Triton", "CHEMICAL", 66, 72], ["Tris-HCl", "CHEMICAL", 40, 48], ["Cryostat sections", "CANCER", 0, 17], ["Tris-HCl", "SIMPLE_CHEMICAL", 40, 48], ["Triton", "SIMPLE_CHEMICAL", 66, 72], ["FBS", "ORGANISM_SUBSTANCE", 80, 83], ["Cryostat sections", "TEST", 0, 17], ["0.3% Triton", "TREATMENT", 61, 72]]], ["Slides were stained for IBA-1 (nb100\u20131028, Novus Biologicals), GFAP (ab4674, abcam and rabbit anti-SARS-CoV-2 nucleocapsid (GeneTex) Slides were mounted with Prolong Gold Antifade reagent (Thermo fisher).", [["IBA-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["nb100\u20131028", "SIMPLE_CHEMICAL", 31, 41], ["Novus Biologicals", "ORGANISM", 43, 60], ["GFAP", "GENE_OR_GENE_PRODUCT", 63, 67], ["ab4674", "GENE_OR_GENE_PRODUCT", 69, 75], ["abcam", "GENE_OR_GENE_PRODUCT", 77, 82], ["rabbit", "ORGANISM", 87, 93], ["Novus Biologicals", "PROTEIN", 43, 60], ["GFAP", "PROTEIN", 63, 67], ["ab4674", "PROTEIN", 69, 75], ["abcam", "PROTEIN", 77, 82], ["CoV", "PROTEIN", 104, 107], ["rabbit", "SPECIES", 87, 93], ["rabbit", "SPECIES", 87, 93], ["Slides", "TEST", 0, 6], ["IBA", "TEST", 24, 27], ["GFAP", "TEST", 63, 67], ["abcam", "TEST", 77, 82], ["rabbit", "TEST", 87, 93], ["anti-SARS", "TEST", 94, 103], ["CoV", "TEST", 104, 107]]], ["All slides were analyzed by fluorescence microscopy (BX51; Olympus).Immunostaining. :::Organoids were fixed in 4% PFA in a BSL3 facility then moved to 30% sucrose solution at 4\u00b0C for at least 24h.", [["sucrose", "CHEMICAL", 155, 162], ["PFA", "CHEMICAL", 114, 117], ["sucrose", "CHEMICAL", 155, 162], ["PFA", "SIMPLE_CHEMICAL", 114, 117], ["sucrose", "SIMPLE_CHEMICAL", 155, 162], ["C", "SIMPLE_CHEMICAL", 177, 178], ["All slides", "TEST", 0, 10], ["fluorescence microscopy", "TEST", 28, 51], ["Immunostaining", "TEST", 68, 82], ["30% sucrose solution", "TREATMENT", 151, 171]]], ["Organoids were then embedded in Tissue Freezing Medium (TFM) and cut into 20 \u03bcm sections using a cryostat and mounted on slides.", [["Tissue", "ANATOMY", 32, 38], ["sections", "ANATOMY", 80, 88], ["Tissue", "TISSUE", 32, 38], ["Tissue Freezing Medium (TFM)", "TREATMENT", 32, 60], ["a cryostat", "TREATMENT", 95, 105]]], ["After blocking and permeabilization with 0.25% Triton-X 100 and 4% donkey serum, sections were incubated overnight with primary antibody: ms anti-Pax6 (1:300, BD Pharmingen, #561462), rb anti-ACE2 (1:500, Abcam, ab15348), ms anti-Sox2 (1:500, Santa Cruz, sc-365823), rat anti-CTIP2 (1:500, Abcam, ab18465), rb anti-TBR1 (1:500, Abcam, ab31940), ms anti-MAP2 (1:500, Millipore, MAB3418), rb anti-SARS-CoV-2 nucleocapsid (1:250, GeneTex, GTX635679), rb anti-HIF1 alpha antibody (Genetex, GTX127309).", [["serum", "ANATOMY", 74, 79], ["sections", "ANATOMY", 81, 89], ["Triton-X 100", "CHEMICAL", 47, 59], ["sc-365823", "CHEMICAL", 255, 264], ["GTX127309", "CHEMICAL", 486, 495], ["Triton-X 100", "SIMPLE_CHEMICAL", 47, 59], ["donkey", "ORGANISM", 67, 73], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["sections", "MULTI-TISSUE_STRUCTURE", 81, 89], ["anti-Pax6", "GENE_OR_GENE_PRODUCT", 141, 150], ["rb anti-ACE2", "SIMPLE_CHEMICAL", 184, 196], ["Abcam", "GENE_OR_GENE_PRODUCT", 205, 210], ["anti-Sox2", "SIMPLE_CHEMICAL", 225, 234], ["sc-365823", "SIMPLE_CHEMICAL", 255, 264], ["rat", "ORGANISM", 267, 270], ["anti-CTIP2", "SIMPLE_CHEMICAL", 271, 281], ["Abcam", "GENE_OR_GENE_PRODUCT", 290, 295], ["rb anti-TBR1", "SIMPLE_CHEMICAL", 307, 319], ["Abcam", "GENE_OR_GENE_PRODUCT", 328, 333], ["anti-MAP2", "SIMPLE_CHEMICAL", 348, 357], ["MAB3418", "SIMPLE_CHEMICAL", 377, 384], ["GeneTex", "SIMPLE_CHEMICAL", 427, 434], ["GTX635679", "SIMPLE_CHEMICAL", 436, 445], ["rb anti-HIF1 alpha", "GENE_OR_GENE_PRODUCT", 448, 466], ["primary antibody: ms anti-Pax6", "PROTEIN", 120, 150], ["BD Pharmingen", "PROTEIN", 159, 172], ["rb anti-ACE2", "PROTEIN", 184, 196], ["anti-Sox2", "PROTEIN", 225, 234], ["rat anti-CTIP2", "PROTEIN", 267, 281], ["1:500, Abcam, ab18465", "PROTEIN", 283, 304], ["rb anti-TBR1", "PROTEIN", 307, 319], ["1:500, Abcam, ab31940", "PROTEIN", 321, 342], ["anti-MAP2", "PROTEIN", 348, 357], ["1:500, Millipore, MAB3418), rb anti-SARS-CoV-2 nucleocapsid", "PROTEIN", 359, 418], ["1:250", "PROTEIN", 420, 425], ["GeneTex", "PROTEIN", 427, 434], ["GTX635679", "PROTEIN", 436, 445], ["rb", "PROTEIN", 448, 450], ["anti-HIF1 alpha antibody", "PROTEIN", 451, 475], ["donkey", "SPECIES", 67, 73], ["rat", "SPECIES", 267, 270], ["donkey", "SPECIES", 67, 73], ["rat", "SPECIES", 267, 270], ["blocking and permeabilization", "TREATMENT", 6, 35], ["0.25% Triton", "TREATMENT", 41, 53], ["BD Pharmingen", "TEST", 159, 172], ["rb anti-ACE2", "TEST", 184, 196], ["Abcam", "TEST", 205, 210], ["ab", "TEST", 212, 214], ["ms anti-Sox2", "TEST", 222, 234], ["rat anti-CTIP2", "TEST", 267, 281], ["Abcam", "TEST", 290, 295], ["Abcam", "TEST", 328, 333], ["ab", "TEST", 335, 337], ["ms anti-MAP2", "TEST", 345, 357], ["Millipore", "TEST", 366, 375], ["rb anti-SARS", "TEST", 387, 399], ["CoV", "TEST", 400, 403], ["GeneTex", "TEST", 427, 434], ["rb anti-HIF1 alpha antibody", "TEST", 448, 475]]], ["TUNEL assay was performed using the Click-It Plus TUNEL Assay for In Situ Apoptosis Detection (Thermofisher, C10617) per the manufacturer\u2019s instructions.", [["TUNEL assay", "TEST", 0, 11], ["the Click", "TEST", 32, 41], ["TUNEL Assay", "TEST", 50, 61]]], ["Alexa Fluor 488, 555, 647 antibodies were applied for 1hr at room temperature (1:500) after three 10min PBS washes.", [["Alexa Fluor 488", "CHEMICAL", 0, 15], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 0, 15], ["647 antibodies", "SIMPLE_CHEMICAL", 22, 36], ["Alexa Fluor 488, 555, 647 antibodies", "PROTEIN", 0, 36], ["Alexa Fluor", "TEST", 0, 11], ["antibodies", "TEST", 26, 36], ["three 10min PBS washes", "TREATMENT", 92, 114]]], ["To mark nuclei, DAPI (1:3000) was added to the secondary antibody incubation.", [["nuclei", "ANATOMY", 8, 14], ["DAPI", "CHEMICAL", 16, 20], ["nuclei", "CELLULAR_COMPONENT", 8, 14], ["DAPI", "SIMPLE_CHEMICAL", 16, 20], ["the secondary antibody incubation", "TREATMENT", 43, 76], ["nuclei", "ANATOMY", 8, 14], ["secondary", "OBSERVATION", 47, 56], ["antibody incubation", "OBSERVATION", 57, 76]]], ["Slides were then washed three times in PBS and then mounted with VectaShield Anti-Fade Mounting Medium.", [["PBS", "TREATMENT", 39, 42]]], ["Images were acquired using a Zeiss LSM 880 confocal microscope (Carl Zeiss) and prepared using Fiji (NIH).Immunostaining. :::Neural progenitor cells on coverslips were fixed in 4% PFA for 15 minutes at room temperature in BSL3 conditions and washed 3x with PBS.", [["Neural progenitor cells", "ANATOMY", 125, 148], ["coverslips", "ANATOMY", 152, 162], ["PFA", "CHEMICAL", 180, 183], ["Neural progenitor cells", "CELL", 125, 148], ["coverslips", "CELL", 152, 162], ["PFA", "SIMPLE_CHEMICAL", 180, 183], ["Neural progenitor cells", "CELL_TYPE", 125, 148], ["Images", "TEST", 0, 6], ["Immunostaining", "TEST", 106, 120], ["Neural progenitor cells on coverslips", "TREATMENT", 125, 162], ["PBS", "TREATMENT", 257, 260], ["progenitor cells", "OBSERVATION", 132, 148]]], ["After blocking and permeabilization with 0.25% Triton-X 100 and 10% donkey serum, coverslips were incubated overnight with primary antibody as described above.", [["serum", "ANATOMY", 75, 80], ["coverslips", "ANATOMY", 82, 92], ["Triton-X 100", "CHEMICAL", 47, 59], ["Triton-X 100", "SIMPLE_CHEMICAL", 47, 59], ["donkey", "ORGANISM", 68, 74], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["coverslips", "CELL", 82, 92], ["primary antibody", "PROTEIN", 123, 139], ["donkey", "SPECIES", 68, 74], ["donkey", "SPECIES", 68, 74], ["blocking and permeabilization", "TREATMENT", 6, 35], ["0.25% Triton", "TREATMENT", 41, 53], ["primary antibody", "TEST", 123, 139]]], ["TUNEL assay was performed as described above.", [["TUNEL assay", "TEST", 0, 11]]], ["Alexa Flour 488, 555, and 647 antibodies were applied for 1hr at room temperature (1:500) after three 10min PBS washes.", [["647 antibodies", "SIMPLE_CHEMICAL", 26, 40], ["Alexa Flour 488, 555, and 647 antibodies", "PROTEIN", 0, 40], ["Alexa Flour", "TEST", 0, 11], ["three 10min PBS washes", "TREATMENT", 96, 118]]], ["Coverslips were then washed three times in PBS and then mounted on slides with Prolong Diamond Anti-Fade Mountant with DAPI (Thermofisher).", [["DAPI", "CHEMICAL", 119, 123], ["DAPI", "SIMPLE_CHEMICAL", 119, 123], ["Coverslips", "TREATMENT", 0, 10], ["DAPI (Thermofisher)", "TREATMENT", 119, 138]]], ["Images were acquired using a Zeiss LSM 880 confocal microscope (Carl Zeiss) and prepared using Fiji (NIH).Immunostaining. :::Human Formalin-fixed Paraffin sections were heated for 30 minutes at 60\u00b0C and treated with xylenes followed by rehydration in decreasing concentrations of ethanol (100%, 90%, 80% 70%).", [["Paraffin sections", "ANATOMY", 146, 163], ["xylenes", "CHEMICAL", 216, 223], ["ethanol", "CHEMICAL", 280, 287], ["xylenes", "CHEMICAL", 216, 223], ["ethanol", "CHEMICAL", 280, 287], ["Human", "ORGANISM", 125, 130], ["Paraffin sections", "CANCER", 146, 163], ["C", "SIMPLE_CHEMICAL", 197, 198], ["xylenes", "SIMPLE_CHEMICAL", 216, 223], ["ethanol", "SIMPLE_CHEMICAL", 280, 287], ["Human", "SPECIES", 125, 130], ["Human", "SPECIES", 125, 130], ["Images", "TEST", 0, 6], ["Immunostaining", "TEST", 106, 120], ["Human Formalin-fixed Paraffin sections", "TREATMENT", 125, 163], ["xylenes", "TREATMENT", 216, 223], ["rehydration", "TREATMENT", 236, 247], ["ethanol", "TREATMENT", 280, 287]]], ["Antigen retrieval was performed using a pressure cooker (Biocare Decloaking Chamber) by boiling in sodium citrate (pH 6.0) for 20 minutes at 115 degrees.", [["sodium citrate", "CHEMICAL", 99, 113], ["sodium citrate", "CHEMICAL", 99, 113], ["sodium citrate", "SIMPLE_CHEMICAL", 99, 113], ["Antigen retrieval", "TREATMENT", 0, 17], ["a pressure cooker (Biocare Decloaking Chamber", "TREATMENT", 38, 83], ["sodium citrate", "TREATMENT", 99, 113], ["pH", "TEST", 115, 117]]], ["After blocking and permeabilization with 0.25% Triton X 100 and 4% donkey serum, sections were incubated overnight with primary antibody: rb anti-ACE2 (1:500, ab15348, Abcam), ms anti-NeuN (1:500, ab104224, Abcam).", [["serum", "ANATOMY", 74, 79], ["sections", "ANATOMY", 81, 89], ["Triton X 100", "CHEMICAL", 47, 59], ["Triton X 100", "SIMPLE_CHEMICAL", 47, 59], ["donkey", "ORGANISM", 67, 73], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["sections", "MULTI-TISSUE_STRUCTURE", 81, 89], ["rb anti-ACE2", "SIMPLE_CHEMICAL", 138, 150], ["Abcam", "GENE_OR_GENE_PRODUCT", 168, 173], ["NeuN", "GENE_OR_GENE_PRODUCT", 184, 188], ["Abcam", "GENE_OR_GENE_PRODUCT", 207, 212], ["primary antibody", "PROTEIN", 120, 136], ["rb anti-ACE2", "PROTEIN", 138, 150], ["1:500", "PROTEIN", 152, 157], ["ab15348", "PROTEIN", 159, 166], ["Abcam", "PROTEIN", 168, 173], ["NeuN", "PROTEIN", 184, 188], ["1:500", "PROTEIN", 190, 195], ["ab104224", "PROTEIN", 197, 205], ["Abcam", "PROTEIN", 207, 212], ["donkey", "SPECIES", 67, 73], ["donkey", "SPECIES", 67, 73], ["blocking and permeabilization", "TREATMENT", 6, 35], ["0.25% Triton", "TREATMENT", 41, 53], ["donkey serum, sections", "TEST", 67, 89], ["Abcam", "TEST", 168, 173], ["ms anti-NeuN", "TEST", 176, 188], ["Abcam", "TEST", 207, 212]]], ["Alexa Fluor 488, 555 antibodies were applied for 1 hr at room temperature (1:500) after three 10min PBS washes.", [["Alexa Fluor 488", "CHEMICAL", 0, 15], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 0, 15], ["555 antibodies", "SIMPLE_CHEMICAL", 17, 31], ["Alexa Fluor 488, 555 antibodies", "PROTEIN", 0, 31], ["Alexa Fluor", "TEST", 0, 11], ["three 10min PBS washes", "TREATMENT", 88, 110]]], ["To mark nuclei, DAPI (1:3000) was added to the secondary antibody incubation.", [["nuclei", "ANATOMY", 8, 14], ["DAPI", "CHEMICAL", 16, 20], ["nuclei", "CELLULAR_COMPONENT", 8, 14], ["DAPI", "SIMPLE_CHEMICAL", 16, 20], ["the secondary antibody incubation", "TREATMENT", 43, 76], ["nuclei", "ANATOMY", 8, 14], ["secondary", "OBSERVATION", 47, 56], ["antibody incubation", "OBSERVATION", 57, 76]]], ["Slides were then washed three times in PBS to remove detergent and treated with TrueBlack Lipofuscin Autofluorescence Quencher (Biotium) according to the manufacturer\u2019s instructions.", [["PBS", "TREATMENT", 39, 42], ["detergent", "TREATMENT", 53, 62], ["TrueBlack Lipofuscin Autofluorescence Quencher (Biotium)", "TREATMENT", 80, 136]]], ["Images were acquired using a Zeiss LSM 880 confocal microscope (Carl Zeiss) and prepared using Fiji (NIH).Electron microscopy. :::Organoids were fixed using 2.5% glutaraldehyde in 0.1M phosphate buffer, osmicated in 1% osmium tetroxide, and dehydrated in ethanol.", [["glutaraldehyde", "CHEMICAL", 162, 176], ["0.1M phosphate", "CHEMICAL", 180, 194], ["osmium tetroxide", "CHEMICAL", 219, 235], ["ethanol", "CHEMICAL", 255, 262], ["glutaraldehyde", "CHEMICAL", 162, 176], ["phosphate", "CHEMICAL", 185, 194], ["osmium tetroxide", "CHEMICAL", 219, 235], ["ethanol", "CHEMICAL", 255, 262], ["glutaraldehyde", "SIMPLE_CHEMICAL", 162, 176], ["0.1M phosphate buffer", "SIMPLE_CHEMICAL", 180, 201], ["osmium tetroxide", "SIMPLE_CHEMICAL", 219, 235], ["ethanol", "SIMPLE_CHEMICAL", 255, 262], ["Images", "TEST", 0, 6], ["Electron microscopy", "TEST", 106, 125], ["2.5% glutaraldehyde in 0.1M phosphate buffer", "TREATMENT", 157, 201], ["1% osmium tetroxide", "TREATMENT", 216, 235]]], ["During dehydration, 1% uranyl acetate was added to the 70% ethanol to enhance ultrastructural membrane contrast.", [["membrane", "ANATOMY", 94, 102], ["dehydration", "DISEASE", 7, 18], ["uranyl acetate", "CHEMICAL", 23, 37], ["ethanol", "CHEMICAL", 59, 66], ["uranyl acetate", "CHEMICAL", 23, 37], ["ethanol", "CHEMICAL", 59, 66], ["uranyl acetate", "SIMPLE_CHEMICAL", 23, 37], ["ethanol", "SIMPLE_CHEMICAL", 59, 66], ["membrane", "CELLULAR_COMPONENT", 94, 102], ["dehydration", "PROBLEM", 7, 18], ["1% uranyl acetate", "TREATMENT", 20, 37], ["ultrastructural membrane contrast", "TEST", 78, 111]]], ["After dehydration the organoids were embedded in Durcupan and 70 nm sections were cut on a Leica ultramicrotome, collected on Formvar coated single-slot grids, and imaged on a Tecnai 12 Biotwin electron microscope (FEI).Single-cell RNA-seq. :::Organoids were collected and single cell suspensions were made using a papain dissociation system (Worthington Biochemical Corporation).", [["organoids", "ANATOMY", 22, 31], ["sections", "ANATOMY", 68, 76], ["Organoids", "ANATOMY", 244, 253], ["cell", "ANATOMY", 280, 284], ["dehydration", "DISEASE", 6, 17], ["organoids", "CELL", 22, 31], ["cell suspensions", "CELL", 280, 296], ["dehydration the organoids", "PROBLEM", 6, 31], ["Durcupan", "TREATMENT", 49, 57], ["a Leica ultramicrotome", "TREATMENT", 89, 111], ["Formvar coated single-slot grids", "TREATMENT", 126, 158], ["single cell suspensions", "TREATMENT", 273, 296], ["a papain dissociation system", "TREATMENT", 313, 341], ["cell RNA", "OBSERVATION", 227, 235]]], ["Single-cell suspensions were loaded onto the Chromium Controller (10x Genomics) for droplet formation. scRNA-seq libraries were prepared using the Chromium Single Cell 3\u2032 Reagent Kit (10x Genomics.", [["cell", "ANATOMY", 7, 11], ["Chromium", "CHEMICAL", 45, 53], ["Chromium", "CHEMICAL", 147, 155], ["Chromium", "CHEMICAL", 45, 53], ["Chromium", "CHEMICAL", 147, 155], ["scRNA-seq libraries", "DNA", 103, 122], ["Single-cell suspensions", "TREATMENT", 0, 23], ["the Chromium Controller", "TREATMENT", 41, 64], ["droplet formation", "PROBLEM", 84, 101]]], ["Samples were sequenced on the on the NovaSeq.Single-cell RNA-seq. :::R v.3.4.2 (R Core Team 2013) was used for all statistical analysis.", [["Samples", "ANATOMY", 0, 7], ["NovaSeq", "DNA", 37, 44], ["Samples", "TEST", 0, 7], ["the NovaSeq", "TREATMENT", 33, 44], ["all statistical analysis", "TEST", 111, 135]]], ["Sequencing results were demultiplexed into Fastq files using the Cell Ranger (10x Genomics, 3.0.2) mkfastq function.", [["Cell", "ANATOMY", 65, 69], ["Fastq files", "DNA", 43, 54], ["Sequencing results", "TEST", 0, 18]]], ["Samples were aligned to GRCh38 10x genome.", [["Samples", "ANATOMY", 0, 7], ["GRCh38 10x genome", "DNA", 24, 41], ["Samples", "TEST", 0, 7]]], ["The count matrix was generated using the count function with default settings.", [["The count matrix", "TEST", 0, 16], ["the count function", "TEST", 37, 55], ["default settings", "TREATMENT", 61, 77]]], ["Matrices were loaded into Seurat v.3.", [["Seurat v.3", "CELL_LINE", 26, 36]]], ["1.5 for downstream analysis.", [["downstream analysis", "TEST", 8, 27]]], ["Cells with less than 200 unique molecular identifiers, or high mitochondrial content were discarded.", [["Cells", "ANATOMY", 0, 5], ["mitochondrial", "ANATOMY", 63, 76], ["Cells", "CELL", 0, 5], ["mitochondrial", "CELLULAR_COMPONENT", 63, 76], ["Cells", "TEST", 0, 5], ["high mitochondrial content", "PROBLEM", 58, 84], ["mitochondrial content", "OBSERVATION", 63, 84]]], ["Using FindIntegrationAnchors and IntegrateData functions, all libraries were integrated into a single matrix.", [["matrix", "CELLULAR_COMPONENT", 102, 108], ["FindIntegrationAnchors", "TREATMENT", 6, 28], ["IntegrateData functions", "TREATMENT", 33, 56], ["all libraries", "TREATMENT", 58, 71]]], ["Principal component values that were statistically significant were identified, and a cut-off point was determined using the inflection point after using the PCElbowPlot function.", [["the PCElbowPlot function", "TEST", 154, 178]]], ["Cells were considered infected if transcripts aligned to viral ORF1ab, Surface glycoprotein (S), ORF3a, Envelope protein (E), Membrane glycoprotein (M), ORF6, ORF7a, ORF8, Nucleocapsid phosphoprotein (N) or ORF10.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 63, 69], ["Surface glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 71, 95], ["ORF3a", "GENE_OR_GENE_PRODUCT", 97, 102], ["Envelope protein (E)", "GENE_OR_GENE_PRODUCT", 104, 124], ["Membrane glycoprotein (M)", "GENE_OR_GENE_PRODUCT", 126, 151], ["ORF6", "GENE_OR_GENE_PRODUCT", 153, 157], ["ORF7a", "GENE_OR_GENE_PRODUCT", 159, 164], ["ORF8", "GENE_OR_GENE_PRODUCT", 166, 170], ["Nucleocapsid phosphoprotein (N)", "GENE_OR_GENE_PRODUCT", 172, 203], ["ORF10", "GENE_OR_GENE_PRODUCT", 207, 212], ["viral ORF1ab", "PROTEIN", 57, 69], ["Surface glycoprotein", "PROTEIN", 71, 91], ["S", "PROTEIN", 93, 94], ["ORF3a", "PROTEIN", 97, 102], ["Envelope protein", "PROTEIN", 104, 120], ["E", "PROTEIN", 122, 123], ["Membrane glycoprotein", "PROTEIN", 126, 147], ["M", "PROTEIN", 149, 150], ["ORF6", "PROTEIN", 153, 157], ["ORF7a", "PROTEIN", 159, 164], ["ORF8", "PROTEIN", 166, 170], ["Nucleocapsid phosphoprotein", "PROTEIN", 172, 199], ["N", "PROTEIN", 201, 202], ["ORF10", "PROTEIN", 207, 212], ["viral ORF1ab", "TEST", 57, 69]]], ["Differentially expressed genes from the FindMarkers function were used to perform PANTHER-GO statistical over-representation tests for up-regulated and downregulated genes in each condition shown in Figure 2F and G. Gene lists for Figure 2H were obtained from GSEA databases (gseamsigdb.org/gsea/index.jsp).Immunohistochemistry. :::Paraffin sections were heated for 30 minutes at 60\u00b0C and treated with xylenes followed by rehydration in decreasing concentrations of ethanol (100%, 90%, 80%, 70%).", [["Paraffin sections", "ANATOMY", 332, 349], ["xylenes", "CHEMICAL", 402, 409], ["ethanol", "CHEMICAL", 466, 473], ["xylenes", "CHEMICAL", 402, 409], ["ethanol", "CHEMICAL", 466, 473], ["Paraffin sections", "CANCER", 332, 349], ["C", "SIMPLE_CHEMICAL", 383, 384], ["xylenes", "SIMPLE_CHEMICAL", 402, 409], ["ethanol", "SIMPLE_CHEMICAL", 466, 473], ["FindMarkers", "DNA", 40, 51], ["downregulated genes", "DNA", 152, 171], ["gsea", "DNA", 291, 295], ["index.jsp", "DNA", 296, 305], ["representation tests", "TEST", 110, 130], ["downregulated genes in each condition", "PROBLEM", 152, 189], ["Figure 2H", "TEST", 231, 240], ["GSEA databases", "TEST", 260, 274], ["Immunohistochemistry", "TEST", 307, 327], ["Paraffin sections", "TEST", 332, 349], ["xylenes", "TREATMENT", 402, 409], ["rehydration", "TREATMENT", 422, 433], ["ethanol", "TREATMENT", 466, 473]]], ["Antigen retrieval was performed by boiling in sodium citrate (pH 6.0) for 15 minutes and peroxidase activity was blocked with hydrogen peroxide for 10 minutes.", [["sodium citrate", "CHEMICAL", 46, 60], ["hydrogen peroxide", "CHEMICAL", 126, 143], ["sodium citrate", "CHEMICAL", 46, 60], ["hydrogen peroxide", "CHEMICAL", 126, 143], ["sodium citrate", "SIMPLE_CHEMICAL", 46, 60], ["peroxidase", "GENE_OR_GENE_PRODUCT", 89, 99], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 126, 143], ["peroxidase", "PROTEIN", 89, 99], ["Antigen retrieval", "TREATMENT", 0, 17], ["sodium citrate", "TREATMENT", 46, 60], ["pH", "TEST", 62, 64], ["hydrogen peroxide", "TREATMENT", 126, 143]]], ["Blocking was performed in 2.5% normal horse serum (Vector Laboratories) and incubated in primary antibody overnight at 4\u00b0C. Mouse anti-SARS-CoV-2 spike antibody (clone 1A9, GeneTex GTX632604) was used at a dilution of 1:400.", [["serum", "ANATOMY", 44, 49], ["horse", "ORGANISM", 38, 43], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["Mouse", "ORGANISM", 124, 129], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 130, 145], ["clone", "ORGANISM", 162, 167], ["primary antibody", "PROTEIN", 89, 105], ["Mouse anti-SARS-CoV-2 spike antibody", "PROTEIN", 124, 160], ["clone 1A9", "PROTEIN", 162, 171], ["horse", "SPECIES", 38, 43], ["Mouse", "SPECIES", 124, 129], ["horse", "SPECIES", 38, 43], ["Mouse", "SPECIES", 124, 129], ["Mouse anti-SARS", "TEST", 124, 139], ["CoV", "TEST", 140, 143], ["spike antibody", "TEST", 146, 160]]], ["Secondary antibody and detection reagents from the VECTASTAIN Elite ABC-HRP Kit (Vector Laboratories PK-7200) were used according to manufacturer instructions.", [["ABC", "PROTEIN", 68, 71], ["HRP", "PROTEIN", 72, 75], ["Secondary antibody", "TEST", 0, 18], ["detection reagents", "TEST", 23, 41], ["the VECTASTAIN Elite ABC", "TEST", 47, 71]]], ["Sections were counterstained with Hematoxylin QS (Vector Laboratories H-3404), dehydrated in increasing concentrations of ethanol, cleared with xylenes, and mounted with VectaMount permanent mounting medium (Vector Laboratories H-5000).ACE2 blocking. :::For ACE2 blocking assays, Organoids were preincubated with anti-ACE2 Antibodies (AF933, R&D Systems) or isotype antibodies at a concentration of 100ug/mL for 1 hour at 4 degrees.", [["H-3404", "CHEMICAL", 70, 76], ["ethanol", "CHEMICAL", 122, 129], ["xylenes", "CHEMICAL", 144, 151], ["Hematoxylin", "CHEMICAL", 34, 45], ["H-3404", "CHEMICAL", 70, 76], ["ethanol", "CHEMICAL", 122, 129], ["xylenes", "CHEMICAL", 144, 151], ["Hematoxylin", "SIMPLE_CHEMICAL", 34, 45], ["ethanol", "SIMPLE_CHEMICAL", 122, 129], ["xylenes", "SIMPLE_CHEMICAL", 144, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 236, 240], ["ACE2", "GENE_OR_GENE_PRODUCT", 258, 262], ["AF933", "SIMPLE_CHEMICAL", 335, 340], ["ACE2", "PROTEIN", 236, 240], ["ACE2", "PROTEIN", 258, 262], ["anti-ACE2 Antibodies", "PROTEIN", 313, 333], ["AF933", "PROTEIN", 335, 340], ["R&D", "PROTEIN", 342, 345], ["isotype antibodies", "PROTEIN", 358, 376], ["Hematoxylin QS", "TEST", 34, 48], ["xylenes", "TREATMENT", 144, 151], ["ACE2 blocking", "TREATMENT", 236, 249], ["ACE2 blocking assays", "TEST", 258, 278], ["anti-ACE2 Antibodies", "TEST", 313, 333], ["isotype antibodies", "PROBLEM", 358, 376], ["blocking", "OBSERVATION", 241, 249]]], ["Organoids were then infected with SARS-CoV-2 as described above.Enzyme-linked immunosorbent assay. ::: CSF neutralization assay. :::ELISAs were performed as previously reported (Israelow et al., 2020).", [["CoV-2", "ORGANISM", 39, 44], ["CSF", "GENE_OR_GENE_PRODUCT", 103, 106], ["SARS-CoV", "SPECIES", 34, 42], ["Enzyme", "TEST", 64, 70], ["immunosorbent assay", "TEST", 78, 97], ["CSF neutralization assay", "TEST", 103, 127], ["ELISAs", "TEST", 132, 138], ["infected", "OBSERVATION", 20, 28], ["neutralization assay", "OBSERVATION", 107, 127]]], ["In short, Triton X-100 and RNase A were added to serum samples at final concentrations of 0.5% and 0.5mg/ml respectively and incubated at room temperature (RT) for 3 hours before use to reduce risk from any potential virus in serum.", [["serum samples", "ANATOMY", 49, 62], ["serum", "ANATOMY", 226, 231], ["Triton X-100", "CHEMICAL", 10, 22], ["Triton X-100", "SIMPLE_CHEMICAL", 10, 22], ["RNase A", "SIMPLE_CHEMICAL", 27, 34], ["serum samples", "ORGANISM_SUBSTANCE", 49, 62], ["serum", "ORGANISM_SUBSTANCE", 226, 231], ["RNase A", "PROTEIN", 27, 34], ["RNase A", "TREATMENT", 27, 34], ["serum samples", "TEST", 49, 62], ["any potential virus in serum", "PROBLEM", 203, 231], ["virus", "OBSERVATION", 217, 222]]], ["96-well MaxiSorp plates (Thermo Scientific #442404) were coated with 50 \u03bcl/well of recombinant SARS Cov-2 S1 protein (ACROBiosystems #S1N-C52H3\u2013100ug) at a concentration of 2 \u03bcg/ml in PBS and were incubated overnight at 4 \u00b0C. The coating buffer was removed, and plates were incubated for 1h at RT with 200\u03bcl of blocking solution (PBS with 0.1% Tween-20, 3% milk powder).", [["Tween-20", "CHEMICAL", 344, 352], ["Tween-20", "CHEMICAL", 344, 352], ["Tween-20", "SIMPLE_CHEMICAL", 344, 352], ["milk", "ORGANISM", 357, 361], ["recombinant SARS Cov-2 S1 protein", "PROTEIN", 83, 116], ["ACROBiosystems", "PROTEIN", 118, 132], ["S1N", "PROTEIN", 134, 137], ["C52H3", "PROTEIN", 138, 143], ["recombinant SARS Cov", "TEST", 83, 103], ["S1 protein", "TEST", 106, 116], ["ACROBiosystems", "TEST", 118, 132], ["S1N", "TEST", 134, 137], ["The coating buffer", "TREATMENT", 226, 244], ["blocking solution", "TREATMENT", 311, 328], ["PBS", "TEST", 330, 333], ["3% milk powder", "TREATMENT", 354, 368], ["coating", "OBSERVATION_MODIFIER", 230, 237], ["buffer", "OBSERVATION_MODIFIER", 238, 244]]], ["Serum was diluted 1:50 in dilution solution (PBS with 0.1% Tween-20, 1% milk powder) and 100\u03bcl of diluted serum was added for two hours at RT.", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 106, 111], ["Tween-20", "CHEMICAL", 59, 67], ["Tween-20", "CHEMICAL", 59, 67], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Tween-20", "SIMPLE_CHEMICAL", 59, 67], ["milk", "ORGANISM", 72, 76], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["Serum", "TEST", 0, 5], ["PBS", "TEST", 45, 48], ["Tween", "TEST", 59, 64], ["1% milk powder", "TREATMENT", 69, 83], ["diluted serum", "TEST", 98, 111]]], ["Plates were washed three times with PBS-T (PBS with 0.1% Tween-20) and 50\u03bcl of mouse IgG-specific secondary antibody (BioLegend #405306, 1:10,000) diluted in dilution solution added to each well.", [["Tween-20", "CHEMICAL", 57, 65], ["Tween-20", "CHEMICAL", 57, 65], ["Tween-20", "SIMPLE_CHEMICAL", 57, 65], ["mouse", "ORGANISM", 79, 84], ["IgG", "GENE_OR_GENE_PRODUCT", 85, 88], ["mouse IgG", "PROTEIN", 79, 88], ["secondary antibody", "PROTEIN", 98, 116], ["mouse", "SPECIES", 79, 84], ["mouse", "SPECIES", 79, 84], ["Plates", "TEST", 0, 6], ["PBS", "TEST", 36, 39], ["PBS", "TEST", 43, 46], ["Tween", "TEST", 57, 62], ["mouse IgG", "TEST", 79, 88]]], ["After 1h of incubation at RT, plates were washed three times with PBS-T.", [["incubation at RT, plates", "TREATMENT", 12, 36], ["PBS", "TEST", 66, 69]]], ["Samples were developed with 100\u03bcl of TMB Substrate Reagent Set (BD Biosciences #555214) and the reaction was stopped after 15 min by the addition of 2 N sulfuric acid.Neutralization assay. ::: CSF neutralization assay. :::Virus for infection was preincubated with 500\u03bcL of healthy or COVID19 CSF in 37 degrees for one hour before infection of organoids.", [["Samples", "ANATOMY", 0, 7], ["organoids", "ANATOMY", 343, 352], ["#555214", "CHEMICAL", 79, 86], ["2 N sulfuric acid", "CHEMICAL", 149, 166], ["infection", "DISEASE", 232, 241], ["infection", "DISEASE", 330, 339], ["TMB", "CHEMICAL", 37, 40], ["2 N sulfuric acid", "CHEMICAL", 149, 166], ["2 N sulfuric acid", "SIMPLE_CHEMICAL", 149, 166], ["CSF", "GENE_OR_GENE_PRODUCT", 193, 196], ["Virus", "ORGANISM", 222, 227], ["CSF", "GENE_OR_GENE_PRODUCT", 292, 295], ["organoids", "CELL", 343, 352], ["Samples", "TEST", 0, 7], ["the reaction", "PROBLEM", 92, 104], ["2 N sulfuric acid", "TREATMENT", 149, 166], ["Neutralization assay", "TEST", 167, 187], ["CSF neutralization assay", "TEST", 193, 217], ["Virus", "PROBLEM", 222, 227], ["infection", "PROBLEM", 232, 241], ["COVID19 CSF", "TREATMENT", 284, 295], ["infection of organoids", "PROBLEM", 330, 352], ["neutralization assay", "OBSERVATION", 197, 217], ["infection", "OBSERVATION", 232, 241], ["infection", "OBSERVATION", 330, 339]]], ["The Organoid culture was supplemented with an additional 500\u03bcL of CSF after infection until the organoid was collected for imaging.Human subjects. :::Research participants were enrolled at Yale University through Human Investigation Committee Protocols HIC#2000027690 and HIC #1502015318.", [["organoid", "ANATOMY", 96, 104], ["infection", "DISEASE", 76, 85], ["CSF", "ORGANISM_SUBSTANCE", 66, 69], ["organoid", "CANCER", 96, 104], ["Human", "ORGANISM", 131, 136], ["Human", "ORGANISM", 213, 218], ["Organoid culture", "CELL_LINE", 4, 20], ["CSF", "PROTEIN", 66, 69], ["Human", "SPECIES", 131, 136], ["participants", "SPECIES", 159, 171], ["Human", "SPECIES", 213, 218], ["The Organoid culture", "TEST", 0, 20], ["infection", "PROBLEM", 76, 85], ["imaging", "TEST", 123, 130]]], ["The Institutional Review Board at Yale approved the protocols, and informed consent was obtained from all participants.Human subjects. :::Post-mortem COVID-19 brain tissues were obtained from COVITIS Biobank (Assistance Publique Hopitaux de Paris, Paris, France).Statistical analysis. :::No statistical methods were used to predetermine sample size.", [["brain tissues", "ANATOMY", 159, 172], ["Human", "ORGANISM", 119, 124], ["brain tissues", "TISSUE", 159, 172], ["participants", "SPECIES", 106, 118], ["Human", "SPECIES", 119, 124], ["Human", "SPECIES", 119, 124], ["Post-mortem COVID", "TEST", 138, 155], ["Statistical analysis", "TEST", 263, 283], ["statistical methods", "TREATMENT", 291, 310], ["brain tissues", "ANATOMY", 159, 172], ["size", "OBSERVATION_MODIFIER", 344, 348]]], ["The investigators were not blinded during experiments and outcome assessment, but outcome assessment was additionally evaluated by animal technicians and vets blinded to the study.", [["outcome assessment", "TEST", 58, 76], ["outcome assessment", "TEST", 82, 100], ["the study", "TEST", 170, 179]]], ["Survival curves were analyzed using a log-rank (Mantle-Cox) test.", [["Survival curves", "TEST", 0, 15], ["a log-rank (Mantle-Cox) test", "TREATMENT", 36, 64]]], ["For other data, normally distributed continuous variable comparisons used a two-tailed unpaired Student\u2019s t-test or paired Student\u2019s t-test with Prism software.", [["Prism software", "TEST", 145, 159]]]], "7c39de4602343eff8fc68e576b3e38336b3ddb71": [["Earthquakes, hurricanes, droughts, and floods are global challenges due to their unpredictability and potential scale of impact in terms of social, environmental, and economic costs.", [["Earthquakes", "DISEASE", 0, 11], ["hurricanes", "DISEASE", 13, 23], ["droughts", "DISEASE", 25, 33], ["global challenges", "TREATMENT", 50, 67]]], ["Many natural disasters displace people.", [["people", "ORGANISM", 32, 38], ["people", "SPECIES", 32, 38]]], ["Furthermore, natural disasters can cause psychological suffering, altering people's behaviors and decision-making, increasing rescue and relocation difficulties, and decreasing social stability and security (Hu and Sheu, 2013; Rennemo et al., 2014) .", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["psychological suffering", "PROBLEM", 41, 64], ["increasing rescue and relocation difficulties", "PROBLEM", 115, 160]]], ["Although few direct evidences of the effects of panic and its spread on post-disaster evacuation and resettlement have been recorded in literature, the synthetic effects of psychological damage on victims have been identified.", [["panic", "DISEASE", 48, 53], ["psychological damage", "DISEASE", 173, 193], ["panic", "PROBLEM", 48, 53], ["post-disaster evacuation", "TREATMENT", 72, 96], ["resettlement", "TREATMENT", 101, 113], ["psychological damage on victims", "PROBLEM", 173, 204], ["few", "OBSERVATION_MODIFIER", 9, 12], ["spread", "OBSERVATION_MODIFIER", 62, 68]]]]}